CA2436699A1 - Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists - Google Patents
Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists Download PDFInfo
- Publication number
- CA2436699A1 CA2436699A1 CA002436699A CA2436699A CA2436699A1 CA 2436699 A1 CA2436699 A1 CA 2436699A1 CA 002436699 A CA002436699 A CA 002436699A CA 2436699 A CA2436699 A CA 2436699A CA 2436699 A1 CA2436699 A1 CA 2436699A1
- Authority
- CA
- Canada
- Prior art keywords
- ylmethyl
- benzoxazol
- piperidin
- mmol
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000005557 antagonist Substances 0.000 title abstract description 17
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title description 10
- 150000003053 piperidines Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 200
- 150000003839 salts Chemical class 0.000 claims abstract description 56
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims abstract description 30
- 208000002193 Pain Diseases 0.000 claims abstract description 21
- 230000036407 pain Effects 0.000 claims abstract description 16
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 6
- 208000014674 injury Diseases 0.000 claims abstract description 6
- 208000004296 neuralgia Diseases 0.000 claims abstract description 6
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 6
- 230000008733 trauma Effects 0.000 claims abstract description 6
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 5
- 208000013016 Hypoglycemia Diseases 0.000 claims abstract description 5
- 208000006011 Stroke Diseases 0.000 claims abstract description 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 5
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 4
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 4
- 206010010904 Convulsion Diseases 0.000 claims abstract description 4
- 230000036506 anxiety Effects 0.000 claims abstract description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 4
- 206010011878 Deafness Diseases 0.000 claims abstract description 3
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 3
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 3
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 3
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims abstract description 3
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 3
- 230000036461 convulsion Effects 0.000 claims abstract description 3
- 230000010370 hearing loss Effects 0.000 claims abstract description 3
- 231100000888 hearing loss Toxicity 0.000 claims abstract description 3
- 208000016354 hearing loss disease Diseases 0.000 claims abstract description 3
- 206010027599 migraine Diseases 0.000 claims abstract description 3
- -1 1-aza-2-cyclobutanon-3,4-diyl Chemical group 0.000 claims description 152
- 238000000034 method Methods 0.000 claims description 130
- 229910052739 hydrogen Inorganic materials 0.000 claims description 129
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- 239000000203 mixture Substances 0.000 claims description 95
- 239000001257 hydrogen Substances 0.000 claims description 54
- 229910052760 oxygen Inorganic materials 0.000 claims description 51
- 229910052717 sulfur Inorganic materials 0.000 claims description 49
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 41
- 125000004432 carbon atom Chemical group C* 0.000 claims description 39
- 125000005842 heteroatom Chemical group 0.000 claims description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 125000004429 atom Chemical group 0.000 claims description 28
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000002619 bicyclic group Chemical group 0.000 claims description 14
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- QLSZYSYFDFIMMQ-UHFFFAOYSA-N 6-[5-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 QLSZYSYFDFIMMQ-UHFFFAOYSA-N 0.000 claims description 7
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- AYJNYKJPUBSWGB-UHFFFAOYSA-N ethyl 4-[(4-fluorophenyl)methyl]-1-[[3-(2-oxo-3h-1,3-benzoxazol-6-yl)-4,5-dihydro-1,2-oxazol-5-yl]methyl]piperidine-4-carboxylate Chemical compound C1CN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CCC1(C(=O)OCC)CC1=CC=C(F)C=C1 AYJNYKJPUBSWGB-UHFFFAOYSA-N 0.000 claims description 5
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 4
- JPHAZIBDWYJPRF-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-1-[[3-(2-oxo-3h-1,3-benzoxazol-6-yl)-4,5-dihydro-1,2-oxazol-5-yl]methyl]piperidine-4-carboxylic acid Chemical compound C1CN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CCC1(C(=O)O)CC1=CC=C(F)C=C1 JPHAZIBDWYJPRF-UHFFFAOYSA-N 0.000 claims description 4
- GZSAXFJVIOUHMQ-UHFFFAOYSA-N 4-chloro-6-[5-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-5-methyl-3h-1,3-benzoxazol-2-one Chemical compound CC1=C(Cl)C=2NC(=O)OC=2C=C1C(C1)=NOC1CN(CC1)CCC1CC1=CC=C(F)C=C1 GZSAXFJVIOUHMQ-UHFFFAOYSA-N 0.000 claims description 4
- DXSJSUFLKCARMK-UHFFFAOYSA-N 5-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-3-(2-oxo-3h-1,3-benzoxazol-6-yl)-4h-1,2-oxazole-5-carboxylic acid Chemical compound C1C(C=2C=C3OC(=O)NC3=CC=2)=NOC1(C(=O)O)CN(CC1)CCC1CC1=CC=C(F)C=C1 DXSJSUFLKCARMK-UHFFFAOYSA-N 0.000 claims description 4
- JYLIMDCIEQAHCU-UHFFFAOYSA-N 6-[2-[(4-benzylpiperidin-1-yl)methyl]-1,3-oxazol-5-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=C2OC(=O)NC2=CC=C1C(O1)=CN=C1CN(CC1)CCC1CC1=CC=CC=C1 JYLIMDCIEQAHCU-UHFFFAOYSA-N 0.000 claims description 4
- SMINLMNHAOZQOE-UHFFFAOYSA-N 6-[2-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-1,3-thiazol-5-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CC=2SC(=CN=2)C=2C=C3OC(=O)NC3=CC=2)CC1 SMINLMNHAOZQOE-UHFFFAOYSA-N 0.000 claims description 4
- XYELIFWRUMQZNH-UHFFFAOYSA-N 6-[5-[(4-benzylpiperidin-1-yl)methyl]-3-methyl-1,2-oxazol-4-yl]-3h-1,3-benzoxazol-2-one Chemical compound C=1C=C2NC(=O)OC2=CC=1C=1C(C)=NOC=1CN(CC1)CCC1CC1=CC=CC=C1 XYELIFWRUMQZNH-UHFFFAOYSA-N 0.000 claims description 4
- FJDDTUMBIPGMEH-UHFFFAOYSA-N 6-[5-[(4-benzylpiperidin-1-yl)methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=C2OC(=O)NC2=CC=C1C(C1)=NOC1CN(CC1)CCC1CC1=CC=CC=C1 FJDDTUMBIPGMEH-UHFFFAOYSA-N 0.000 claims description 4
- SCMCMEILIHUNKB-UHFFFAOYSA-N 6-[5-[(4-benzylpiperidin-1-yl)methyl]-4,5-dihydro-1,3-thiazol-2-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=C2OC(=O)NC2=CC=C1C(S1)=NCC1CN(CC1)CCC1CC1=CC=CC=C1 SCMCMEILIHUNKB-UHFFFAOYSA-N 0.000 claims description 4
- KATXXPWPAADUFE-UHFFFAOYSA-N 6-[5-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CCC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 KATXXPWPAADUFE-UHFFFAOYSA-N 0.000 claims description 4
- KWIWDKFZDFVYLT-UHFFFAOYSA-N 6-[5-[[4-(4-fluorophenoxy)piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1OC1CCN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 KWIWDKFZDFVYLT-UHFFFAOYSA-N 0.000 claims description 4
- XQJXNDHQTOROTB-UHFFFAOYSA-N 6-[5-[[4-(4-fluorophenyl)sulfinylpiperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1S(=O)C1CCN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 XQJXNDHQTOROTB-UHFFFAOYSA-N 0.000 claims description 4
- RMTIKRSRDXZODW-UHFFFAOYSA-N 6-[5-[[4-[(4-fluorophenyl)methyl]-4-hydroxypiperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1CN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CCC1(O)CC1=CC=C(F)C=C1 RMTIKRSRDXZODW-UHFFFAOYSA-N 0.000 claims description 4
- ATBTZRUAAQDQIZ-UHFFFAOYSA-N 6-[5-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-5-methyl-4h-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1C(C=2C=C3OC(=O)NC3=CC=2)=NOC1(C)CN(CC1)CCC1CC1=CC=C(F)C=C1 ATBTZRUAAQDQIZ-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- CONNZCWJAGNWFP-UHFFFAOYSA-N 5-[2-[(4-benzylpiperidin-1-yl)methyl]-1,3-oxazol-5-yl]-1,3-dihydroindol-2-one Chemical compound C=1C=C2NC(=O)CC2=CC=1C(O1)=CN=C1CN(CC1)CCC1CC1=CC=CC=C1 CONNZCWJAGNWFP-UHFFFAOYSA-N 0.000 claims description 3
- BMCFXZJFAGHECH-UHFFFAOYSA-N 6-[2-[(4-benzylpiperidin-1-yl)methyl]-4,5-dihydro-1,3-thiazol-5-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=C2OC(=O)NC2=CC=C1C(S1)CN=C1CN(CC1)CCC1CC1=CC=CC=C1 BMCFXZJFAGHECH-UHFFFAOYSA-N 0.000 claims description 3
- PRLGITCVKXZDLM-UHFFFAOYSA-N 6-[2-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-1,3-oxazol-5-yl]-3h-1,3-benzothiazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CC=2OC(=CN=2)C=2C=C3SC(=O)NC3=CC=2)CC1 PRLGITCVKXZDLM-UHFFFAOYSA-N 0.000 claims description 3
- OLSPPABVDMWDLC-UHFFFAOYSA-N 6-[2-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-1,3-thiazol-5-yl]-3h-1,3-benzothiazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CC=2SC(=CN=2)C=2C=C3SC(=O)NC3=CC=2)CC1 OLSPPABVDMWDLC-UHFFFAOYSA-N 0.000 claims description 3
- PNPKRGHUDIJLNO-UHFFFAOYSA-N 6-[5-[(4-benzyl-4-hydroxypiperidin-1-yl)methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1CN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CCC1(O)CC1=CC=CC=C1 PNPKRGHUDIJLNO-UHFFFAOYSA-N 0.000 claims description 3
- CIPYWKXCSSMDCZ-UHFFFAOYSA-N 6-[5-[2-[4-(4-fluorophenyl)piperidin-1-yl]ethyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1C1CCN(CCC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 CIPYWKXCSSMDCZ-UHFFFAOYSA-N 0.000 claims description 3
- MSODQXFQSOLDES-UHFFFAOYSA-N 6-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(C(=O)C2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 MSODQXFQSOLDES-UHFFFAOYSA-N 0.000 claims description 3
- HYOPVBIOWBLYPF-UHFFFAOYSA-N 6-[5-[[4-(4-fluorophenyl)sulfanylpiperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1SC1CCN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 HYOPVBIOWBLYPF-UHFFFAOYSA-N 0.000 claims description 3
- SXPMKTHJEWVIMI-UHFFFAOYSA-N 6-[5-[[4-[(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1CN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CCC1C(O)C1=CC=C(F)C=C1 SXPMKTHJEWVIMI-UHFFFAOYSA-N 0.000 claims description 3
- CWDJYCBLXBZMRV-UHFFFAOYSA-N 6-[5-[[4-[(4-fluorophenyl)methyl]-3-hydroxypiperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound OC1CN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CCC1CC1=CC=C(F)C=C1 CWDJYCBLXBZMRV-UHFFFAOYSA-N 0.000 claims description 3
- PQDGPXDDHBZYGF-UHFFFAOYSA-N 6-[5-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CC=2ON=C(C=2)C=2C=C3OC(=O)NC3=CC=2)CC1 PQDGPXDDHBZYGF-UHFFFAOYSA-N 0.000 claims description 3
- JQDQGZIIZOGIBM-UHFFFAOYSA-N 6-[5-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-4,5-dihydro-1,3-thiazol-2-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CC2SC(=NC2)C=2C=C3OC(=O)NC3=CC=2)CC1 JQDQGZIIZOGIBM-UHFFFAOYSA-N 0.000 claims description 3
- ZGRFQSSOSBUIGX-UHFFFAOYSA-N methyl 5-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-3-(2-oxo-3h-1,3-benzoxazol-6-yl)-4h-1,2-oxazole-5-carboxylate Chemical compound C1C(C=2C=C3OC(=O)NC3=CC=2)=NOC1(C(=O)OC)CN(CC1)CCC1CC1=CC=C(F)C=C1 ZGRFQSSOSBUIGX-UHFFFAOYSA-N 0.000 claims description 3
- DFZGZYKQLWJIHF-UHFFFAOYSA-N 5-[2-[(4-benzylpiperidin-1-yl)methyl]-1,3-thiazol-5-yl]-1,3-dihydrobenzimidazole-2-thione Chemical compound C1=C2NC(=S)NC2=CC=C1C(S1)=CN=C1CN(CC1)CCC1CC1=CC=CC=C1 DFZGZYKQLWJIHF-UHFFFAOYSA-N 0.000 claims description 2
- YUXQSANVSRRNGZ-UHFFFAOYSA-N 6-[3-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-5-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CC=2CC(ON=2)C=2C=C3OC(=O)NC3=CC=2)CC1 YUXQSANVSRRNGZ-UHFFFAOYSA-N 0.000 claims description 2
- WZSGGYSFHCDRBC-UHFFFAOYSA-N 6-[5-[[4-(4-fluorobenzoyl)piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 WZSGGYSFHCDRBC-UHFFFAOYSA-N 0.000 claims description 2
- PXPMXSDJJQRRSP-UHFFFAOYSA-N 6-[5-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1CC1CCN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 PXPMXSDJJQRRSP-UHFFFAOYSA-N 0.000 claims description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 abstract description 10
- 230000002490 cerebral effect Effects 0.000 abstract description 4
- 208000019553 vascular disease Diseases 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 254
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 222
- 235000019439 ethyl acetate Nutrition 0.000 description 120
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 112
- 239000000243 solution Substances 0.000 description 111
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 96
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 94
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 74
- 239000007787 solid Substances 0.000 description 74
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 71
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 56
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 56
- 230000002829 reductive effect Effects 0.000 description 52
- 239000011541 reaction mixture Substances 0.000 description 50
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 46
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- 238000004128 high performance liquid chromatography Methods 0.000 description 41
- 239000002904 solvent Substances 0.000 description 41
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 37
- 101150041968 CDC13 gene Proteins 0.000 description 34
- 150000001336 alkenes Chemical class 0.000 description 34
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 34
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 32
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
- 238000000746 purification Methods 0.000 description 32
- 239000003921 oil Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 29
- 238000011282 treatment Methods 0.000 description 28
- 238000004587 chromatography analysis Methods 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 230000008878 coupling Effects 0.000 description 24
- 238000010168 coupling process Methods 0.000 description 24
- 238000005859 coupling reaction Methods 0.000 description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 239000012267 brine Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 19
- 125000002947 alkylene group Chemical group 0.000 description 19
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 238000010992 reflux Methods 0.000 description 18
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 17
- 239000000377 silicon dioxide Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 15
- 150000001412 amines Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 12
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 11
- 230000006399 behavior Effects 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- OJKWWANXBGLGQN-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]piperidine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1CC1CCNCC1 OJKWWANXBGLGQN-UHFFFAOYSA-N 0.000 description 10
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 9
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 9
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 210000000287 oocyte Anatomy 0.000 description 9
- 150000002923 oximes Chemical class 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 239000000010 aprotic solvent Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 150000003840 hydrochlorides Chemical class 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- 108091008757 nuclear thyroid hormone receptors Proteins 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- 229910052720 vanadium Inorganic materials 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 108020001305 NR1 subfamily Proteins 0.000 description 6
- 102000034570 NR1 subfamily Human genes 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 6
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 229960003998 ifenprodil Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 5
- 229910017974 NH40H Inorganic materials 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- 108010038912 Retinoid X Receptors Proteins 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000001665 trituration Methods 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- HJVANSUYXOOKQA-UHFFFAOYSA-N 2-(4-benzylpiperidin-1-yl)acetic acid Chemical compound C1CN(CC(=O)O)CCC1CC1=CC=CC=C1 HJVANSUYXOOKQA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 4
- 108020002076 NR2 subfamily Proteins 0.000 description 4
- 102000038100 NR2 subfamily Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- GCSAXWHQFYOIFE-UHFFFAOYSA-N dipyridin-2-yl carbonate Chemical compound C=1C=CC=NC=1OC(=O)OC1=CC=CC=N1 GCSAXWHQFYOIFE-UHFFFAOYSA-N 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 239000012154 double-distilled water Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- FZENGILVLUJGJX-NSCUHMNNSA-N (E)-acetaldehyde oxime Chemical compound C\C=N\O FZENGILVLUJGJX-NSCUHMNNSA-N 0.000 description 3
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical group C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 3
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical group C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 3
- WFQQBMOZRDPZQW-UHFFFAOYSA-N 2-[3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC(O)CN(CC1)CCC1CC1=CC=CC=C1 WFQQBMOZRDPZQW-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- ZUHPKQGYWIDGSU-UHFFFAOYSA-N benzyl n-[3-(4-benzylpiperidin-1-yl)-2-[tert-butyl(dimethyl)silyl]oxypropyl]carbamate Chemical compound C1CC(CC=2C=CC=CC=2)CCN1CC(O[Si](C)(C)C(C)(C)C)CNC(=O)OCC1=CC=CC=C1 ZUHPKQGYWIDGSU-UHFFFAOYSA-N 0.000 description 3
- KHQWJFBNMTYTDM-UHFFFAOYSA-N benzyl n-[3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]carbamate Chemical compound C1CC(CC=2C=CC=CC=2)CCN1CC(O)CNC(=O)OCC1=CC=CC=C1 KHQWJFBNMTYTDM-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- UXOLDCOJRAMLTQ-UTCJRWHESA-N ethyl (2z)-2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(\Cl)=N\O UXOLDCOJRAMLTQ-UTCJRWHESA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- DQQFRTSBEPBELA-UHFFFAOYSA-N n-[3-(4-benzylpiperidin-1-yl)-2-[tert-butyl(dimethyl)silyl]oxypropyl]-2-oxo-3h-1,3-benzoxazole-6-carboxamide Chemical compound C=1C=C2NC(=O)OC2=CC=1C(=O)NCC(O[Si](C)(C)C(C)(C)C)CN(CC1)CCC1CC1=CC=CC=C1 DQQFRTSBEPBELA-UHFFFAOYSA-N 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 2
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 2
- CPXRCEAWAVJXFE-UHFFFAOYSA-N 2-(4-benzylpiperidin-1-yl)-n-[2-oxo-2-(2-oxo-1,3-dihydroindol-5-yl)ethyl]acetamide Chemical compound C=1C=C2NC(=O)CC2=CC=1C(=O)CNC(=O)CN(CC1)CCC1CC1=CC=CC=C1 CPXRCEAWAVJXFE-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- BCTFBIJUMGLXGU-UHFFFAOYSA-N 2-oxo-3h-1,3-benzoxazole-6-carbothioic s-acid Chemical compound SC(=O)C1=CC=C2NC(=O)OC2=C1 BCTFBIJUMGLXGU-UHFFFAOYSA-N 0.000 description 2
- BZRKWTCIDCRBMY-UHFFFAOYSA-N 2-oxo-3h-1,3-benzoxazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=O)OC2=C1 BZRKWTCIDCRBMY-UHFFFAOYSA-N 0.000 description 2
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 2
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- MAXQGBVIFZOPJE-UHFFFAOYSA-N 5-(2-aminoacetyl)-1,3-dihydrobenzimidazol-2-one;hydrochloride Chemical compound Cl.NCC(=O)C1=CC=C2NC(=O)NC2=C1 MAXQGBVIFZOPJE-UHFFFAOYSA-N 0.000 description 2
- ALLVVCKAZAIZDT-UHFFFAOYSA-N 5-(2-azidoacetyl)-1,3-dihydrobenzimidazol-2-one Chemical compound [N-]=[N+]=NCC(=O)C1=CC=C2NC(=O)NC2=C1 ALLVVCKAZAIZDT-UHFFFAOYSA-N 0.000 description 2
- XVJCMNPIXOVPIA-UHFFFAOYSA-N 5-(2-chloroacetyl)-1,3-dihydrobenzimidazol-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)NC2=C1 XVJCMNPIXOVPIA-UHFFFAOYSA-N 0.000 description 2
- WXJWBEAGVWVEDM-UHFFFAOYSA-N 5-(2-chloroacetyl)-1,3-dihydroindol-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)CC2=C1 WXJWBEAGVWVEDM-UHFFFAOYSA-N 0.000 description 2
- FSYJRFKMKKJKNS-UHFFFAOYSA-N 6-(2-azido-1-hydroxyethyl)-3h-1,3-benzoxazol-2-one Chemical compound [N-]=[N+]=NCC(O)C1=CC=C2NC(=O)OC2=C1 FSYJRFKMKKJKNS-UHFFFAOYSA-N 0.000 description 2
- NLYJCWCLGOHDHD-UHFFFAOYSA-N 6-(2-azidoacetyl)-1,3-dihydroindol-2-one Chemical compound [N-]=[N+]=NCC(=O)C1=CC=C2CC(=O)NC2=C1 NLYJCWCLGOHDHD-UHFFFAOYSA-N 0.000 description 2
- GPPDNNQHTSOBDL-UHFFFAOYSA-N 6-(2-azidoacetyl)-3h-1,3-benzothiazol-2-one Chemical compound [N-]=[N+]=NCC(=O)C1=CC=C2NC(=O)SC2=C1 GPPDNNQHTSOBDL-UHFFFAOYSA-N 0.000 description 2
- IYBCEMNVTVBJOH-UHFFFAOYSA-N 6-(2-chloroacetyl)-3h-1,3-benzothiazol-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)SC2=C1 IYBCEMNVTVBJOH-UHFFFAOYSA-N 0.000 description 2
- UZFQNGBMHFDWHR-UHFFFAOYSA-N 6-[2-amino-1-[tert-butyl(dimethyl)silyl]oxyethyl]-3h-1,3-benzoxazol-2-one Chemical compound CC(C)(C)[Si](C)(C)OC(CN)C1=CC=C2NC(=O)OC2=C1 UZFQNGBMHFDWHR-UHFFFAOYSA-N 0.000 description 2
- LSRVGBRFMDCFHH-UHFFFAOYSA-N 6-[2-azido-1-[tert-butyl(dimethyl)silyl]oxyethyl]-3h-1,3-benzoxazol-2-one Chemical compound CC(C)(C)[Si](C)(C)OC(CN=[N+]=[N-])C1=CC=C2NC(=O)OC2=C1 LSRVGBRFMDCFHH-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- DCRXLQCPGFZEES-UHFFFAOYSA-N benzyl 2-(4-benzylpiperidin-1-yl)acetate Chemical compound C=1C=CC=CC=1COC(=O)CN(CC1)CCC1CC1=CC=CC=C1 DCRXLQCPGFZEES-UHFFFAOYSA-N 0.000 description 2
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DDNKJFBQMQOIKI-UHFFFAOYSA-N cincreasin Chemical compound BrC1=CC=C2NC(=O)OC2=C1 DDNKJFBQMQOIKI-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 229950005455 eliprodil Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000000848 glutamatergic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000000917 hyperalgesic effect Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OCZXDVNSNDITBS-UHFFFAOYSA-N methyl 4-amino-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(O)=C1 OCZXDVNSNDITBS-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- BYXLCUHZMZVIPI-UHFFFAOYSA-N n-[3-(4-benzylpiperidin-1-yl)-2-[tert-butyl(dimethyl)silyl]oxypropyl]-2-oxo-3h-1,3-benzoxazole-6-carbothioamide Chemical compound C=1C=C2NC(=O)OC2=CC=1C(=S)NCC(O[Si](C)(C)C(C)(C)C)CN(CC1)CCC1CC1=CC=CC=C1 BYXLCUHZMZVIPI-UHFFFAOYSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 108091008646 testicular receptors Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- ABERUOJGWHYBJL-UHFFFAOYSA-N (4-fluorophenyl)-piperidin-4-ylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCNCC1 ABERUOJGWHYBJL-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- NXLBYNFDNFZYJB-UHFFFAOYSA-N 1-(4-benzylpiperidin-1-yl)-3-chloropropan-2-ol Chemical compound C1CN(CC(CCl)O)CCC1CC1=CC=CC=C1 NXLBYNFDNFZYJB-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- DAIOJCDYNLTECV-UHFFFAOYSA-N 1-amino-3-(4-benzylpiperidin-1-yl)propan-2-ol Chemical compound C1CN(CC(O)CN)CCC1CC1=CC=CC=C1 DAIOJCDYNLTECV-UHFFFAOYSA-N 0.000 description 1
- MGYCVQPWXHYTLV-UHFFFAOYSA-N 1-chloro-3-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]propan-2-ol Chemical compound C1CN(CC(CCl)O)CCC1CC1=CC=C(F)C=C1 MGYCVQPWXHYTLV-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical group C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- AUBBVPIQUDFRQI-UHFFFAOYSA-N 3-hydroxy-4-nitrobenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1[N+]([O-])=O AUBBVPIQUDFRQI-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MYYKARGPLYQDLN-UHFFFAOYSA-N 3h-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2SC(=O)NC2=C1 MYYKARGPLYQDLN-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NIIGVDMAHQTQSA-UHFFFAOYSA-N 4-(4-fluorophenoxy)piperidine;hydron;chloride Chemical compound Cl.C1=CC(F)=CC=C1OC1CCNCC1 NIIGVDMAHQTQSA-UHFFFAOYSA-N 0.000 description 1
- FJAXUSZPOIHXJR-UHFFFAOYSA-N 4-(4-fluorophenyl)sulfanylpiperidine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1SC1CCNCC1 FJAXUSZPOIHXJR-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical group FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- MLACDGUOKDOLGC-UHFFFAOYSA-N 5-(2-aminoethyl)benzene-1,2,4-triol;hydron;bromide Chemical compound Br.NCCC1=CC(O)=C(O)C=C1O MLACDGUOKDOLGC-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- IUKDRGBAUVZUNC-UHFFFAOYSA-N 6-(2-aminoacetyl)-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.NCC(=O)C1=CC=C2CC(=O)NC2=C1 IUKDRGBAUVZUNC-UHFFFAOYSA-N 0.000 description 1
- UHTHQCOOLULWPT-UHFFFAOYSA-N 6-(2-aminoacetyl)-3h-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.NCC(=O)C1=CC=C2NC(=O)SC2=C1 UHTHQCOOLULWPT-UHFFFAOYSA-N 0.000 description 1
- KSWXQMJZIPVXJD-UHFFFAOYSA-N 6-[2-[[4-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]-4,5-dihydro-1,3-thiazol-5-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CC=2SC(CN=2)C=2C=C3OC(=O)NC3=CC=2)CC1 KSWXQMJZIPVXJD-UHFFFAOYSA-N 0.000 description 1
- XYOPDODFZGSXHG-UHFFFAOYSA-N 6-[5-[[4-(4-fluorophenyl)piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1C1CCN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CC1 XYOPDODFZGSXHG-UHFFFAOYSA-N 0.000 description 1
- QOZSXXPNVCZPDI-UHFFFAOYSA-N 6-[5-[[4-[1-(4-fluorophenyl)-1-hydroxyethyl]piperidin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1CN(CC2ON=C(C2)C=2C=C3OC(=O)NC3=CC=2)CCC1C(O)(C)C1=CC=C(F)C=C1 QOZSXXPNVCZPDI-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
- 101100460385 Caenorhabditis elegans nhx-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101100294653 Chlamydomonas reinhardtii NRT2.1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- 229940127427 Glycine Agonists Drugs 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DMPRDSPPYMZQBT-CEAXSRTFSA-N Ifenprodil tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1.C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 DMPRDSPPYMZQBT-CEAXSRTFSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000001393 Lathyrism Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 1
- 108091008644 NR2D Proteins 0.000 description 1
- 208000006079 Near drowning Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101100030351 Schizosaccharomyces pombe (strain 972 / ATCC 24843) dis2 gene Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- XYQRXRFVKUPBQN-UHFFFAOYSA-L Sodium carbonate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]C([O-])=O XYQRXRFVKUPBQN-UHFFFAOYSA-L 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- IDJSGFYLQJCBNH-UHFFFAOYSA-N [N].BrC(Br)(Br)Br Chemical compound [N].BrC(Br)(Br)Br IDJSGFYLQJCBNH-UHFFFAOYSA-N 0.000 description 1
- VCIPYIKCFOAOPU-UHFFFAOYSA-N [N].CC=NO Chemical compound [N].CC=NO VCIPYIKCFOAOPU-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- PFCUZDIEKKTHCH-UHFFFAOYSA-N acetonitrile oxide Chemical compound CC#N=O PFCUZDIEKKTHCH-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- NCWUXMRGNQTCOF-UHFFFAOYSA-N benzyl n-[2-[tert-butyl(dimethyl)silyl]oxy-3-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]propyl]carbamate Chemical compound C1CC(CC=2C=CC(F)=CC=2)CCN1CC(O[Si](C)(C)C(C)(C)C)CNC(=O)OCC1=CC=CC=C1 NCWUXMRGNQTCOF-UHFFFAOYSA-N 0.000 description 1
- NRLXJHDJFANSAG-UHFFFAOYSA-N benzyl n-[3-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-hydroxypropyl]carbamate Chemical compound C1CC(CC=2C=CC(F)=CC=2)CCN1CC(O)CNC(=O)OCC1=CC=CC=C1 NRLXJHDJFANSAG-UHFFFAOYSA-N 0.000 description 1
- FHRRJZZGSJXPRQ-UHFFFAOYSA-N benzyl phenylmethoxycarbonyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OC(=O)OCC1=CC=CC=C1 FHRRJZZGSJXPRQ-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- ORRNHFXTIFQQIA-UHFFFAOYSA-N ethyl 2-(acetyloxymethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)COC(C)=O ORRNHFXTIFQQIA-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229960000204 ifenprodil tartrate Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004245 medial forebrain bundle Anatomy 0.000 description 1
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 description 1
- 229960001794 melevodopa Drugs 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- FUJBKRLYHYJMNF-UHFFFAOYSA-N methyl 2-oxo-3h-1,3-benzoxazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2NC(=O)OC2=C1 FUJBKRLYHYJMNF-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- IMAKHNTVDGLIRY-UHFFFAOYSA-N methyl prop-2-ynoate Chemical compound COC(=O)C#C IMAKHNTVDGLIRY-UHFFFAOYSA-N 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- MOTIRSXFFXLRDH-UHFFFAOYSA-N n-[3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]-2-oxo-3h-1,3-benzoxazole-6-carbothioamide Chemical compound C=1C=C2NC(=O)OC2=CC=1C(=S)NCC(O)CN(CC1)CCC1CC1=CC=CC=C1 MOTIRSXFFXLRDH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000002385 psychotomimetic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940018038 sodium carbonate decahydrate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Described are piperlines of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) ar antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retitins, opioid tolerance or withdrawal, pain, especially chronic pain, neuropathic pain, or surgical pain, or urinary incontinence.
Description
PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS
FIELD OF INVENTION
The invention relates to piperidine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists useful in the treatment of diseases and disorders responsive to antagonism of NMDA receptors.
BACKGROUND OF THE INVENTION
Many of the physiological and pathophysiological effects of the endogenous excitatory neurotransmitter glutamate are mediated via actions at N-Methyl-D-Asparate (NMDA) receptors. Over-excitation of the NMDA
receptors on postsynaptic cells-mediated by excessive release of glutamate from nerve endings or glial cells-results in a massive calcium ion influx through a calcium ion channel into neuronal cells, leading to neuronal cell death. These events occur under ischemic or hypoxic conditions such as, for example, stroke, hypoglycemia, cardiac arrest, or acute physical trauma.
NMDA receptors in vivo form an NMDA receptor channel complex in cell walls comprising at least three binding domains, including a glutamic acid (or NMDA) recognition site, a channel blocking binding site, and a strychnine-insensitive glycine binding site. Physiologically, a blockade of at least one of these sites terminates the channel opening of the NMDA receptor, thereby preventing calcium ion influx into cells. Accordingly, an NMDA receptor antagonist is therapeutically useful because it minimizes damage to the central nervous system induced by calcium ion influx under ischemic or hypoxic conditions.
A functional NMDA receptor is comprised of the combination of at least one subunit termed "NR1", which has 8 splice variants including NR1A, and one (or more) subunit termed "NR2A", "NR2B", "NR2C", and "NR2D". The combinations are designated NR1/2A, NR1/2B, NR1/2C and NRl/2D, respectively. The different NR2 subunits have distinct developmental and anatomical distributions. This suggests that agents that selectively antagonize one NR1/NR2 combination would have therapeutic actions without the psychotomimetic or dysphoric side effects associated with antagonists which block multiple NRl/NR2 combinations.
A subtype-selective NMDA receptor antagonist may be identified by methods well known in the pharmaceutical arts, such as, for example, screening compounds in an electrophysiology assay. In one such electrophysiology assay, different subunit combinations of recombinant NR1 and NR2 receptors are expressed in Xenopus oocytes, and a potential agent is administered at different concentrations. NMDA-based electrical currents are activated by co-administration of fixed concentrations of an excitatory amino acid such as, for example, glutamic acid or glycine. The ability of an agent to antagonize the activation of the electrical current by an excitatory amino acid is measured by recording the change in the current versus the change in the concentration of the agent.
Screening of compounds in recent years have identified a number of NMDA receptor antagonists that have been used in animal and clinical human studies to demonstrate proof of concept for use of such an antagonist in the treatment of a variety of disorders. Disorders known to be responsive to blockade of NMDA receptors include acute cerebral ischemia (stroke or cerebral trauma, for example), muscular spasm, convulsive disorders, pain, including chronic and neuropathic pain, anxiety, and chronic neurodegenerative disorders such as Parkinson's disease. NMDA receptor antagonists may also be used to prevent tolerance to opiate analgesia or to help control symptoms of withdrawal from addictive drugs. In fact, excessive excitation by neurotransmitters may be responsible for the loss of neurons in a wide variety of conditions.
Additional conditions include cerebral vascular disorders such as cerebral ischemia or cerebral infarction resulting in a range of conditions such as thromboembolic or hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, perinatal, asphyxia anoxia, such as from near drowning, pulmonary surgery and cerebral trauma, as well as lathyrism, Alzheimer's disease, and Huntington's disease. Other conditions amendable to treatment with an subtype-selective NMDA receptor antagonist include amyotrophic lateral sclerosis (ALS), epilepsy, and schizophrenia.
For example, studies have demonstrated that compounds that act as antagonists at NMDA receptors have beneficial pharmacological effects on patients suffering from Parkinson's disease. In Parkinson's disease, there is a loss of dopamine neurons in the substantia nigra. Secondary to this dopamine loss is a hyperactivity of specific brain glutamatergic pathways. This glutamatergic hyperactivity is thought to mediate some of the pathophysiological aspects of Parkinson's disease, as well as some of the side effects associated with the long term treatment of the disease by dopamine agonists, such as L-DOPA, pergolide, ropinirole or pramipexole. Clinical studies in humans have demonstrated that antagonists at NMDA receptors have beneficial effects in Parkinson's disease or in treating the side effects associated with the treatment of Parkinson's disease with dopamine agonists.
Pain is another example of a condition shown to be responsive to NMDA
receptor antagonism. For example in previous studies, stimulation of NMDA
receptors by afferent nerves transmitting painful stimuli has been demonstrated to be involved in hyperalgesic and neuropathic pain states. Animal studies have demonstrated that compounds that act as antagonists at NMDA receptors have beneficial effects in treating hyperalgesic and neuropathic pain states.
However, while NMDA antagonists have been successfully used to demonstrate the proof of concept mentioned above, very few, if any, of these antagonists have shown a suitable drug profile in clinical studies. This is so even though numerous NMDA receptor antagonists have been synthesized and tested.
For example, U.S. Patent Nos. 5,714,502; 6,124,317; 6,124,323; and 6,130,234 describes the piperidine-based NMDA receptor antagonists shown below.
U.5. Patent No. 5,714,502 provides piperidines of formula R~
N
,N O
O
in which R1 and R2 in each case independently of one another are unsubstituted or mono-to disubstituted phenyl radicals whose substituents can be A, OA, aryloxy having 6 to 10 C atoms, aralkyloxy having 7 to 11 C atoms, -O-(CH2)n-O-(bonded in directly adjacent positions or in the meta- or para-position to one another on the phenyl ring), -O-(CH2)n-OH, Hal, CF3, OH, N02, NH2, NHA, NA2, NHR3, NAR3, S02NH2, S02NHA, S02NA2, S02NHR3 (excluding R3=S02A), S02N(R3)2 (excluding R3=S02A) or R3, R3 is COH, CO-alkyl having 1 to 7 C atoms in the alkyl portion, CO-alkyl-aryl having 8 to 12 C atoms in the alkyl and aryl portions, CO-aryl having 7 to 13 C atoms in the aryl portion, or S02A
A is an alkyl radical having 1 to 6 C atoms n is 1 or 2 Hal is F, Cl, Br, or I, and their physiologically acceptable salts. The invention also relates to the preparation of these novel compounds and their use as psychopharmacologically active substances.
U.S. Patent No. 6,124,317 provides 2-substituted piperidine NMDA
receptor antagonists of formula Art X (CHR~)m N
(CHRz)~ Y Ar2 or a pharmaceutically acceptable salt thereof wherein Arl and Ar2 are independently aryl or a heteroaryl group, either of which may be independently substituted by hydrogen, hydroxy, alkyl, a halogenated alkyl group, halogen, nitro, aryl, aralkyl, amino, a lower alkyl amino group or a lower alkoxy group;
each R1 is independently hydrogen, alkyl or hydroxy;
each R2 is independently hydrogen, alkyl or hydroxy;
X is -CH2-, O, S, or NR3, wherein R3 is hydrogen or a lower alkyl group having 1 to 6 carbon atoms;
Y is -CH2-, -CH=CH-, -C=C-, O, S or NR3;
m is 0, 1 or 2; and nis0, 1,2,3,4or5, provided that when m is 0 and X is -CH2-, or m is 1, R1 is H and X is -CH2-that either Y is not -CH2- or at least one of R2 is not hydrogen and further provided that when Y is -C=C- then X is not O.
U.S. Patent No. 6,124,323 provides 4-substituted piperidine-based NMDA
receptor antagonists of formula Art-X Z N-(CHRZ)~ Y-Ar2 Rs or a pharmaceutically acceptable salt thereof wherein Arl and Ar2 are independently aryl or a heteroaryl group, either of which may be independently substituted by hydrogen, hydroxy, alkyl, halogen, vitro, cyano, carboxaldehyde, aldehyde oxime, lower alkoxy carbonylmethyl, hydroxy lower alkyl, amino carbonylmethyl, hydrazinocarbonylmethyl, acetamido, aryl, aralkyl, amino, a halogenated alkyl group, a lower alkyl amino group or a lower alkoxy group;
z is a single or double bond;
X is -(CHR3)m-, O, S or NR4, wherein each R3 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms, R4 is hydrogen or a lower alkyl group having 1 to 6 carbon atoms and m is 0, 1 or 2, provided that when z is a double bond then X is not O or NR4;
Rlis hydrogen or hydroxy;
each R2 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms;
n is 0, 1, 2, 3 or 4;
Y is O, S, NR4 or a single bond; and RS is hydrogen or hydroxy when z is a single bond preferably provided that:
(i) R2 cannot be hydroxy in a position alpha to Ar2; (ii) if X is a single bond, z is a double bond or RS is hydroxy and Ar2 is phenyl then Y cannot be O; (iii) if Y
is O, n is 3 or 4, R2 is exclusively hydrogen, z is a single bond, R1 and RS are hydrogen and Ar2 is phenyl, or halogen, methoxy, or trifluoromethyl substituted phenyl then X cannot be methylene or ethylene; (iv) if X is -(CHR3)m-, m is 2 and R3 is exclusively hydrogen then Arl cannot be imidazolyl substituted; (v) if Y
is O, n is 2, 3 or 4, R2 is hydrogen or hydroxy, z is a single bond, R1 and RS
are hydrogen, and Ar2 is phenyl, or N02, CN, 1-imidazoyl, or 1,2,4-triazol-1-yl substituted phenyl then X cannot be methylene, hydroxymethylene, or O; (vi) if Y
is O or S, R1 and RS are hydrogen and R2 is hydroxy then X is not methylene or a single bond; or (vii) if Y is a single bond, R2 is exclusively hydrogen and Ar2 is phenyl, then either R1 or RS must be hydroxy.
U.S. Patent No. 6,130,234 provides piperidine-based NMDA receptor antagonists of formula R~
Art -X N-CHz-(CH2)n-Q-Ar2 Ra or a pharmaceutically acceptable salt thereof wherein Arl and Ar2 are independently aryl or a heteroaryl group, either of which may be independently substituted by hydrogen, hydroxy, alkyl, halogen, vitro, aryl, aralkyl, amino, a halogenated alkyl group, -NHAc, -NHS02Me, -N(S02Me)2, -CONHalkyl, -S02NH2, an alkylguanidine group, a lower alkyl amino group or a lower alkoxy group;
z is a single or double bond;
X is -(CHR2)m-, O, S or NR3, wherein each R2 is independently hydrogen, hydroxy, lower alkoxy or a lower alkyl group having 1 to 6 carbon atoms and m is 0, 1 or 2, and R3 is hydrogen or a lower alkyl group having 1 to 6 carbon atoms, provided that when z is a double bond then X is not O, S
or NR3;
Rl is hydrogen or hydroxy;
n is 0, 1 or 2;
Q is -CH=CH- or -C=C-; and R4 is hydrogen or hydroxy when z is a single bond provided that: (i) when n is 0, then z is a double bond and R4 is not present; (ii) when n is 1 or 2 and Q is -C=C- and z is a double bond or R4 is hydroxy, then Arl is aryl substituted by halogen; and (iii) when R4 is hydroxy then R2 is not hydroxy or lower alkoxy.
The difficulty referenced above with demonstrating clinical utility of NMDA receptor antagonists has been the antagonists' lack of NMDA receptor subtype selectivity and/or biological activity when dosed orally. Before the present invention, many of the drugs of the NMDA receptor antagonist class were nonselective antagonists of NMDA receptor subtypes that were administered intravenously (IV), which accounts for their undesired side effects and lack of efficacy, respectively. Given that the need for medicinal agents that treat diseases responsive to antagonism of NMDA receptors remains unmet, the search for NMDA receptor antagonists that are subtype-selective and orally efficacious continues.
A series of novel piperidines have been discovered that are subtype-selective NMDA receptor antagonists and are efficacious in vivo when dosed orally. All that is needed to practice the invention is to administer from 1 to 6 times daily to a patient in need thereof, a therapeutically effective amount of a compound of the invention. As is discussed below, determination of dosage forms and amounts of the invention compounds, routes of administration, and identification of patients in need of treatment, is within the average skill in the pharmaceutical and medical arts.
g SUMMARY OF THE INVENTION
Described are piperidines of Formula I
Z N-V-B Y I
~i~g R3 and pharmaceutically acceptable salts thereof wherein:
R1 is independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, alkylaminoalkyl, hydroxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, carboxyalkyl, haloalkyl, and halogen;
g is an integer of from 0 to 3;
Z is (CH2)h, C=O, O, S, SO, 502, CHOH, or C(Me)OH;
h is an integer of from 0 or 1;
R2 is hydrogen, OH, alkoxy, or substituted alkoxy;
R3 is hydrogen, OH, alkoxy, or substituted alkoxy;
V is (CH2)n or (CH2)m-C=O, wherein n is an integer of from 1 to 4, and m is an integer of from 0 to 4;
B is a 4-, 5-, or 6-membered, carbon-linked, substituted or unsubstituted, heterocyclene, containing from 1 to 3 heteroatoms, which are N, O, or S, selected from the group consisting of:
(i) 1-aza-2-cyclobutanon-3,4-diyl of formula O O
HN NH
~d (ii) a 5-membered aromatic, nonaromatic dihydro, or nonaromatic tetrahydro diradical heterocyclic ring having carbon atoms and from 1 to 3 heteroatoms selected from N, O, and S;
(iii) a 5-membered oxo-substituted, nonaromatic tetrahydro, diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S;
(iv) a 6-membered aromatic, nonaromatic tetrahydro, or nonaromatic hexahydro diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms, which heteroatoms are nitrogen, and (v) a 6-membered nonaromatic oxo-substituted hexahydro diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms which are nitrogen and 0 or 1 heteroatom which is oxygen wherein the atoms of the heterocyclene ring that are bonded to the group V and the phenyl bearing the group (X1)d are carbon atoms, and further wherein when B is a nonaromatic heterocycle containing sulfur, said sulfur may further comprise IS \'S~
~ or / ~ , X 1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted 1 S alkoxy, aralkyl, substituted aralkyl, halogen, haloalkyl, cyano, nitro, amino, aminoalkyl, alkylaminoalkyl, hydroxyalkyl, carboxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, or C(O)-alkyl;
d is an integer of from 0 to 2;
E is hydrogen; and Y is OH; or E and Y may be taken together with the phenylene to which they are attached to form a fused 9- or 10-membered bicyclic ring, containing from 0 to 3 heteroatoms in E to Y selected from N, O, and S, wherein E is a linker group containing 2 or 3 atoms of the bicyclic ring, and Y is a hydrogen bond donor group containing 1 atom of the bicyclic rmg.
Preferred is a compound of Formula I wherein:
B is a heterocyclene selected from the group consisting of X-N X/N~ CH3 , , X-N X-N
w , ,~ , H H
N--X X
, , N
N X
, , X N
X-N N-X
, and / / , wherein X is selected from O, S, and N-R, wherein R is hydrogen or alkyl;
X1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, aralkyl, halogen, haloalkyl, cyano, vitro, amino, aminoalkyl, 5 alkylaminoalkyl, hydroxyalkyl, carboxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, or C(O)CH3, and one X1 is ortho to V and para to E; and R2 is hydrogen or OH;
R3 is hydrogen or OH;
V is CH2 or C=O;
10 Z is (CH2)h; and h is 1.
Preferred is a compound of Formula II
z N-V -B ~ ~ off II
~l~g R3 ~Xl~d and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, B, X1, and d are as defined above for Formula I; and wherein when B is a 5-membered, oxo-substituted, nonaromatic tetrahydro, diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S which is an oxazolidinone, the oxazolidinone is selected from:
O O O
O NH ~ O
O
O O
O O
NH O
O ~ ~N , and N
H H
Also preferred is a compound of Formula III
R
Z N-V-B Y III
~l~g R3 and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, B, X1, and d are as defined above for Formula I; and E and Y together with the phenylene to which they are attached form a 9- or 10-membered bicyclic ring, containing from 0 to 3 heteroatoms selected from N, O, and S wherein E is a linker group containing 2 or 3 atoms of the bicyclic ring; and Y is a hydrogen bond donor group containing 1 atom of the bicyclic ring.
More preferred is a compound of Formula III wherein Y is selected from -N(H)-, -CH(OH)-, and -N(OH)-, and E is selected from -CH=CH-, -CH2-CH2-, -CH=N-, -C(O)-CH2-, -CH2-C(O)-, -CH2-S(O)-, -CH2-S(O)2-, -N=C(H)-, -N(H)-C(O)-, -O-C(O)-, -S-C(O)-, -N=N-, -CH=CH-C(H)-, -CH2-CH2-CH2-, -CH2-CH2-C(O)-, -CH2-CH2-S(O)-, -CH2-CH2-S(O)2-, -CH=CH-C(O)-, -N=CH-C(O)-, -O-CH2-C(O)-, -S-CH2-C(O)-, and -N(H)-C(O)-C(O)-; or Y is selected from =C(OH)-; and E is selected from -CH=CH-C(H)=, -C(O)-C(H)=, -C(O)-N=, -O-N=, -S-N=, -C(O)-N(H)-N=, -CH=N-N=, -CH=N(O)-N=, and -N(H)-C(O)-N=.
More preferred is a compound of Formula III wherein:
-E-Y- is selected from the group consisting of -CH=CH-N(H)-, -(CH2)2-N~)-~
-CH=N-N(H)-, -C(O)-CH2-N(H)-, -CH2-C(O)-N(H)-, -CH2-S(O)-N(H)-, -CH2-S(O)2-N(H)--CH=CH-CH(OH)-, -(CH2)2-CH(OH)-, -C(O)-C(H)=C(OH)-, -C(O)-N=C(OH)-, -N=CH-N(H)-, -N(H)-C(O)-N(H)-, -O-C(O)-NH-, -S-C(O)-NH-, -O-N=CH(OH)-, -S-N=CH(OH)-, -N=N-N(H)-, -N=N-N(OH)-, -CH=CH-CH=C(OH)-, -(CH2)3-CH(OH)-, -(CH2)2-C(O)-N(H)-~
-(CH2)2-S(O)-N(H)-, -(CH2)2-S(O)2-N(H)-~
-CH=CH-C(O)-N(H)-, -C(O)-NH-N=C(OH)-, -CH=N-N=C(OH)-, -CH=N(O)-N=C(OH)-, -N(H)-C(O)-N=C(OH)-, -N=CH-C(O)-NH-, -O-CH2-C(O)-NH-, -S-CH2-C(O)-NH-, and -N(H)-C(O)-C(O)-N(H)-.
Also preferred is a compound of Formula IV
~;~~ Z
Z N-V-B ~ ~ NH IV
(R1)g R3 (X1)d and pharmaceutically acceptable salts thereof wherein Rl, g, h, R2, V, B, X1, and d are as defined above for Formula I; and X2 is selected from O, S, NH, and CH2; and B is selected from the group consisting of X-N X/N~ CH3 X-N X-N
\ , _- \
H H
N-X X
N
N X
X N ' X-N N -X
, and / / , wherein X is selected from O, S, and N-R, wherein R is hydrogen or alkyl, and wherein Z is selected from O or S.
More preferred is a compound of Formula IV selected from the group consisting of:
6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H
benzoxazol-2-one;
6-[5-(4-Benzylpiperidin-1-ylmethyl)-3-methylisoxazol-4-yl]-3H
benzoxazol-2-one;
6-{S-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazo1-3-y1}-3H benzoxazol-2-one hydrochloride;
(+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
(-)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{3-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazo1-5-y1}-3H benzoxazol-2-one;
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H
benzoxazol-2-one;
6-{2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]thiazol-S-yl}-3H
benzothiazol-2-one;
5-[2-(4-Benzylpiperidin-1-ylmethyl)thiazol-5-yl]-1, 3-dihydrobenzimidazole-2-thione;
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]oxazol-5-yl}-3H
benzothiazol-2-one;
6-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-3H benzoxazol-2-one;
10 5-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-1,3-dihydroindol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylrnethyl]-4,5-dihydrothiazo1-2-y1}-3H benzoxazol-2-one;
6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-2-yl]-3H
benzoxazol-2-one;
15 6-[2-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-5-yl]-3H
benzoxazol-2-one;
6-{ 5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]isoxazol-3-yl }-3H
benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-yl]methyl}-4,5-dihydroisoxazo1-3-yl}-3H benzothiazol-2-one;
6-[5-(4-Benzyl-4-hydroxypiperidin-1-ylmethyl)-4,5-dihydroisoxazo1-3-y1]-3H benzoxazol-2-one;
6-{S-[4-(4-Fluorobenzyl)piperidine-1-carbonyl]-4,5-dihydroisoxazo1-3-yl}-3H benzoxazol-2-one;
6-(5-{2-[4-(4-Fluorobenzyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)-4-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-5-methyl-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid;
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid methyl ester;
FIELD OF INVENTION
The invention relates to piperidine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists useful in the treatment of diseases and disorders responsive to antagonism of NMDA receptors.
BACKGROUND OF THE INVENTION
Many of the physiological and pathophysiological effects of the endogenous excitatory neurotransmitter glutamate are mediated via actions at N-Methyl-D-Asparate (NMDA) receptors. Over-excitation of the NMDA
receptors on postsynaptic cells-mediated by excessive release of glutamate from nerve endings or glial cells-results in a massive calcium ion influx through a calcium ion channel into neuronal cells, leading to neuronal cell death. These events occur under ischemic or hypoxic conditions such as, for example, stroke, hypoglycemia, cardiac arrest, or acute physical trauma.
NMDA receptors in vivo form an NMDA receptor channel complex in cell walls comprising at least three binding domains, including a glutamic acid (or NMDA) recognition site, a channel blocking binding site, and a strychnine-insensitive glycine binding site. Physiologically, a blockade of at least one of these sites terminates the channel opening of the NMDA receptor, thereby preventing calcium ion influx into cells. Accordingly, an NMDA receptor antagonist is therapeutically useful because it minimizes damage to the central nervous system induced by calcium ion influx under ischemic or hypoxic conditions.
A functional NMDA receptor is comprised of the combination of at least one subunit termed "NR1", which has 8 splice variants including NR1A, and one (or more) subunit termed "NR2A", "NR2B", "NR2C", and "NR2D". The combinations are designated NR1/2A, NR1/2B, NR1/2C and NRl/2D, respectively. The different NR2 subunits have distinct developmental and anatomical distributions. This suggests that agents that selectively antagonize one NR1/NR2 combination would have therapeutic actions without the psychotomimetic or dysphoric side effects associated with antagonists which block multiple NRl/NR2 combinations.
A subtype-selective NMDA receptor antagonist may be identified by methods well known in the pharmaceutical arts, such as, for example, screening compounds in an electrophysiology assay. In one such electrophysiology assay, different subunit combinations of recombinant NR1 and NR2 receptors are expressed in Xenopus oocytes, and a potential agent is administered at different concentrations. NMDA-based electrical currents are activated by co-administration of fixed concentrations of an excitatory amino acid such as, for example, glutamic acid or glycine. The ability of an agent to antagonize the activation of the electrical current by an excitatory amino acid is measured by recording the change in the current versus the change in the concentration of the agent.
Screening of compounds in recent years have identified a number of NMDA receptor antagonists that have been used in animal and clinical human studies to demonstrate proof of concept for use of such an antagonist in the treatment of a variety of disorders. Disorders known to be responsive to blockade of NMDA receptors include acute cerebral ischemia (stroke or cerebral trauma, for example), muscular spasm, convulsive disorders, pain, including chronic and neuropathic pain, anxiety, and chronic neurodegenerative disorders such as Parkinson's disease. NMDA receptor antagonists may also be used to prevent tolerance to opiate analgesia or to help control symptoms of withdrawal from addictive drugs. In fact, excessive excitation by neurotransmitters may be responsible for the loss of neurons in a wide variety of conditions.
Additional conditions include cerebral vascular disorders such as cerebral ischemia or cerebral infarction resulting in a range of conditions such as thromboembolic or hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, perinatal, asphyxia anoxia, such as from near drowning, pulmonary surgery and cerebral trauma, as well as lathyrism, Alzheimer's disease, and Huntington's disease. Other conditions amendable to treatment with an subtype-selective NMDA receptor antagonist include amyotrophic lateral sclerosis (ALS), epilepsy, and schizophrenia.
For example, studies have demonstrated that compounds that act as antagonists at NMDA receptors have beneficial pharmacological effects on patients suffering from Parkinson's disease. In Parkinson's disease, there is a loss of dopamine neurons in the substantia nigra. Secondary to this dopamine loss is a hyperactivity of specific brain glutamatergic pathways. This glutamatergic hyperactivity is thought to mediate some of the pathophysiological aspects of Parkinson's disease, as well as some of the side effects associated with the long term treatment of the disease by dopamine agonists, such as L-DOPA, pergolide, ropinirole or pramipexole. Clinical studies in humans have demonstrated that antagonists at NMDA receptors have beneficial effects in Parkinson's disease or in treating the side effects associated with the treatment of Parkinson's disease with dopamine agonists.
Pain is another example of a condition shown to be responsive to NMDA
receptor antagonism. For example in previous studies, stimulation of NMDA
receptors by afferent nerves transmitting painful stimuli has been demonstrated to be involved in hyperalgesic and neuropathic pain states. Animal studies have demonstrated that compounds that act as antagonists at NMDA receptors have beneficial effects in treating hyperalgesic and neuropathic pain states.
However, while NMDA antagonists have been successfully used to demonstrate the proof of concept mentioned above, very few, if any, of these antagonists have shown a suitable drug profile in clinical studies. This is so even though numerous NMDA receptor antagonists have been synthesized and tested.
For example, U.S. Patent Nos. 5,714,502; 6,124,317; 6,124,323; and 6,130,234 describes the piperidine-based NMDA receptor antagonists shown below.
U.5. Patent No. 5,714,502 provides piperidines of formula R~
N
,N O
O
in which R1 and R2 in each case independently of one another are unsubstituted or mono-to disubstituted phenyl radicals whose substituents can be A, OA, aryloxy having 6 to 10 C atoms, aralkyloxy having 7 to 11 C atoms, -O-(CH2)n-O-(bonded in directly adjacent positions or in the meta- or para-position to one another on the phenyl ring), -O-(CH2)n-OH, Hal, CF3, OH, N02, NH2, NHA, NA2, NHR3, NAR3, S02NH2, S02NHA, S02NA2, S02NHR3 (excluding R3=S02A), S02N(R3)2 (excluding R3=S02A) or R3, R3 is COH, CO-alkyl having 1 to 7 C atoms in the alkyl portion, CO-alkyl-aryl having 8 to 12 C atoms in the alkyl and aryl portions, CO-aryl having 7 to 13 C atoms in the aryl portion, or S02A
A is an alkyl radical having 1 to 6 C atoms n is 1 or 2 Hal is F, Cl, Br, or I, and their physiologically acceptable salts. The invention also relates to the preparation of these novel compounds and their use as psychopharmacologically active substances.
U.S. Patent No. 6,124,317 provides 2-substituted piperidine NMDA
receptor antagonists of formula Art X (CHR~)m N
(CHRz)~ Y Ar2 or a pharmaceutically acceptable salt thereof wherein Arl and Ar2 are independently aryl or a heteroaryl group, either of which may be independently substituted by hydrogen, hydroxy, alkyl, a halogenated alkyl group, halogen, nitro, aryl, aralkyl, amino, a lower alkyl amino group or a lower alkoxy group;
each R1 is independently hydrogen, alkyl or hydroxy;
each R2 is independently hydrogen, alkyl or hydroxy;
X is -CH2-, O, S, or NR3, wherein R3 is hydrogen or a lower alkyl group having 1 to 6 carbon atoms;
Y is -CH2-, -CH=CH-, -C=C-, O, S or NR3;
m is 0, 1 or 2; and nis0, 1,2,3,4or5, provided that when m is 0 and X is -CH2-, or m is 1, R1 is H and X is -CH2-that either Y is not -CH2- or at least one of R2 is not hydrogen and further provided that when Y is -C=C- then X is not O.
U.S. Patent No. 6,124,323 provides 4-substituted piperidine-based NMDA
receptor antagonists of formula Art-X Z N-(CHRZ)~ Y-Ar2 Rs or a pharmaceutically acceptable salt thereof wherein Arl and Ar2 are independently aryl or a heteroaryl group, either of which may be independently substituted by hydrogen, hydroxy, alkyl, halogen, vitro, cyano, carboxaldehyde, aldehyde oxime, lower alkoxy carbonylmethyl, hydroxy lower alkyl, amino carbonylmethyl, hydrazinocarbonylmethyl, acetamido, aryl, aralkyl, amino, a halogenated alkyl group, a lower alkyl amino group or a lower alkoxy group;
z is a single or double bond;
X is -(CHR3)m-, O, S or NR4, wherein each R3 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms, R4 is hydrogen or a lower alkyl group having 1 to 6 carbon atoms and m is 0, 1 or 2, provided that when z is a double bond then X is not O or NR4;
Rlis hydrogen or hydroxy;
each R2 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms;
n is 0, 1, 2, 3 or 4;
Y is O, S, NR4 or a single bond; and RS is hydrogen or hydroxy when z is a single bond preferably provided that:
(i) R2 cannot be hydroxy in a position alpha to Ar2; (ii) if X is a single bond, z is a double bond or RS is hydroxy and Ar2 is phenyl then Y cannot be O; (iii) if Y
is O, n is 3 or 4, R2 is exclusively hydrogen, z is a single bond, R1 and RS are hydrogen and Ar2 is phenyl, or halogen, methoxy, or trifluoromethyl substituted phenyl then X cannot be methylene or ethylene; (iv) if X is -(CHR3)m-, m is 2 and R3 is exclusively hydrogen then Arl cannot be imidazolyl substituted; (v) if Y
is O, n is 2, 3 or 4, R2 is hydrogen or hydroxy, z is a single bond, R1 and RS
are hydrogen, and Ar2 is phenyl, or N02, CN, 1-imidazoyl, or 1,2,4-triazol-1-yl substituted phenyl then X cannot be methylene, hydroxymethylene, or O; (vi) if Y
is O or S, R1 and RS are hydrogen and R2 is hydroxy then X is not methylene or a single bond; or (vii) if Y is a single bond, R2 is exclusively hydrogen and Ar2 is phenyl, then either R1 or RS must be hydroxy.
U.S. Patent No. 6,130,234 provides piperidine-based NMDA receptor antagonists of formula R~
Art -X N-CHz-(CH2)n-Q-Ar2 Ra or a pharmaceutically acceptable salt thereof wherein Arl and Ar2 are independently aryl or a heteroaryl group, either of which may be independently substituted by hydrogen, hydroxy, alkyl, halogen, vitro, aryl, aralkyl, amino, a halogenated alkyl group, -NHAc, -NHS02Me, -N(S02Me)2, -CONHalkyl, -S02NH2, an alkylguanidine group, a lower alkyl amino group or a lower alkoxy group;
z is a single or double bond;
X is -(CHR2)m-, O, S or NR3, wherein each R2 is independently hydrogen, hydroxy, lower alkoxy or a lower alkyl group having 1 to 6 carbon atoms and m is 0, 1 or 2, and R3 is hydrogen or a lower alkyl group having 1 to 6 carbon atoms, provided that when z is a double bond then X is not O, S
or NR3;
Rl is hydrogen or hydroxy;
n is 0, 1 or 2;
Q is -CH=CH- or -C=C-; and R4 is hydrogen or hydroxy when z is a single bond provided that: (i) when n is 0, then z is a double bond and R4 is not present; (ii) when n is 1 or 2 and Q is -C=C- and z is a double bond or R4 is hydroxy, then Arl is aryl substituted by halogen; and (iii) when R4 is hydroxy then R2 is not hydroxy or lower alkoxy.
The difficulty referenced above with demonstrating clinical utility of NMDA receptor antagonists has been the antagonists' lack of NMDA receptor subtype selectivity and/or biological activity when dosed orally. Before the present invention, many of the drugs of the NMDA receptor antagonist class were nonselective antagonists of NMDA receptor subtypes that were administered intravenously (IV), which accounts for their undesired side effects and lack of efficacy, respectively. Given that the need for medicinal agents that treat diseases responsive to antagonism of NMDA receptors remains unmet, the search for NMDA receptor antagonists that are subtype-selective and orally efficacious continues.
A series of novel piperidines have been discovered that are subtype-selective NMDA receptor antagonists and are efficacious in vivo when dosed orally. All that is needed to practice the invention is to administer from 1 to 6 times daily to a patient in need thereof, a therapeutically effective amount of a compound of the invention. As is discussed below, determination of dosage forms and amounts of the invention compounds, routes of administration, and identification of patients in need of treatment, is within the average skill in the pharmaceutical and medical arts.
g SUMMARY OF THE INVENTION
Described are piperidines of Formula I
Z N-V-B Y I
~i~g R3 and pharmaceutically acceptable salts thereof wherein:
R1 is independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, alkylaminoalkyl, hydroxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, carboxyalkyl, haloalkyl, and halogen;
g is an integer of from 0 to 3;
Z is (CH2)h, C=O, O, S, SO, 502, CHOH, or C(Me)OH;
h is an integer of from 0 or 1;
R2 is hydrogen, OH, alkoxy, or substituted alkoxy;
R3 is hydrogen, OH, alkoxy, or substituted alkoxy;
V is (CH2)n or (CH2)m-C=O, wherein n is an integer of from 1 to 4, and m is an integer of from 0 to 4;
B is a 4-, 5-, or 6-membered, carbon-linked, substituted or unsubstituted, heterocyclene, containing from 1 to 3 heteroatoms, which are N, O, or S, selected from the group consisting of:
(i) 1-aza-2-cyclobutanon-3,4-diyl of formula O O
HN NH
~d (ii) a 5-membered aromatic, nonaromatic dihydro, or nonaromatic tetrahydro diradical heterocyclic ring having carbon atoms and from 1 to 3 heteroatoms selected from N, O, and S;
(iii) a 5-membered oxo-substituted, nonaromatic tetrahydro, diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S;
(iv) a 6-membered aromatic, nonaromatic tetrahydro, or nonaromatic hexahydro diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms, which heteroatoms are nitrogen, and (v) a 6-membered nonaromatic oxo-substituted hexahydro diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms which are nitrogen and 0 or 1 heteroatom which is oxygen wherein the atoms of the heterocyclene ring that are bonded to the group V and the phenyl bearing the group (X1)d are carbon atoms, and further wherein when B is a nonaromatic heterocycle containing sulfur, said sulfur may further comprise IS \'S~
~ or / ~ , X 1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted 1 S alkoxy, aralkyl, substituted aralkyl, halogen, haloalkyl, cyano, nitro, amino, aminoalkyl, alkylaminoalkyl, hydroxyalkyl, carboxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, or C(O)-alkyl;
d is an integer of from 0 to 2;
E is hydrogen; and Y is OH; or E and Y may be taken together with the phenylene to which they are attached to form a fused 9- or 10-membered bicyclic ring, containing from 0 to 3 heteroatoms in E to Y selected from N, O, and S, wherein E is a linker group containing 2 or 3 atoms of the bicyclic ring, and Y is a hydrogen bond donor group containing 1 atom of the bicyclic rmg.
Preferred is a compound of Formula I wherein:
B is a heterocyclene selected from the group consisting of X-N X/N~ CH3 , , X-N X-N
w , ,~ , H H
N--X X
, , N
N X
, , X N
X-N N-X
, and / / , wherein X is selected from O, S, and N-R, wherein R is hydrogen or alkyl;
X1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, aralkyl, halogen, haloalkyl, cyano, vitro, amino, aminoalkyl, 5 alkylaminoalkyl, hydroxyalkyl, carboxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, or C(O)CH3, and one X1 is ortho to V and para to E; and R2 is hydrogen or OH;
R3 is hydrogen or OH;
V is CH2 or C=O;
10 Z is (CH2)h; and h is 1.
Preferred is a compound of Formula II
z N-V -B ~ ~ off II
~l~g R3 ~Xl~d and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, B, X1, and d are as defined above for Formula I; and wherein when B is a 5-membered, oxo-substituted, nonaromatic tetrahydro, diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S which is an oxazolidinone, the oxazolidinone is selected from:
O O O
O NH ~ O
O
O O
O O
NH O
O ~ ~N , and N
H H
Also preferred is a compound of Formula III
R
Z N-V-B Y III
~l~g R3 and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, B, X1, and d are as defined above for Formula I; and E and Y together with the phenylene to which they are attached form a 9- or 10-membered bicyclic ring, containing from 0 to 3 heteroatoms selected from N, O, and S wherein E is a linker group containing 2 or 3 atoms of the bicyclic ring; and Y is a hydrogen bond donor group containing 1 atom of the bicyclic ring.
More preferred is a compound of Formula III wherein Y is selected from -N(H)-, -CH(OH)-, and -N(OH)-, and E is selected from -CH=CH-, -CH2-CH2-, -CH=N-, -C(O)-CH2-, -CH2-C(O)-, -CH2-S(O)-, -CH2-S(O)2-, -N=C(H)-, -N(H)-C(O)-, -O-C(O)-, -S-C(O)-, -N=N-, -CH=CH-C(H)-, -CH2-CH2-CH2-, -CH2-CH2-C(O)-, -CH2-CH2-S(O)-, -CH2-CH2-S(O)2-, -CH=CH-C(O)-, -N=CH-C(O)-, -O-CH2-C(O)-, -S-CH2-C(O)-, and -N(H)-C(O)-C(O)-; or Y is selected from =C(OH)-; and E is selected from -CH=CH-C(H)=, -C(O)-C(H)=, -C(O)-N=, -O-N=, -S-N=, -C(O)-N(H)-N=, -CH=N-N=, -CH=N(O)-N=, and -N(H)-C(O)-N=.
More preferred is a compound of Formula III wherein:
-E-Y- is selected from the group consisting of -CH=CH-N(H)-, -(CH2)2-N~)-~
-CH=N-N(H)-, -C(O)-CH2-N(H)-, -CH2-C(O)-N(H)-, -CH2-S(O)-N(H)-, -CH2-S(O)2-N(H)--CH=CH-CH(OH)-, -(CH2)2-CH(OH)-, -C(O)-C(H)=C(OH)-, -C(O)-N=C(OH)-, -N=CH-N(H)-, -N(H)-C(O)-N(H)-, -O-C(O)-NH-, -S-C(O)-NH-, -O-N=CH(OH)-, -S-N=CH(OH)-, -N=N-N(H)-, -N=N-N(OH)-, -CH=CH-CH=C(OH)-, -(CH2)3-CH(OH)-, -(CH2)2-C(O)-N(H)-~
-(CH2)2-S(O)-N(H)-, -(CH2)2-S(O)2-N(H)-~
-CH=CH-C(O)-N(H)-, -C(O)-NH-N=C(OH)-, -CH=N-N=C(OH)-, -CH=N(O)-N=C(OH)-, -N(H)-C(O)-N=C(OH)-, -N=CH-C(O)-NH-, -O-CH2-C(O)-NH-, -S-CH2-C(O)-NH-, and -N(H)-C(O)-C(O)-N(H)-.
Also preferred is a compound of Formula IV
~;~~ Z
Z N-V-B ~ ~ NH IV
(R1)g R3 (X1)d and pharmaceutically acceptable salts thereof wherein Rl, g, h, R2, V, B, X1, and d are as defined above for Formula I; and X2 is selected from O, S, NH, and CH2; and B is selected from the group consisting of X-N X/N~ CH3 X-N X-N
\ , _- \
H H
N-X X
N
N X
X N ' X-N N -X
, and / / , wherein X is selected from O, S, and N-R, wherein R is hydrogen or alkyl, and wherein Z is selected from O or S.
More preferred is a compound of Formula IV selected from the group consisting of:
6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H
benzoxazol-2-one;
6-[5-(4-Benzylpiperidin-1-ylmethyl)-3-methylisoxazol-4-yl]-3H
benzoxazol-2-one;
6-{S-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazo1-3-y1}-3H benzoxazol-2-one hydrochloride;
(+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
(-)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{3-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazo1-5-y1}-3H benzoxazol-2-one;
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H
benzoxazol-2-one;
6-{2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]thiazol-S-yl}-3H
benzothiazol-2-one;
5-[2-(4-Benzylpiperidin-1-ylmethyl)thiazol-5-yl]-1, 3-dihydrobenzimidazole-2-thione;
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]oxazol-5-yl}-3H
benzothiazol-2-one;
6-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-3H benzoxazol-2-one;
10 5-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-1,3-dihydroindol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylrnethyl]-4,5-dihydrothiazo1-2-y1}-3H benzoxazol-2-one;
6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-2-yl]-3H
benzoxazol-2-one;
15 6-[2-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-5-yl]-3H
benzoxazol-2-one;
6-{ 5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]isoxazol-3-yl }-3H
benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-yl]methyl}-4,5-dihydroisoxazo1-3-yl}-3H benzothiazol-2-one;
6-[5-(4-Benzyl-4-hydroxypiperidin-1-ylmethyl)-4,5-dihydroisoxazo1-3-y1]-3H benzoxazol-2-one;
6-{S-[4-(4-Fluorobenzyl)piperidine-1-carbonyl]-4,5-dihydroisoxazo1-3-yl}-3H benzoxazol-2-one;
6-(5-{2-[4-(4-Fluorobenzyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)-4-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-5-methyl-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid;
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid methyl ester;
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester;
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid;
6-{5-[4-(4-Fluorobenzyl)-3-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{ 5-[4-(4-Fluorophenoxy)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{ 5-[4-(4-Fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3IX benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzenesulfinyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzoyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazo1-3-yl}-3H benzoxazol-2-one;
6-(5-{4-[(4-Fluorophenyl)hydroxymethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one;
4-Chloro-6-{ 5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-5-methyl-3H benzoxazol-2-one;
- { 5-[4-(4-Fluorophenyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl }-3H benzoxazol-2-one;
6-[5-(4-Phenyl-4-hydroxy)piperidin-1-ylmethyl)-4,5-dihydroisoxazo1-3-yl]-3H benzoxazol-2-one; and 6-(5-{2-[4-(4-Fluorophenyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one.
More preferred is a compound of Formula IV named (-)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one.
Still more preferred is a compound of Formula IV named (+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one.
Preferred is a compound of Formula V
Rz Z N-V V
(Rt)g R3 and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
X is O, S, or N-R, wherein R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula VI
E
~X
RZ ~ * ~ ~ Y VI
- ~Z N-V
(Xt )a (Rl)g R3 and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
X is O, S, or N-R, wherein R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula VII
E
X' Z N-V
_~_ I VII
(X~)a (Rt)g R
and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I; and X is O, S, or N-R, wherein R is hydrogen or alkyl.
Preferred is a compound of Formula VIII
Rz - ~Z N-V
I J VIII
and pharmaceutically acceptable salts thereof wherein Rl, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I; and X is O, S, or N-R, wherein R is independently hydrogen or alkyl.
Preferred is a compound of Formula IX
N
RZ I
Z N-V ~ Y
IX
~1)g and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I; and X is O, S, or N-R, wherein R is hydrogen or alkyl.
Preferred is a compound of Formula X
Rz N R
- ~Z N-V
X
X
and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
X is O, S, or N-R, wherein R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula XI
Rz Z N V
X Y
~1)g XI
and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
X is O, S, or N-R, wherein R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula XII
Z N-V Y
(RI)g R3 XII
and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I.
Preferred is a compound of Formula XIII
Z N-V Y XIII
R
~Rl~g 3 ~Xl~d and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I.
Preferred is a compound of Formula XIV
r--Z N-V Y XI V
~l~g and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula XV
O
ll R E
R O/'N i Z N-V * * ~ ~ Y
XV
~l~g Rg ~Xl~d and pharmaceutically acceptable salts thereof wherein Rl, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
R is hydrogen, alkyl, or substituted alkyl; and 5 * means a chiral center designated R, S, or mixtures thereof.
The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a diluent, carrier, or excipient.
10 In a preferred embodiment, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula II or Formula IV together with a diluent, carrier, or excipient.
In a more preferred embodiment, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound 15 selected from the group consisting of (+)-6-{ 5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one;
(-)-6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one, or 20 a pharmaceutically acceptable salt thereof., together with a diluent, carrier, or excipient.
The invention also provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom which comprises administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
In a preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein the disorders are selected from stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV
retinitis, opioid tolerance or withdrawal, pain, including chronic pain, neuropathic pain, or surgical pain, and urinary incontinence.
In a more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein the disorder is pain.
In another more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein the disorder is Parkinson's disease.
In a still more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula II or Formula IV.
In a still more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound selected from the group consisting o~
(+)-6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one;
(-)-6-{ 5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one, or a pharmaceutically acceptable salt thereof.
In another more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, further comprising administering a dopamine agonist.
In another more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, further comprising administering a dopamine agonist wherein said dopamine agonist is L-DOPA.
In another preferred embodiment, the invention provides a method of treating disorders comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof in unit dosage form.
Also, the invention provides a compound selected from the group consisting of:
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid;
6-{5-[4-(4-Fluorobenzyl)-3-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{ 5-[4-(4-Fluorophenoxy)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{ 5-[4-(4-Fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3IX benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzenesulfinyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzoyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazo1-3-yl}-3H benzoxazol-2-one;
6-(5-{4-[(4-Fluorophenyl)hydroxymethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one;
4-Chloro-6-{ 5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-5-methyl-3H benzoxazol-2-one;
- { 5-[4-(4-Fluorophenyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl }-3H benzoxazol-2-one;
6-[5-(4-Phenyl-4-hydroxy)piperidin-1-ylmethyl)-4,5-dihydroisoxazo1-3-yl]-3H benzoxazol-2-one; and 6-(5-{2-[4-(4-Fluorophenyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one.
More preferred is a compound of Formula IV named (-)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one.
Still more preferred is a compound of Formula IV named (+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one.
Preferred is a compound of Formula V
Rz Z N-V V
(Rt)g R3 and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
X is O, S, or N-R, wherein R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula VI
E
~X
RZ ~ * ~ ~ Y VI
- ~Z N-V
(Xt )a (Rl)g R3 and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
X is O, S, or N-R, wherein R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula VII
E
X' Z N-V
_~_ I VII
(X~)a (Rt)g R
and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I; and X is O, S, or N-R, wherein R is hydrogen or alkyl.
Preferred is a compound of Formula VIII
Rz - ~Z N-V
I J VIII
and pharmaceutically acceptable salts thereof wherein Rl, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I; and X is O, S, or N-R, wherein R is independently hydrogen or alkyl.
Preferred is a compound of Formula IX
N
RZ I
Z N-V ~ Y
IX
~1)g and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I; and X is O, S, or N-R, wherein R is hydrogen or alkyl.
Preferred is a compound of Formula X
Rz N R
- ~Z N-V
X
X
and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
X is O, S, or N-R, wherein R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula XI
Rz Z N V
X Y
~1)g XI
and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
X is O, S, or N-R, wherein R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula XII
Z N-V Y
(RI)g R3 XII
and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I.
Preferred is a compound of Formula XIII
Z N-V Y XIII
R
~Rl~g 3 ~Xl~d and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I.
Preferred is a compound of Formula XIV
r--Z N-V Y XI V
~l~g and pharmaceutically acceptable salts thereof wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
R is hydrogen or alkyl; and * means a chiral center designated R, S, or mixtures thereof.
Preferred is a compound of Formula XV
O
ll R E
R O/'N i Z N-V * * ~ ~ Y
XV
~l~g Rg ~Xl~d and pharmaceutically acceptable salts thereof wherein Rl, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above for Formula I;
R is hydrogen, alkyl, or substituted alkyl; and 5 * means a chiral center designated R, S, or mixtures thereof.
The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a diluent, carrier, or excipient.
10 In a preferred embodiment, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula II or Formula IV together with a diluent, carrier, or excipient.
In a more preferred embodiment, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound 15 selected from the group consisting of (+)-6-{ 5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one;
(-)-6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one, or 20 a pharmaceutically acceptable salt thereof., together with a diluent, carrier, or excipient.
The invention also provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom which comprises administering a compound of Formula I or a pharmaceutically acceptable salt thereof.
In a preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein the disorders are selected from stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV
retinitis, opioid tolerance or withdrawal, pain, including chronic pain, neuropathic pain, or surgical pain, and urinary incontinence.
In a more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein the disorder is pain.
In another more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein the disorder is Parkinson's disease.
In a still more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula II or Formula IV.
In a still more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound selected from the group consisting o~
(+)-6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one;
(-)-6-{ 5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-3-one, or a pharmaceutically acceptable salt thereof.
In another more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, further comprising administering a dopamine agonist.
In another more preferred embodiment, the invention provides a method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof, further comprising administering a dopamine agonist wherein said dopamine agonist is L-DOPA.
In another preferred embodiment, the invention provides a method of treating disorders comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof in unit dosage form.
Also, the invention provides a compound selected from the group consisting of:
6-(2-Azido-1-hydroxyethyl)-3H benzoxazol-2-one;
6-[2-Azido-1-(tert-butyldimethylsilanyloxy)ethyl]-3H benzoxazol-2-one;
6-[2-Amino-1-(tert-butyldimethylsilanyloxy)ethyl]-3H benzoxazol-2-one;
2-(4-Benzylpiperidin-1-yl)-N [2-(tert-butyldimethylsilanyloxy)-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]acetamide;
2-(4-Benzylpiperidin-1-yl)-N [2-(tert-butyldimethylsilanyloxy)-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]thioacetamide;
2-(4-Benzylpiperidin-1-yl)-N [2-hydroxy-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]thioacetamide;
1-Chloro-3-[4-(4-fluorobenzyl)piperidin-1-yl]propan-2-ol;
1-Chloro-3-(4-benzylpiperidin-1-yl)propan-2-ol;
2- { 3-[4-(4-Fluorobenzyl)piperidin-1-yl]-2-hydroxypropyl } i soindole-1, 3-dione;
2-[3-(4-Benzylpiperidin-1-yl)-2-hydroxypropyl]isoindole-1,3-dione;
1-Amino-3-[4-(4-fluorobenzyl)piperidin-1-yl]propan-2-of bis-hydrochloride salt;
1-Amino-3-[4-benzylpiperidin-1-yl]propan-2-of bis-hydrochloride salt;
{3-[4-(4-Fluorobenzyl)piperidin-1-yl]-2-hydroxypropyl}carbamic acid benzyl ester;
[3-(4-Benzylpiperidin-1-yl)-2-hydroxypropyl]carbamic acid benzyl ester;
{2-(tert-Butyldimethylsilanyloxy)-3-[4-(4-fluorobenzyl)piperidin-1-yl]propyl}carbamic acid benzyl ester;
{2-(tert-Butyldimethylsilanyloxy)-3-[4- benzylpiperidin-1-yl]propyl}carbamic acid benzyl ester;
{2-(tert-Butyldimethylsilanyloxy)-3-[4-(4-fluorobenzyl)piperidin-1-yl]propylamine;
Methyl2-oxo-2,3-dihydrobenzoxazole-6-carboxylate;
2-Oxo-2,3-dihydrobenzoxazole-6-carboxylic acid;
2-Oxo-2,3-dihydrobenzoxazole-6-carboxylic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethylsilanyloxy)propyl] amide;
2-Oxo-2,3-dihydrobenzoxazole-6-carboxylic acid [3-(4-(4-fluorobenzyl)piperidin-1-yl)-2-(tert-butylimethylsilanyloxy)propyl]amide;
2-Oxo-2,3-dihydrobenzoxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-(tent-butyldimethylsilanyloxy)propyl] amide;
2-Oxo-2,3-dihydrobenzooxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]amide;
6-(2-Azido-1-hydroxyethyl)-3H benzoxazol-2-one;
6-[2-Azido-1-(tert-butyldimethylsilanyloxy)ethyl]-3H benzoxazol-2-one;
6-[2-Amino-1-(tert-butyldimethylsilanyloxy)ethyl]-3H benzoxazol-2-one;
2-(4-Benzylpiperidin-1-yl)-N [2-(tent-butyldimethylsilanyloxy)-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]acetamide;
~ 2-(4-Benzylpiperidin-1-yl)-N [2-(tert-butyldimethylsilanyloxy)-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]thioacetamide; and 2-(4-Benzylpiperidin-1-yl)-N [2-hydroxy-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]thioacetamide.
Also, the invention provides a process for preparing the compound of Formula I and pharmaceutically acceptable salts thereof comprising the steps of:
1) aminating a precursor alkyl halide;
2) cyclizing the product of Step 1;
3) recovering the desired compound of Formula I; and 4) converting, if desired, to a pharmaceutically acceptable salt.
Also, the invention provides a process for preparing the compound of Formula I and pharmaceutically acceptable salts thereof comprising the steps of:
1) halogenating an unsaturated side chain of a precursor to the compound;
2) cyclizing the product of Step. 1;
3) recovering the desired compound of Formula I; and 4) converting, if desired, to a pharmaceutically acceptable salt.
DETAILED DESCRIPTION OF THE INVENTION
As recited above, one aspect of the present invention is a compound of Formula I
Z N-V- 1' I
~l~g R3 and a pharmaceutically acceptable salt thereof, wherein R1, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above.
All of the references cited herein, including patents, are incorporated herein by reference.
The following definitions apply to terms used in this specification and claims.
The term "patient" means a mammal, including a human.
Preferred patients are humans, cats, and dogs.
The term "IC50" means the concentration of test compound required to inhibit activity of a receptor or enzyme by 50%.
The term "L-DOPA" means 3-hydroxy-L-tyrosine.
The term "(X1)d" wherein d is an integer of from 0 to 2 means the group X 1 is present 0 to 2 times on the phenylene to which it is attached. The groups X 1 are independently the same or different. Illustrative examples of substituted phenylenes are drawn below.
dis0:
E
5 d is 1:
dis2:
E E
and ~ ~ Y ; and Cl OMe E F E
Y ~ and Cl ~Cl H3C
Likewise the term "(R1)g" wherein g is an integer of from 0 to 3 means the 10 group R1 is present 0 to 3 times on the phenyl to which it is attached. The groups R1 are independently the same or different. Illustrative examples of substituted phenyls are drawn below.
gis0:
15 gis 1:
Me0 d g is t:
Me0 and Me ~ ~ ; and Me0 Cl gis3:
Me0 , arid Me The term "comprising", which is synonymous with the terms "including", "containing", or "characterized by", is inclusive or open-ended and does not exclude additional, unrecited elements or method steps from the scope of the invention that follows.
The phrase "consisting off', is closed-ended and excludes any element, step, or ingredient not specified in the description of the invention that follows.
The phrase "consisting essentially off' limits the scope of the invention that follows to the specified elements or steps and those further elements or steps that do not materially affect the basic and novel characteristics of the invention.
The phrase "filter aid" means a filter medium comprising small particulates. Illustrative examples of filter aids include kieselguhr and CELITE
(Celite Corporation, Lompoc, California), a diatomaceous earth filter aid.
The term "alkyl" means a straight or branched, unsubstituted or substituted, hydrocarbon group having from 1 to 12 carbon atoms. Preferred alkyl groups are C1-C6 alkyl. Typical examples of unsubstituted alkyl groups include methyl (i.e., CH3-), ethyl, 1-propyl, and 2-propyl, 1-butyl, 2-butyl, 2-methyl-1-propyl, 1,1-dimethylethyl, 1-pentyl, 2-pentyl, 3-pentyl, 2,2-dimethylpropyl, 1-hexyl, 2-hexyl, 3-hexyl, 4-methyl-1-pentyl, 1-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 5-methyl-1-hexyl, 1-octyl, 2-octyl, 3-octyl, 4-octyl, 6-methyl-1-heptyl, S,5-dimethylhexyl, 1-nonyl, 2-nonyl, 1-decyl, 2-decyl, 1-undecyl, 2-undecyl, 1-dodecyl, and S-dodecyl. Substituted alkyl groups are described below.
The term "alkenyl" means a straight or branched, unsubstituted or substituted, hydrocarbon group having from 2 to 12 carbon atoms and 1 or 2 sites of unsaturation. Preferred groups are C2-C6 alkenyl. Illustrative examples of unsubstituted alkenyl groups include ethenyl [i.e., CH2=C(H)-], 1-propenyl, 2-propenyl, 1-buten-1-yl, 2-buten-1-yl, 1-penten-1-yl, 2-penten-1-yl, 1-penten-3-yl, 1-penten-5-yl, 1-hexen-1-yl, 1-hexen-4-yl, 2-hexen-1-yl, 3-hexen-1-yl, 2-octen-3-yl, 5-nonen-2-yl, 4-undecen-4-yl, and 5-dodecen-2-yl. Substituted alkenyl groups are defined below.
The term "alkoxy" means a straight or branched, substituted or unsubstituted, alkyl group of from 1 to 12 carbon atoms linked through an oxygen atom. Preferred is C1-C6 alkoxy. Illustrative examples of unsubstituted alkoxy groups include methoxy (i.e., CH3-O-), ethoxy, isopropoxy, tert-butoxy, iso-pentoxy, octyloxy, and 7,7-dimethyloctyloxy. Substituted alkoxy groups are defined below.
The term "aryl" means an unsubstituted or substituted aromatic carbocyclic ring having 6 or 10 carbon atoms. Illustrative examples of unsubstituted aryl groups include phenyl (i.e., C6H5-), 1-naphthyl, and 2-naphthyl. Substituted aryl groups are defined below.
The term "aralkyl" means an unsubstituted or substituted aromatic carbocyclic ring having 6 or 10 carbon atoms (i.e., an aryl group) linked through an alkylene group, wherein alkylene is as defined below. Illustrative examples of unsubstituted aralkyl groups include benzyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, 3-methyl-3-phenylpropyl, 1-naphthylmethyl, 1-naphthylethyl, 3-(1-naphthyl)-propyl, 4-( 1-naphthyl)-butyl, 4-(2-naphthyl)-butyl, 4-phenylheptyl, and 12-(2-hydroxyphenyl)-dodec-3-yl. Substituted aralkyl groups are defined below.
The term "alkylene" means a straight or branched hydrocarbon chain diradical of from 1 to 12 carbon atoms. Preferred groups are C1-C6 alkylene.
Illustrative examples of alkylene groups include methylene (i.e., -CH2-), 1,2-ethylene, 1,2-propylene, 1,3-propylene, 2,2-dimethyl-hexane-1,6-diyl, and dodecan-1,12-diyl.
The term "cycloalkyl" means an unsubstituted or substituted, saturated carbocyclic ring having from 3 to 7 carbon atoms. Illustrative examples of unsubstituted cycloalkyl groups include cyclopentyl, cyclopropyl, cyclohexyl or cycloheptyl. Substituted cycloalkyl is defined below.
As discussed above, the groups alkyl, alkenyl, alkoxy, aryl, aralkyl, and cycloalkyl may be substituted. These substituted groups are respectively termed:
"substituted alkyl", "substituted alkenyl", "substituted alkoxy", "substituted aryl", "substituted aralkyl", and "substituted cycloalkyl".
The groups can be substituted with from 1 to 3 substituents independently selected from halogen, OH, O-(C1-C6 alkyl), OC(O)-(C1-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O-(C1-C6 alkyl), NH2, N(H)-(C1-C6 alkyl), N-(C1-C6 alkyl)2, NHC(O)-(C1-C6 alkyl), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-N(H)-(C1-C6 alkyl), -(C1-C6 alkylene)-N-(C1-C6 alkyl)2, SH, S-(C1-C6 alkyl), S-C(O)-(C1-C6 alkyl), -(C1-C6 alkylene)-SH, -(C1-C6 alkylene)-S-(C1-C6 alkyl), unsubstituted cycloalkyl, C(O)-(C1-C6 alkyl), C02H, C02-(C1-C6 alkyl), C(O)NH2, C(O)NH-(C1-C6 alkyl), and C(O)N-(C1-C6 alkyl)2, wherein (C1-C6 alkyl) means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms, (C1-Cg alkylene) means a straight or branched hydrocarbon chain diradical of from 1 to 6 carbon atoms, and unsubstituted cycloalkyl is as defined above. Further, 1 of the 3 substituents in substituted alkyl, substituted alkenyl (on saturated carbons only), substituted alkoxy, substituted aralkyl (on saturated carbon atoms only) and substituted cycloalkyl may be oxo.
Examples of these substituted groups are provided below.
Illustrative examples of substituted alkyl groups include HOCH2, CF3, (CH2)4SCH3, (CH2)gNH2, C(CH3)2CH[C02C(CH3)3]CH3, CF20H, and CH(C02H)CH2CH2C(O)NMe2.
Illustrative examples of substituted alkenyl groups include 2-fluoro-ethen-1-yl [i.e., CH(F)=C(H)-], methyl propenoate-2-yl, and 5-iso-butoxy-1-penten-5-yl.
Illustrative examples of substituted alkoxy groups include fluoromethoxy (i.e., FCH2-O-), 2-ethoxycarbonyl-ethoxy, 4-aminocarbonyl-oxybutyl, and 8-thio-nonyloxy [i.e., CH3CH(SH)-(CH2)~-O-]
Illustrative examples of substituted aryl groups include 2-fluorophenyl, 2,4,6-trimethoxyphenyl, 4-chloro-2-methylphenyl, 5,6-dichloro-naphth-1-yl, and 8-(dimethylaminomethyl)-naphth-2-yl.
Illustrative examples of substituted aralkyl groups include 4-fluorophenylmethyl, 2-(2,4,6-trimethoxyphenyl)-ethyl, 3-(2-carboxyphenyl)-propyl, 4-phenyl-4-hydroxy-butyl, 4-(2-dimethylaminomethyl-naphth-1-yl)-butyl, and 12-(2-hydroxyphenyl)-dodec-3-yl.
Illustrative examples of substituted cycloalkyl groups include 3-methyl-cyclopentyl, 4-hydroxy-cyclohexyl, and 1-methoxy-cycloheptyl.
The term "heteroatom" includes nitrogen, oxygen, and sulfur. When the heteroatom is incorporated in a nonaromatic ring, the heteroatom further includes II \\//
~ and/s~
The term "oxo" means =O.
The term "oxo-substituted" means any group which contains a carbon atom that is substituted with an oxo group (i.e., =O). A carbon atom substituted with an oxo group forms a carbonyl group of formula C=O.
The phrase "fused 9- or 10-membered bicyclic ring containing from 0 to 3 heteroatoms" means a group wherein 2 ring systems share 2 and only 2 atoms.
Illustrative examples of a fused bicyclic group containing 0 heteroatoms include w ~d ~ w The term "halogen" means bromine, chlorine, fluorine, or iodine.
The term "aminoalkyl" means a H2N group linked through an alkylene group, wherein alkylene has the meaning as defined above. Illustrative examples of aminoalkyl groups include aminomethyl (i.e., H2N-CH2-), 3-aminopropyl, and 1-amino-1,1-dimethylethyl.
The term "alkylaminoalkyl" means an alkyl group, linked through an N(H) group, which in turn is linked through an alkylene group, wherein alkyl and alkylene are as defined above. Illustrative examples of alkylaminoalkyl groups include methylaminomethyl (i.e., CH3NHCH2-), 3-(tert-butylamino)-propyl, and 5 6-(hexylamino)-hexyl.
The term "hydroxyalkyl" means an OH group linked through an alkylene group, wherein alkylene has the meaning defined above. Illustrative examples of hydroxyalkyl groups include hydroxymethyl, 2-hydroxyethyl, and 2-hydroxy-1,1-dimethylethyl.
10 The term "(aminocarbonyl)-alkyl" means an C(O)NH2 group linked through an alkylene group, wherein alkylene has the meaning defined above.
Illustrative examples of (aminocarbonyl)-alkyl groups include H2NC(O)-CH2-and H2NC(O)-C(CH3)3.
The term "(alkylthio)-alkyl-" means an alkyl group linked through a sulfur 15 atom, which in turn is linked through an alkylene group, wherein alkyl and alkylene have the meanings defined above. Illustrative examples of (alkylthio)-alkyl groups include CH3-S-CH2-, CH3CH2-S-(CH2)2-, and CH3CH(CH3)CH2C(CH3)2-S-C(CH3)2CH2-.
The term "carboxyalkyl" means a C02H group linked through an alkylene 20 group, wherein alkylene has the meaning defined above. Illustrative examples of carboxyalkyl groups include carboxymethyl, 2-carboxyethyl, and 2-carboxy-1,1-dimethylethyl.
The term "amino" means the -NH2 group.
The term "haloalkyl" means a halogen linked through an alkylene group, 25 wherein halogen and alkylene are as defined above. Illustrative examples of haloalkyl include trifluoromethyl, difluoromethyl, fluoromethyl, and 2,2,2-trichloroethyl.
The term "C(O)-alkyl" means an alkyl group as defined above linked through a carbonyl carbon atom. Illustrative examples of C(O)-alkyl groups 30 include acetyl (i.e., C(O)CH3), 2,2-dimethylpropionyl, and dodecanoyl.
The term "heterocyclene" means a 4-, 5-, or 6-membered, carbon-linked, unsubstituted or substituted with, for example, alkyl, carboxylic acid, or ester, heterocyclic diradical ring, containing from 1 to 3 heteroatoms which are N, O, or S, selected from the group consisting of:
(i) 1-aza-2-cyclobutanon-3,4-diyl of formula O O
HN NH
and (ii) a 5-membered aromatic, nonaromatic dihydro, or nonaromatic tetrahydro ring having carbon atoms and from 1 to 3 heteroatoms selected from N, O, and S;
(iii) a 5-membered oxo-substituted nonaromatic tetrahydro ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S;
(iv) a 6-membered aromatic, nonaromatic tetrahydro, or nonaromatic hexahydro ring having carbon atoms and 1 or 2 heteroatoms, which heteroatoms are nitrogen, and (v) a 6-membered nonaromatic oxo-substituted hexahydro ring having carbon atoms and 1 or 2 heteroatoms which are nitrogen and 0 or 1 heteroatom which is oxygen;
wherein the radical atoms of the heterocyclene are carbon atoms, and further wherein when B is a nonaromatic heterocyclene containing sulfur, said sulfur may further comprise ~ or Illustrative examples of S- and 6-membered heterocyclenes include:
1 ) A 5-membered heterocyclic ring having one heteroatom such as, for example, the following rings:
x x x x , , , \ ~, x x x x ' , , x x x x , ' , and wherein X is O, S, or N-R wherein R is H or alkyl.
2) A S-membered, substituted or unsubstituted, wherein "substituted" is defined as above, heterocyclic ring having 2 heteroatoms such as, for example, the following rings:
X~
N X~N X~N X~N
' , \ ~ , ~ ~, X X N
~ / ,~ X w N N / ' R/ ~ N , X , R
X~ ,R X x N
N ~N~R
, N ' , and x , R
wherein X and R are as defined above.
3) A 5-membered heterocyclic ring having 3 heteroatoms such as, for example, the following rings:
x X
~N ~ X W O R
'N ~
N , N-N ~ I~ , , N N
R
X
~N X X,N~N, R
N ' R/ /N-N , R
X~ ,R X X
N ' ~ ~ ~R
X N-X ~ ~d N , R/ ~ R
wherein X and R are as defined above.
4) A 6-membered aromatic heterocyclic ring having 1 to 3 nitrogen atoms such as, for example, following rings:
-N -N -N -N
, N / , ~ N , N-N -N -N -N
' , ~ , N ~ , -N N-N ~N
, N
N ~ ~ , and ~ N
5) A 6-membered nonaromatic tetrahydro heterocyclic ring having 1 or 2 nitrogen atoms such as, for example, the following rings:
N-R \ N-R \ N-R
, , and , wherein R is independently hydrogen or alkyl;
6) A 6-membered nonaromatic hexahydro heterocyclic ring having 1 or 2 nitrogen atoms such as, for example, the following rings:
N-R N-R ~N-R
N
R~
R R
N~
N-R N
N-R ~ and wherein R is independently hydrogen or alkyl;
6-[2-Azido-1-(tert-butyldimethylsilanyloxy)ethyl]-3H benzoxazol-2-one;
6-[2-Amino-1-(tert-butyldimethylsilanyloxy)ethyl]-3H benzoxazol-2-one;
2-(4-Benzylpiperidin-1-yl)-N [2-(tert-butyldimethylsilanyloxy)-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]acetamide;
2-(4-Benzylpiperidin-1-yl)-N [2-(tert-butyldimethylsilanyloxy)-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]thioacetamide;
2-(4-Benzylpiperidin-1-yl)-N [2-hydroxy-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]thioacetamide;
1-Chloro-3-[4-(4-fluorobenzyl)piperidin-1-yl]propan-2-ol;
1-Chloro-3-(4-benzylpiperidin-1-yl)propan-2-ol;
2- { 3-[4-(4-Fluorobenzyl)piperidin-1-yl]-2-hydroxypropyl } i soindole-1, 3-dione;
2-[3-(4-Benzylpiperidin-1-yl)-2-hydroxypropyl]isoindole-1,3-dione;
1-Amino-3-[4-(4-fluorobenzyl)piperidin-1-yl]propan-2-of bis-hydrochloride salt;
1-Amino-3-[4-benzylpiperidin-1-yl]propan-2-of bis-hydrochloride salt;
{3-[4-(4-Fluorobenzyl)piperidin-1-yl]-2-hydroxypropyl}carbamic acid benzyl ester;
[3-(4-Benzylpiperidin-1-yl)-2-hydroxypropyl]carbamic acid benzyl ester;
{2-(tert-Butyldimethylsilanyloxy)-3-[4-(4-fluorobenzyl)piperidin-1-yl]propyl}carbamic acid benzyl ester;
{2-(tert-Butyldimethylsilanyloxy)-3-[4- benzylpiperidin-1-yl]propyl}carbamic acid benzyl ester;
{2-(tert-Butyldimethylsilanyloxy)-3-[4-(4-fluorobenzyl)piperidin-1-yl]propylamine;
Methyl2-oxo-2,3-dihydrobenzoxazole-6-carboxylate;
2-Oxo-2,3-dihydrobenzoxazole-6-carboxylic acid;
2-Oxo-2,3-dihydrobenzoxazole-6-carboxylic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethylsilanyloxy)propyl] amide;
2-Oxo-2,3-dihydrobenzoxazole-6-carboxylic acid [3-(4-(4-fluorobenzyl)piperidin-1-yl)-2-(tert-butylimethylsilanyloxy)propyl]amide;
2-Oxo-2,3-dihydrobenzoxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-(tent-butyldimethylsilanyloxy)propyl] amide;
2-Oxo-2,3-dihydrobenzooxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]amide;
6-(2-Azido-1-hydroxyethyl)-3H benzoxazol-2-one;
6-[2-Azido-1-(tert-butyldimethylsilanyloxy)ethyl]-3H benzoxazol-2-one;
6-[2-Amino-1-(tert-butyldimethylsilanyloxy)ethyl]-3H benzoxazol-2-one;
2-(4-Benzylpiperidin-1-yl)-N [2-(tent-butyldimethylsilanyloxy)-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]acetamide;
~ 2-(4-Benzylpiperidin-1-yl)-N [2-(tert-butyldimethylsilanyloxy)-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]thioacetamide; and 2-(4-Benzylpiperidin-1-yl)-N [2-hydroxy-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]thioacetamide.
Also, the invention provides a process for preparing the compound of Formula I and pharmaceutically acceptable salts thereof comprising the steps of:
1) aminating a precursor alkyl halide;
2) cyclizing the product of Step 1;
3) recovering the desired compound of Formula I; and 4) converting, if desired, to a pharmaceutically acceptable salt.
Also, the invention provides a process for preparing the compound of Formula I and pharmaceutically acceptable salts thereof comprising the steps of:
1) halogenating an unsaturated side chain of a precursor to the compound;
2) cyclizing the product of Step. 1;
3) recovering the desired compound of Formula I; and 4) converting, if desired, to a pharmaceutically acceptable salt.
DETAILED DESCRIPTION OF THE INVENTION
As recited above, one aspect of the present invention is a compound of Formula I
Z N-V- 1' I
~l~g R3 and a pharmaceutically acceptable salt thereof, wherein R1, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above.
All of the references cited herein, including patents, are incorporated herein by reference.
The following definitions apply to terms used in this specification and claims.
The term "patient" means a mammal, including a human.
Preferred patients are humans, cats, and dogs.
The term "IC50" means the concentration of test compound required to inhibit activity of a receptor or enzyme by 50%.
The term "L-DOPA" means 3-hydroxy-L-tyrosine.
The term "(X1)d" wherein d is an integer of from 0 to 2 means the group X 1 is present 0 to 2 times on the phenylene to which it is attached. The groups X 1 are independently the same or different. Illustrative examples of substituted phenylenes are drawn below.
dis0:
E
5 d is 1:
dis2:
E E
and ~ ~ Y ; and Cl OMe E F E
Y ~ and Cl ~Cl H3C
Likewise the term "(R1)g" wherein g is an integer of from 0 to 3 means the 10 group R1 is present 0 to 3 times on the phenyl to which it is attached. The groups R1 are independently the same or different. Illustrative examples of substituted phenyls are drawn below.
gis0:
15 gis 1:
Me0 d g is t:
Me0 and Me ~ ~ ; and Me0 Cl gis3:
Me0 , arid Me The term "comprising", which is synonymous with the terms "including", "containing", or "characterized by", is inclusive or open-ended and does not exclude additional, unrecited elements or method steps from the scope of the invention that follows.
The phrase "consisting off', is closed-ended and excludes any element, step, or ingredient not specified in the description of the invention that follows.
The phrase "consisting essentially off' limits the scope of the invention that follows to the specified elements or steps and those further elements or steps that do not materially affect the basic and novel characteristics of the invention.
The phrase "filter aid" means a filter medium comprising small particulates. Illustrative examples of filter aids include kieselguhr and CELITE
(Celite Corporation, Lompoc, California), a diatomaceous earth filter aid.
The term "alkyl" means a straight or branched, unsubstituted or substituted, hydrocarbon group having from 1 to 12 carbon atoms. Preferred alkyl groups are C1-C6 alkyl. Typical examples of unsubstituted alkyl groups include methyl (i.e., CH3-), ethyl, 1-propyl, and 2-propyl, 1-butyl, 2-butyl, 2-methyl-1-propyl, 1,1-dimethylethyl, 1-pentyl, 2-pentyl, 3-pentyl, 2,2-dimethylpropyl, 1-hexyl, 2-hexyl, 3-hexyl, 4-methyl-1-pentyl, 1-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 5-methyl-1-hexyl, 1-octyl, 2-octyl, 3-octyl, 4-octyl, 6-methyl-1-heptyl, S,5-dimethylhexyl, 1-nonyl, 2-nonyl, 1-decyl, 2-decyl, 1-undecyl, 2-undecyl, 1-dodecyl, and S-dodecyl. Substituted alkyl groups are described below.
The term "alkenyl" means a straight or branched, unsubstituted or substituted, hydrocarbon group having from 2 to 12 carbon atoms and 1 or 2 sites of unsaturation. Preferred groups are C2-C6 alkenyl. Illustrative examples of unsubstituted alkenyl groups include ethenyl [i.e., CH2=C(H)-], 1-propenyl, 2-propenyl, 1-buten-1-yl, 2-buten-1-yl, 1-penten-1-yl, 2-penten-1-yl, 1-penten-3-yl, 1-penten-5-yl, 1-hexen-1-yl, 1-hexen-4-yl, 2-hexen-1-yl, 3-hexen-1-yl, 2-octen-3-yl, 5-nonen-2-yl, 4-undecen-4-yl, and 5-dodecen-2-yl. Substituted alkenyl groups are defined below.
The term "alkoxy" means a straight or branched, substituted or unsubstituted, alkyl group of from 1 to 12 carbon atoms linked through an oxygen atom. Preferred is C1-C6 alkoxy. Illustrative examples of unsubstituted alkoxy groups include methoxy (i.e., CH3-O-), ethoxy, isopropoxy, tert-butoxy, iso-pentoxy, octyloxy, and 7,7-dimethyloctyloxy. Substituted alkoxy groups are defined below.
The term "aryl" means an unsubstituted or substituted aromatic carbocyclic ring having 6 or 10 carbon atoms. Illustrative examples of unsubstituted aryl groups include phenyl (i.e., C6H5-), 1-naphthyl, and 2-naphthyl. Substituted aryl groups are defined below.
The term "aralkyl" means an unsubstituted or substituted aromatic carbocyclic ring having 6 or 10 carbon atoms (i.e., an aryl group) linked through an alkylene group, wherein alkylene is as defined below. Illustrative examples of unsubstituted aralkyl groups include benzyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, 3-methyl-3-phenylpropyl, 1-naphthylmethyl, 1-naphthylethyl, 3-(1-naphthyl)-propyl, 4-( 1-naphthyl)-butyl, 4-(2-naphthyl)-butyl, 4-phenylheptyl, and 12-(2-hydroxyphenyl)-dodec-3-yl. Substituted aralkyl groups are defined below.
The term "alkylene" means a straight or branched hydrocarbon chain diradical of from 1 to 12 carbon atoms. Preferred groups are C1-C6 alkylene.
Illustrative examples of alkylene groups include methylene (i.e., -CH2-), 1,2-ethylene, 1,2-propylene, 1,3-propylene, 2,2-dimethyl-hexane-1,6-diyl, and dodecan-1,12-diyl.
The term "cycloalkyl" means an unsubstituted or substituted, saturated carbocyclic ring having from 3 to 7 carbon atoms. Illustrative examples of unsubstituted cycloalkyl groups include cyclopentyl, cyclopropyl, cyclohexyl or cycloheptyl. Substituted cycloalkyl is defined below.
As discussed above, the groups alkyl, alkenyl, alkoxy, aryl, aralkyl, and cycloalkyl may be substituted. These substituted groups are respectively termed:
"substituted alkyl", "substituted alkenyl", "substituted alkoxy", "substituted aryl", "substituted aralkyl", and "substituted cycloalkyl".
The groups can be substituted with from 1 to 3 substituents independently selected from halogen, OH, O-(C1-C6 alkyl), OC(O)-(C1-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O-(C1-C6 alkyl), NH2, N(H)-(C1-C6 alkyl), N-(C1-C6 alkyl)2, NHC(O)-(C1-C6 alkyl), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-N(H)-(C1-C6 alkyl), -(C1-C6 alkylene)-N-(C1-C6 alkyl)2, SH, S-(C1-C6 alkyl), S-C(O)-(C1-C6 alkyl), -(C1-C6 alkylene)-SH, -(C1-C6 alkylene)-S-(C1-C6 alkyl), unsubstituted cycloalkyl, C(O)-(C1-C6 alkyl), C02H, C02-(C1-C6 alkyl), C(O)NH2, C(O)NH-(C1-C6 alkyl), and C(O)N-(C1-C6 alkyl)2, wherein (C1-C6 alkyl) means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms, (C1-Cg alkylene) means a straight or branched hydrocarbon chain diradical of from 1 to 6 carbon atoms, and unsubstituted cycloalkyl is as defined above. Further, 1 of the 3 substituents in substituted alkyl, substituted alkenyl (on saturated carbons only), substituted alkoxy, substituted aralkyl (on saturated carbon atoms only) and substituted cycloalkyl may be oxo.
Examples of these substituted groups are provided below.
Illustrative examples of substituted alkyl groups include HOCH2, CF3, (CH2)4SCH3, (CH2)gNH2, C(CH3)2CH[C02C(CH3)3]CH3, CF20H, and CH(C02H)CH2CH2C(O)NMe2.
Illustrative examples of substituted alkenyl groups include 2-fluoro-ethen-1-yl [i.e., CH(F)=C(H)-], methyl propenoate-2-yl, and 5-iso-butoxy-1-penten-5-yl.
Illustrative examples of substituted alkoxy groups include fluoromethoxy (i.e., FCH2-O-), 2-ethoxycarbonyl-ethoxy, 4-aminocarbonyl-oxybutyl, and 8-thio-nonyloxy [i.e., CH3CH(SH)-(CH2)~-O-]
Illustrative examples of substituted aryl groups include 2-fluorophenyl, 2,4,6-trimethoxyphenyl, 4-chloro-2-methylphenyl, 5,6-dichloro-naphth-1-yl, and 8-(dimethylaminomethyl)-naphth-2-yl.
Illustrative examples of substituted aralkyl groups include 4-fluorophenylmethyl, 2-(2,4,6-trimethoxyphenyl)-ethyl, 3-(2-carboxyphenyl)-propyl, 4-phenyl-4-hydroxy-butyl, 4-(2-dimethylaminomethyl-naphth-1-yl)-butyl, and 12-(2-hydroxyphenyl)-dodec-3-yl.
Illustrative examples of substituted cycloalkyl groups include 3-methyl-cyclopentyl, 4-hydroxy-cyclohexyl, and 1-methoxy-cycloheptyl.
The term "heteroatom" includes nitrogen, oxygen, and sulfur. When the heteroatom is incorporated in a nonaromatic ring, the heteroatom further includes II \\//
~ and/s~
The term "oxo" means =O.
The term "oxo-substituted" means any group which contains a carbon atom that is substituted with an oxo group (i.e., =O). A carbon atom substituted with an oxo group forms a carbonyl group of formula C=O.
The phrase "fused 9- or 10-membered bicyclic ring containing from 0 to 3 heteroatoms" means a group wherein 2 ring systems share 2 and only 2 atoms.
Illustrative examples of a fused bicyclic group containing 0 heteroatoms include w ~d ~ w The term "halogen" means bromine, chlorine, fluorine, or iodine.
The term "aminoalkyl" means a H2N group linked through an alkylene group, wherein alkylene has the meaning as defined above. Illustrative examples of aminoalkyl groups include aminomethyl (i.e., H2N-CH2-), 3-aminopropyl, and 1-amino-1,1-dimethylethyl.
The term "alkylaminoalkyl" means an alkyl group, linked through an N(H) group, which in turn is linked through an alkylene group, wherein alkyl and alkylene are as defined above. Illustrative examples of alkylaminoalkyl groups include methylaminomethyl (i.e., CH3NHCH2-), 3-(tert-butylamino)-propyl, and 5 6-(hexylamino)-hexyl.
The term "hydroxyalkyl" means an OH group linked through an alkylene group, wherein alkylene has the meaning defined above. Illustrative examples of hydroxyalkyl groups include hydroxymethyl, 2-hydroxyethyl, and 2-hydroxy-1,1-dimethylethyl.
10 The term "(aminocarbonyl)-alkyl" means an C(O)NH2 group linked through an alkylene group, wherein alkylene has the meaning defined above.
Illustrative examples of (aminocarbonyl)-alkyl groups include H2NC(O)-CH2-and H2NC(O)-C(CH3)3.
The term "(alkylthio)-alkyl-" means an alkyl group linked through a sulfur 15 atom, which in turn is linked through an alkylene group, wherein alkyl and alkylene have the meanings defined above. Illustrative examples of (alkylthio)-alkyl groups include CH3-S-CH2-, CH3CH2-S-(CH2)2-, and CH3CH(CH3)CH2C(CH3)2-S-C(CH3)2CH2-.
The term "carboxyalkyl" means a C02H group linked through an alkylene 20 group, wherein alkylene has the meaning defined above. Illustrative examples of carboxyalkyl groups include carboxymethyl, 2-carboxyethyl, and 2-carboxy-1,1-dimethylethyl.
The term "amino" means the -NH2 group.
The term "haloalkyl" means a halogen linked through an alkylene group, 25 wherein halogen and alkylene are as defined above. Illustrative examples of haloalkyl include trifluoromethyl, difluoromethyl, fluoromethyl, and 2,2,2-trichloroethyl.
The term "C(O)-alkyl" means an alkyl group as defined above linked through a carbonyl carbon atom. Illustrative examples of C(O)-alkyl groups 30 include acetyl (i.e., C(O)CH3), 2,2-dimethylpropionyl, and dodecanoyl.
The term "heterocyclene" means a 4-, 5-, or 6-membered, carbon-linked, unsubstituted or substituted with, for example, alkyl, carboxylic acid, or ester, heterocyclic diradical ring, containing from 1 to 3 heteroatoms which are N, O, or S, selected from the group consisting of:
(i) 1-aza-2-cyclobutanon-3,4-diyl of formula O O
HN NH
and (ii) a 5-membered aromatic, nonaromatic dihydro, or nonaromatic tetrahydro ring having carbon atoms and from 1 to 3 heteroatoms selected from N, O, and S;
(iii) a 5-membered oxo-substituted nonaromatic tetrahydro ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S;
(iv) a 6-membered aromatic, nonaromatic tetrahydro, or nonaromatic hexahydro ring having carbon atoms and 1 or 2 heteroatoms, which heteroatoms are nitrogen, and (v) a 6-membered nonaromatic oxo-substituted hexahydro ring having carbon atoms and 1 or 2 heteroatoms which are nitrogen and 0 or 1 heteroatom which is oxygen;
wherein the radical atoms of the heterocyclene are carbon atoms, and further wherein when B is a nonaromatic heterocyclene containing sulfur, said sulfur may further comprise ~ or Illustrative examples of S- and 6-membered heterocyclenes include:
1 ) A 5-membered heterocyclic ring having one heteroatom such as, for example, the following rings:
x x x x , , , \ ~, x x x x ' , , x x x x , ' , and wherein X is O, S, or N-R wherein R is H or alkyl.
2) A S-membered, substituted or unsubstituted, wherein "substituted" is defined as above, heterocyclic ring having 2 heteroatoms such as, for example, the following rings:
X~
N X~N X~N X~N
' , \ ~ , ~ ~, X X N
~ / ,~ X w N N / ' R/ ~ N , X , R
X~ ,R X x N
N ~N~R
, N ' , and x , R
wherein X and R are as defined above.
3) A 5-membered heterocyclic ring having 3 heteroatoms such as, for example, the following rings:
x X
~N ~ X W O R
'N ~
N , N-N ~ I~ , , N N
R
X
~N X X,N~N, R
N ' R/ /N-N , R
X~ ,R X X
N ' ~ ~ ~R
X N-X ~ ~d N , R/ ~ R
wherein X and R are as defined above.
4) A 6-membered aromatic heterocyclic ring having 1 to 3 nitrogen atoms such as, for example, following rings:
-N -N -N -N
, N / , ~ N , N-N -N -N -N
' , ~ , N ~ , -N N-N ~N
, N
N ~ ~ , and ~ N
5) A 6-membered nonaromatic tetrahydro heterocyclic ring having 1 or 2 nitrogen atoms such as, for example, the following rings:
N-R \ N-R \ N-R
, , and , wherein R is independently hydrogen or alkyl;
6) A 6-membered nonaromatic hexahydro heterocyclic ring having 1 or 2 nitrogen atoms such as, for example, the following rings:
N-R N-R ~N-R
N
R~
R R
N~
N-R N
N-R ~ and wherein R is independently hydrogen or alkyl;
7) A 5-membered oxo-substituted heterocyclic nonaromatic tetrahydro ring having 1 or 2 heteroatoms O, S, or N-R such as, for example, the following rings:
x O X x X O
O
O
O X x' ~X
NH ~ O
HN ~ NH ~ , O O
X'I
Y O O N
HN-so2 ~ NH , and , wherein X and R are as defined above.
x O X x X O
O
O
O X x' ~X
NH ~ O
HN ~ NH ~ , O O
X'I
Y O O N
HN-so2 ~ NH , and , wherein X and R are as defined above.
8) A 6-membered oxo-substituted hexahydro nonaromatic heterocyclic rings having 1 or 2 nitrogen atoms, and 0 or 1 heteroatoms selected from O and S, such as, for example, the following rings:
R O O O R
N N
N-R
> >
N
R
S
O R O
X-s( ~N
and N-R
wherein R and X are as defined above.
It is to be appreciated that the above rings do not represent all possible isomers or rings that are described above by the term "heterocyclene".
It is also to be appreciated that the compounds of Formula I may have 10 chiral centers, in which case all stereoisomers thereof, both separately and as racemic and/or diastereoisomeric mixtures, are included.
Some of the compounds of Formula I are capable of further forming nontoxic pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the present invention.
15 For example, pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy 20 alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfate, nitrate, phosphate, monohydrogenphosphate, dihyrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977;66:1-19.
The acid addition salts of basic invention compounds are prepared by contacting the free base form of the invention compounds with a sufficient amount of the desired acid to produce the salt in the conventional manner.
Pharmaceutically acceptable base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as canons are sodium, potassium, magnesium, calcium, and the like.
Examples of suitable amines are N,N dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge, supra., 1977).
Base salts of acidic invention compounds are prepared by contacting the free acid form of the invention compounds with a sufficient amount of the desired base to produce a salt in the conventional manner.
Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
The compounds of the invention may be prepared by a number of methods well known to a person of average skill in the arts of organic and medicinal chemistries.
It should be appreciated that the organic and medicinal chemistry arts provide the skilled artisan with electronically searchable literature, reaction, and reagent databases and a wide variety of commercially available starting materials.
For example, see the databases of the Chemical Abstracts service (Columbus, Ohio); Katritzky, Alan R., Handbook of Heterocyclic Chemistry, Pergamon Press, Ltd., 1985, Volumes 4 and 5; and The Aldrich Catalog (Sigma-Aldrich Corporation, St. Louis, Missouri).
For examples of the preparation of optically pure 02-isoxazolines (i.e., chiral ~2-isoxazolines that consist of only one enantiomer, or substantially one enantiomer), see Yang, K-S, et al., Tetrahedron Letters, 2000;41:1453-1456 or Shimizu, M. et al., Chemistry Letters, 1996:455-456.
As described above, some of the invention compounds possess chiral centers. It should be appreciated that a person skilled in the medicinal and organic chemistry arts is able to prepare chiral invention compounds by classical resolution techniques and/or asymmetric synthesis.
It should also be appreciated for purposes of synthesizing the compounds of the invention that reactive functional groups present in starting materials, reaction intermediates, or reaction products may be protected during chemical reactions using protecting groups which render the reactive functional groups substantially inert to the reaction conditions (see for example, Protective Groups in Organic Synthesis, 2nd ed., Green TW and Wuts PG, John Wiley & Sons, New York, NY 1991 ). Thus, for example, protecting groups such as the following may be utilized to protect suitable amino, hydroxyl, and other groups of related reactivity: carboxylic acyl groups, such as formyl, acetyl, trifluoroacetyl;
alkoxycarbonyl groups, such as ethoxycarbonyl, t-butoxycarbonyl (BOC), (3,(3,(3-trichloroethoxycarbonyl (TCEC), ~i-iodoethoxycarbonyl;
aryloxycarbonyl groups, such as benzyloxycarbonyl (CBZ), p-methoxybenzyloxycarbonyl, phenoxycarbonyl; trialkyl silyl groups, such as trimethylsilyl and t-butyldimethylsilyl (TBDMS); and groups such as trityl, tetrahydropyranyl, vinyloxycarbonyl, o-nitrophenylsulfenyl, diphenylphosphinyl, p-toluenesulfonyl, and benzyl may all be utilized. The protecting group may be removed, after completion of the synthetic reaction of interest, by procedures known to those skilled in the art. For example, a BOC group may be removed by acidolysis, a trityl group by hydrogenolysis, TBDMS by treatment with fluoride ions, and TCEC by treatment with zinc. Use of protecting groups in organic synthesis is well within the skill of the average artisan.
It should be appreciated that reagents, solvents, and starting materials necessary for the preparation of the compounds of the invention may be purchased from a number of commercial sources or may be readily prepared by a number of methods well known to one of average skill in the art of organic chemistry.
Further, reactions used to prepare the invention compounds can be carried out under a wide variety of conditions comprising solvents, reagents, catalysts, temperatures, time, atmosphere, and pressure.
Many different methods may be used to prepare the invention compounds.
However for purposes of practicing the invention, which comprises compounds, pharmaceutical compositions, and methods of treating certain disorders and diseases, it does not matter how the compounds are made. Nevertheless, novel methods of preparing the invention compounds are valuable as they may afford improvements in ease of synthesis or purification, cost of preparation, or process time. As discussed above, the invention provides novel methods of making the invention compounds.
For example, one method of preparing the compounds of the invention is described below in Scheme 1.
Scheme 1 - ~Z IVH + L-V- Y~
(R~)g R _ _ Z N-V- Y
~1)g R3 wherein Rl, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above and L
is a leaving group such that when V is (CH2)n or (CH2)m-C=O, wherein m is not 0, L
is, for example, halogen, CH3C02-, CF3C02-, CF3S03-, p-toluyl-S03-, and the like; and when V is C=O, L is, for example, halogen, hydroxy, which can form intermediates activated for displacement by a compound of formula A by reaction with coupling agents such as, for example, carbonyldiimidazole (CDI), N,N'-dicyclohexylcarbodiimide (DCC), and the like, benzotriazol-1-yl, imidazol-1-yl, CH3C02-, and the like.
In Scheme 1, a compound of formula A, wherein R1, g, and R2 are as defined above, is allowed to react with a compound of formula B, wherein L is a leaving group which is displaced by a compound of formula A, to provide a compound of Formula I. In a preferred procedure, a compound of formula A is dissolved or suspended in an aprotic, polar solvent such as, for example, N,N-dimethylformamide (DMF), ethyl acetate, dimethylsulfoxide (DMSO), acetonitrile, nitromethane, acetone, and the like, and optionally a 1 to 2 molar equivalents of a non-nucleophilic base such as, for example, triethylamine, diisopropylethylamine, sodium hydride, and the like is added, followed by addition of a compound of formula B as a neat material (i.e., only the material itself in solid or liquid form) or in a solution of an aprotic, polar solvent such as, for example, the aprotic, polar solvents recited above, at an addition rate that maintains a desired reaction temperature, and the mixture is stirred in air or under an inert atmosphere such as, for example, nitrogen or argon, to give a compound of Formula I. In another preferred procedure, a compound of formula A is dissolved or suspended in an aprotic, nonpolar solvent such as, for example, 5 tetrahydrofuran (THF), diethylether, hexanes, and the like, and about one molar equivalent of a strong base such as, for example, n-butyl lithium, sec-butyl lithium, tert-butyl lithium, potassium hexamethyldisilazide (KI~VIDS), and the like is added, followed by addition of a compound of formula B as a neat material or in a solution of a nonpolar, aprotic solvent such as, for example, the nonpolar, 10 aprotic solvents recited above, at an addition rate that maintains a desired reaction temperature, and the mixture is stirred to give a compound of Formula I. In still another preferred procedure, a compound of formula B, wherein L-V- is HO-C(O)-, is dissolved or suspended in an aprotic solvent such as, for example, THF, DMF, ethyl acetate, and the like, and about 1 molar equivalent of a coupling 15 agent such as, for example, CDI, DCC, bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl), and the like, followed by addition of a compound of formula A
as a neat material or in a solution of an aprotic solvent such as, for example, the aprotic solvents recited above, at an addition rate that maintains a desired reaction temperature, and the mixture is stirred to give a compound of Formula I. In 20 Scheme 1, the preferred molar ratio of a compound of formula A to a compound of formula B is about 1:1.
Another method of preparing the compounds of the invention is described below in Scheme 2.
Scheme 2 PGI
r--Z N-V-B ~ ~ PGZ
~l~g R3 ~xl~d C
- ~Z N-V-B
~l~g R3 wherein R1, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above, and and PG2 are protecting groups which may be deprotected to provide the groups E
and Y, respectively, of compounds of Formula I. Illustrative examples of PG1 are hydrogen (when E is H), -O-benzyl, -S-benzyl, -NH-benzyl, -NH-(4-methoxybenzyl), -NH-BOC, -NH-CBZ, -O-TBDMS, -CH2-halo, C(O)-CH2-halo, -C02Me, C(O-CH2)2, CH2CH2C02Me, and the like. Illustrative examples of PG2 are -NH-benzyl, -NH-(4-methoxybenzyl), -NH-BOC, -NH-CBZ, C02Me, -O-benzyl, -O-TBDMS, and the like.
In Scheme 2, a compound of formula C is deprotected to give a compound of Formula I. In a preferred procedure, a compound of formula C, wherein PG1 and/or PG2 is -O-benzyl, -S-benzyl, -NH-benzyl, -NH-CBZ, and the like, is dissolved or suspended in a suitable solvent such as, for example, acetic acid, ethanol, THF, dichloromethane, and the like, and allowed to react with a deprotecting reagent such as, for example, a mixture of hydrogen gas and a suitable hydrogenation catalyst such as, for example, palladium on carbon, palladium on barium sulfate, platinum on carbon, sponge nickel, and the like, under pressure, phosphorous tribromide, hydrochloric acid, titanium tetrachloride, and the like, at an addition rate that maintains a desired reaction temperature, to give a compound of Formula I. Examples 1, 3, 4a, 4b, 5, and 9 are representative of the chemistry described in Scheme 2.
Another method of preparing the compounds of the invention is described below in Scheme 3.
Scheme 3 E
- ~Z N-V-U ~ /r-Y
(It)g R D (It)a - ~Z N-V-B
(Rt)g R
wherein R1, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above, and U
is -C(H)=C(H)- or -C=C-.
In Scheme 3, a compound of formula D is allowed to react with a 3- or 4-membered cyclization reagent to give a compound of Formula I, wherein B is a S- or 6-membered heterocyclene, respectively. In a preferred procedure, a compound of formula D is dissolved or suspended in an aprotic solvent such as, for example, THF, dichloromethane, acetone, DMF, and the like, and allowed to react with a 3-membered cyclizing reagent such as, for example, an alkylazide, alkyldiazomethane, acetonitrile oxide, prepared by reaction of an aldoxime such as, for example, acetaldoxime [i.e., CH3C(H)=N-OH] with a radical generating agent such as, N-bromosuccinimide (NBS), N-chlorosuccinimde (NCS), and the like, or a 4-membered cyclizing reagent such as, for example, H2C=C(H)-C(H)=N-EDG, wherein EDG is an electron donating group such as, for example, -N(CH3)2, -OMe, and the like, to give a compound of Formula I. Example 2 is representative of the chemistry described in Scheme 3.
Another method of preparing the compounds of the invention is described below in Scheme 4.
Scheme 4 Rz - ~Z N-(~~)g R E
~i)g wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above, B is oxazole, dihydrooxazole, thiazole, or dihydrothiazole, and T is C=O or C(H)OH.
In Scheme 4, a compound of formula E is allowed to react with a reagent and/or catalyst under cyclizing conditions to provide a compound of Formula I.
In a preferred procedure, a compound of formula D is dissolved in an aprotic solvent such as, for example, THF, ethyl acetate, DMF, DMSO, and the like, and a dehyrdating reagent such as, for example, anhydrous magnesium sulfate, anhydrous calcium chloride, activated 3 angstrom molecular sieves, trimethoxymethane, oxalyl chloride, PCIS, phosphorous pentoxide and the like, is added and optionally an acid catalyst such as, for example, trifluoroacetic acid, para-toluenesulfonic acid, and the like, is added, and the mixture is stirred to provide a compound of Formula I, wherein B is oxazole or dihydrooxazole. In another preferred procedure, a compound of formula D is dissolved in an aprotic solvent such as, for example, THF, ethyl acetate, DMF, DMSO, and the like, and a sulfurating reagent (i.e., a reagent that introduces a sulfur atom) such as, for example, P2S5, [2,4-bis(4-methoxyphenyl)-1,3-dithian-2,4-diphosphetane-2,4-disulfide] (i.e., Lawesson's reagent), and the like, is added, and the mixture is stirred to provide a compound of Formula I, wherein B is thiazole or dihydrothiazole. Examples 6(a)-6(f) and 8 are representative of the chemistry described in Scheme 4.
Another method of preparing the compounds of the invention is described below in Scheme 5.
Scheme S
E
Z R N-V-T-CH2~NHC Y
_~r v ~R1)g R3 ~X1)d F
E
-~~Z N-V-B ~ ~ Y
(R~)g R3 (X~)d wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above, B is oxazole, dihydrooxazole, thiazole, or dihydrothiazole, and T is C=O or C(H)OH.
5 In Scheme 5, a compound of Formula F is allowed to react with a reagent and/or catalyst under cyclizing conditions to provide a compound of Formula I.
Preferred procedures are as described above in Scheme 4. Examples 7(a) and 7(b) are representative of the chemistry described in Scheme 5.
Another method of preparing the compounds of the invention is described 10 below in Scheme 6.
Scheme 6 E
-~~Z N-V-B ~ ~ Y I
(R~)g R~ (X~)d Rz Z N-V- Y
(R ~ )g R
wherein R1, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above.
In Scheme 6, a compound of Formula I is allowed to react with a reagent to provide a different compound of Formula I. In a preferred procedure, a compound of Formula I wherein V is (CH2)mC=O is dissolved or suspended in a suitable aprotic, nonpolar solvent such as, for example, THF, methyl-tert-butylether (MTBE), hexanes, and the like, and a reducing agent such as, for example, lithium aluminum hydride, sodium borohydride, sodium triacetoxyborohydride, diisobutylaluminum hydride (DIBAL), and the like, is added at an addition rate that maintains a desired reaction temperature, and the mixture is stirred to give a compound of Formula I wherein V is (CH2)n.
Another method of preparing the compounds of the invention is described below in Scheme 7.
Scheme 7 E
Rz - ~Z N- \ + K ~ ~ Y---~
I
(Rt)g R3 (Xt)d G
H
E
- ~Z N-V-B ~ ~ Y
~1)g R3 ~Xl)d wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above, B is isoxazole, dihydroisoxazole (i.e., isoxazoline), dihydrothiazoline, or oxazole; J is C(H)=CH2 or C=C-H, and K is C(Cl)=N-OH.
In Scheme 7, a compound of formula G is allowed to react with a compound of formula H under [3+2] cyclization conditions to provide a compound of formula I. In a preferred procedure, a compound of formula G and a compound of formula H are dissolved or suspended in a solvent such as, for example, methanol, ethanol, THF, ethyl acetate, toluene, dichloromethane, and the like, and optionally a non-nucleophilic base such as, for example, triethylamine, diisopropylethylamine, sodium hydride, and the like is added, and the mixture is stirred to provide a compound of Formula I. Examples 10 to 16 are representative of the chemistry described in Scheme 7.
Examples of the preparation of the invention compounds are described below.
6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H benzoxazol-2-one N,OH
HO / CHO Bn0 / CHO Bn0 BnBr, K CO _ z 3 ~ NHzOH / 1) NCS/DMF
OzN \ MeCN OzN \ Na O
2 3 OZN 2) ~COZMe N~O COZMe N.O OH
Bn0 / ~ DIBAL Bn0 / ~ pph CBr O N \ I THF O N \ ~ MeCN
z z OBn N.O \ \ O~N -Bn0 / ~ Br I / 6 NH ~ / N ~ ~ NOz O N \ I KZC03,MeCN
z OBn Hz, \ O.N -/ N ~ ~ NOz p~0 .N
CDI i ( \ O ~ \ / NH
/ N
Step 1: A mixture of 3-hydroxy-4-nitrobenzaldehyde (10.0 g, 0.0598 mol), benzyl bromide (7.20 mL, 0.0598 mol) and anhydrous potassium carbonate (18.20 g, 0.1316 mol) in 250 mL MeCN was heated at 60°C for 5 hours with vigorous stirring. The reaction mixture was filtered, and the filtrate was concentrated. The residue was taken up in chloroform, and an orange precipitate was removed. The filtrate was reconcentrated to an oil which crystallized on standing to give 1 (15.38 g, 100%): TLC Rf= 0.58 (1:1 hexanesBtOAc).
Step 2: To a suspension of compound of formula 1 (3.0 g, 0.0117 mol) in 30 mL
isopropanol was added hydroxylamine hydrochloride (812 mg,' 0.0117 mol), followed by sodium carbonate (2.47 g, 0.0234 mol). After addition was complete the reaction mixture was vigorously stirred at 40°C for 30 minutes (all starting material went into solution) and concentrated. The residue was taken up in water, and the aqueous mixture was washed 2X with EtOAc. The organic washings were combined and washed with saturated NaCI(a~, dried over magnesium sulfate and concentrated to a yellow solid which was used without further purification to give 2 (2.63 g, 82%); TLC Rf= 0.55 (1:1 hexanes/EtOAc); CI -MS (m/z): 273 [M + H]+.
Step 3: Compound of formula 2 (2.63 g, 9.66 mmol) was dissolved in 30 mL
N,N-dimethylformamide (DMF), and N-chlorosuccinimide (NCS, 1.29 g, 9.66 mmol) was added. The reaction mixture was stirred at room temperature under nitrogen for 4 hours and concentrated. The residue was partitioned between water and EtOAc and after thorough mixing the aqueous layer was discarded, and the organic layer was washed with saturated NaCI(a~, dried over magnesium sulfate, filtered and concentrated to an oil. The crude chlorooxime was taken up in 30 mL 1:1 (v/v) water/tetrahydrofuran (THF) and methyl acrylate (1.18 mL, 12.6 mmol) was added, followed by adding sodium bicarbonate (2.46 g, 29.0 mmol). The reaction mixture was stirred at room temperature for 1.5 hours and extracted with EtOAc. The organic extract was dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel 60, 230-400 mesh, 3:2 Hexanes/Ethyl acetate) to give 3 (3.19 g, 93%) as a yellow oil: TLC Rf= 0.40 (1:1 hexanes/EtOAc); APCI-MS
(m/z): 357 [M + H]+.
Step 4: To a solution of compound of formula 3 (3.10 g, 8.70 mmol) in 30 mL
anhydrous THF, cooled to 0°C under nitrogen, is added slowly 26.10 mL
(26.10 mmol) 1.0 molar (1.0 M) diisobutylaluminum hydride (DIBAL or DiBAIH) solution in cyclohexane (note: effervescence). After addition was complete, the reaction mixture was stirred at 0°C for 1 hour and quenched by slow addition of MeOH. The reaction mixture was partitioned between saturated aqueous potassium sodium tartrate and EtOAc and stirred for 30 minutes. The organic layer was removed, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over magnesium sulfate, filtered and concentrated to a yellow-orange oil which was used without further purification to give 4 (2.76 g, 97%): TLC Rf= 0.13 (1:1 hexanes/EtOAc); APCI-MS (m/z): 329 [M + H]+.
Step 5: To a solution of triphenylphosphine (3.42 g, 12.98 mmol) in 30 mL
MeCN is added under nitrogen carbon tetrabromide (4.29 g, 12.98 mmol), followed by compound of formula 4 (2.13 g, 6.49 mmol). After stirring at room temperature for 1.5 hours an additional 2.57 g (9.74 mmol) triphenylphosphine and 3.22 g (9.74 mmol) carbon tetrabromide was added, and stirring was continued for 15 minutes. The reaction mixture was concentrated and the crude 5 product was purified by flash chromatography (4:1 Hexanes/Ethyl acetate to 3:2 Hexanes/Ethyl acetate) to give 5 (1.57 g, 62%) as a yellow, crystalline solid:
TLC
Rf= 0.54 (1:1 hexanes/EtOAc); APCI-MS (m/z): 391 and 393 [M + H]+.
Step 6: A mixture of 4-benzylpiperidine (6) (0.56 mL, 3.26 mmol), compound of formula 5 (1.16 g, 2.96 mmol) and anhydrous potassium carbonate (1.35 g, 10 9.78 mmol) in 30 mL MeCN was heated at reflux for 24 hours. The reaction mixture was concentrated, and the residue was partitioned between water and EtOAc. The organic layer was washed with water, dried over magnesium sulfate, filtered and concentrated. The crude product was flash chromatographed (EtOAc) to give 7 (1.36 g, 95%) as a yellow oil which crystallized on standing: TLC
15 Rf= 0.36 (EtOAc); APCI-MS (m/z): 486 [M + H]+; Anal. Calcd for C29H31N304~ C~ 71.73; H, 6.43; N, 8.65. Found: C, 71.70; H, 6.59; N, 8.41.
Step 7: A mixture of compound of formula 7 (410 mg, 0.84 mmol) and 50 mg 20% Pd on C catalyst in SO mL 1:1 (v/v) MeOH/THF was hydrogenated for 11 hours under a hydrogen pressure of 47.8 psi. The catalyst was filtered off 20 (CELITE), and the filtrate was concentrated to give 8 as a brown, glassy solid;
(307 mg (100%): TLC Rf= 0.10 (EtOAc); APCI-MS (m/z): 366 [M + H]+.
Step 8: A mixture of compound of formula 8 (330 mg, 0.90 mmol) and N,N'-carbonyldiimidazole (218 mg, 1.35 mmol) in 10 mL anhydrous THF was refluxed under nitrogen for 1 hour. The reaction mixture was concentrated, and the residue 25 was taken up in EtOAc. The organic layer was washed with water, saturated aqueous NaCI, dried over magnesium sulfate, filtered and concentrated. The crude product was flash chromatographed (3% MeOH in CHCl3 to S% MeOH in CHC13) to give 6-[5-(4-benzylpiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H benzoxazol-2-one (176 mg, 50%) as an oil which crystallized on standing:
30 (176 mg, 50%): TLC Rf = 0.23 (9:1 CHC13/MeOH); APCI-MS (m/z): 392 [M +
H]+; Anal. Calcd for C23H25N303~ C~ 70.57; H, 6.44; N, 10.73. Found C, 70.04;
H, 6.52; N, 10.63.
6-[5-(4-Benzylpiperidin-1-ylmethyl)-3-methylisoxazol-4-yl]-3H benzoxazol-2-one / O Br / O
O NBS O
HOAc \
N
H H
THF H
\ I NH \ ~ N
H
6 Bra 10 Pd(PPh3)2C12/Et3N /
uI DMF \ I N
C , / ~ O.N CH3 Acetaldoxime NBS, Et3N, DMF ~ N \ O
/ ~O
N
H
Step 1: To a solution of benzoxazolinone (20 g, 0.148 mol) in 220 mL glacial acetic acid was added N-bromosuccinimide (NBS, 26.36 g, 0.148 mol), and the reaction mixture was stirred at room temperature for 63 hours before pouring into 1500 mL water. The precipitated product was washed thoroughly with water upon collection and recrystallized from EtOH to give 6-bromo-3H benzoxazol-2-one (9) (25.09 g, 79%): Theory: C, 39.28; H, 1.88; N, 6.54; Br, 37.33. Found: C, 39.36; H, 2.02; N, 6.36; Br, 37.43. MP 192-194°C.
Step 2: A mixture of 4-benzylpiperidine (6) (25 mL, 0.14 mol) and propargyl bromide (10.40 g, 0.07 mol, 80% wt. solution in toluene) in 250 mL anhydrous THF was heated at reflux under nitrogen for 19 hours. The reaction mixture was concentrated, and the residue was taken up in chloroform. The organic layer was washed with 1.0N aqueous NaOH, dried over magnesium sulfate, filtered and concentrated. The crude product was flash chromatographed (1:1 Hexanes/Ethyl acetate to 3:2 Hexanes/Ethyl acetate) to give 10 (11.90 g, 80%), as an orange oil, MS(APCI) M + 1 = 214, TLC (0.34, 1:1 Hexanes/Ethyl acetate; iodine stain).
Step 3: A mixture of compound of formula 10 (7.44 g, 0.0349 mol) and compound of formula 8 (8.19 g, 0.0383 mol) with copper (I) iodide (245 mg, 1.29 mmol), dry triethylamine (14.5 mL, 0.1048 mol), and dichlorobis(triphenylphosphine)palladium(II) (476 mg, 0.68 mmol) in 70 mL
anhydrous DMF was heated at 80°C under nitrogen with vigorous stirnng for 18 hours. The reaction mixture was concentrated, and the residue was taken up in acetone and refrigerated for a few hours. The precipitated product was washed with acetone upon collection to give 11 (4.67 g, 39%) as a tan solid, MS(APCI) M + 1 = 347, M - 1 = 345. Melting point (MP) 235-236°C (dec.), TLC
(0.44, EtOAc).
Step 4: To a solution of N-bromosuccinimide (910 mg, 5.11 mmol) in 7.0 mL
anhydrous DMF containing 2 drops pyridine was slowly added under nitrogen acetaldoxime (0.32 mL, 5.11 mmol). After addition was complete (5 minutes), the reaction mixture was stirred for 30 minutes at room temperature after which time compound of formula 11 (700 mg, 2.03 mmol) was added in one portion. The reaction mixture was heated to 90°C and triethylamine (0.70 mL, 5.11 mmol) was added in one portion. Heating was continued for 24 hours, and the reaction mixture was concentrated. The residue was allowed to stand in a small amount of acetone and over a period of time 212 mg of unreacted compound of formula 11 precipitated and was filtered off. The filtrate was concentrated, and the residue was taken up in chloroform. The organic layer was washed with water, dried over magnesium sulfate, filtered and concentrated. The crude product was flash chromatographed (EtOAc) to give 6-[5-(4-benzyl-piperidin-1-ylmethyl)-3-methyl-isoxazol-4-yl]-3H benzoxazol-2-one as an orange oil which solidified on standing, 100 mg (12%), MS(APCI) M + 1 = 404, M - 1 = 402. Theory: C, 71.44; H, 6.25;
N, 10.41. Found: C, 68.81; H, 6.20; N, 10.07. HPLC (C-18, 1:1 Water/Acetonitrile, isocratic) retention time (RT) = 15.34 min (93.8%).
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one hydrochloride -HCI F
N-O Br Bn0 1 12 \ KZCO3, KI, LiBr, CH3CN
OZN
i. 50 psi H2, 10% Pd/C, THF, 4h ii. carbonic acid di-2-pyridyl ester Et3N, THF, reflex 5 Step 1: To a solution of bromide of formula 5 (2.84 g, 7.26 mmol) and amine of formula 12 (1.67 g, 7.26 mmol) in THF (25 mL) was added K2C03 (2.25 g, 16.3 mmol), KI (120 mg, 0.726 mmol), and Liar (150 mg, 1.72 mmol). The mixture was warmed to SO°C overnight (ca. 12 hours). After cooling to ambient temperature, the reaction solvent was removed under reduced pressure. The residue was partitioned between water and ethyl acetate. Warming was necessary to form a homogenous organic layer. The organic extract was washed with brine, dried (Na2S04), filtered, and concentrated to give amine of formula 13 as a yellow residue. Purification by chromatography (silica, 1:99 to 5:95 MeOH/CH2Cl2) gave amine of formula 13 (2.36 g, 65%) as a pale yellow solid.
Step 2: To a solution of amine of formula 13 (1.25 g, 2.48 mmol) in THF (80 mL) was added 10% Pd/C (200 mg). The mixture was shaken under 50 pounds per square inch (psi) of H2 for 4 hours then rapidly filtered through CELITE under reduced pressure into a round bottom flask. The flask was capped with a septum and purged with nitrogen. To the clear solution was added carbonic acid di-2-pyridyl ester (590 mg, 2.78 mmol) and Et3N (800 ~,L, 5.45 mmol). The solution was refluxed overnight (ca. 12 hours). Although no change in RF (TLC:
1:9 MeOH/CH2C12, Rf= 0.22) was observed, a color change from green to red was observed using ninhydrin that distinguished the starting material from the product. The solvent was removed under reduced pressure to afford a yellow residue. Purification by chromatography (silica gel, 1:99 to 5:95 MeOH/CH2C12) gave a yellow product. The colored product was taken up in MeOH and the solution acidified with 1 M HCl/Et20. This solution was dripped into 200 mL of Et20. The resulting suspension was briefly sonicated, and then the solid was collected by filtration to give (~)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one hydrochloride (728 mg, 66%) as a white solid.
EXAMPLES 4(a) AND 4(b) 4(a): (+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one i HNw o S
OBn Oi ~ ~ ~ N02 H
OBn OBn N O ~ ~ ~ N~
O ~ ~ NOZ
s _ v N
~s ~ 19 Br Step 1: Washed (heptane) NaH (1.45 g, 36.3 mmol, 60% in mineral oil) in toluene (150 mL) was treated with the (1R)-sultam 14 (5.20 g, 24.2 mmol) at room temperature under N2. After stirring at room temperature for 1.5 hours, CuICI
5 (239 mg, 2.42 mmol) was added followed by acryloyl chloride (4.38 g, 4.84 mmol, 3.93 mL). After stirring for 3 hours at room temperature, the reaction was quenched with H20 (1 mL) and the solvents removed. The mixture was taken up in EtOAc and passed through a 'plug' (~20 g) of silica gel, and the EtOAc removed. The product was purified by chromatography (CH2Cl2) to yield 10 compound 15 as a white solid (3.92 g, 60%).
See J. Org. Chem., 1990;55:4585 for spectral data R f (EtOAc/C7) - 0.62 R f (2% MeOH/CH2C12) - 0.50.
Step 2: The oxime 15 (3.86 g, 14.20 mmol) and NCS (1.90 g, 14.2 mmol) were 15 stirred in DMF (75 mL) for 3 hours at room temperature. The DMF was removed and the product taken up in EtOAc, washed with brine and dried (MgS04). After removal of the solvent the material was taken up in THF/H20 (100:100 mL) and the sultam (IIa, 3.82 g, 14.20 mmol) and NaHC03 (3.78, 45 mmol) were added.
After 1 hour the mixture was diluted with EtOAc, washed with H20, brine and dried (MgS04). The crude material obtained was purified by recrystallization (EtOAc) to afford compound 16 as a very pale yellow 'fluffy' crystals (5.17 g, 68% from 3 crops of crystals).
Product from (1R)-sultam -[a]D23 = +224° (c=0.30, MeCN) m/z 540.0 (MH+), vm~ 2761, 1698, 1519, 1338, 1273, 849, 737 cm-1, 8H 1.00 (3H, s, CH3), 1.22 (3H, s, CH3), 1.40 (2H, m, CH2), 1.92 (3H, m, alkyl), 2.10 (1H, dd, CH, J8.0, 13.6 Hz), 2.20 (1H, dd, CH, J3.6, 13.6 Hz), 3.48 (1H, d, CHHS02, J 14.0 Hz), 3.59 (1H, dd, CHH, J 11.2, 17.2 Hz), 3.59 (1H, d, CHHS02, J 13.6 Hz), 3.71 (1H, dd, CHN, J6.8, 17.2 Hz), 5.26 (2H, s, OCH2), 5.76 (1H, dd, CHN, J6.8, 11.2 Hz), 7.18 (1H, dd, aromatic Carom.) J 1.6, 8.4 Hz), 7.32-7.48 (5H, m, Ph), 7.58 (1H, d, arom., J 1.2 Hz), 7.88 (1H, d. arom., J7.6 Hz).
Step 3: DiBAIH reduction of compound 16 as in Example 1, Step 4; and purification by chromatography (0-70% EtOAc/C7) gave 17 (2.19 g , 71 %).
Step 4: Bromination of compound 17 as in Example 1, Step 5 gave 18.
Step 5: Coupling of compound 18 as in Example 1, Step 6 gave 19: [a]D24 -+57° (c=0.42, CH2Cl2).
Step 6: Reduction of compound 19 as in Example 1, 7 gave 20.
Step 7: Benzoxazol-2-one ring formation of compound 20 as in Example 1, Step 8 gave (+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl }-3~benzoxazol-2-one: [a]D24 ° + 102° (c=0.31, MeOH).
Example 4(b): (-)-6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one N
O ~O
O
OBn OBn ~N
Oi \ ~ \ N~ O ~ NOZ
/N i 24 O ~O o 23 off OBn OBn o~ \ ~ ~ N~
O N
s ~ ~ ~N
B~ 25 F
S Step 1: Compound 22 was prepared in a manner similar to Example 4a, Step 1, except ( 1 S~-sultam (21) was used in place of the ( 1 R)-sultam.
Step 2: Compound 23 was prepared in a manner similar to Example 4a, Step 2:
[oc]D23 = -224° (c=0.27, MeCN).
Step 3: DiBAIH reduction of compound 23 as in Example l, Step 4 gave 24.
Step 4: Bromination of compound 24 as in Example 1, Step 5 gave 25.
Step 5: Coupling of compound 25 as in Example 1, Step 6 gave 26: [a]D24 =
_69°
(c=0.46, CH2C12).
Step 6: Reduction of compound 26 as in Example 1, Step 7 gave 27.
Step 7: Benzoxazol-2-one ring formation of compound 27 as in Example 1, Step 8 gave (-)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one: [a]D23 = -105° (c=0.44, MeOH).
6- { 3-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4, 5-dihydroisoxazol-5-yl } -3 H
benzoxazol-2-one NOZ NOZ ~ NOZ
-~ y O~ / OBn ~ / OBn EtO2C \ / OBn / OBn -~ 'OBn HO ~N~p 30 Br N-O
NOz 12 ~ F / N \ / OBn N-O
F / N ' / OH
N-O
H
~ N
~O
F / \ / O
N-O
Step 1: Butyllithium (16.0 mL, 40 mmol, 2.5 M in hexanes) was added to a suspension of methyltriphenylphosphonium bromide (12.50 g, 35.0 mmol) in THF
(300 mL at 0°C. After stirring for 1 hour, a solution of 2 (7.72 g, 30.04 mmol) was added, and the mixture stirred at room temperature for 3 hours. The solvent was removed, and the crude material was taken up in EtOAc and triturated with heptane, the solids were filtered off (x 5). The filtrate was then purified by chromatography (0-10% EtOAc in heptane) to give 28 as a yellow oil (3.04 g, 40%).
m/z 254.09 (M-H-) vm~ 1601, 1585, 1514, 1345 cm-1 SH 5.26 (2H, s, CH20), 5.45 (1H, d, CH=, J 10.4 Hz), 5/82 (1H, d, CH=, J 17.6 Hz), 6.68 ( 1 H, dd, dd, CH=, J 10.8, 17.6 Hz), 7.07 ( 1 H, dd, arom., J 1.6, 8.4 Hz), 7.11 (1H, s, arom.), 7.34 (1H, m, arom.), 7.39 (2H, m, arom.), 7.48 (2H, m, arom.), 7.88 (1H, d, arom., J8.4 Hz).
Step 2: Compound 28 (1.50 g, 5.88 mmol), ethyl 2-chloro-2-(hydroxyimino)acetate (888 mg, 5.88 mmol), NaHC03 (988 mg, 11.76 mmol) were stirred at room temperature in THF/H20 ( 10/5 mL). After 1 hour a further aliquot (888 mg, 5.88 mmol) of ethyl 2-chloro-2-(hydroxyimino)acetate was added, and stirring continued for a further 1 hour. The mixture was then diluted with EtOAc, washed with brine and dried (MgS04). Purification by chromatography (0-40% EtOAc in heptane) gave 29 as a yellow oil which solidified on standing (1.91 g, 88%).
m/z 371.15 (MH+) vm~ 1722, 1609, 1593, 1519, 1251 cm-1 8H 1.39 (3 H, t, CH3, J 7.2 Hz), 3.12 ( 1 H, dd, CHH, J 8.0, 18.0 Hz), 3.70 ( 1 H, dd, CHH, J 12.0, 17.6 Hz), 4.37 (2H, q, CH2, J 7.2 Hz), 5.25 (2H, s, CH20), 5.80 ( 1 H, dd, CH, J 8.0, 11.6 Hz), 6.94 ( 1 H, dd, arom., J 1.2, 8.0 Hz), 7.12 ( 1 H, s, arom.), 7.32-7.47 (5H, m, Ph), 7.88 (1H, d, arom., J 8.0 Hz).
Step 3: DiBAIH (12.90 mL, 12.90 mmol, 1 M in THF) was added to a solution of 29 (1.91 g, 5.16 mmol) in THF (SO mL) at 0°C. After 1 hour a further aliquot of DiBAIH (6.50 mL, 6.50 mmol, 1 M in THF) was added and the mixture stirred for another 1 hour. MeOH (1 mL) was added followed by saturated NaHC03 (20 mL) and the mixture stirred for 20 minutes. The solids were filtered off and the filtrate taken up in EtOAc, washed with brine and dried (MgS04). The material was 5 purified by chromatography (0-SO% EtOAc in heptane) to give 30 as a straw colored oil (66 mg, 39%).
m/z 329.21 (MH+) vm~ 3390, 1609, 1519, 1352 cm-1 8H 1.84 ( 1 H, t, OH, 6.0 Hz), 2.93 ( 1 H, dd, CHI, J 7.2, 17.2 Hz), 3 .54 ( 1 H, dd, 10 CHH, J 11.2, 17.2 Hz), 4.43 (2H, d, CH20H, J 6.0 Hz), 5.26 (2H, d, CH20, J
3.6 Hz), 5.65 ( 1 H, dd, CH, J 7.2, 11.2 Hz), 6.93 ( 1 H, dd, arom., J 1.2, 8.0 Hz), 7.1 S
(1H, d, arom., J 1.2 Hz), 7.32-7.48 (5H, m, Ph), 7.86 (1H, d, arom., J 8.0 Hz).
Step 4: Triphenylphosphine (799 mg, 3.05 mmol) and carbontetrabromide (1.01 g, 3.05 mmol) were added to a solution of 30 (667 mg, 2.03 mmol) in MeCN (20 15 mL) and the resulting mixture stirred at room temperature for 2 hours. The solvent was removed and the crude material purified by chromatography (0-50% EtOAc in heptane) to 31 as a yellow oil (719 mg, 90%).
m/z 393.11/391.11 (MH+) vm~ 1608, 1519, 1350 cm-1 20 8H 3.00 ( 1 H, dd, CHH, J 7.2, 17.2 Hz), 3.60 ( 1 H, dd, CHH, J 11.2, 17.2 Hz), 4.18 (2H, s, CH2Br), 5.25 (2H, s, CH20), 5.68 ( 1 H, dd, CH, J 7.6, 11.2 Hz), 6.94 ( 1 H, d, arom., J8.4 Hz), 7.13 (1H, s, arom.), 7.32-7.47 (5H, m, Ph), 7.87 (1H, d, arom., J 8.0 Hz).
Step 5: Compound 31 (7.15 mg, 1.83 mmol), 4-(4-fluorobenzyl)piperidine 25 hydrochloride (12) (504 mg, 2.19 mmol) and anhydrous K2C03 (507 mg, 3.66 mmol) in MeCN (10 mL) were stirred and heated to reflux for 16 hours. The solution was then diluted with EtOAc, washed with brine and dried (MgS04). The product was purified by chromatography (0-70% EtOAc in heptane) to yield 32 as a yellow oil (662 mg, 72%). ' m/z 504.26 (MH+) vm~ 2902, 1608, 1509, 850 cm-1 8H 1.89 (2H, m, alkyl), 1.45 ( 1 H, m, alkyl), 1.60 (2H, m, alkyl), 1.97 (2H, m, alkyl), 2.47 (2H, d, ArCH2, J 7.2 Hz), 2.67 ( 1 H, d, CH, J 11.2 Hz), 2.80 ( 1 H, d, CH, Jl 0.8 Hz), 2.90 ( 1 H, dd, CHH, J 7.2, 17.2 Hz), 3.21 (2H, dd, CH2N, J
14.0, 22.0 Hz), 3.49 ( 1 H, dd, CHH, J 11.2, 17.2 Hz), 5.22 (2H, dd, CH20, J 12.0, 16.0 Hz), 5.59 (1H, dd, CH, J7.2, 11.2 Hz), 6.95 (3H, m, arom.), 7.06 (2H, m, arom.), 7.15 ( 1 H, s, arom.), 7.31-7.47 (5H, m, Ph), 7.86 ( 1 H, d, arom., J 8.0 Hz).
Step 6: Compound 32 (595 mg, 1.38 mmol) and Pd-C (10%, 150 mg) in MeOH
(100 mL) were (in two batches) subjected to hydrogenation at 50 psi and 30°C for 1 hour. The catalyst was removed by filtration through a 'filter aid' and yielded 33 as an orange colored glass upon removal of the solvent (490 mg, 90%).
m/z 383.18 (MH+) vm~ 3370, 2923, 1509, 1219 cm-1 8H 1.25 (2H, bm, alkyl), 1.60 (4H, m, alkyl, NH2), 1.98 ( 1 H, m, alkyl), 2.48 (2H, d, ArCH2, J 6.8 Hz), 2.83 (2H, m, alkyl), 2.94 ( 1 H, dd, CHH, J 8.8, 17.6 Hz), 3.23 (2H, s, CH2N), 3 .32 ( 1 H, dd, CHH, J 10.8, 17.2 Hz), 3 .67 ( 1 H, bs, OH), 5.42 ( 1 H, dd, CH, J 8.8, 10.8 Hz), 6.70 (2H, s, arom.), 6.73 (1H, s, arom.), 6.96 (1H, s, arom.), 7.06 (2H, m, arom.).
Step 7: Compound 33 (490 mg, 1.28 mmol) and carbonyldiimidazole (CDI) (311 mg, 1.92 mmol) in THF (20 mL) were heated to reflux for 1 hour. The mixture was diluted with EtOAc, washed with brine and dried (MgS04). The compound was purified by chromatography (0-4% MeOH in CH2Cl2) and repeated (0-100%
EtOAc in heptane) to yield 6-{3-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-S-yl}-3~lbenzoxazol-2-one as a yellow foam (220 mg, 42%).
m/z 410.20 (MH+) vm~ 1776, 1509, 1219 cm-1 $H 1.26 (2H, bm, alkyl) 1.43-1.65 (3H, m, alkyl), 1.98 (1H, m, alkyl), 2.48 (2H, d, ArCH2, J 7.2 Hz), 2.75 ( 1 H, d, CHH, J 11.6 Hz), 2.84 ( 1 H, dd, CHH, J
10.8 Hz), 2.96 ( 1 H, dd, CHH, J 8.0, 17.6 Hz), 3.23 (2H, s, CH2N), 3.24 (2H, s, CH2N), 3.44 ( 1 H, dd, CHH, J 10.8, 17.2 Hz), 5.5 8 ( 1 H, dd, CH, J 8.0,.10.8 Hz), 6.93-7.16 (6H, m, arom.), 7.20 (1H, s, arom.), 7.99 (1H, bs, NH).
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H benzoxazol-2-one F / ~ ~ ~ ~COZBn COZH
F
O
\ O
~O ~ \
H ~~N
H
O O
N3 \ ~ HzN \ O
N~O ~ ~HCI I O
N
O
35 I \ O \ O
F ~ ~ I
~N
H
H
N
~0 O
~1 ~s F
Step 1: To a stirring solution of 4-(4-fluorobenzyl)piperidine (12) (10.0 g, 51.744 mmol) in dichloromethane (10 mL) at 0°C was added triethylamine (7.21 mL, 51.744 mmol), followed by benzyl-2-bromoacetate (8.20 mL, S 1.744 mmol). The resulting solution was allowed to warm to room temperature stirnng for 20 hours, then heated to 30°C for a further 6.5 hours. The reaction mixture was evaporated to dryness in vacuo to give a yellow gum. This was adsorbed onto silica gel, and subjected to column chromatography [EtOAc/Heptane (1:10)] to give 34 (5.07 g, 29%) as a colorless oil:
m/z (APCI+) 342 (MH+, 100%), S H 1.36 (2H, t, J 6.8), 1.25 (2H, t, J 3.6 Hz), 1.36 (2H, dt, J 3 .6 Hz), 1.50 ( 1 H, m), 1.60 (2H, d, J 12.4 Hz), 2.10 (2H, dt, J 2.4, 12 Hz), 2.49 (2H, d, J 6.8 Hz), 2.89 (2H, d, J 11.2 Hz), 3.20 (2H, s, N-CH2-CO), 5.14 (2H, s, OCH2Ph), 6.94 (2H, t, J 8.4 Hz), 7.05 (2H, dt, J 2 and 5.2 Hz), 7.32-7.35 (5H, m).
HPLC Rt = 1.73 min; 69.5%; (5-100% MeCN in H20 (both +0.1% trifluoroacetic acid) over 2.5 minutes at 3 mL/min, held at 100% MeCN for 0.5 minute; Prodigy ODSIIIS~,,SOx4.6mm).
Step 2: To a solution of 34 (5.07 g, 14.85 mmol) in methanol (60 mL) was added 5% palladium on activated carbon (2.50 g, 50% by wgt.) and hydrogenated at 48 psi/25°C for 15 hours. The reaction mixture was then filtered through CELITE, the catalyst washed with methanol (3 x 25 mL) and the filtrate condensed to dryness in vacuo to give a pale yellow solid. The solid was subject to column chromatography [MeOH/DCM (1:9)] to give 35 (1.70, 46.6%) as a colorless solid:
m/z (APCI+) 252 (MH+, 100%) and 266 ([M+MeOH]+, 50%), m/z (APCI-) 250 ([M-H]-, 100%).
vm~ (KBr) 1608 (C=O), 1502s, 1379s cm-1 8H 1.71 (1H, m), 1.78 (2H, m), 2.58 (2H, d, J6.4 Hz), 2.72 (2H, m), 3.48 (2H, d, J 4.8 Hz), 3.68 (2H, d, J 12.0 Hz), 4.1 ( 1 H, s, OH), 6.95 (2H , t, J 8.6 Hz), 7.07 (2H, dt, J 2.0, 5.6 Hz), HPLC Rt = 1.36 min; 100%; (5-100% MeCN in H20 (both +0.1% trifluoroacetic acid) over 2.5 minutes at 3 mL/minute, held at 100% MeCN for 0.5 minute;
Prodigy ODS III 5 ~,, 50 x 4.6 mm).
Step 3: To a stirred slurry of aluminum trichloride (49.34 g, 370.05 mmol) in 1,2-dichloroethane (150 mL) at 0°C under nitrogen was added chloroacetyl chloride (33.43 g, 23.58 mL, 296.04 mmol) dropwise over 30 minutes. After 1 hour, a suspension of 2-benzoxalinone (36) (20.0 g, 148.02 mmol) in 1,2-dichloroethane (50 mL) was added over 30 minutes. The resulting suspension was stirred at 0°C
for 2.5 hours, then heated to 50°C for 20 hours. The mixture was then poured onto crushed ice, stirred for 30 minutes, and the resulting mixture filtered. The residue was dried in vacuo at 60°C for 3 days to give 37 as a pale brown solid (13.70 g, 43%).
8H (d6-Me2S0) 5.16 (2H, s, CH2C1), 7.23 (1H, d, arom., J8.0 Hz) 7.84 (1H, dd, arom., J 1.5, 8.0 Hz) 7.88 (1H, s, arom.) HPLC retention time (R~ = 1.53 min; 79.71%; (5-100% MeCN in H20 (both +0.1 % trifluoroacetic acid) over 2.5 minutes at 3 mL/min, held at 100% MeCN
for 0.5 minute; Prodigy ODS III 5 ~,, 50 x 4.6 mm.
Step 4: To a stirred solution of 37 (6.00 g, 28.4 mmol) in DMF (60 mL) was added sodium azide (1.85 g, 28.5 mmol). After 3 hours, the DMF was removed under reduced pressure to give a solid which was washed well with water, filtered and dried to yield 38 as a brown solid (4.5 g, 73%).
m/z 217.09 ( M-H-) vm~ 3405, 2921, 2135, 1770, 1660, 1606, 1442, 1268, 1240, 1190, 920 cm-1 8H (DMSO) 4.86 (2H, s, CH2), 7.22 (1H, d, arom., J 8.1 Hz), 7.79-7.82 (1H, m, arom.), 7.83 (1H, s, arom.) NH not seen.
Step 5: A solution of 38 (100 mg, 0.46 mmol) and Pd-C (5%, 15 mg) in methanol (20 mL) and concentrated HCl (6 drops) was subjected to hydrogenation at 10 psi and 25°C for 25 minutes. The catalyst was removed by filtration through a 'filter aid' and the solvent removed to give 39 (85 mg, 81 %) as a pale brown solid.
m/z 192.97 (MH+) vm~ 3374, 2967, 1767, 1695, 1623, 1495, 1419, 1268, 1149 cm 1 8H (DMSO) 4.56 (2H, s, CH2), 7.27 (1H, d, arom., J8.3Hz), 7.89 (1H, d, arom., J8.lHz), 7.93 (1H, s, arom.), 8.34 (3H, s, NH3+), 12.34 (1H, s, NH).
Step 6: To a stirnng solution of 35 (2.43 g, 9.68 mmol) in dimethylformamide (50 mL) was added N,N diisopropylethylamine (DIPEA) (3.37 g, 19.36 mmol) 5 followed by O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) (3.67 g, 9.68 mmol). After 45 minutes, 39 (1.86 g, 9.68 mmol) was added, and the resulting solution stirred at room temperature for 3 hours. The reaction mixture was condensed to dryness in vacuo, redissolved in EtOAc, and washed with saturated aqueous sodium bicarbonate solution. A
10 precipitate formed in the partition, this was filtered and dried. The organic phase was then was then dried with magnesium sulfate and condensed to dryness in vacuo. The resulting brown oil and the filtered solid were combined, adsorbed onto silica gel, and subject to column chromatography [MeOH/DCM (0-5%
MeOH over 60 minutes)] to give 40 (0.493 g, 12%) as a tan solid:
15 vm~ (KBr) 3401w, 3079w, 1777s, 1675w, 1621s, 1510m, 1451m, 1270s, 947m, 844s.
NMR SH (DMSO-d6) 1.45 (2H, dd, J 11.2 Hz), 1.70 (3H, m), 2.53 (2H, d, J 5.5 Hz) 2.94 (2H, m), 3.37 (4H, m), 3.93 (2H, s), 4.41 (4H, s), 4.73 (2H, d, J 5.6 Hz), 7.12-7.17 (2H, t, arom., J 8.8 Hz), 7.21 (3H, m, arom.), 7.87-7.97 (2H, m, arom.), 20 8.85 (1H, brs, amide NH), m/z (APCI+) 426 (MH+, 100%), 251 (Acid+, 25%) m/z (APCI-) 424 ([M-H]-, 100%).
Step 7: Purified by preparative HPLC ( 10-100% ACN (0.1 % TFA) over 30 minutes, held at 100% for 5 minutes at 20 mLlmin, YMC-PACK ODS-A, 25 5 micron, 100 x 30 mm, 254 nm) to give 6-{2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H benzoxazol-2-one (0.031 g, 6%) as a yellow solid:
vm~ (KBr) 3420br, 3124br, 2921ms, 1613w, 151 1w, 1466s (C(S)NH), 1333ms (NC(S)N), 1190s, 807ws, m/z (APCI+) 421 (MH+, 100%), 248 ( 10%) 30 m/z (APCI-) 419 ([M-H]-, 100%), 246 (10%), NMR 8H (DMSO-d6) 1.23 (2H, m), 1.51 ( 1 H, m), 1.54 (2H, d, J 12.2 Hz), 2.04 (2H, t, J 11.0 Hz), 2.88 (2H, d, J 11.2 Hz), 3.26 (2H, d, J 10.0 Hz), 3.75 (2H, s) 7.15 (4H, d, atom., J 8.0 Hz), 7.25 (3H, t, atom., J 8.3 Hz), 7.40 (1H, d, atom., J 8.3 Hz), 8.0 (1H, s, atom.) HPLC Rt = 5.94 minutes, 97.48% (20% to 100% ACN (0.1 % TFA) in 20 minutes, held at 100% ACN for 1 minute at 1.5 mL/min, 40°C liquid chromatography-mass spectrometry (LC-MS) Prodigy ODS(3), 3 micron, 150 x 4.6 mm 250 nm.
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H benzothiazol-2-one H
N
O
S
v I ~ ~1 ~s F
Step 1: Treatment of 2-hydroxybenxothiazole with chloroacetyl chloride and aluminum trichloride, following the procedure described in Example 6, Step 3, gave 6-(2-chloroethanoyl)-3H benzothiazol-2-one: 8H (d6-Me2S0) 5.14 (2H, s, CH2C1), 7.23 ( 1 H, d, atom., J 8.5 Hz), 7.92 ( 1 H, dd, atom., J 9.0, 2.0 Hz), 8.27 ( 1 H, d, atom., J 1.5 Hz) and 12.34 ( 1 H, s, NH):
mlz (APCI-) 228 and 226 (each [M-H]-, 25 and 55%).
Step 2: Treatment of 6-(2-chloroethanoyl)-3H benzothiazol-2-one with sodium azide, following the procedure described in Example 6, Step 4, gave 6-(2-azidoethanoyl)-3H benzothiazol-2-one (6.95 g, 96%):
m/z 233.08 (M-H-) vm~ 3441, 2117, 1676, 1595, 1399, 1343, 1269, 1214, 1067cm-1 8H (DMSO) 4.84 (2H, s, CH2), 7.23 (1H, d, atom., J 8.3Hz), 7.85-7.88 (1H, m, atom.), 8.20 (1H, s, atom.), NH not seen; and Step 3: 6-(2-Azidoethanoyl)-3H benzothiazol-2-one (0.5 g, 2.14 rnmol) and Pd-C
(5%, 0.17 g) in methanol (40 mL) and concentrated HCl (0.5 mL) were subjected to hydrogenation at 20 psi and 25°C for 1 hour. The catalyst was removed by filtration through a 'filter aid' and the solvent removed to give 6-(2-aminoethanoyl)-3H benzothiazol-2-one hydrochloride as a light brown solid (0.5 g, 96%).
m/z 209.04 (MH+) vm~ 3405, 2958, 1681, 1642, 1591, 1222, 1179, 814 cm-1 8H (DMSO) 4.53 (2H, s, CH2), 7.31 ( 1 H, d, arom., J 8.5 Hz), 7.94-7.97 ( 1 H, m, arom.), 8.33 (1H, s, arom.), 8.43 (3H, s, NH3+), 12.61 (1H, s, NH).
Step 4: Coupling of 6-(2-aminoethanoyl)-3~f benzothiazol-2-one hydrochloride with 35 following the procedure described in Example 6, Step 6, gave 2-[4-(4-fluorobenzyl)piperidin-1-yl]-~ [2-oxo-2-(2-oxo-2,3-dihydrobenzothiazol-6-yl)ethyl]acetamide:
vm~ (KBr) 3404m, 3346m, 4047, 1708s (ketone C=O), 1681s and 1653s (2 x amide C=O), 1596m, 1508m, 1218m and 841s cm-1 NMR 8H (DMSO-d6) 1.40-1.60 (2H, m), 1.71-1.80 (3H, m), 2.97-2.99 (2H, m), 3.45 (2H, d, J 11 Hz, CH2C6H4F), 3.98 [2H, s, C(O)CH2N], 4.73 [2H, d, J 5 Hz, C(O)CH2NH], 7.10 (2H, t, J8.5 Hz), 7.21-7.24 (3H, m), 7.93 (1H, dd, J8 and 1 Hz), 8.31 ( 1 H, d, J 1 Hz), 8.90 ( 1 H, brs), 9.5 7 ( 1 H, brs) and 12.43 ( 1 H, brs), m/z (APCI+) 442 (MH+, 100%), mlz (APCI-) 440 ([M-H]-, 50%) and 413 (100), HPLC Rt = 8.98 min; 97.24%; (20-100% MeCN in H20 (both +0.1%
trifluoroacetic acid) over 15 minutes at 1 mL/min, held at 100% MeCN for S minutes; Prodigy ODS III 5 ~., 250 x 4.6 mm, 40°C).
Step 5: To a stirred solution of 2-[4-(4-fluorobenzyl)piperidin-1-yl]-N [2-oxo-(2-oxo-2,3-dihydrobenzothiazol-6-yl)ethyl]acetamide (0.50 g, 1.13 mmol) in 1,4-dioxan (30 mL) was added [2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide] (Lawesson's reagent) (0.69 g, 1.70 mmol). The resulting suspension was heated at reflux for 24 hours. The reaction mixture was condensed to dryness in vacuo, redissolved in EtOAc, and washed with saturated aqueous sodium hydrogen carbonate, and saturated brine. The organic phase was dried (MgS04) and condensed to dryness in vacuo. The material was then subject to column chromatography [silica gel, EtOAc/Heptanes (0-50% EtOAc over 60 min)] gave 6-{2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H
benzothiazol-2-one (0.087 g, 18%) as an off white solid:
vm~ (KBr) 2918ms, 2852m, 1681 s (ketone C=O), 1599m, 1507s, 1454ms, 1214m, 1214ms, 804ms, m/z (APCI+) 440 (MH+, 100%), 249 (10%) m/z (APCI-) 438 ([M-H]-, 100%), 247 (10%), NMR SH (DMSO-d6) 1.18-1.26 (2H, dd, J8.8, 11.7 Hz), 1.48 (1H, m), 1.56 (2H, d, J 12.9 Hz), 2.09 (2H, t, J 11.2 Hz), 2.90 (2H, d, J 11.2 Hz), 3.28 (2H, d, J 9.5 Hz), 3.75 (2H, s), 7.06-7.18 (4H, m), 7.20 (2H, t, J 8.5 Hz), 7.52 ( 1 H, dd, J 2.0, 8.3 Hz), 7.91 ( 1 H, s), 7.92 ( 1 H, s), 12.0 ( 1 H, br, NH) HPLC Rt = 5.49 Min; 98.023%, (20% to 100% in 12 minutes, held at 100% ACN
for 1 minute at 1.5 mL/min, 40 degrees. Prodigy ODS (3), 3 micron, 150 x 4.6 mm, 250 nm).
5-(2-(4-Benzylpiperidin-1-ylmethyl)thiazol-5-yl]-1,3-dihydrobenzimidazole-2-thione H
N
S
~ N
N \~ v _H
N V S
Step 1: To a stirnng solution of 4-benzylpiperidine (6) (2.00 g, 11.41 mmol) in dichloromethane (20 mL) at 0°C was added triethylamine (1.59 mL, 11.41 mmol), followed by benzyl-2-bromoacetate ( 1.81 mL, 11.41 mmol). After 10 minutes a white precipitate was observed. The reaction mixture was allowed to warm to room temperature. After 45 minutes the reaction mixture was condensed to dryness in vacuo, redissolved in EtOAc (50 mL), the organic phase washed with saturated aqueous sodium hydrogen carbonate (50 mL), and saturated brine (50 mL). The organic phase was dried (MgS04) and condensed to dryness to give (4-benzylpiperidin-1-yl)acetic acid benzyl ester (3.69 g, 100%). as a pale yellow oil:
m/z (APCI+) 324 (MH+, 100%), 8H 1.36 (2H, dt, J3.2, 8.8 Hz), 1.42 (1H, M) 1.60 (2H, d, J 13.2), 2.10 (2H, dt, J 2, 9.6 Hz), 2.52 (2H, d, J 6.8 Hz), 2.88 (2H, d, J 11.6 Hz), 3.21 (2H, s, N-CO), 5.14 (2H, s, OCH2Ph), 7.17 (2H, d, J 7.2 Hz), 7.24 (2H, d, J 6.0 Hz).
HPLC Rt = 1.64 min; 68.1 %; (S-100% MeCN in H20 (both +0.1 % trifluoroacetic acid) over 2.5 minutes at 3 mL/min, held at 100% MeCN for 0.5 minute; Prodigy ODS III 5 ~,, SO x 4.6 mm).
Step 2: Hydrogenolysis of (4-benzylpiperidin-1-yl)acetic acid benzyl ester, following the procedure described on Example 6, Step 2, gave (4-benzylpiperidin-1-yl)acetic acid (2.66 g, 100%) as a white solid:
vm~ (KBr) 1626 (C=O), 1403s cm-1 m/z (APCI+) 234 (MH+, 100%), SH 1.75-1.85 (5H, m), 2.60 (2H, d, J 5.6 Hz), 2.73 (2H, m), 3.57 (2H, d, J 5.6 Hz), 3.67 (2H, d, J 11.6 Hz), 4.0 ( 1 H, s, OH), 7.12 (2H, d, J 7.2 Hz), 7.20 ( 1 H, d, J 7.2 Hz), 7.26 (2H, t, J 7.2 Hz).
(high performance liquid chromatography) HPLC Rt = 1.25 min; 100%; (S-100%
MeCN in H20 (both +0.1 % trifluoroacetic acid) over 2.5 minutes at 3 mL/min, held at 100% MeCN for 0.5 minute; Prodigy ODS III 5 ~., 50 x 4.6 mm).
Step 3: To a stirred solution of 1,2-phenylenediamine (10.00 g, 0.092 mol) in dimethylformamide (150 cm3) was added 1,1'-carbonyldiimidiazole (CDI, 14.99 g, 0.092 mol). After 22 hours, the reaction mixture was evaporated and then slurried in ethyl acetate. The resulting mixture was filtered, washed with ethyl acetate, and the residue dried in vacuo to give 1,3-dihydrobenzoimidazol-2-one (12.10 g, 98%) as a white solid:
vm~ (KBr) 1755 (C=O) cm-1 $H (DMSO-d6) 6.91 (4H, s, arom.), 10.55 (2H, brs, 2 x NH).
Step 4: To a stirred slurry of aluminum trichloride (22.76 g, 170.73 mmol) in 1,2-dichloroethane (20 mL) at 0°C was added chloroacetyl chloride (15.42 g, 136.57 mmol). After 30 minutes, the substrate (9.16 g, 68.29 mmol) was added in three portions, along with further 1,2-dichloroethane (20 mL). A red-brown color 5 was observed. The reaction mixture was heated at 50°C for 2 hours.
The mixture was then poured onto ice, and the resulting mixture filtered. The residue was washed with ethanol, which gave a white solid (17.00 g). The material was recrystallized by dissolving the crude product in DMF (70 mL), heating to 80°C, adding ethanol (70 mL), cooling to ambient temperature, and then cooling further 10 to 0°C. The resulting precipitate was collected by filtration, washed with ethanol, and dried in vacuo to give 5-(2-chloroethanoyl)-1,3-dihydrobenzimidazol-2-one (8.09 g, 56%) as a light brown solid:
vm~ (KBr) 1747 (C=O), 1687s, 1636s, 1473s, 1398s, 1321s, 1267s, 1202s, 1157s and 101 is cm-1 15 8H (DMSO-d6) 5.12 (2H, s, CH2C1), 7.04 (1H, d, arom., J 8 Hz), 7.49 (1H, s, arom.), 7.68 ( 1 H, dd, arom., J 8.5, 1.5 Hz), 10.96 ( 1 H, s, arom.) and 11.11 ( 1 H, s, arom.).
Step 5: Treatment of give 5-(2-chloroethanoyl)-1,3-dihydrobenzimidazol-2-one with sodium azide, following the procedure described in Example 6. Step 4, gave 20 6-(2-azidoethanoyl)-1,3-dihydrobenzimidazol-2-one (5.75 g, 93%):
vm~ 3415, 2106, 1723, 1681, 1476, 1268 cm-1 8H (DMSO) 4.84 (2H, s, CH2), 7.04 (1H, d, arom., J8.3Hz), 7.45 (1H, d, arom., J 1.2 Hz), 7.63 (1H, dd, arom., J 1.5, 8.1 Hz), 10.90-11.15 (2H, m, NHx2).
Step 6: 6-(2-Azidoethanoyl)-1,3-dihydrobenzimidazol-2-one (1.0 g, 4.6 mmol) 25 and Pd-C (S%, 0.3g) in methanol (150mL) and concentrated HCl (2mL), were subjected to hydrogenation at 25 psi and 27°C for lhour. The catalyst was removed by filtration through a 'filter aid' and the solvent removed to give 6-(2-aminoethanoyl)-1,3-dihydrobenzimidazol-2-one hydrochloride (1.01 g, 96%) as a brown solid:
30 m/z 192.10 (MH+) vm~ 3183, 1681, 1625, 1475, 1276, 1178 cm-1 8H (DMSO) 4.54 (2H, d, CH2, J5.4 Hz), 7.08 (1H, d, arom., J8.1 Hz), 7.52 (1H, s, arom.), 7.71 (1H, dd, arom., J 1.5, 8.1 Hz), 8.34 (3H, s, NH3+), 11.08 (1H, s, NH), 11.24 ( 1 H, s, NH).
Step 7: Condensation of 6-(2-aminoethanoyl)-1,3-dihydrobenzimidazol-2-one hydrochloride with (4-benzylpiperidin-1-yl)acetic acid, following the procedure described in Example 6, Step 6, gave S-[2-(4-benzylpiperidin-1-ylmethyl)thiazol-5-yl]-1,3-dihydrobenzimidazole-2-one:
vm~ (KBr) 3431br, 1730s (ketone C=O), 1691s, 1681s, 1645s, 1528s, 1365s, 1288s, 1232s, 815s and 750s cm-1 NMR 8H (DMSO-d6) 1.28-1.34 (2H, m), 1.49-1.57 (3H, m), 2.00 (2H, m), 2.87-2.94 (4H, m), 4.61 (2H, d, J S.5 Hz), 7.04 (1 H, d, J 8.5 Hz), 7.16-7.20 (3H, m), 7.27-7.30 (2H, m), 7.48 ( 1 H, s), 7.69 ( 1 H, dd, J 8.5 and 1.5 Hz), 7.98 (brs, 1 H, amide NH), 10.94 and 11.11 (each 1 H, s, 2 x NH):
mlz (APCI+) 407 (MH+, 60%) and 169 (100), HPLC Rt = 3 .74 min; 96.11 %; (20-100% MeCN in H20 (both +0.1 trifluoroacetic acid) over 12 minutes at 1.5 mL/minute, held at 100% MeCN for 1 minute; Prodigy ODS III 3 ~, 150 x 4.6 mm, 40°C).
Step 8: Treatment of 5-[2-(4-benzylpiperidin-1-ylmethyl)thiazol-S-yl]-1,3-dihydrobenzimidazole-2-thione with Lawesson's reagent, following the procedure described in Example 6, Step 7, gave5-[2-(4-benzylpiperidin-1-ylmethyl)thiazol-yl]-1,3-dihydrobenzimidazole-2-thione.
Purified by preparative HPLC (10-100% ACN (0.1% TFA) over 30 minutes, held at 100% for 5 minutes at 20 mL/minute, YMC-PACK ODS-A, 5 micron, 100 x 30 mm, 254 nm). Yellow solid (0.031 g, 6%).
vm~ (KBr) 3420br, 3124br, 2921ms, 1613w, 1511w, 1466s (C(S)NH), 1333ms (NC(S)N), 1190s, 807ws, m/z (APCI+) 421 (MH+, 100%), 248 ( 10%) m/z (APCI-) 419 ([M-H]-, 100%), 246 (10%), NMR 8H (DMSO-d6) 1.23 (2H, m), 1.51 (1H, m), 1.54 (2H, d, J 12.2 Hz), 2.04 (2H, t, J 11.0 Hz), 2.88 (2H, d, J 11.2 Hz), 3.26 (2H, d, J 10.0 Hz), 3.75 (2H, s) 7.15 (4H, d, arom., J 8.0 Hz), 7.25 (3H, t, arom., J 8.3 Hz), 7.40 (1H, d, arom., J8.3 Hz), 8.0 (1H, s, arom.) S HPLC Rt = 5.94 minutes, 97.48%, (20-100% ACN (0.1% TFA) in 20 minutes, held at 100% ACN for 1 minute at 1.5 mL/minute, 40°C. liquid chromatography-mass spectrometry (LC-MS) Prodigy ODS(3), 3 micron, 150 x 4.6 mm 250 nm.
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]oxazol-5-yl}-3H benzothiazol-2-one H
N
\ ~/ ~S
I ~1 \~o vm~ (KBr) 3436br, 1682 (amide C=O), 1508s, 1468s, 1346s, 1270s, 1175s, 1136s, 1087s, 989s, 947s, 822s, and 783s cm-1 NMR 8H (DMSO-d6) 1.40-1.50 (2H, m), 1.75-1.79 (3H, m), 3.05-3.10 (2H, m), 3.55-3.58 (2H, m), 4.59 (2H, brs), 7.12 (2H, t, J 9 Hz), 7.21 (2H, t, J 8 Hz), 7.67 ( 1 H, dd, J 9 and 1.5 Hz), 7.75 ( 1 H, s), 7.86 ( 1 H, s), 8.00 ( 1 H, d, J 8 Hz) and 9.95 ( 1 H, brs), m/z (APCI-) 422 ([M-H]' 100%), HPLC Rt = 4.55 min; 96.86%; (20-100% MeCN in H20 (both +0.1%
trifluoroacetic acid) over 7 minutes at 1.5 mL/minute, held at 100% MeCN for 1 minute; Prodigy ODS III 5 ~,, 250 x 4.6 mm, 40°C).
6-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-3H benzoxazol-2-one H
N
~O
N \ ~ O
I ~ ~ I ~o Step 1: Coupling of (4-benzylpiperidin-1-yl)acetic acid with 39, following the procedure described in Example 6, Step 6, gave 2-(4-benzylpiperidin-1-yl)-N [2-oxo-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]acetamide:
vm~ (KBr) 3380w, 3091w, 3023m, 291 1w, 1773s, 1676w, 1648s, 1616m, 1528m, 1450m, 1424m, 1353w, 1266s, 923m, 912m, and 748m cm-1 NMR SH (DMSO-d6) 1.17-1.33 (2H, m), 1.50-1.57 (3H, m), 1.99-2.04 (2H, m), 2.87-2.89 (2H, m), 2.94 (2H, s), 3.29 (2H, s), 4.61 (2H, d, J S.5 Hz), 7.16-7.21 (4H, m), 7.28 (2H, t, J 8 Hz), 7.84-7.87 (2H, m), and 8.01 ( 1 H, brs, amide NH):
m/z (APCI+) 408 (MH+, 100%), m/z (APCI-) 406 ([M-H]-, 100%), HPLC Rt = 5.30 min; 96.05%; (20-100% MeCN in H20 (both +0.1 trifluoroacetic acid) over 20 minutes at 1.5 mL/minute, held at 100% MeCN for 3 minutes; Prodigy ODS III 3 ~,, 150 x 4.6 mm, 40°C).
Step 2: 6-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-3H benzoxazol-2-one was prepared from 2-(4-benzylpiperidin-1-yl)-N [2-oxo-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]acetamide following the procedure described in Example 9, Step 1:
vm~ (KBr) 3435br, 1783s, 1766s, 1495m, 1485m, 1311m, 1286m, 128m, 1053m, 968w, and 753w cm-1 NMR SH (DMSO-d6) 1.20-1.40 (2H, m), 1.25-1.70 (3H, m), 2.10-2.40 (2H, m), 2.90-3.10 (2H, m), 3.70-3.85 (2H, m), 7.16-7.26 (4H, m), 7.48-7.63 (3H, m) and 11.82 ( 1 H, brs) m/z (APCI+) 390 (MH+, 18%) and 169 (100) HPLC Rt = 6.26 min; 95.61 %; (20-100% MeCN in H20 (both +0.1 trifluoroacetic acid) over 20 minutes at 1.5 mL/minute, held at 100% MeCN for 3 minutes; Prodigy ODS III 3 ~,, 150 x 4.6 mm, 40°C).
5-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-1,3-dihydroindol-2-one H
N
O
I ~1 Step 1: 5-(2-Chloroethanoyl)-1,3-dihydroindol-2-one was prepared following the procedure decribed in Example 6, Step 3:
8H (d6-Me2S0) 3.57 (2H, s, ArCH2C(O)NH), 5.08 (2H, s, CH2Cl), 6.93 (1H, d, arom., J 8.0 Hz), 7.83 ( 1 H, s, arom.), 7.88 ( 1 H, d, arom., J 8.0 Hz) and 10.82 ( 1 H, brs, NH), m/z (APCI-) 210 and 208 (each [M-H]-, 35 and 100%).
Step 2: Treatment of 5-(2-chloroethanoyl)-1,3-dihydroindol-2-one with sodium azide, following the procedure described in Example 6, Step 4, gave 6-(2-azidoethanoyl)-1,3-dihydroindol-2-one (6.58 g, 91%):
m/z 215.08 (M-H-) vm~ 3229, 2122, 1715, 1679, 1615, 1236, 1123, 824 cm-1 8H (DMSO) 3.57 (2H, s, CH2C0), 4.79 (2H, s, CH2N3), 6.93 (1H, d, arom., J 8.1 Hz), 7.79 ( 1 H, s, arom.), 7.83 ( 1 H, s, arom., J 8.3 Hz), 10.78 ( 1 H, bs, NH).
Step 3: Reduction of 6-(2-azidoethanoyl)-1,3-dihydro-indol-2-one, following the procedure described in Example 6, Step 5, gave 6-(2-aminoethanoyl)-1,3-dihydroindol-2-one hydrochloride (2.96 g, 63%):
m/z 191.05 (MH+) vm~ 3401, 3205, 1687, 1619, 1493, 1423, 1312, 1247 cm-1 8H (DMSO) 3.58 (2H, s, CH2C0), 4.49 (2H, d, CH2~ J5.4 Hz), 6.98 (1H, d, arom., J 8.3 Hz), 7.87 (1H, s, arom.), 7.92 (1H, d, arom., J 8.3Hz), 8.35 (3H, s, NH3+), 10.95 (1H, s, NH).
Step 4: Condensation of 6-(2-aminoethanoyl)-1,3-dihydroindol-2-one 5 hydrochloride with (4-benzylpiperidin-1-yl)acetic acid, following the procedure described in Example 6, Step 6, gave 2-(4-benzyl-piperidin-1-yl)-N [2-oxo-2-(2-oxo-2,3-dihydro-1H indol-5-yl)ethyl]acetamide:
vm~ (KBr) 3352br, 3173br, 2918m, 1717s (ketone C=O), 1679s, 1649s, 1621s, 1523s, 1361s, 1252s, 1101s 10 m/z (APCI+) 406 (MH+, 100%), 169 (25%) m/z (APCI-) 404 ([M-H]-, 100%).
NMR 8H (DMSO-d6) 1.31 (2H, dt, J3.0, 12.4 Hz), 1.51 (1H, m), 1.54-1.57 (2H, d, J 12.4 Hz), 2.86 (2H, d, J 11.6 Hz), 2.92 (2H, s), 3.29 (2H, d, J 9.2 Hz), 3.56 (2H, s), 4.56 (2H, d, J 6 Hz), 6.90 (1 H, d, J 8 Hz), 7.18 (3H, m), 7.26 (2H, t, 15 arom., J 7.2 Hz) 7.90 ( 1 H, d, arom., J 8.4 Hz) 7.95 ( 1 H, t, arom., J
5.6) HPLC Rt = 4.00 Min; 97.49%, (20-100% ACN (0.1% TFA) in 12 minutes, held at 100% acetonitrile (ACN) for 1 minute at 1.5 mL/minute, 40 degrees. Prodigy ODS
(3), 3 micron, 150 x 4.6 mm, 250 nm.
Step 5:5-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-1,3-dihydroindol-2-was 20 prepared from 2-(4-benzyl-piperidin-1-yl)-N [2-oxo-2-(2-oxo-2,3-dihydro-1H
indol-5-yl)ethyl]acetamide following the procedure described in Example 9, Step 1:
vm~ (KBr) 3439br, 1697s, 1624m, 1485m, 1239m, 1112m, IOSOm and 815m ' cm-1 25 NMR 8H (DMSO-d6) 1.15-1.18 (2H, m), 1.20-1.46 (3H, m), 2.02 (2H, t, J 11 Hz), 2.83 (2H, d, J 12 Hz), 3.54 (2H, s), 3.63 (2H, s), 6.89 (1 H, d, J 8Hz), 7.13-7.18 (3 H, m), 7.24-7.2 8 (2H, m), 7.42 ( 1 H, s), 7.49 ( 1 H, d, J 8 Hz), 7. S 3 ( 1 H, s) and 10.53 (1H, s, amide NH) m/z (APCI+) 388 (MH+, 100%) 30 m/z (APCI-) 386 ([M-H]-, 100%) HPLC Rt = 4.40 minutes; 99.40%; (20-100% MeCN in H20 (both +0.1 trifluoroacetic acid) over 12 minutes at 1.5 mL/minute, held at 100% MeCN for 1 minute; Prodigy ODS III 3 ~,, 1 SO x 4.6 mm, 40°C).
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydrothiazol-2-yl}-3H
benzoxazol-2-one OH
I ~ H ~' I ~ C~
o I ~ 1 °IH
F / N~N
v42 F / F /
43 NHz 2HC1 44 NH-CBZ
HO HO
OTBDMS
/ N ~NH-CBZ
v vF
OTBDMS
F / N ~~z H H
NH2 ~ N ~ N
I~ -' I o -. I~
MeOZC OH MeO2C ~O H02C O
H
N
46 ~ ~ OTBDMS
I H I
F ~ N / O
O
H
N
OTBDMS
_ I H I
F / N N / O
51 s H
N
OH \
-~ H I ~O
F ~ N / O
52 s H
N
~O
O
F ~~'~N
Step 1: 4-(4-Fluorobenzyl)piperidine hydrochloride (12) (20.0 g, 87.1 mmol), epichlorohydrin (8.06 g, 87.0 mmol) and triethylamine (8.80 g, 87.1 mmol) in EtOH (200 mL) were stirred at ambient temperature for 96 hours. The solvent was 5 removed and the material taken up in EtOAc, washed with saturated NaHC03, brine and dried (MgS04) to give 41 (16.69 g, 67%) as an orange solid:
1H-NMR (CDC13) 8H inter alia 1.22-1.35 (2H, m), 1.47-1.53 (1H, m), 1.62 (2H, dd, J 13 and 2.5 Hz), 1.95 and 2.24 (each 1 H, dt, J 11.5, 2.5 and 2.5 Hz), 2.42-2.44 (2H, m, CH2Ph), 2.50 (2H, d, J 7 Hz), 2.80 and 2.94 (each 1 H, d, J
10 11.5 Hz), 3.55 (2H; d, JS Hz, CH2C1), 3.87-3.93 (1H, m, CHOH), 6.93-6.99 and 7.06-7.10 (each 2H, m) m/z (APCI+) 286 (MH+, 100%) and 250 ([M-Cl]+, 60).
Step 2: Compound 41 (16.69 g, 58.46 mmol) and potassium phthalimide (10.81 g, 58.46 mmol) in DMF (100 mL) were heated to 100°C for 2 hours. The solvent was removed and the material taken up in EtOAc, washed with brine dried (MgS04) and evaporated. The residue was partially purified by silica gel column chromatography (CH2C12) to yield a 1:1 mixture of 42 and phthalimide (13.91 g, 44%) as a white solid:
1H-NMR (CDC13) SH 1.16-1.30 (2H, m), 1.43-1.51 (3H, m), 1.88 and 2.20 (each 1 H, dt, J 11.5 and 2.5 Hz), 2.33-2.43 (2H, m), 2.47 (2H, d, J 7 Hz), 2.78 and 2.89 (each 1 H, d, J 4.5 Hz), 3.63-3.82 (2H, m), 3.94-4.02 ( 1 H, m), 6.97 (2H, t, J 11 Hz), 7.05-7.08 (2H, m), 7.69-7.79 (2H, m) and 7.84-7.89 (2H, m) m/z (APCI+) 267 (MH+, 100%).
Step 3: Compound 42 (13.91 g, 25.6 mmol - impure mixture) and hydrazine hydrate (3.84 g, 76.89 mmol) in ethanol (100 mL) and water (100 mL) were heated under reflux conditions for 3 hours, and then left to stir at ambient temperature for 16 hours. The solvent was removed, and the crude material was acidified with 10% aqueous hydrochloric acid. The precipitate was filtered and the pad washed with water; the filtrate was concentrated to yield 43 (13.5 g, >100%, wet) as a yellow solid which was partially dried in vacuo:
NMR SH (MeOH-d4) inter alia 1.55-1.69 (2H, m), 1.85-1.92 (3H, m), 2.60 (2H, d, J6.5 Hz), 2.86-3.24 (6H, m), 3.60-3.68 (2H, m), 4.30-4.36 (1H, m), 7.01 (2H, t, J 8.5 Hz) and 7.18-7.24 (2H, m) m/z (APCI+) 267 (MH+, 100%).
Step 4: Benzyl chloroformate (4.26 g, 25.0 mmol) was added to a mixture of 43 (5.92 g, 17.57 mmol) and sodium carbonate decahydrate (21.45 g, 75.0 mmol) in dioxane-water (100-10 mL), and the resulting mixture stirred at ambient temperature for 4 hours. The solvent was removed, the material diluted with EtOAc, washed with water followed by brine, and then dried (MgS04) and evaporated. The product was purified by column chromatography (silica gel, 0%
to 5% MeOH in CH2Cl2) 44 (2.10 g, 30%) as a clear oil which solidified on standing:
m/z 401.21 (MH+) vm~ 3339, 2924, 1716, 1509, 1220 cm-1 1H-NMR (CDC13) 8H 1.25 (3H, m, alkyl), 1.60 (2H, m, alkyl), 1.82 (1H, m, alkyl), 2.22 (1H, m, alkyl), 2.28 (2H, d, CH2, J7.2 Hz), 2.49 (2H, d, CH2, S J 7.2 Hz), 2.72 ( 1 H, d, CHH, J 12.0 Hz), 2.93 ( 1 H, d, CHH, J 12.0 Hz), 3 .10 ( 1 H, m, CHIC, 3.41 ( 1 H, m, CHH), 3.70 ( 1 H, m, CHO), 5.10 (2H, s, CH20), 5.20 ( 1 H, bs, NH), 6.98 (2H, m, arom.), 7.07 (2H, m, arom.), 7.32 (5H, m, Ph).
Step 5: tert-Butyldimethylsilyl trifluorosulfonate (1.94 g, 7.35 mmol) was added to a cooled (0°C) solution of 44 (2.10 g, 5.25 mmol) and 2,6-lutidine (1.12 g, 10.50 mmol) in dichloromethane (20 mL). After 15 minutes, the mixture was diluted with dichloromethane, washed with saturated NaHC03 followed by brine, and then dried (MgS04) and evaporated to give 45 (2.80 g, quantitative) as a clear oil:
m/z 515.29 (MH+) vm~ 3350, 1721, 1510, 1255, 1222 cm-1.
Step 6: Compound 45 (2.70 g, 5.25 mmol) was hydrogenated at 50 psi and 30°C
in the presence of Pd(OH)2-C (100 mg) in MeOH (20 mL) for 8 hours. The mixture was filtered through a 'filter-aid' and the solvent removed to yield (1.83 g, 92%) as a clear gum:
mlz 3 81.31 (MH+) vm~ 3382, 2928, 1510, 1030, 837 cm 1 1H-NMR (CDC13) bH 0.08 (6H, s, Si(CH3)2), 0.88 (9H, s, tBu), 1.25 (2H, m, CH2), 1.45 (1H, m, CH), 1.60 (2H, m, CH2), 2.02 (2H, m, CH2), 2.25 (2H, bs, NH2), 2.47 (4H, m, 2x CH2), 2.88 (2H, d, CH2, J4.4 Hz), 2.89 (2H, bt, CH2, J 12.0 Hz), 3.81 ( 1 H, m, CHO).
Step 7: Methyl 4-amino-3-hydroxybenzoate (47) (11.01 g, 65.9 mmol) and CDI
(11.21 g, 69.2 mmol) were stirred in DMF (75 mL) at room temperature for 1 hour. The DMF was then removed and the mixture diluted with EtOAc, washed with 0.5 M NaOH, 10% HC1, brine and dried (MgS04) to give 48 (7.52 g, 59%) as a brown solid:
m/z 191.98 (M-H)-vm~ 3402, 1746, 1708, 1290 cm-1 5 1H-NMR (CDC13) 8H (DMSO-d6) 3.85 (3H, s, OCH3), 7.19 (1H, d, arom., J 8.4 Hz), 7.76 ( 1 H, d, arom., J 1.6 Hz), 7.82 ( 1 H, dd, arom., J 1.6, 8.4 Hz), 12.07 (1H, bs, NH).
Step 8: Compound 48 (8.0 g, 41.5 mmol) and LiOH~H20 (3.49 g, 83.0 mmol) in MeOH-H20 (100-10 mL) were heated under reflux conditions for 4 hours. An 10 aliquot of LiOH.H20 (1.75 g, 42.0 mmol) was added and the heating continued for a further 3 hours. The solvent was removed, and the solids were slurried in 10% HCl then filtered and washed with H20 and dried in vacuo to give 49 (7.40 g, quantitative) as a brown solid:
m/z 177 (M-H)-15 vm~ 3431, 3120, 1769, 1685, 1619, 1427, 1296 cm-1 NMR SH (DMSO-d6) 7.17 ( 1 H, d, arom., J 8.4 Hz), 7.40 ( 1 H, d, arom., J 1.2 Hz), 7.80 ( 1 H, dd, arom., J 1.2, 8.4 Hz), 12.02 ( 1 H, bs, NH), 13.89 ( 1 H, bs, OH).
Step 9: Compound 49 (980 mg, 69%) as a brown foam:
20 mlz 542.27 (MH+) 1H-NMR (CDC13) SH 0.12 (3H, s, SiCH3), 0.13 (3H, s, SiCH3), 0.89 (9H, s, SitBu), 1.66 (1H, bs, alkyl), 1.80 (2H, bs, alkyl), 2.40 (2H, bs, alkyl), 2.57 (2H, m alkyl), 2.79 (1H, bs, alkyl), 2.96 (1H, bs, alkyl), 3.31 (1H, bs, alkyl), 3.53 (2H, bs, alkyl), 3.66 (2H, m, alkyl), 4.20 (1H, bs, CHO), 6.96-7.12 (5H, m, arom.), 7.58 25 ( 1 H, s, arom.), 7.66 ( 1 H, d, arom., J 8.0 Hz), 7.99 ( 1 H, bs, NH).
Step 10: Compound 50 (980 mg, 1.81 mmol) and Lawesson's reagent (366 mg, 906 ~,mol) in dioxane (5 mL) were heated under reflex conditions for 1 hour. A
further aliquot of Lawesson's reagent (732 mg, 1.81 mmol) was added, and heating continued for 1.5 hours. The solvent was removed and the product was diluted with EtOAc, washed extensively with saturated NaHC03, brine, and dried.
The product was purified by chromatography (silica gel, 0-50% EtOAc in heptane) to give 6-[5-(4-(4-fluorobenzyl)piperidin-1-ylmethyl)-4,5-dihydro-thiazol-2-yl]-3H benzoxazol-2-one (194 mg, 25%) as a white solid:
m/z 426.18 (MH+) vm~ 1773, 1509 cm-1 1H-NMR (CDC13) 8H 1.25 (2H, m, alkyl), 1.56 (3H, m, alkyl), 1.97 (2H, t, CH2, J 11.2 Hz), 2.56 (4H, m, alkyl), 2.89 (2H, bm, alkyl), 4.11 ( 1 H, 1, CHS, J
6.4 Hz), 4.35 (2H, m, CH2N), 6.96 (2H, m, arom.), 7.06 (3H, m, arom.), 7.63 (1H, dd, arom., J 1.0, 8.0 Hz), 7.73 ( 1 H, d, arom.,. J 1.2 Hz) HPLC Rt = 3.81 minutes, 99.10% (20-100% MeCN in H20 (both +0.1 % formic acid) over 7 minutes at 1.5 mL/min; Prodigy ODS III 3 ~., 150 x 4.6 mm, 40°C) 6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-2-yl]-3H benzoxazol-2-one H
N
O
S
O
I
~~"~~N
Step 1: Treatment of amine 6 with epichlorohydrin, following the procedure described in Example 12, Step l, gave crude 1-chloro-3-(4-benzylpiperidin-1-yl)propan-2-of (29.03 g, >100%) as a clear, colorless oil:
vm~ (neat) 3300 (brs, OH), 2921s, 1603m, 1494m, 1453s, 1091s, 1058s, 747s 1H-NMR (CDC13) 8H 1.24-1.30 (2H, m), 1.50-1.60 (1H, m), 1.61-1.65 (2H, m), 1.93, 2.24 (each 1 H, dt, J 11.5 and 2 Hz), 2.36-2.46 (2H, m), 2.53 (2H, d, J
7 Hz, CH2N), 2.78, 2.92 (each 1H, d, J 12 Hz, CH2Ph), 3.53-3.55 (2H, m, CH2C1), 3.86-3.92 (1H, m, CHOH), 7.09-7.29 (5H, m, Ph) mlz (APCI+) 270 and 268 (each MH+, 40 and 100%) and 232 ([M-Cl]+, 40).
Step 2: Treatment of 1-chloro-3-(4-benzylpiperidin-1-yl)propan-2-of with potassium phthalimide, following the procedure described in Example 12, Step 2, gave 2-[3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]isoindole-1,3-dione (32.44 g, 86%) as a white solid:
1H-NMR (CDC13) 8H 1.13-1.35 (2H, m), 1.45-1.49 (1H, m), 1.50-1.58 (2H, m), 1.87 and 2.19 (each 1H, dt, J 11.5, 11.5 and 2 Hz), 2.31-2.45 (2H, m), 2.50 (2H, d, J 7 Hz, NCH2CH(OH), 2.76 and 2.86 (each 1 H, d, J 12 Hz), 3.68 and 3.79 (each 1H, dd, J 13.5 and 4.5 Hz, CH2N), 3.96-4.03 (1H, m, CHOH), 7.10-7.28 (5H, m, Ph), 7.68-7.75, and 7.82-7.86 (each 2H, m, phthalimide) m/z (APCI+) 379 (MH+, 100%).
Step 3: Treatment of 2-[3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]-isoindole-1,3-dione with hydrazine hydrate, following the procedure described in Example 12, Step 3, gave 1-amino-3-[4-benzylpiperidin-1-yl]propan-2-of bis-hydrochloride salt (24.32 g) as a yellow hygroscopic solid:
vm~ (KBr) 3418br, 2934br, 1712m, 1603m, 1494m, 1454m, 1066m, 945m and 748m NMR 8H (CD30D) 1.59-1.62 (2H, m), 1.86-1.93 (3H, m), 2.61 (2H, d, J6.5 Hz), 2.90-3.31 (6H, m), 3.60-3.64 (2H, m), 4.30-4.40 (1H, m, CHOH), 7.17-7.20 (2H, m) and 7.22-7.26 (2H, m).
mlz (APCI+) 249 (MH+, 100%).
Step 4: To a stirring solution of 1-amino-3-(4-benzylpiperidin-1-yl)propan-2-of (2.00 g, 6.23 mmol) in 1,4-dioxan/H20 (4:1, 25 mL) was added solid sodium hydroxide (0.28 g, 6.85 mmol). On full dissolution of the sodium hydroxide, dibenzyl dicarbonate ( 1.96 g, 6.85 mmol) was added. The resulting solution was stirred for 22 hours. The reaction mixture was condensed to dryness in vacuo to give a yellow gum. This was redissolved in EtOAc, washed with saturated aqueous sodium bicarbonate solution, and saturated brine. The organic phase was dried (MgS04) and condensed to dryness in vacuo to give a yellow oil. The oil was subject to column chromatography [silica gel, MeOH-DCM (0-20% MeOH over 30 minutes)] to give [3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]carbamic acid benzyl ester (1.64 g, 69%) as an orange solid:
mlz (APCI+) 383 (MH+, 100%) 1H-NMR (CDC13) SH 1.2-1.3 (2H, m), 1.5 (1H, m), 1.60 (2H, d, ~ 13.1 Hz), 1.85 (1H, t, 711.2 Hz), 2.20 (1H, t, 711.2 Hz), 2.27 (2H, d, 76.8 Hz), 2.51 (2H, d, 77.0 Hz), 2.70 ( 1 H, d, ~ 11.2 Hz), 2.90 ( 1 H, d, 711.2 Hz), 3.10 ( 1 H, m), 3.40 ( 1 H, d, ~ 3.6 Hz), 3.70 ( 1 H, d, 7 3.4 Hz), 5.10 (2H, s, CH20), 5.25 ( 1 H, s, NH), 7.11 (2H, d, atom., 97.2 Hz), 7.18 (1H, t, atom., 77.6 Hz), 7.25-7.35 (7H, m, atom.) HPLC Rt = 1.62 min; 71.1 %; (5-100% MeCN in H20 (both +0.1 % trifluoroacetic acid) over 2.5 minutes at 3 mL/minute, held at 100% MeCN for 0.5 minute;
Prodigy ODS III 5 ~., 50 x 4.6 mm).
Step 5: Treatment of [3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]carbamic acid benzyl ester with tert-Butyldimethylsilyl trifluorosulfonate, following the procedure described in Example 12, Step S, gave {2-(tert-butyldimethylsilanyloxy)-3-[4-benzylpiperidin-1-yl]propyl}carbamic acid benzyl ester as a yellow oil:
m/z 497.42 (MH+) vm~ 3353, 2927, 1726, 1253, 1100, 836 cm-1 1H-NMR (CDC13) 8H 0.05 (6H, s, Si(CH3)2), 0.86 (9H, s, SitBu), 1.25 (2H, m, alkyl), 1.45 (1H, m, CH), 1.60 (2H, m, alkyl), 1.90 (2H, m, alkyl), 2.33 (2H, d, 2 x CH, J 6.0 Hz), 2.48 (2H, d, CH2, J 7.2 Hz), 2.83 (2H, bd, CH2, J 10.4 Hz), 3.27 (2H, m, CH2), 3.82 (1H, m, CHO), 5.10 (2H, s, CH20), 5.85 (1H, bm, NH), 7.11 (2H, m, atom.), 7.18 (1H, m, atom.), 7.28-7.37 (5H, m, atom.).
Step 6: Hydrogenation of {2-(tert-butyldimethylsilanyloxy)-3-[4-benzylpiperidin-1-yl]propyl}carbamic acid benzyl ester, following the procedure described in Example 12, Step 6, gave {2-(tert-butyldimethylsilanyloxy)-3-[4-benzylpiperidin-1-yl]-propylamine as a white semi-solid:
m/z 363.19 (MH+) vm~ 2927, 1252, 1075, 836, 770 cm 1 1H-NMR (CDC13) 8H 0.075 (3H, s, SiCH3), 0.08 (3H, s, SiCH3), 0.89 (9H, s, SitBu), 1.28 (1H, m, alkyl), 1.63 (5H, m, alkyl, NH2), 1.92 (2H, m, alkyl), 2.30 (2H, d, 2 x CH), 2.51 (2H, d, CH2, J 6.8 Hz), 2.69 ( 1 H, dd, CH, J 5.2, 12.8 Hz), 2.78 (0.5H, d, 0.5 x CH, J4.4 Hz), 2.82 (2.5H, m, alkyl), 3.73 (1H, m, CHO), 7.14 (2H, m, arom.), 7.20 (1H, m, arom.), 7.26 (2H, m, arom.).
Step 7: Compound 49 (271 mg, 1.51 mmol), HBTU (574 mg, 1.51 mmol) and DIPEA (391 mg, 3.03 mmol) were stirred in DMF (5 mL) for 10 minutes, then {2-(tert-butyldimethylsilanyloxy)-3-[4-(benzyl)piperidin-1-yl]propylamine (548 mg, 1.51 mmol), was added and stirring continued for 1 hour. The solvent was removed, and the mixture diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04). The crude material was purified by chromatography (silica gel, CH2C12) to give 2-oxo-2,3-dihydrobenzoxazole-6-carboxylic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethyl-silanyloxy)propyl]amide (786 mg, 99%) as a brown foam:
m/z 542.22 (MH+) vm~ 3376, 2929, 1781, 1640, 1494, 840 cm-1.
Step 8: 2-Oxo-2,3-dihydrobenzoxazole-6-carboxylic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethylsilanyloxy)propyl]amide (686 mg, 1.31 mmol) and Lawesson's reagent (530 mg, 1.31 mmol) in dioxane (5 mL) were heated under reflux conditions for 2 hours. The solvent was removed, and.the product was purified by chromatography (silica gel, 0-50% EtOAc in heptane) to give 2-oxo-2,3-dihydrobenzoxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethylsilanyloxy)propyl]amide (559 mg, 79%): as a green gum:
m/z 540.33 (MH+) vm~ 3218, 1771, 1595, 1495, 1255, 1108 cm-1 1 H-NMR (CDC13) 8H aliphatics of little use due to rotamers, 7.07 ( 1 H, d, arom., J 7.2 Hz), 7.20 ( 1 H, d, arom., 7.2 Hz), 7.21-7.29 (5H, m, Ph), 7.74 ( 1 H, s, arom.).
Step 9: Tetrabutylammonium fluoride (TBAF) ( 1.24 ~mol, 1.24 mL, 1 M in THF) was added to a mixture of 2-oxo-2,3-dihydrobenzoxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethylsilanyloxy)propyl]amide (336 mg, 623 ~.mol) and 4th molecular sieves ( 1 g) in THF (2 mL). After stirring at room temperature for 1.5 hours, the mixture was diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04) to yield 2-oxo-2,3-5 dihydrobenzoxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]amide (280 mg, quantitative) as a solid yellow foam:
m/z 426.29 (MH+) vm~ 3306, 2924, 1770, 1660, 1264, 1059 cm-1 1H-NMR (CDC13) 8H some TBAF still present, hence aliphatics unclear; 2.52 10 (2H, d, CH2, J 7.2 Hz), 2.80 ( 1 H, d, CHH, J 11.2 Hz), 2.99 ( 1 H, d, CHH, J 11.2 Hz), 3.25 (2H, m, CH2), 3.83 ( 1 H, m, OH), 4.07 ( 1 H, m, CHO), 7.05 ( 1 H, d, arom., J 8.4 Hz), 7.12 (2H, d, arom., J 8.4 Hz), 7.20 ( 1 H, d, arom., J
7.2 Hz), 7.28 (2H, m, arom.), 7.59 (1H, d, arom., J8.0 Hz), 7.12 (1H, d, arom., J 1.6 Hz), 8.42 (1H, bs, NH).Step 10: 2-Oxo-2,3-dihydrobenzoxazole-6-carbothioic acid [3-15 (4-benzylpiperidin-1-yl)-2-hydroxypropyl]amide (240 mg, 565 ~.mol) and Burgess reagent (134 mg, 565 ~mol) in THF (5 mL) were heated under reflux conditions for 1 hour. The mixture was diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04). Purification by chromatography (silica gel, CH2C12) gave the product as a yellow foam (91 mg), this was then repurified by 20 chromatography (silica gel, 0-50% EtOAc in heptane) to give 6-[5-(4-benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-2-yl]-3H benzoxazol-2-one (52 mg, 23%) as an off white solid:
m/z 408.21 (MH+) vm~ 3261, 1777, 1494, 1447, 1273 cm-1 25 1H-NMR (CDC13) SH 1.31 (4H, m, alkyl), 1.60 (3H, m, alkyl), 1.97 (2H, t, CH2, J 7.2 Hz), 2.53 (4H, 2 x d, alkyl, J 6.4, 7.2 Hz), 2.90 (2H, bs, alkyl), 4.12 ( 1 H, m, CHS), 4.35 (2H, m, CH2N), 7.03 (1H, d, arom., J 8.0 Hz), 7.13-7.30 (5H, m, Ph), 7.62 (1H, dd, arom., J 1.6, 8.0 Hz), 7.73 (1H, d, arom., J 1.6 Hz).
6-[2-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-5-yl]-3H benzoxazol-2-one OH
N3 ~ O N3 O
I~ ~o ~ Iw N ~ N
OTBDMS OTBDMS
N3 \ O HZN ~ O
I ~ ~o ~ I ~o o NV \
O
~O
56 ~ N
H
O
N OTBDMS
F
O
N
H
S
N 'I OTBDMS
F
N
H
S
OH
N
F
~N
H
F ~~S ~ O
O
N
H
Step 1: Sodium borohydride (603 mg, 15.46 mmol) was added to a solution of 38 (3.37 g, 15.46 mmol) in EtOH-MeOH (50-SO mL) at 0°C and stirred and allowed to warm to room temperature over 1 hour. The solvent was removed and the mixture diluted with EtOAc, washed with brine and dried (MgS04) to give 53 (2.09 g, 61 %) as an orange/brown solid:
mlz 219.07 (M-H)-vm~ 3258, 2105, 1758 cm-1 NMR SH (DMSO-d6) 3.34 (2H, ddd, CH2, J4.0, 7.6, 12.8 Hz), 4.80 (1H, ddd, CHO, J 3.6, 4.4, 7.2 Hz), 5.48 ( 1 H, d, OH, J 4.8 Hz), 7.04 ( 1 H, d, arom., J 8.0 Hz), 7.17 ( 1 H, dd, arom., J 0.8, 7.6 Hz), 7.3 0 ( 1 H, s, arom.), 11.60 ( 1 H, bs, NH).
Step 2: 2,6-Lutidine (1.02 g, 9.5 mmol) was added to a solution of 53 (2.09 g, 9.5 mmol) in THF (50 mL) at 0°C, followed by TBDMSOTf (2.51 g, 9.50 mmol) and the solution allowed to warm to room temperature. After 2 hours, a further aliquot of TBDMSOTf (1.25 g, 4.75 mmol) was added and the solution stirred for a further 1 hour. The mixture was diluted with EtOAc, washed with saturated NaHC03, 10% HCI, brine and dried (MgS04). The material was partially purified by chromatography (silica gel, 0-30% EtOAc in heptane) to yield 54 (3.20 g, quantitative)as a yellow oil:
mlz 449.24 (M+TBDMS+H+) vm~ 3227, 2102, 1771, 1260, 838 cm-1 NMR 8H (DMSO-d6) 0.10 (3H, SICH3), 0.10 (3H, s, SiCH3), 0.87 (9H, s, SitBu), 3.32 (2H, m, CH2), 4.97 (1H, dd, CHO, J3.6, 6.8 Hz), 7.06 (1H, d, arom., J 7.6 Hz), 7.18 ( 1 H, dd, arom., J 1.2 8.0 Hz), 7.29 ( 1 H, s, arom.), 11.62 ( 1 H, bs, NH).
Step 3: Compound 54 (3.20 g, 9.5 mmol assumed) and 10% Pd-C (400 mg) in MeOH (50 mL) were hydrogenated at 50 psi and 30°C for 2 hours. The mixture was filtered through Kieselguhr, the filter cake was then washed with DMF
0300 mL), and these washings were concentrated to yield 55 (1.81 g, 62%) as an off white solid:
mlz 309.18 (MH+) vm~ 3418, 1677, 1582, 1263 cm-1 NMR SH (DMSO-d6) 0.12 (3H, SICH3), 0.05 (3H, s, SiCH3), 0.85 (9H, s, SitBu), 2.62 ( 1 H, dd, CH2, J 5.2, 6.4 Hz), 4.62 ( 1 H, dd, CHO, J 5.2, 6.4 Hz), 7.01 ( 1 H, d, arom., J 8.0 Hz), 7.06 ( 1 H, dd, arom., J 1.6 8.0 Hz), 7.17 ( 1 H, s, arom.).
Step 4: Compound 35 (1.69 g, 5.88 mmol), HBTU (2.29 g, 5.88 mmol) and DIPEA (3.03 g, 23.51 mmol) in DMF (25 mL) were stirred at room temperature for 10 minutes, then 55 (1.81 g, 5.88 mmol) was added, and the mixture stirred at room temperature for 4 hours. The solvent was removed and the mixture taken up in EtOAc, washed with saturated NaHC03, brine and dried (MgS04). The product was purified by chromatography (silica gel, 0-5% MeOH in CH2C12) to yield 56 (1.32 g, 42%) as a fawn colored foam:
m/z 542.30 (MH+) vm~ 3351, 1778, 1657, 1509 cm-1 1H-NMR (CDC13) 8H 0.09 (3H, SICH3), 0.08 (3H, s, SiCH3), 0.94 (9H, s, SitBu), 1.27 (2H, m, alkyl), 1.58 (3H, m, alkyl), 2.04 (1H, t, CH, J 11.2 Hz), 2.18 (1 H, t, CH, J 10.8 Hz), 2.51 (2H, d, CH2, J 6.8 Hz), 2.75 (2H, m, alkyl), 2.92 (2H, m, alkyl), 3.28 ( 1 H, m, alkyl), 3.56 ( 1 H, m, alkyl), 4.82 ( 1 H, dd, CHO, J 4.4, 6.0 Hz), 6.91-7.00 (3H, m, arom.), 7.09 (3H, m, arom.), 7.22 (1H, s, arom.), 7.56 (1H, bm, CONH), 8.36 (1H, bs, NH).
Step 5: Compound 56 (1.32 g, 2.44 mmol) and Lawesson's reagent (493 mg, 1.22 mmol) in dioxane (10 mL) were stirred and heated to reflux for 1.5 hours.
A
further aliquot of Lawesson's reagent (493 mg, 1.22 mmol) was added and heating continued for 1 hour. The mixture was diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04). The crude material was purified by chromatography (silica gel, 0-50% EtOAc/heptane) to give 57 (806 mg, 59%) as a cream colored oil which solidified on standing:
m/z 557.31 (MH+) vm~ 3250, 1776, 1509, 1259, 836 cm-1 1H-NMR (CDC13) 8H 0.07 (3H, SICH3), 0.07 (3H, s, SiCH3), 0.90 (9H, s, SitBu), 1.18 (2H, m, alkyl), 1.47-1.65 (3H, m, alkyl), 2.04 (1H, dt, CH, J2.2, 11.6 Hz), 2.22 ( 1 H, dt, CH, J 2.2, 11.6 Hz), 2.51 (2H, d, CH2, J 6.8 Hz), 2.57 ( 1 H, d, CHH, J 12.0 Hz), 2.72 ( 1 H, d, CHH, J 12.0 Hz), 3.40 (2H, dd, CH2, J 17.6, 25.2 Hz), 3.80 ( 1 H, m, alkyl), 4.03 ( 1 H, m, alkyl), 5.09 ( 1 H, dd, CHO, J
4.0, 6.0 Hz), 6.98 (3H, m, arom.), 7.09 (2H, m, arom.), 7.16 (1 H, d, arom., J 8.0 Hz), 7.29 ( 1 H, s, arom.), 7.90 ( 1 H, s, CONH), 9.56 ( 1 H, bs, NH).
Step 6: Compound 57 (806 mg, 1.45 mmol) in THF (10 mL) was treated with TBAF (1 M in THF, 2.90 mL, 2.90 mmol) and stirred at room temperature for 4 hours. The mixture was diluted with EtOAc, washed with 10% citric acid, saturated NaHC03, brine and dried (MgS04). The product was purified by chromatography (silica gel, 0-2% MeOH/CH2C12) to give 58 as a fawn colored foam (348 mg, 64%):
mla 444.19 (MH+) 5 vm~ 3210, 1766, 1509 cm-1 1H-NMR (CDCl3) bH 1.15 (2H, m, alkyl), 1.49-1.61 (3H, m, alkyl), 2.15 (2H, t, alkyl, J 12.0 Hz), 2.49 (2H, d, CH2, J 7.2 Hz), 2.68 (2H, t, CH2, J 12.4 Hz), 2.76 ( 1 H, bs, OH), 3.44 ~(2H, dd, CH2, J 18.0, 19.2 Hz), 3.76 ( 1 H, dd, CHH, J
8.0, 14.0 Hz), 4.25 ( 1 H, dd, CHH, J 2.8, 14.0 Hz), 5.13 ( 1 H, dd, CHO, J 3.2, 7.2 Hz), 10 6.95-7.00 (2H, m, arom.), 7.03-7.09 (3H, m, arom.), 7.22 (1H, d, arom., J
8.4 Hz), 7.33 (1H, s, arom.), 9.69 (1H, bs, NH).
Step 7: Compound 58 (348 mg, 786 ~mol) and Burgess reagent (187 mg, 786 p,mol) in THF (10 mL) were stirred and heated to reflux for 4 hours. An aliquot of Burgess Reagent (37 g, 157 p.mol) was added and heating continued for 15 a further 2 hours. Diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04). The product was purified by chromatography (silica gel, 0-2%
MeOH/CH2C12) and then again using (silica gel, 0-75% EtOAc/heptane) to yield 6- { 2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4, 5-dihydrothiazol-5-yl } -3H
benzoxazol-2-one (98 mg, 29%) as a white solid:
20 mlz 426.26 (MH+) vm~ 3111, 1771, 1622, 1509, 1219 cm-1 1H-NMR (CDC13) 8H 1.34 (2H, m, alkyl), 1.49 (1H, m, alkyl), 1.59 (2H, m alkyl), 2.06 (2H, dd, alkyl, J 9.6, 19.2 Hz), 2.50 (2H, d, CH2, J 7.2 Hz), 2.93 (2H, dd, CH2, J 10.8, 10.8 Hz), 3.39 (2H, dd, CH2, J 16.2, 16.2 Hz), 4.37 (1H, dd, 25 CHH, J 4.8, 15.6 Hz), 4.5 8 ( 1 H, dd, CHH, J 9.2, 16.0 Hz), 4. 87 ( 1 H, dd, CHO, J5.2, 9.2 Hz), 6.94 (3H, m, arom.), 7.06 (3H, m, arom.), 7.15 (1H, d, arom., J 1.2 Hz), 8.41 ( 1 H, bs, NH).
General Methods for Examples 15-36:
HCl salts were prepared by treatment of a MeOH solution of the amine with excess HCl in Et20 (1 M). The salts were isolated either by filtration if they precipitated directly from the etherial solution, or by first removal of the solvent S under reduced pressure, and then crystallization (Et20/MeOH).
Purity was determined by reversed phase HPLC by the following methods:
Method A: column: YMC J' Sphere C 18, ODS-M80, 150 x 4.6 mm, 4 ~.; solvent A: 0.1% H3P04 in 95:5 H20/CH3CN; solvent B: 0.1% H3P04 in 95:5 CH3CN/H20; gradient: 10-100% B over 15 minutes; flow: 1 mL min-1;
detection: 210 nm.
Method B: column: YMC J'Sphere C18, ODS-M80, 150 x 4.6 mm, 4 ~,; solvent A: 0.1% H3P04 in 95:5 H20/MeOH; solvent B: 0.1% H3P04 in 95:5 MeOH/H20; gradient: 10-100% B over 15 minutes; flow: 1 mL min-1; detection:
21 S nm.
Method C: column: SYNERGI MAX-RP C 12, 80~, 150 x 4.6 mm, 4 ~,; solvent A: 95:5 H20/ CH3CN; solvent B: 95:5 CH3CN/H20; gradient: 10-100% B over 15 minutes; flow: 1 mL min-l; detection: 215 nm.
Method D: column: SYNERGI MAX-RP C 12, 80 ~, 1 SO x 4.6 mm, 4 p,; solvent A: 95:5 H20/MeOH; solvent B: 95:5 MeOH/H20; gradient: 10-100% B over 15 minutes; flow: 1 mL min' 1; detection: 215 nm.
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethylJisoxazol-3-yl}-3H benzoxazol-2-one N-OH N _O
Bn0 ~ 1. NCS, DMF Bn0 I / COzMe Dh \ ,H _ ~ \ v / 2. methyl propriolate 02N 1:1 THF/H20 02N
2 NaHC03 59 N_p OH N~O Br Bn0 I / NBS, PPh3 Bn0 \ I / ~ 1 ~F
\ v O N I ~ 61 KZCOs, ~. CH3CN
_O N-O
I
Bn0 N / i. Hy Pd/C O \ /
N ii. carbonic acid di-2-pyridyl ester O~ I / N
F ~ / F
S Step 1: A solution of oxime of formula 2 (8.41 g, 30.9 mmol) and freshly crystallized (benzene) N chlorosuccinimide (4.12 g, 30.9 mmol) in DMF (30 mL) was stirred at room temperature for 1 hour. The reaction was partitioned between EtOAc and H20. The organic layer was washed with saturated NaCI, dried (Na2S04), and concentrated under reduced pressure. The residue was dissolved in 1:1 THF/H20 (30 mL). Sodium bicarbonate (7.80 g, 92.7 mmol) and methyl propiolate (2.4 mL, 40.2 mmol) were added, and the reaction mixture was stirred overnight. The reaction was diluted with EtOAc and the organic layer was dried (Na2S04), and concentrated under reduced pressure. Ester of formula 59 (7.21 g, 66%) was isolated as a yellow solid following trituration with EtOAc/hexanes:
1 H NMR (500 MHz, CDC13): 8 7.96 (d, J 9 Hz, 1 H), 7.70 (d, J 2 Hz, 1 H), 7.48 (dd, J8, 1 Hz, 2H), 7.42-7.39 (m, 3H), 7.36-7.33 (m, 1H), 7.25 (s, 1H), 5.32 (s, 2H), 4.01 (s, 3H).
Step 2: To an ice-cold solution of the ester of formula 59 (7.21 g, 20.3 mmol) in THF (100 mL) was added diisobutylaluminum hydride (51.0 mL of a 1.0 M
solution in cyclohexane, 51.0 mmol). After 1 hour, the reaction was diluted with MeOH (2 mL) and a saturated solution of Rochelle's salt (50 mL) was added.
After stirring briefly, the solution became gel like. The gel dissolved upon addition of EtOAc (150 mL) and the solution was stirred for several hours. The organic layer was washed with H20 and saturated NaCI, dried (Na2S04) and concentrated under reduced pressure to give the alcohol of formula 60 (6.57 g, 99%) as a yellow solid:
1 H NMR (300 MHz, CDCl3): 8 7.96 (d, J 9 Hz, 1 H), 7.70 (d, J 2 Hz, 1 H), 7.49 (dd, J 8, 1 Hz, 2H), 7.42-7.30 (m, 4H), 6.60 (s, 1 H), 5.32 (s, 2H), 4.85 (s, 2H), 2.15 (s, 1 H).
Step 3: Triphenylphosphine (6.56 g, 25.0 mmol) and N bromosuccinimide (4.45 g, 25.0 mmol) were added to an ice-cold solution of alcohol of formula (6.53 g, 20.0 mmol) in THF (SO mL) and the solution was stirred for 1 hour.
The mixture was partitioned between EtOAc and saturated NaHC03. The organic layer was washed with saturated NaCI, dried (Na2S04), and concentrated under reduced pressure. Purification by chromatography (silica gel, 1:4 hexanes/EtOAc) gave bromide of formula 61 (6.88 g, 88%):
1 H NMR (500 MHz, CDC13): S 7.94 (d, J 8 Hz, 1 H), 7.67 (d, J 2 Hz, 1 H), 7.49 (dd, J8, 1 Hz, 2H), 7.42-7.34 (m, 4H), 6.62 (s, 1H), 5.30 (s, 2H), 4.51 (s, 2H).
Step 4: A solution of bromide of formula 61 (3.42 g, 8.79 mmol), amine of formula 12 (2.01 g, 8.79 mmol), K2C03 (2.41 g, 17.5 mmol), KI (146 mg, 0.879 mmol), and Liar (200 mg, 2.30 mmol) in CH3CN (30 mL) was stirred at 50°C overnight. The reaction solvent was removed under reduced pressure. The residue was partitioned between EtOAc and water. The organic layer was washed with saturated NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by chromatography (silica gel, 99:1 to 95:5 CH2C12/MeOH) gave compound of formula 62 (3.26 g, 74%) as a pale yellow oil:
1 H NMR (300 MHz, CDCl3): 8 7.94 (d, J 8 Hz, 1 H), 7.67 (d, J 2 Hz, 1 H), 7.49 (dd, J 8, 1 Hz, 2H), 7.42-7.30 (m, 4H), 7.08 (dd, J 8, 7 Hz, 2H), 6.95 (dd, J
8, 7 Hz, 2H), 6.50 (s, 1H), 5.32 (s, 2H), 3.73 (s, 2H), 2.92 (d, J 12 Hz, 2H), 2.51 (d, J7 Hz, 2H), 2.08 (ddd, J 12, 12, 2 Hz, 2H), 1.67-1.25 (m, SH).
Step 5: Palladium on charcoal (10% Pd, 200 mg) was added to a solution of compound of formula 62 (2.42 g, 4.80 mmol) in THF (100 mL), and the mixture was shaken under an atmosphere of H2 (g) at 50 psi for 4 hours. The reaction mixture was rapidly filtered through CELITE under reduced pressure into a reaction flask. The flask was capped with a septum and purged with nitrogen.
To the clear solution was added carbonic acid di-2-pyridyl ester (1.15 g, 5.28 mmol) and Et3N (1.50 mL, 10.56 mmol), and the solution was refluxed for 6 hours. The solvent was removed under reduced pressure. Purification by chromatography (silica gel, 99:1 to 95:5 CH2C12/MeOH) and subsequent crystallization from hot EtOH gave 6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]isoxazol-3-yl}-3H
benzoxazol-2-one (665 mg, 34%) as an off white solid:
mp 237-244°C
IR (KBr): 2934, 2825, 1775 cm-1;
1 H NMR (300 MHz, DMSO-d6): 8 11.87 (s, 1 H), 7.78 (d, J 1 Hz, 1 H), 7.70 (dd, J 8, 1 Hz, 1 H), 7.20-7.15 (m, 3H), 7.07 (dd, J 8, 7 Hz, 2H), 6.93 (s, 1 H), 3.66 (s, 2H), 2.84 (d, J 11 Hz, 2H), 2.47 (d, J6 Hz, 2H), 1.99 (dd, J 11, 10 Hz, 2H), 1.54-1.45 (m, 3H), 1.25-1.18 (m, 2H); ESI -MS
(m/z): 408 [M + H]+; HPLC: method A, 5.91 minutes(>99%); method B, 11.23 minutes(>99%); Anal. Calcd for C23H22~303~ C~ 67.80; H, 5.44; N, 10.31.
Found: C, 67.67; H, 5.52; N, 10.11.
6- { 5-[4-(4-Fluorobenzyl)piperidin-1-yl) methyl } -4, 5-dihydroi soxazol-3-yl } -3H
benzothiazol-2-one HN \ ~ F NaHC03, CH3CN ~N \ I F
allyl bromide HO, N
S \ Br i. MeMgBr g \ CHO NHZOHHCI S
O O '~\~H
O I ~ I 2-PrOH
N
~ \
ii. t- , a H iii. DMF H H
HO.N N~O
HCI/DMF O~S / I O~S / I N
I CI EtOH, NaHC03, O
~ N \ N \
OXONE H \ H _ 67 I ~ / F
~N
/
Step 1: 4-(4-Fluorobenzyl)piperidine hydrochloride 12 (2.55 g, 11.1 mmol) and NaHC03 (2.3 g, 27.7 mmol) were added to a solution of allyl bromide in CH3CN.
The mixture was warmed to 40°C for 3 hours. The solvent was removed under 5 reduced pressure and the residue was partitioned between EtOAc and water.
The organic layer was washed with saturated NaCI, dried (Na2S04), filtered, and the solvent removed under reduced pressure. Purification by flash chromatography (silica gel, 95:5 to 9:1 CH2C12/MeOH) gave alkene of formula 63 (1.13 g, 44%) as an oil:
10 1H NMR (500 MHz, DMSO-d6): 8 7.18-7.14 (m, 2H), 7.08-7.03 (m, 2H), 5.81-5.73 (m, 1 H), 5.11 (dd, J 17, 2 Hz, 1 H), 5.06 (dd, J 11, 2 Hz, 1 H), 2.87 (d, J 6 Hz, 2H), 2.77 (d, J 12 Hz, 2H), 2.47 (d, J7 Hz, 2H), 1.79 (dt, J 12, 2 Hz, 2H), 1.50-1.39 (m, 3H), 1.15 (tt, J 13, 3 Hz, 2H).
Step 2: To a -78°C solution of bromide of formula 64 (5.02 g, 21.8 mmol) in THF
15 (50 mL) was added MeMgBr (8.0 mL of a 3.0 M solution in diethyl ether, 24.0 mmol). After 30 minutes, anhydrous THF (170 mL) was added at a rate that maintained the internal reaction temperature below a threshold of -SO°C. After the solution returned to -78°C, tent-butyl lithium (50 mL of a 1.7 M
solution in pentane, 85 mmol) was added. After 10 minutes, DMF (10 mL, 130 mmol) was 20 added to the yellow mixture, and the cold bath was removed. After 1 hour, the reaction was quenched with water, and the THF was removed under reduced pressure. The residue was partitioned between EtOAc and 1N HCI. The aqueous layer was extracted with three portions of EtOAc. The organic extracts were combined and washed with saturated NaCI, dried (Na2S04), filtered, and concentrated under reduced pressure to give aldehyde of formula 65 (3.74 g, 96%) as a white solid:
1H NMR (500 MHz, DMSO-d6): b 12.39 (s, 1H), 9.90 (s, 1H), 8.17 (d, J 1 Hz, 1 H), 7.85 (dd, J 8, 1 Hz, 1 H), 7.3 0 (d, J 8 Hz, 1 H).
Step 3: A mixture of aldehyde of formula 65 (3.74 g, 20.8 mmol), hydroxylamine hydrochloride (1.60 g, 22.9 mmol), and sodium bicarbonate (2.18 g, 26.0 mmol) in 2-PrOH (75 mL) was heated to 75°C for 3 hours. After stirring overnight at room temperature, the mixture was diluted with 2-PrOH (200 mL). The solution was filtered and concentrated under reduced pressure to give oxime of formula 66 (4.00 g, 99%), as a white solid:
1H NMR (300 MHz, DMSO-d6): b 11.96 (s, 1H), 11.15 (s, 1H), 8.10 (s, 1H), 7.79 (d, J 1 Hz, 1 H), 7.52 (dd, J 8, 1 Hz, 1 H), 7.14 (d, J 8 Hz, 1 H).
Step 4: A mixture of oxime of formula 66 (4.00 g, 20.6 mmol) and OXONE~
(13.9 g, 22.6 mmol) was stirred in a solution of HCl in DMF (43 mL of a 0.53 M, 22.6 mmol) for 3.5 hours. The reaction mixture was partitioned between EtOAc and 1N HCI. The organic layer was washed with saturated NaCI, dried (Na2S04), filtered, and concentrated under reduced pressure. The yellow solid was triturated with 1:1 EtOAc/hexanes and filtered to give compound of formula 67 (3.53 g, 75%):
1 H NMR (300 MHz, DMSO-d6): 812.33 (s, 1 H), 12.15 (s, 1 H), 8.03 (d, J 2 Hz, 1 H), 7.73 (dd, J 8, 2 Hz, 1 H), 7.20 (d, J 8 Hz, 1 H).
Step 5: Coupling of compound of formula 67 and alkene of formula 63 following the procedure described in Example 17, Step 5, followed by conversion to the HCl salt, gave 6-{5-[4-(4-fluorobenzyl)piperidin-1-yl]methyl}-4,5-dihydroisoxazo1-yl}-3H benzothiazol-2-one (484 mg, 41%):
mp 271-276 °C
IR (KBr): 3422, 2932, 1686, 1670, 1603 cm-1 1H NMR (500 MHz, DMSO-d6): 812.19 (s, 1H), 10.58 (s, 1H), 7.88 (s, 1H), 7.60 (d, J8 Hz, 1H), 7.23-7.20 (m, 3H), 7.11 (dd, J9, 8 Hz, 2H), 5.30-5.24 (m, 1H), 3.66 (dd, J 17, 11 Hz, 1 H), 3.58 (d, J 12 Hz, 1 H), 3.48 (d, J 11 Hz, 1 H), 3.34-3.17 (m, 3H), 2.95 (m, 2H), 2.53 (d, J 5 Hz, 2H), 1.75-1.74 (m, 3H), 1.64-1.54 (m, 2H);
ESI -MS (m/z): 426 [M + H]+; HPLC: method A, 6.05 minutes (>99%); method B, 11.48 minutes (>99%); Anal. Calcd for C23H24~3C2S~HC1~0.25H20: C, 59.22; H, 5.51; N, 9.01. Found: C, 59.37; H, 5.38; N, 8.82.
6-[5-(4-Benzyl-4-hydroxypiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H
benzoxazol-2-one O / I Br i. MeMgBr O~O / I CHO ~20H~HCl ii. t-BuLi N' v NaHCO
H iii. DMF H 3 N,OH N,OH
O O / I I OXONE~ O O / I I Cl \ HCI, DMF ~ \
H H
OH OH
\ ~ Br \ EtOH, NaHC03, O
/ N O ~N I / HO..
N
/ ~Cl to O~ \ I 70 H
Step 1: To a -78°C solution of 9 (20.0 g, 93.4 mmol) in THF (180 mL) was added MeMgBr (34.5 mL of a 3.0 M solution in diethyl ether, 103 mmol). After 45 minutes, anhydrous THF (750 mL) was added at a rate that maintained the internal reaction temperature below a threshold of -SO°C. After the solution returned to -78°C, tert-butyl lithium (200 mL of a 1.7 M solution in pentane, 118 mmol) was added via a dropping funnel. After 15 minutes, DMF (44 mL, 561 mmol) was added to the yellow mixture, and the cold bath was removed.
After 2 hours, the reaction was quenched with water and the THF removed under reduced pressure. The residue was partitioned between EtOAc and 1N HCI. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. The crude solid was dissolved in hot EtOAc and hexane was added to the solution until a precipitate formed. The precipitate was collected by filtration to give 68 (12.44 g, 81%) as an off white solid:
1 H NMR (500 MHz, DMSO-d6): 812.13 (s, 1 H), 9.92 (s, 1 H), 7.78 (d, J 8 Hz, 1 H), 7.75 (s, 1 H), 7.29 (d, J 8 Hz, 1 H).
Step 2: A mixture of aldehyde 68 (10.0 g, 61.3 mmol), hydroxylamine hydrochloride (4.26 g, 61.3 mmol), and sodium bicarbonate (5.15 g, 61.3 mmol) in 2-PrOH (75 mL) was heated to 40°C for 3 hours. After cooling to ambient temperature, the mixture was diluted with 2-PrOH and filtered. Concentration under reduced pressure gave oxime 69 (11.6 g, 100%), as a white solid:
1H NMR (300 MHz, DMSO-d6): b 11.82 (s, 1H), 11.15 (s, 1H), 8.14 (s, 1H), 7.49 (s, 1H), 7.39 (d, J 8 Hz, 1H), 7.12 (d, J 8 Hz, 1H).
Step 3: A mixture of oxime 69 (11.6 g, 61.3 mmol) and OXONE~ (41.4 g, 67.4 mmol) was stirred in HCl (62 mL of a 1.09 M solution in DMF, 67.4 mmol) for 2.5 hours. The reaction mixture was partitioned between EtOAc and water.
The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. Trituration of the yellow solid with EtOAc gave 70 (7.03 g, 54%).
The washings were concentrated under reduced pressure and the residue triturated with 3:1 EtOAc/hexanes to give a second crop of 70 (2.34 g, 18%):
1H NMR (300 MHz, DMSO-d6): 812.33 (s, 1H), 11.93 (s, 1H), 7.63 (s, 1H), 7.60 (d, J 8 Hz, 1 H), 7.18 (d, J 8 Hz, 1 H).
Step 4: Alkene of formula 72 was prepared following the procedure described below for alkene of formula 63 in Example 16, Step 1, to give 420 mg, (14%):
NMR (500 MHz, CDCl3): 8 7.30 (dd, J 8, 7 Hz, 2H), 7.24-7.23 (m, 1H), 7.19 (d, J
7 Hz, 2H), 5.91-5.83 (m, 1 H), 5.17 (dd, J 17, 2 Hz, 1 H), 5.12 (dd, J 10, 2 Hz, 1 H), 3.01 (d, J 6 Hz, 2H), 2.75 (s, 2H), 2.67-2.63 (m, 2H), 2.28 (dt, J 10, 2 Hz, 2H), 1.74 (dt, J 13, 4 Hz, 2H), 1.53 (dd, J 14, 2 Hz, 2H), 1.17 (s, 1H).
Step 5: A solution of alkene of formula 72 (420 mg, 1.81 mmol) in EtOH (10 mL) was added to a mixture of NaHC03 and compound of formula 70 (425 mg, 2.0 mmol). The mixture was heated to reflux for 2 hours. Methanol and CH2C12 were added to dissolve an organic precipitate that had formed during the course of the reaction. Silica gel was added and the solvent was removed under reduced pressure. Purification by flash chromatography (silica gel, 89:10:1 CH2C12/MeOH/NH40H), trituration of the isolated solid with MeOH, and conversion to the HCl salt gave ICJPAC: 6-[5-(4-benzyl-4-hydroxypiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H benzoxazol-2-one (425 mg, 52%) as a white solid:
mp 166-170°C
IR (KBr): 3387, 2958, 1773 cm-1 1 H NMR (500 MHz, DMSO-d6): 812.01 (s, 1 H), 10.20 (s, 1 H), 7.57 (s, 1 H), 7.47 (d, J 8 Hz, 1 H), 7.30 (dd, J 8, 7 Hz, 2H), 7.24 (d, J 7 Hz, 2H), 7.14 (d, J 8 Hz, 2H), 5.23 (m, 1 H), 4.82 (s, 1 H), 3.66 (dd, J 17, 11 Hz, 1 H), 3.37-3.33 (m, 4H), 3.19-3.16 (m, 2H), 2.74 (s, 2H), 1.93-1.85 (m, 2H), 1.61 (d, J 15 Hz, 2H); ESI-MS
(mlz): 408 [M + H]+
HPLC: method A, 4.14 minutes (98.2%); method B, 9.92 minutes (>99%); Anal.
Calcd for C23H25N304' 1.125 H20: C, 59.22; H, 6.08; N, 9.01. Found: C, 59.34;
H, 5.94; N, 8.96.
6-{5-[4-(4-Fluorobenzyl)piperidine-1-carbonyl]-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one F acryloyl chloride N / F EtOH, NaHC03, OXONE~ -OH
CH
CN
Na 3, ~ N
I
12 7 O~O / I
N
H
Step 1: A mixture of 4-(4-fluorobenzyl)piperidine hydrochloride 12 (2.09 g, 9.09 mmol), NaHC03 (765 mg, 9.09 mmol) and acryloyl chloride (815 p,L, 10.0 mmol) in CH3 CN ( 15 mL) was stirred at ambient temperature for 6 hours.
The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and water. The organic layer was washed with sat. NaHC03 and sat. NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by flash chromatography (silica, 99:1 to 95:5 CH2Cl2/MeOH) gave 73 (730 mg, 33%) as an oil:
1 H NMR (500 MHz, CDCl3): 8 7.09 (dd, J 9, 8 Hz, 2H), 6.96 (dd, J 9, 8 Hz, 2H), 6.56 (dd, J 17, 11 Hz, 1 H), 6.25 (dd, J 17, 1 Hz, 1 H), 5.65 (dd, J 11, 1 Hz, 1 H), 4.65-4.58 (m, 1 H), 3.95 (d, J 13 Hz, 1 H), 2.98-2.94 (m, 1 H), 2.64-2.45 (m, 3H), 1.78-1.70 (m, 3H), 1.29-1.16 (m, 2H).
Step 2: A mixture of oxime 69 (525 mg, 2.95 mmol) and OXONE~ (1.90 g, 3.10 mmol) was stirred in HCl (2.85 mL of a 1.09 M solution in DMF, 3.10 mmol) for 1.5 hours. The reaction mixture was partitioned between EtOAc and 1N HCI. The organic layer was washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. The residue was combined with NaHC03 (750 mg, 8.85 mmol) and a solution of amide 73 (730 mg, 2.95 mmol) in 1:1 THF/H20 ( 10 mL) was added. The reaction mixture was stirred for 24 hours at ambient temperature. The solvent was removed under reduced pressure and the residue was partitioned between EtOAc and 1N HCI. The organic layer was washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by flash chromatography (silica, 5:2 hexanes/EtOAc to 9:1 CH2C12/MeOH) followed by trituration with 3:1 hexanes/EtOAc gave 6-{5-[4-(4-fluorobenzyl)piperidine-1-carbonyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (507 mg, 40%):
mp 210-213°C
IR (KBr): 3193, 2931, 1779, 1632 cm-1 1 H NMR (500 MHz, DMSO-d6): 811.84 (s, 1 H), 7.59 (s, 1 H), 7.50 (d, J 8 Hz, 1 H), 7.23-7.20 (m, 2H), 7.16 (d, J 8 Hz, 1 H), 7.10 (dd, J 9, 8 Hz, 2H), 5.58-5.51 (m, 1 H), 4.35-4.30 (m, 1 H), 4.03 (d, J 14 Hz, 1 H), 3.90-3.77 (m, 1 H), 3.54-3.47 (m, 1 H), 3:09-3 .00 (m, 1 H), 2.64-2.5 8 (m, 1 H), 2.54 (d, J 7 Hz, 2H), 1.79 (m, 1 H), 1.68-1.58 (m, 2H), 1.24-1.16 (m, 1H), 1.08-0.97 (m, 1H) ESI-MS (m/z): 424 [M + H]+
HPLC: method A, 10.06 min (98.6%); Anal. Calcd for C23H22~304~ C~ 65.24;
H, 5.24; N, 9.92. Found: C, 65.03; H, 5.20; N, 9.87.
6-(5- { 2-[4-(4-Fluorobenzyl)piperidin-1-yl] ethyl } -4, 5-dihydroisoxazol-3-yl)-3H
benzoxazol-2-one ~Br I ~ EtOH, NaHC03, O
HN / ~ wN / F
F NaHC03 70 F
N~O
I
~N
H
Step 1: Coupling of amine 12 (4.00 g, 17.4 mmol) with 4-bromo-1-butene (3.53 mL, 34.8 mmol) following the procedure described in Example 16, Step 1, followed by conversion to the HCl salt gave alkene 75 (3.57 g, 72%):
1H NMR (500 MHz, DMSO-d6): 8 10.52 (s, 1H), 7.23-7.20 (m, 2H), 7.13-7.07 (m, 2H), 5.83-5.72 (m, 1 H), 5.16 (dd, J 17, 2 Hz, 1 H), 5.09 (dd, J 10, 2 Hz, 1 H), 3.43-3.38 (m, 2H), 3.18-3.14 (m, 1H), 3.04-3.00 (m, 2H), 2.85-2.78 (m, 2H), 2.52-2.47 (m, 3H), 1.80-1.68 (m, 3H), 1.59-1.51(m, 2H).
Step 2: Coupling of 70 (156 mg, 0.734 mmol) and alkene 75 (207 mg, 0.734 mmol) following the procedure described in Example 17, Step 5, followed by conversion to the HCl salt, gave 6-(5-{2-[4-(4-fluorobenzyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one (200 mg, 58%):
mp 254-258°C
IR (KBr): 3448, 2934, 2713, 1774 cm-1 1H NMR (500 MHz, DMSO-d6): 8 11.90 (s, 1H), 10.09 (s, 1H), 7.55 (s, 1H), 7.46 (d, J 8 Hz, 1 H), 7.21 (dd, J 9, 8 Hz, 2H), 7.16 (d, J 8 Hz, 1 H), 7.11 (dd, J
9, 8 Hz, 2H), 4.79-4.73 (m, 1 H), 3.54 (dd, J 17, 11 Hz, 1 H), 3.45 (d, J 11 Hz, 2H), 3.18-3.09 (m, 4H), 2.83 (m, 2H), 2.53-2.49 (m, 2H), 2.06 (dd, J 15, 8 Hz, 2H), 1.73-1.70 (m, 2H), 1.52-1.48 (m, 2H) ESI-MS (m/z): 424 [M + H]+
HPLC: method A, 5.69 min (98.0%); method B, 10.96 min (98.4%); Anal. Calcd for C24H26~303'HC1~0.5H20: C, 61.47; H, 6.02; N, 8.96. Found: C, 61.59; H, 6.02; N, 9.87.
6- { 5-[4-(4-Fluorobenzyl)-4-hydroxypiperidin-1-ylmethyl]-4, 5-dihydroisoxazol-yl}-3H benzoxazol-2-one F ally! acetate, Pd(PPh3)a F EtOH, NaHC03, D
OH ~ ~ ~N OH ~ ~ 70 N-O
I
O~ \ I N
H OH
F
Step 1: To a suspension of the formate salt of amine 76 (14.3 g, 43.4 mmol) in toluene (225 mL) was added ally! acetate (5.2 mL, 47.7 mmol) and Et3N
(12.1 mL, 86.8 mmol). Solubility of the amine was problematic. Addition of pyridine (20 mL) and then MeOH (40 mL) resulted in a homogenous solution. The solution was deoxygenated with an argon sparge for 1 S minutes, then palladium tetrakis(triphenylphosphine)palladium(0) (500 mg, 0.434 mmol) was added. The reaction mixture was heated to 100°C in an oil bath for 1 hour and then cooled to ambient temperature. The mixture was filtered and the solution concentrated under reduced pressure. Purification by chromatography (silica, 95:5 to 9:1 CH2C12/MeOH) gave 77 (7.15 g, 70%) as a clear oil:
1 H NMR (500 MHz, CDCl3): S 7.17 (dd, J 9, 8 Hz, 2H), 7.02 (dd, J 9, 8 Hz, 2H), 6.23-6.09 (m, 1H), 5.53-5.43 (m, 2H), 3.54 (d, J7 Hz, 2H), 3.31-3.27 (m, 2H), 3.01 (br. t, J 11 Hz, 2H), 2.83 (s, 2H), 2.37 (dt, J 13, 4 Hz, 2H), 2.06 (s, 1H), 1.71 (br. d, J 13 Hz, 2H).
Step 2: Coupling of 70 (978 mg, 4.16 mmol) and alkene 77 (975 mg, 4.57 mmol) following the procedure described in Example 17, Step S, followed by conversion to the HCl salt, gave 6-{5-[4-(4-fluorobenzyl)-4-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (840 mg, 43%):
mp 195-204°C
IR (KBr): 3380, 2958, 1770, cm-1 1 H NMR (500 MHz, CD30D): 8 7.58 (s, 1 H), 7.52 (d, J 8 Hz, 1 H), 7.29-7.24 (m, 2H), 7.15 (dd, J 8, 2 Hz, 1 H), 7.06-7.00 (m, 2H), 5.28-5.23 (m, 1 H), 3.71 (dd, J 17, 11 Hz, 1H), 3.52-3.20 (m, 6H), 2.83 (s, 2H), 2.03-1.90 (m 2H), 1.79-1.70 (m, 2H), 1.18 (dt, J 7, 2 Hz, 1 H) APCI-MS (m/z): 426 [M + H]+
HPLC: method A, 5.37 min (96.4%); method B, 10.38 min (98.3%); Anal. Calcd for C23H24~304'HC1~O.SH20: C, 58.66; H, 5.56; N, 8.92. Found: C, 58.61; H, 5.60; N, 8.40.
6-{ 5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-5-methyl-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one N-O
I
I \ EtOH, NaHC03, ~ O ~ N
~N I / F ~O O~ \
% v 7g H
F
Step 1: A mixture of 4-(4-fluorobenzyl)piperidine hydrochloride (12) (3.05 g, 13.2 mmol) and NaHC03 (2.76 g, 32.8 mmol) in CH3CN (50 mL) was heated to reflux for 30 minutes. After cooling to ambient temperature, methallyl bromide (1.7 mL, 17 mmol) was added, and the mixture was heated to reflux for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure.
Purification liy flash chromatography (silica, 98:2 to 9:1 CH2C12/MeOH) gave (2.67 g, 81 %) as an oil:
1H NMR (300 MHz, DMSO-d6): b 7.21-7.16 (m, 2H), 7.11-7.05 (m, 2H), 4.81 (m, 2H), 2.75-2.70 (m, 4H), 2.49 (m, 2H), 1.72 (m, 2H), 1.65 (s, 3H), 1.51-1.48 (m, 3H), 1.17-1.13 (m, 2H).
Step 2: Coupling of 70 (610 mg, 2.87 mmol) and alkene 78 (644 mg, 2.60 mmol) following the procedure described in Example 17, Step 5, gave 6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-5-methyl-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one (299 mg, 26%) as a white solid: mp 82-86°C
IR (KBr): 2925, 1774 cm-1 1 H NMR (500 MHz, DMSO-d6): 811.79 ,(s, 1 H), 7.54 (d, J 1 Hz, 1 H), 7.43 (dd, J 8, 1 Hz, 1 H), 7.17-712 (m, 3 H), 7.05 (dd, J 9, 9 Hz, 2H), 3 .3 8 (d, J 17 Hz, 1 H), 3.17 (s, 2H), 3.07 (d, J 17 Hz, 1 H), 2.90-2.88 (m, 2H), 2.44 (d, J 7 Hz, 2H), 2.07 1.97 (m, 2H), 1.49-1.36 (m, 3H), 1.29 (s, 3H), 1.20-1.06 (m, 2H) APCI-MS (m/z): 424 [M + H]+
HPLC: method A, 6.57 min (97.8%); method B, 11.89 min (96.5%); Anal. Calcd for C24H26~303'0.75H20: C, 65.96; H, 6.34; N, 9.62. Found: C, 66.03; H, 6.62; N, 9.25.
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid COZEt \ i. EtOH, NaHC03, D
%vN I ~ 70 ii. LiOH, MeOH
S Step 1: To a suspension of the hydrochloride salt of amine 12 (2.06 g, 8.96 mmol) in toluene (50 mL) was added 2-acetoxymethylacrylic acid ethyl ester (1.70 g, 9.86 mmol) and Et3N (1.37 mL, 9.86 mmol). The solution was deoxygenated with an argon sparge for 10 minutes, then palladium tetrakis(triphenylphosphine)-palladium(0) (260 mg, 0.224) was added. The reaction mixture was heated to 100°C in an oil ,bath for 1 hour, and then cooled to ambient temperature. The mixture was filtered and then concentrated under reduced pressure.
Purification by chromatography (silica, 95:5 to 9:1 CH2C12/MeOH) gave a yellow oil. The oil was dissolved in 3:1 EtOAc/hexanes and then acidified with 1N HCl/Et20 to give alkene 79 (7.1 S g, 70%) as a white solid:
1H NMR (500 MHz, DMSO-d6): 812.44 (s, 1H), 7.07 (dd, J 8, 8 Hz, 2H), 6.96 (dd, J 8, 8 Hz, 2H), 6.89 (s, 1 H), 6.84 (s, 1 H), 4.25 (q, J 7 Hz, 2H), 3.87 (d, J 5 Hz, 2H), 3.47 (br. d, J 12 Hz, 2H), 2.66-2.62 (m, 2H), 2.60 (d, J 7 Hz, 2H), 2.11-2.03 (m, 2H), 1.79 (br. d, J 14 Hz, 2H), 1.69-1.63 (m, 1H), 1.31 (t, J7 Hz, 3H).
Step 2: Coupling of 70 (600 mg, 2.82 mmol) and alkene 79 (875 mg, 2.56 mmol) following the procedure described in Example 17, Step 5, gave the ester as an impure solid. The crude ester was saponified with excess LiOH in 1:1 MeOH/THF
(15 mL). After stirnng overnight, the reaction solvent was removed under reduced pressure. Purification by chromatography (silica, 89:10:1 to 79:20:1 CH2C12/MeOH/AcOH) followed by trituration with MeOH gave 5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid (275 mg, 85%) as a white solid:
mp 188-194°C
IR (KBr): 2959, 2921, 1774, 1630, 1509 cm-1 1 H NMR (300 MHz, DMSO-d6): 8 11.92 (s, 1 H), 7.58 (s, 1 H), 7.48 (d, J 8 Hz, 1H), 7.24-7.07 (m, 8H), 3.89 (d, J 17 Hz, 1H), 3.45-3.16 (m, SH), 2.60-2.50 (m, 2H), 1.64 (m, 3H), 1.31 (m, 2H) ESI-MS (m/z): 454 [M + H]+
HPLC: method C, 6.56 min (97.0%); method D, 12.33 min (99.5%); Anal. Calcd for C24H24~305'O.SH20: C, 62.33; H, 5.45; N, 9.09. Found: C, 62.57; H, 5.47;
N, 9.00.
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid methyl ester N-O COzMe I
O~O / I N
N
H
/ F
To a solution of 5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-S-carboxylic acid (687 mg, 0.909 mmol) in MeOH (20 mL) and TFA (1.5 mL) was addedp-toluenesulfonic acid monohydrate (190 mg, 0.999 mmol). The reaction mixture was heated to reflux overnight, then concentrated and purified by flash chromatography (silica gel, 5% MeOH in CH2C12) to give S-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid methyl ester (133 mg, 31%), as an off white solid:
mp 146-155°C
IR (KBr): 2930, 1767, 1508, 1448 cm-1 1H NMR (S00 MHz, CD30D): b 7.58 (d, J 1 Hz, 1H), 7.51 (dd, J 8, 1 Hz, 1H), 7.20 (dd, J 8, 5 Hz, 2 H), 7.16 (d, J 8 Hz, 1 H), 7.03 (d, J 9 Hz, 1 H), 7.00 (d, J 9 Hz, 1 H), 3.96 (d, J 18 Hz, 1 H), 3.92-3.90 (m, 4H), 3.68 (d, J 18 Hz, 1 H), 3.68-3.55 (m, 3H), 3.21-3.05 (m, 2H), 2.62 (d, J7 Hz, 2H), 1.97-1.83 (m, 3H), 1.71-1.55 (m, 2H) APCI (m/z): 468 [M + H]+
HPLC: method A, 6.32 min, 98.7%; Anal. Calcd for C24H26~305'HCI: C, 59.58; H, 5.40; N, 8.34. Found: C, 59.19; H, 5.56; N, 8.01.
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester COZEt Pd(Ph3)4, toluene /~ LDA, TI-IF
~N~COZEt N allyl acetat ~/e H ~ ~ F
Br N-O
COzEt I
N 0 O ~ N
NaHC03, EtOH, D ~ /
N
/ -70 H EtO2C ~ ~ F
Step 1: Treatment of amine 80 (2.0 g, 13 mmol) with allyl acetate (1.6 mL, 14 mmol), and Pd(Ph3)4 (440 mg, 3.8 mmol), following the procedure described in Example 20, Step 1, gave 81 (2.3 g, 88%):
1H NMR (300 MHz, CDC13): b 5.97-5.79 (m, 1H), 5.26-5.10 (m, 2H), 4.21-4.09 (m, 2H), 2.99-2.87 (m, 4H), 2.35-2.20 (m, 1H), 2.04-1.65 (m, 6H), 1.27-1.22 (m, 3H).
Step 2: To an ice-cold solution of diisopropylamine (0.78 mL, 5.6 mmol) in THF
(22 mL) was added n-BuLi (2.2 mL of a 2.5 M solution in hexanes, 5.6 mmol).
After 15 minutes, the reaction mixture was cooled in a -78°C dry ice/2-PrOH bath and then a solution of 81 (1.0 g, 5.1 mmol) in THF (10 mL) was added dropwise over 15 minutes. After 1.5 hours, a solution of 4-fluorobenzyl bromide (0.66 mL, 5.3 mmol) in THF ( 10 mL) was added dropwise to the reaction mixture over 1.5 hours. The reaction mixture was stirred for an additional 35 minutes and then warmed to ambient temperature. The reaction mixture was poured into H20 and extracted with EtOAc (3x). The combined organics were dried (Na2S04) and concentrated under reduced pressure. Purification by flash chromatography (silica, 95:4.5:0.5 CH2Cl2/MeOH/NH40H) gave 82 ( 1.3 g, 81 %):
1H NMR (300 MHz, CDC13) 8 7.03-6.90 (m, 4H), 5.90-5.79 (m, 1H), 5.18-5.11 (m, 2H), 4.09 (q, J 7 Hz, 2H), 2.94 (d, J 7 Hz, 2H), 2.78 (s, 4H), 2.13 (d, J
13 Hz, 2H), 1.96 (dd, J 12, 12 Hz, 2H), 1.61-1.51 (m, 2H), 1.19 (t, J 7 Hz, 3H).
Step 3: Coupling of 70 (1.0 g, 4.7 mmol) and alkene 82 (1.3 g, 4.2 mmol) following the procedure described in Example 17, Step 5, gave 4-(4-fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester (630 mg, 31 %), as a white solid:
mp 212-214°C
IR (KBr): 2836, 1767, 1705, 1511, 1451 cm-1 1H NMR (300 MHz, DMSO-d6): ~ 11.80 (br s, 1H), 7.55 (d, J 1 Hz, 1H), 7.45 (dd, J 8, 1 Hz, 1 H), 7.14 (d, J 8 Hz, 1 H), 7.08 (d, J 8 Hz, 4H), 4.83-4.77 (m, 1 H), 4.04 (dd, J 14, 7 Hz, 2H), 3.44 (dd, J 17, 7 Hz, 1 H), 3.12 (dd, J 17, 7 Hz, 1 H), 2.84-2.76 (m, 4H), 2.52- 2.43 (m, 2H), 2.08-2.00 (m, 2H), 1.94-1.91 (m, 2H), 1.53-1.47 (m, 2H), 1.14 (dd, J 7, 7 Hz, 3H) APCI (m/z): 482 [M + H]+
HPLC: method B, 11.50 min (97.5%); Anal. Calcd for C26H28~305~ C~ 64.85;
H, 5.86; N, 8.73. Found: C, 64.56; H, 5.74; N, 8.62.
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid N_O N_O
I NaOH, EtOH I
O~N I / N O"1N I / N
H EtOZC ~ ~ F HOZC ~ ~ F
Step 1: A mixture of 4-(4-fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester (390 mg, 0.81 mmol) and 20% aq. NaOH (4.5 mL) in EtOH (4.5 mL) was heated to reflux for 16 hours. After stirring at ambient temperature overnight, the reaction solvent was removed under reduced pressure. The reaction mixture was diluted with water, brought to pH 3 with 1N HCI, and extracted with EtOAc (2x). The combined extracts were dried (Na2S04) and concentrated under reduced pressure.
Purification by chromatography (silica, 79:20:1 CH2C12/MeOH/AcOH) followed by recrystallization from MeOH/Et20 gave 4-(4-fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid (28 mg, 8%) as a yellow solid:
IR (KBr): 2922, 1767, 1600, 1508, 1448 cm'1 1 H NMR (500 MHz, DMSO-d6): 8 7.55 (d, J 1 Hz, 1 H), 7.45 (dd, J 8, 2 Hz, 1 H), 7.14-7.11 (m, 3H), 7.07 (d, J 8, 8 Hz, 2H), 3.46-3.10 (m, 4H), 2.79-2.73 (m, 4H), 2.52-2.43 (m, 2H), 2.13-2.06 (m, 2H), 1.89-1.87 (m, 2H), 1.47-1.42 (m, 2H) ESI-MS (m/z): 454 [M + H]+
HPLC: method A, 5.30 min (>99%).
6-{5-[4-(4-Fluorobenzyl)-3-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one / F
O O F ~ ~ Bt O \ I O
~o~ of \
N NaH,~MF N HCI, E ~tOH N I
O F
/ I 83 \ I 84 \ I 85 OH
~.' \ HC02NHy, Pd(OH)z/C ~H
K-Selectride N~~, I / F MeOH, A
F
OH N-O
~ ~I ~
~ %Y \ " N
Pd(Phy)4. toluene N~'~'' I ~ NeHC03, EtOH, D O~N I // ~" OH
allyl acetate r F 70 H
/ 88 ~ ~ F
Step 1: To an ice-cold suspension of NaH (2.6 g, 110 mmol) in DMF (130 mL) was added 83 (15.0 g, 50 mmol) portionwise so that the internal reaction temperature was maintained between 5°C to 10°C. After stirring at ambient temperature for 1 hour, the reaction mixture was cooled in an ice/H20 bath and a solution of 4-fluorobenzyl bromide (9.4 g, 50 mmol) in DMF (26 mL) was added.
After stirnng at ambient temperature for 15 hours, the reaction mixture was cooled in an ice/H20 bath, and quenched by the addition of sat. NaHC03. The mixture was diluted with H20 (200 mL) and extracted with EtOAc (3 x 200 mL). The combined extracts were washed with H20 (100 mL) and sat. NaCI (100 mL), dried (MgS04), and concentrated under reduced pressure. Purification by flash chromatography (silica, 8:1 hexanes/EtOAc followed by 4:1 hexanes/EtOAc) gave 84 (9.0 g, 49%):
1H NMR (300 MHz, CDC13): 8 7.35-7.19 (m, 5H), 7.11 (dd, J 8, 3 Hz, 2H), 6.92 (dd, J 8, 8 Hz, 2H), 4.16-3.99 (m, 2H), 3.51 (q, J 13 Hz, 2H), 3.28-2.84 (m, 4H), 2.78-2.61 (m, 1H), 2.61-2.48 (m, 2H), 1.68-1.58 (m, 1H), 1.09 (t, J7 Hz, 3H).
Step 2: To a solution of 84 (8.9 g, 24 mmol) in EtOH (13 mL) was added conc.
HCl (30 mL), and the solution was heated to reflux. After 21 hours, the reaction mixture was cooled in an ice/H20 bath, brought to pH 8 with 1N NaOH and then extracted with EtOAc (3 x 200 mL). The combined extracts were washed with H20 (100 mL) and sat. NaCI (100 mL), dried (Na2S04), and concentrated under reduced pressure to give 85 (6.5 g, 89%), which was used without further purification:
1H NMR (500 MHz, CDC13) 8 7.34-7.23 (m, 5H), 7.11 (dd, J 8, 3 Hz, 2H), 6.95 (dd, J 8, 8 Hz, 2H), 3.57 (s, 2H), 3.26 (d, J 12 Hz, 2H), 2.94-2.79 (m, 2H), 2.47-2.34 (m, 3H), 1.93-1.87 (m, 1H), 1.71-1.52 (m, 1H).
Step 3: To a cold (-78°C dry ice/2-PrOH bath) solution of 85 (8.8 g, 29 mmol) in THF (200 mL) was added K-selectrideTM (44 mL of a 1 M solution in THF, 44 mmol) at a rate that maintained the internal reaction temperature below -65°C.
After the addition was complete, the reaction mixture was stirred for 1 hour (internal temperature -65°C) and then warmed to ambient temperature.
The reaction was quenched by the addition of sat. NaHC03 (100 mL) and then extracted with EtOAc (2 x 200 mL). The combined extracts were washed with H20 (100 mL) and sat. NaCI (100 mL), dried (Na2S04), and concentrated under reduced pressure. Purification by flash chromatography (silica, 2:1 hexanes/EtOAc followed by 1:2 hexaneslEtOAc) gave 86 (4.0 g, 46%):
1H NMR (300 MHz, CDC13): 8 7.33-7.25 (m, SH), 7.15 (dd, J6, 3 Hz, 2H), 6.95 (dd, J8, 8 Hz, 2H), 3.57-3.52 (m, 1H), 3.50 (s, 2H), 2.96-2.71 (m, 3H), 2.58-2.49 (m, 1H), 2.07 (d, J 12 Hz, 1H), 2.09-1.92 (m, 1H), 1.62-1.30 (m, 4H).
Step 4: A mixture of compound 86 (4.0 g, 13 mmol), ammonium formate (1.7, 27 mmol), and 20% Pd(OH)2/C (500 mg) in MeOH (50 mL) was heated at reflux for 1.5 hours. The reaction mixture was cooled to ambient temperature, filtered through Celite, and the filtrate was concentrated under reduced pressure to give amine 87 (2.8 g, 100%), which was used without further purification:
1 H NMR (300 MHz, CDC13): S 7.1 S (dd, J 6, 3 Hz, 2H), 6.96 (dd, J 8, 8 Hz, 2H), 3.55 (br. s, 1H), 3.48 (s, 2H), 3.03 (dd, J 12, 12 Hz, 2H), 2.75-2.48 (m, 4H), 1.68-1.31 (m, 3H).
Step 5: Treatment of amine 87 (1.4 g, 6.6 mmol) with allyl acetate (0.79 mL, 7.3 mmol), and Pd(Ph3)4 (380 mg, 0.30 mmol), following the procedure described in Example 20, Step l, gave 88 (1.1 g, 66%):
1H NMR (300 MHz, CDCI3): S 7.14 (dd, J 8, 3 Hz, 2H), 6.96 (dd, J 8, 8 Hz, 2H), 5.90-5.76 (m, 1H), 5.18-5.11 (m, 2H), 3.58-3.56 (m, 1H), 3.00-2.48 (m, 6H), 2.05 1.81 (m, 2H), 1.61-1.31 (m, 4H).
Step 6: Coupling of 70 (500 mg, 2.4 mmol) and alkene 88 (530 mg, 2.1 mmol) following the procedure described in Example 17, Step 5, followed by conversion to the HCl salt, gave 6-{S-[4-(4-fluorobenzyl)-3-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (288 mg, 29%), as a white solid:
mp 224-233°C
IR (KBr): 2957, 1771, 1509, 1453 cm-I
1H NMR (300 MHz, CD30D): 8 7.58-7.57 (m, 1H), 7.53-7.49 (m, 1H), 7.27-7.23 (m, 2H), 7.16-7.12 (m, I H), 7.05-6.99 (m, 2H), 5.28-5.07 (m, 1 H), 3.89 (br s, 1 H), 3.76-3.62 (m, 1H), 3.48-3.01 (m, 6H), 2.82-2.59 (m, 2H), 2.11-1.85 (m, 2H), 1.75-1.62 (m, 2H) APCI (m/z): 426 [M + H]+
HRMS-API (m/z): [M + H]+ Calcd for C23H24~304~ 426.1829; Found, 426.1834 HPLC: method A, 6.15 min (96.1 %); method B, 11.07 min (>99%); Anal. Calcd for C23H24~304'HC1~0.25H20: C, 59.23; H, 5.51; N, 9.01. Found: C, 59.16; H, 5.41; N, 8.87.
6-{ 5-[4-(4-Fluorophenoxy)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl }-3H
benzoxazol-2-one N~O I ~ EtOH, NaHC03, O
1~ ~IJ F 70 Step 1: A mixture of 4-(4-fluorophenoxy)piperidine hydrochloride (1.48 g, 6.40 mmol) and NaHC03 (1.34 g, 16.0 mmol) in DMF (30 mL) was heated to 50°C for 30 minutes. Allyl bromide (0.550 mL, 6.40 mmol) was added and the reaction mixture was stirred at 50°C for 2 hours. The reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (lx). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. Purification by flash chromatography (silica, 95:5 to 9:1 CH2Cl2/MeOH) gave 89 (621 mg, 41%) as an oil:
1H NMR (300 MHz, CDC13): 8 6.96 (dd, J9, 9 Hz, 2H), 6.88-6.83 (m, 2H), 5.95-5.82 (m, 1 H), 5.22-5.13 (m, 2H), 4.26-4.19 (m, 1 H), 3.03 (d, J 7 Hz, 2H), 2.74-2.72 (m, 2H), 2.32-2.25 (m, 2H), 2.02-1.95 (m, 2H), 1.86-1.75 (m, 2H).
Step 2: To a mixture of alkene 89 (620 mg, 2.63 mmol) and NaHC03 (400 mg, 4.76 mmol) in 2:1 DMF/H20 (3 mL) was added a solution of 70 (500 mg, 2.35 mmol) in DMF (2 mL). The mixture was heated to 50°C for 2 hours.
The reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by flash chromatography (silica, 89:10:1 CH2C12/MeOH/NH40H) and (silica, 1:1 hexanes/EtOAc to EtOAc to 89:10:1 CH2C12/MeOH/NH40H) followed by crystallization from MeOH gave 6-{5-[4-(4-fluorophenoxy)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (225 mg, 19%):
mp 192-194°C
IR (KBr): 2951, 1779 cm-1 1H NMR (500 MHz, DMSO-d6): 8 11.78 (s, 1H), 7.55 (d, J 1 Hz, 1H), 7,45 (dd, J 8, 1 Hz, 1 H), 7.13 (d, J 8 Hz, 1 H), 7.07 (dd, J 9, 9 Hz, 2H), 6.94 (dd, J
9, 4 Hz, 2H), 4.86-4.80 (m, 1 H), 4.31-4.26 (m, 1 H), 3.46 (dd, J 17, 11 Hz, 1 H), 3.16 (dd, J 17, 8 Hz, 1H), 2.81-2.75 (m, 2H), 2.60-2.51 (m, 2H), 2.38-2.30 (m, 2H), 1.91-1.88 (m, 2H), 1.63-1.56 (m, 2H) APCI-MS (m/z): 412 [M + H]+
HPLC: method A; 6.23 min (>99%) Anal. Calcd for C22H22~304~ C~ 64.22; H, 5.39; N, 10.21. Found: C, 64.00; H, 5.46; N, 10.08.
6-{5-[4-(4-Fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one N-O
S
~N~ I ~ EtOH, NaHC03, D O ,O / I N
/ F 70 ~(N
S ~ / F
Step 1: Coupling of 4-(4-fluorophenylsulfanyl)piperidine hydrochloride (647 mg, 2.61 mmol) with allyl bromide (250 ~,L, 2.87 mmol) following the procedure described in Example 16, Step 1, gave alkene 90 (271 mg, 40%):
1 H NMR (500 MHz, CD30D): S 7.46 (dd, J 9, 5 Hz, 2H), 7.05 (dd, J 9, 9 Hz, 2H), 5.89-5.80 (m, 1 H), 5.21-5.15 (m, 2H), 3.08-3.02 (m, 1 H), 3.00 (d, J 7 Hz, 2H), 2.90-2.87 (m, 2H), 2.13-2.08 (m, 2H), 1.95-1.91 (m, 2H), 1.63-1.56 (m, 2H).
Step 2: Coupling of 70 (252 mg, 1.18 mmol) and alkene 90 (271 mg, 1.08 mmol) following the procedure described in Example 17, Step 5, gave 6-{5-[4-(4-fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl }-3H
benzoxazol-2-one (370 mg, 80%):
mp 190-192°C
IR (KBr): 2945, 1774 cm-1 1 H NMR (500 MHz, DMSO-d6): S 11.80 (s, 1 H), 7.54 (d, J 1 Hz, 1 H), 7.47-7.43 (m, 3 H), 7.18 (dd, J 9, 9 Hz, 1 H), 7.13 (d, J 8 Hz, 1 H), 4.84-4.78 (m, 1 H), 3 .44 (dd, J 17, 11 Hz, 1H), 3.18-3.09 (m, 2H), 2.90-2.83 (m, 2H), 2.56-2.48 (m, 2H), 2.21-2.14 (m, 2H), 1.85-1.83 (m, 2H), 1.51-1.42 (m, 2H) ESI-MS (m/z): 428 [M + H]+
HPLC: method A, 6.40 min (98.9%); method B, 11.50 min (99.0%) Anal. Calcd for C22H22~3035~ C, 61.81; H, 5.19; N, 9.83. Found: C, 62.13; H, 5.05; N, 9.86.
6-{5-[4-(4-Fluorobenzenesulfinyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one O
NaI04 r S
/\~N
/ F MeOH, H20 /~N~~
/ F
EtOH, NaHC03, O
Step 1: To a solution of 90 (0.80 g, 3.18 mmol) in MeOH (10 mL) and H20 (1.5 mL) was added NaI04 (680 mg, 3.18 mmol) at ambient temperature. The reaction mixture was stirred for 12 hours, and then additional NaI04 (100 mg, 0.47 mmol) was added. After 12 hours, the reaction mixture was filtered through Celite and concentrated under reduced pressure. Purification by flash chromatography (silica, 9:1 to 8:2 CH2CI2/MeOH) gave 91 (240 mg, 28%) as a yellow wax:
1H NMR (300 MHz, CDCI3): 8 7.69-7.57 (m, 2H), 7.33-7.16 (m, 2H), 5.82 (dddd, J 17, 13, 10, 7 Hz, 1H), 5.22-5.12 (m, 2H), 3.10-2.93 (m, 4H), 2.65-2.52 (m, 1H), 2.03-1.88 (m, 2H), 1.81-1.52 (m, 4H).
Step 2: Coupling of 70 (209 mg, 0.98 mmol) and alkene 91 (230 mg, 0.86 mmol) following the procedure described in Example 17, Step 5, followed by conversion to the HCl salt, gave 6-{5-[4-(4-fluorobenzenesulfinyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (290 mg, 76%):
mp 170-178°C
IR (KBr): 2954, 1764 cm-1 1H NMR (500 MHz, DMSO-d6): 8 11.92 (s, 1H), 10.23 (br s, 1H), 7.73 (d, J 6 Hz, 1 H), 7.71 (d, J 5 Hz, 1 H), 7.56 (s, 1 H), 7.52-7.44 (m, 3H), 7.15 (d, J 8 Hz, 1H), 5.22 (br s, 1H), 3.72 (m, 3H), 3.40-3.25 (m, 3H), 3.12 (m, 3H), 2.12 (br s, 1H), 2.01-1.75 (m, 2H), 1.67 (br s, 1H); APCI-MS (m/z): 444 [M + H]+
HPLC: method A, 4.61 min (95.0%); method B, 8.76 min (93.8%) Anal. Calcd for C22H22~304S~HC1~O.SH20: C, 54.04; H, 4.95; N, 8.59. Found:
C, 54.06; H, 4.73; N, 8.38.
6-{5-(4-(4-Fluorobenzoyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one O N~O
I
\ EtOH, NaHC03, O O ,O / I N
~N / F 70 ~(N \
O ~ / F
Step 1: Coupling of (4-fluorophenyl)piperidin-4-yl-methanone (1.50 g, 6.62 mmol) with allyl bromide (630 ~L, 7.28 mmol) following the procedure described in Example 16, Step 1 gave alkene 92 (830 mg, 51%):
1H NMR (300 MHz, CDC13): 8 7.97 (dd, J 8, 6 Hz, 2H), 7.14 (dd, J 9, 8 Hz, 2H), 5.94-5.85 (m, 1 H), 5.23-5.14 (m, 2H), 3.22-3.17 (m, 1 H), 3.04-3.00 (m, 4H), 2.13-2.05 (m, 2H), 1.92-1.80 (m, 4H) Step 2: Coupling of 708 (787 mg, 3.70 mmol) and alkene 92 (830 mg, 3.36 mmol) following the procedure described in Example 17, Step 5 gave 6-{5-[4-(4-fluorobenzoyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (465 mg, 33%):
mp 188-190°C; IR (KBr): 2950, 1776 cm-1 1H NMR (500 MHz, DMSO-d6): S 11.76 (s, 1H), 8.05 (dd, J9, 5 Hz, 2H), 7.56 (s, 1 H), 7.47 (dd, J 9, 2 Hz, 1 H), 7.34 (t, J 9 Hz, 2H), 7.14 (d, J 9 Hz, 1 H), 4.92-4.80 (m, 1 H), 3 .48-3.09 (dd, J 17, 10 Hz, 1 H), 3.3 9 (m, 1 H), 3.18 (dd, J 17, 8 Hz, 1H), 2.99 (m, 2H), 2.70-2.50 (m, 2H), 2.37-2.18 (m, 2H), 1.80-1.70 (m, 2H), 1.65-1.54 (m, 2H) ESI-MS (m/z): 424 [M + HJ+
HPLC: method A, 5.81 min (95.1 %); method B, 10.92 min (97.1 %) Anal. Calcd for C23H22~304'0.25H20: C, 64.55; H, 5.30; N, 9.82. Found: C, 64.64; H, 5.04; N, 9.75.
6-(5-{4-[(4-Fluorophenyl)hydroxymethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one OH N-O
I
\ EtOH, NaHC03, D O
N
~N 93 ~ g 70 N \
H
HO
Step 1: To an ice-cold solution of alkene 92 (507 mg, 2.05 mmol) in 1:1 MeOH/CH2C12 (10 mL) was added NaBH4 (67.3 mg, 2.41 mmol) portionwise.
The reaction was quenched with sat. NH4C1 (1 mL) and the solvent was removed under reduced pressure. The residue was partitioned between EtOAc and water.
The organic layer was washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. Purification by flash chromatography (silica, 89:10:1 CH2C12/MeOH/NH40H) gave alkene 93 (252 mg, 49%) as an off white solid:
1H NMR (300 MHz, CDC13): 8 7.29-7.25 (m, 3H), 7.05-7.00 (m, 2H), 5.92-5.78 (m, 1H), 5.18-5.10 (m, 2H), 4.37 (d, J7 Hz, 1H), 3.01-2.85 (m, 4H), 2.00-1.21 (m, 7H).
Step 2: Coupling of 70 (738 mg, 3.48 mmol) and alkene 93 (722 mg, 2.90 mmol) following the procedure described in Example 17, Step S, followed by conversion to the HCl salt gave 6-(S- f 4-[(4-fluorophenyl)hydroxymethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one (951 mg, 81%):
mp 186-191°C
IR (KBr): 3393, 2958, 1771 cm-1 1H NMR (300 MHz, CD30D): 8 7.58 (s, 1H), 7.51 (d, J 8 Hz, 1H), 7.37 (dd, J 8, 5 Hz, 2H), 7.15-7.39 (m, 3H), 5.26-5.13 (m, 1 H), 4.46 (d, J 7 Hz, 1 H), 4.04-3.62 (m, 3H), 3.42-3.19 (m, 4H), 3.12-2.97 (m, 2H), 2.19-2.10 (m, 1H), 1.98-1.82 (m, 1H), 1.80-1.55 (m, 3H) APCI-MS (m/z): 426 [M + H]+
HPLC: method A, 5.51 min (>99%); method B, 10.40 min (97.9%) Anal. Calcd for C23H24~304'HC1~0.25H20: C, 59.23; H, 5.51; N, 9.01. Found:
C, 59.11; H, 5.29; N, 8.75.
6-(5- { 4-[ 1-(4-Fluorophenyl)-1-hydroxyethyl]piperidin-1-ylmethyl } -4, 5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one OH
\ EtOH, NaHC03, 0 ~N~~F 70 Step 1: To an ice-cold solution of MeMgBr ( 1.1 S mL of a 3.0 M solution in Et20, 3.46 mmol) was added dropwise a solution of ketone 92 (712 mg, 2.88 mmol) in dry Et20. After 1 hour, the reaction was quenched with MeOH (1 mL) and sat.
NH4C1 ( 1 mL). The mixture was partitioned between water and Et20. The aqueous layer was extracted with Et20. The combined organic layers were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by flash chromatography (silica, 90:10 CH2C12/MeOH) gave alkene 94 as a yellow oil (755 mg, 92%):
1H NMR (300 MHz, CDC13): ~ 7.39-7.34 (m, 2H), 7.03-6.97 (m, 2H), 5.93-5.79 (m, 1H), 5.18-5.12 (m, 2H), 2.96 (d, J6 Hz, 4H), 1.89-1.81 (m, 3H), 1.63-1.48 (m, SH), 1.44-1.26 (m, 3H).
Step 2: Coupling of 70 (755 mg, 3.56 mmol) and alkene 94 (693 mg, 3.23 mmol) following the procedure described in Example 17, Step S gave 6-(5-{4-(1-(4-fluorophenyl)-1-hydroxyethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one (1.00 g, 64%):
mp 125-134°C
IR (KBr): 3427, 2944, 1774 cm-1 1H NMR (300 MHz, DMSO-d6): 8 11.79 (s, 1H), 7.55 (s, 1H), 7.46-7.38 (m, 3H), 7.14-7.07 (m, 3H), 4.85-4.79 (m, 2H), 3.48-3.38 (m, 1H), 3.14-3.06 (m, 1H), 2.99 2.89 (m, 2H), 2.51-2.46 (m, 2H), 2.00-1.80 (m, 2H), 1.65-1.51 (m, 1H), 1.50-1.45 (m, 4H), 1.35-1.10 (m, 3H) APCI-MS (m/z): 440 [M + H]+
HPLC: method A, 5.60 min (97.0%); method B, 10.70 min (98.2%) Anal. Calcd for C24H26~304'0.25H20: C, 64.93; H, 6.02; N, 9.46. Found: C, 64.65; H, 5.85; N, 9.26.
4-Chloro-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-5-methyl-3H benzoxazol-2-one HO, N
O / Br i. MeMgBr O~CHO NHZOH~HCI O
H
O \ I ii. t-BuLi O~ \ I 2-PrOH, NaHC03 O
H 95 iii. DMF H 96 H I 97 HO.N ~N \ F N~O
HC~ O~O ~ I CI I ~ O ~ I N
\ \
OXONE~ H 63 CI CI
EtOH, NaHC03, D ~ ~ F
Step 1: To a -78°C solution of bromide 95 (10.3 g, 45.2 mmol) in THF
(40 mL) was added MeMgBr (16.6 mL of a 3.0 M solution in diethyl ether, 49.7 mmol).
After 40 minutes, anhydrous THF (410 mL) was added at a rate that maintained the internal reaction temperature below a threshold of -50°C. After the solution returned to -78°C, tert-butyl lithium (85 mL of a 1.7 M solution in pentane, 144 mmol) was added via a dropping funnel. After 10 minutes, DMF (21.0 mL, 271 mmol) was added to the yellow mixture, and then the cold bath was removed.
After 2 hours, the reaction was quenched with water and the THF removed under reduced pressure. The residue was partitioned between EtOAc and 1N HCI. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. Purification by crystallization from hot EtOH gave aldehyde 96 (2.86 g, 35%):
1H NMR (300 MHz, CDC13): 8 11.60 (s, 1H), 10.23 (s, 1H), 7.58 (s, 1H), 6.91 (s, 1H), 2.68 (s, 3H).
Step 2: A mixture of aldehyde 96 (2.80 g, 15.8 mmol), hydroxylamine hydrochloride (1.21 g, 17.4 mmol), and sodium bicarbonate (1.99 g, 23.7 mmol) in 2-PrOH (80 mL) was heated to 50°C for 4 hours. The warm mixture was diluted with MeOH, and filtered. Concentration under reduced pressure gave oxime 97 (3.69 g, 100%):
1H NMR (300 MHz, DMSO-d6): 8 11.17 (s, 1H), 8.30 (s, 1H), 7.41 (s, 1H), 6.91 (s, 1H), 2.36 (s, 3H).
Step 3: A mixture of oxime 97 (3.69 g, 15.8 mmol) and OXONE~ (10.7 g, 17.4 mmol) was stirred in HCl (32.8 mL of a 0.53 M solution in DMF, 17.4 mmol) for 3 hours. The reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with water, sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. The yellow solid was dissolved in hot EtOAc. Addition of hexane to the solution gave 98 (3.04 g, 73%) as an off white solid:
1H NMR (300 MHz, DMSO-d6): 812.45 (s, 1H), 7.96 (s, 1H), 7.42 (s, 1H), 2.33 (s, 3H); ESI-MS (negative mode) (m/z): 224 [(M-H)-HCl]-.
Step 4: Coupling of 98 (1.82 g, 6.99 mmol) and alkene 63 (1.63 g, 6.99 mmol) following the procedure described in Example 11, Step 2, gave 4-chloro-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-5-methyl-3H
benzoxazol-2-one (1.0 g, 31%):
mp 131-132°C
IR (KBr): 2922, 1780 cm-1 1H NMR (500 MHz, DMSO-d6): S 12.20 (s, 1H), 7.35 (s, 1H), 7.17 (dd, J 8, 6 Hz, 2H), 7.07 (dd, J 9, 8 Hz, 2H), 4.82-4.76 (m, 1 H), 3.48 (dd, J 17, 11 Hz, 1H), 3.18 (dd, J 17, 8 Hz 1H), 2.91 (m, 2H), 2.58-2.46 (m, 4H), 2.45 (s, 3H), 2.08-1.99 (m, 2H), 1.52-1.42 (m, 3H), 1.22-1.13 (m, 2H) ESI-MS (mlz): 458 [M + H]+
HPLC: method A, 6.95 min (96.0%); method B, 12.21 min (95.9%) Anal. Calcd for C24H25C1~303 ~ C, 62.34; H, 5.56; N, 9.09. Found: C, 62.52;
H, 5.44; N, 8. 8 8.
-{S-[4-(4-Fluorophenyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one Br HN ~ ~ F ~ ~N ~ ~ F
NaHC03 N-O
EtOH, NaHC03, D I
O~O / I N
HO,, N N
O ~ H
O~ \ I ~Cl H
Step 1: Alkene of formula 100 was prepared following the procedure described below for alkene of formula 63 in Example 16, Step 1, to give 1.34 g, (50%):
1 H NMR (300 MHz, CDC13): 0 7.20-7.15 (m, 2H), 7.00-6.94 (m, 2H), 5.98-5.85 (m, 1 H), 5.23 (d, J 16 Hz, 1 H), 5.14 (d, J 10, 1 H), 3.07-3.02 (m, 4H), 2.48 (dt, J
11, 5 Hz, 1H), 2.07-1.98 (m, 2H), 1.81-1.65 (m, 4H).
Step 2: Coupling of compound of formula 70 and alkene of formula 100 following the procedure described above in Example 17, Step 5, gave 6-{5-[4-(4-fluorophenyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (719 mg, 70%):
mp 214-217°C
IR (KBr): 2926, 1774 cm-1 1H NMR (S00 MHz, DMSO-d6): 8 11.80 (s, 1H), 7.57 (d, J 1 Hz, 1H), 7.48 (dd, J 8, 1 Hz, 1 H), 7.27 (dd, J 8, 6 Hz, 2H), 7.15 (d, J 8 Hz, 1 H), 7.08 (dd, J
8, 6 Hz, 2H), 4.90-4.84 (m, 1 H), 3.49 (dd, J 17, 11 Hz, 1 H), 3.18 (dd, J 17, 8 Hz, 1 H), 3.05 (d, J 11 Hz, 1 H), 3.02 (d, J 11 Hz, 1 H), 2.63-2.52 (m, 2H), 2.51-2.47 (m, 1 H), 2.20-2.13 (m, 2H), 1.74-1.71 (m, 2H), 1.67-1.58 (m, 2H) ESI-MS (m/z): 396 [M + H]+
HPLC: method A, 4.83 minutes(98.3%); method B, 10.60 minutes(>99%) Anal. Calcd for C22H22~303'0.25H20: C, 66.07; H, 5.67; N, 10.51. Found: C, 66.13; H, 5.60; N, 10.52.
6-[5-(4-Phenyl-4-hydroxy)piperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H
benzoxazol-2-one OH - ~ Br OH -N
NaHC03 EtOH, NaHC03, O N'O
O~O / I N
HO,, N
N \
N \ 70 H
Step 1: Alkene of formula 102 was prepared following the procedure described below for alkene of formula 63 in Example 16, Step 1, to give 1.24 g, (50%):
1 H NMR (300 MHz, CDC13): 8 7.53 (d, J 7 Hz, 2H), 7.36 (dd, J 7, 7 Hz, 1 H), 7.28 (d, J7 Hz, 2H), 6.00-5.86 (m, 1H), 5.25 (d, J 17 Hz, 1H), 5.16 (d, J 10 Hz, 1 H), 3.10 (d, J 7 Hz, 2H), 2.86 (d, J 12 Hz, 2H), 2.45 (ddd, J 12, 12, 2 Hz, 2H), 1.31 (ddd, J 13, 13, 4 Hz, 2H), 1.79 (d, J 12 Hz, 2H), 1.63-1.55 (m, 1H).
Step 2: Coupling of compound of formula 70 and alkene of formula 102 following the procedure described'above in Example 17, Step 5, gave 6-[5-(4-phenyl-4-hydroxy)piperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H
benzoxazol-2-one (423 mg, 38%):
mp 115-118°C
IR (KBr): 2951, 1771 cm-1 1H NMR (500 MHz, DMSO-d6): 0 11.80 (s, 1H), 7.57 (s, 1H), 7.48-7.45 (m, 3H), 7.30 (dd, J 8, 8 Hz, 2H), 7.19 (dd, J 7, 6 Hz, 1 H), 7.14 (d, J 8 Hz, 1 H), 4.90-4.84 (m, 1 H), 4.74 (s, 1 H), 3.48 (dd, J 17, 11 Hz, 1 H), 3.19 (dd, J 17, 8 Hz, 1 H), 2.76-2.69 (m, 2H), 2.64-2.50 (m, 4H), 1.92 (dt, J 13, 4 Hz, 2H), 1.60-1.55 (m, 2H) ESI-MS (m/z): 394 [M + H]+
HPLC: method A, 5.48 min (>99%); method B, 9.63 min (>99%) Anal. Calcd for C22H23N304'0~75H20: C, 64.93; H, 6.07; N, 10.33. Found: C, 65.16; H, 6.03; N, 10.27.
6-(5- { 2-[4-(4-Fluorophenyl)piperidin-1-yl] ethyl } -4, 5-dihydroisoxazol-3-yl)-3H
benzoxazol-2-one HN~~ ~ F ~ N ~ ~ F
NaHC03 EtOH, NaHC03, 0 N-O
I
HO~ O ~
N F
N o~ \ I ~
O ~ Cl H
\ I 70 H
Step 1: Alkene of formula 103 was prepared following the procedure described below for alkene of formula 63 in Example 16, Step 1, to give 2.29 g, (85%):
1H NMR (300 MHz, CDC13): S 7.22 (dd, J9, 8 Hz, 2H), 6.99 (dd, J9, 8 Hz, 2H), 5.85-5.72 (m, 1 H), 5.14 (dd, J 18, 1 Hz, 1 H), 5.12 (d, J 10 Hz, 1 H), 3.48 (d, J 12 Hz, 2H), 2.88-2.83 (m, 2H), 2.71-2.59 (m, SH), 2.36-2.31 (m, 2H), 1.97 (d, J 13 Hz, 2H).
Step 2: Coupling of compound of formula 70 and alkene of formula 103 following the procedure described above in Example 17, Step S, gave 6-(S-{2-[4-(4-fluorophenyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-one (759 mg, 71%):
mp 188-194°C
IR (KBr): 3448, 2934, 1773, 1654 cm-1 1H NMR (500 MHz, DMSO-d6): S 7.55 (d, J 1 Hz, 1H), 7.46 (dd, J8, 1 Hz, 1H), 7.23 (dd, J 9, 8 Hz, 2H), 7.14 (d, J 8 Hz, 1 H), 7.08 (dd, J 9, 8 Hz, 2H), 4.76-4.70 (m, 1 H), 3.45 (dd, J 17, 11 Hz, 1 H), 3.12 (dd, J 11, 8 Hz, 1 H), 3.00 (d, J
12 Hz, 1H), 2.95 (d, J 12 Hz, 1H), 2.49-2.36 (m, 4H), 2.04-1.98 (m, 2H), 1.86-1.48 (m, 6H) ESI-MS (m/z): 410 [M + H]+
HPLC: method A, 5.58 min (98.8%); method B, 10.45 min (>99%) Anal. Calcd for C23H24~303'0.25H20: C, 66.73; H, 5.97; N, 10.15. Found: C, 66.81; H, 5.99; N, 9.91.
As noted above, the invention compounds are subtype selective NMDA
receptor antagonists. The compounds have been evaluated in standard assays commonly used to measure activity. Typical assays were carried out as follows.
BIOLOGICAL METHODS
I. Electrophysiological assays at NMDA receptor subunits (in vitro):
a. The NR1A/NR2B assay:
(i) Preparation of subunit RNA's:
cDNA clones encoding the NR1A, NR2A, NR2B, and NR2C rat NMDA receptor subtypes were used. (See, Moriyoshi et al., Nature (Lond.), 1991;354:31-37; Kutsuwada et al., Nature (Loud.), 1992;358:36-41; Monyer et al., Science (Washington, D.C.) 1992;256:1217-1221; Ikeda et al., FEBSLett. 1992;313: 34-38; Ishii et al., J. Biol. Chem., 1993;268:2836-2843 for details of these clones or their mouse homologs). The clones were transformed into appropriate host bacteria and plasmid preparations were made with conventional DNA purification techniques. A sample of each clone was linearized by restriction enzyme digestion of cRNA was synthesized with T3 RNA polymerase. The cRNA was diluted to 400 ng/~1 and stored in 1 ~1 aliquots at -80°C until injection.
(ii) The Xenopus oocyte expression system:
Mature female Xenopus laevis were anaesthetized (20 to 40 minutes) using 0.15% 3-aminobenzoic acid ethyl ester (MS-222) and 2 to 4 ovarian lobes were surgically removed. Oocytes at developmental stages IV-VI (Dumont, J.N., J. Morphol., 1972;136:153-180) were dissected from the ovary still surrounded by enveloping ovarian tissues. Follicle-enclosed oocytes were micro-injected with 1:1 mixtures of NR1A:NR2A, 2B or 2C; injecting 1 to 10 ng of RNA
encoding each receptor subunit. NR1A encoding RNA was injected alone at ~20 ng. Oocytes were stored in Barth's medium containing (in mM) :NaCI, 88; KC1, 1; CaCl2, 0.41; Ca (N03)2, 0.33; MgS04, 0.82 NaHC03, 2.4; HEPES 5, pH 7.4, with 0.11 mg/mL gentamicin sulphate. While oocytes were still surrounded by enveloping ovarian tissues the Barth's medium was supplemented with 0.1 % bovine serum. Oocytes were defolliculated 1 to 2 days following injections by treatment with collagenase (0.5 mg/mL Sigma Type I for 0.5 to 1 hour) (Miledi and Woodward, J. Phsyiol. (Loud.), 1989;416:601-621) and subsequently stored in serum-free medium.
(iii) Electrical recordings:
Electrical recordings were made using a conventional two-electrode voltage clamp (Dagan TEV-200) over periods ranging between 3 to 21 days following injection. (Woodward et al., Mol. Pharmacol., 1992;41:89-103). Oocytes were placed in a 0.1 mL recording chamber continuously perfused (5-15 mL min-1) with frog Ringer's solution containing (in mM) :NaCI, 115; KCL, 2; BaCl2, 1.8; HEPES, S; pH
7.4. Drugs were applied by bath perfusion. Using oocytes expressing different subunit combinations of NMDA receptor, NMDA currents were activated by co-application of glutamate (100 ~,M) and glycine (1-100 ~,M) as agonists. Inhibitory potency of the novel antagonists of this invention was assessed on responses elicited by fixed concentrations of glutamate and glycine agonists, by measuring reductions in current induced by progressively increasing concentrations of invention compounds.
(iv) Concentration-inhibition curves:
Concentration-inhibition curves were fitted with equation 1 control - 1/(1 + ((antagonist]/10-pIC50)n) Eq. 1 in which Icontrol is the current evoked by the agonists alone, pIC50 = -log ICSp, IC50 is the concentration of invention compound that produced half maximal inhibition of the electrical current, and n is the slope factor (see De Lean et al., Am. J. Physiol., 1978;235:
E97-102). For incomplete curves, analysis by fitting was unreliable, and IC50 values were calculated by simple regression over linear portions of the curves using an ORIGIN software (Microcal Software, Boston, MA), a computer program for collection, analysis, and presentation of scientific data. The results of this assay for representative invention compounds is given in Table 1, in the column labeled "NR1A/NR2B", and the activity is reported as the IC50 in micromolar (pM) concentration.
b. [3H]Ifenprodil Binding Assay (IFPNR) Protocol:
(i) Materials:
Ifenprodil, [phenyl-3H]- (specific activity, 66.2 Ci/mmol) was purchased from Dupont NEN Research Products (Boston, MA).
Ifenprodil tartrate was purchased from Research Biochemicals International (Natick, MA). HEPES, glutamate and glycine were purchased from Sigma Chemical Co. (St. Louis, MO).
(ii) Preparations:
All buffers and reagents used in assay incubations or to dissolve drugs were prepared using water purified through a Milli-Q reverse osmosis system (Millipore Corp., Bedford, MA) and treated with UV
emissions. Prior to use in the assays buffers were further filtered through a sterile Corning filtration unit (Corning Glass Works, Corning, N~ containing a 0.2 micron filter. Buffer used to rinse the membranes on the assay filters was prepared with purified water, but was not refiltered and was stored no longer than 5 days. Stock solutions of the drugs (usually 10 mM) were dissolved in 20 mM
HEPES-KOH buffer pH 7.4 (assay buffer) with the addition of 1 to 5 pL of glacial AcOH, if needed to keep them in solution. Eliprodil was used as the reference NMDA antagonist. A stock solution of eliprodil was prepared, and was buffered with the addition of 10%
DMSO. All subsequent dilutions from the stock solution were made in buffer.
An extensively washed huffy coat membrane fraction was prepared from frozen adult rat forebrains (Zivic-Miller Laboratories, Inc., Zelienople, PA) as described by Coughenour L.L.; Cordon, J.J., J. Pharmacol. Exp. Ther., 1997;280:584-592, and stored at -80°C.
On the day of the assay, pellets of the frozen membrane fractions were resuspended in 35 mL of assay buffer at pH 7.4 using a POLYTRON (Kinematica A.G. Company, Littau, Switzerland) mixer at setting 6. After incubation at 37°C for 30 minutes in a shaking water bath, the homogenate was centrifuged 40,000 x g for 10 minutes at 4°C. The pellets were resuspended in fresh buffer and 1 S centrifuged 3 more times before final suspension for use in the assay.
(iii) [3H]Ifenprodil Binding protocol:
Triplicate incubations were carried out in a volume of 0.5 mL in 1.3 mL polypropylene tubes (Marsh Biomedical Products Inc, Rochester, NY) for 2 hours at room temperature. Incubations contained invention compounds, membranes (100-200 pg protein) and 4 nM [3H]-ifenprodil in 20 mM HEPES-KOH buffer, pH 7.4 (assay buffer). Assays were started by addition of the membranes.
Bound radioligand was separated by filtration under reduced pressure using a TOMTEC Mach II, 96-well cell harvester (Tomtec Inc, Orange, Connecticut). Filtration was through Whatman GF/B glass fiber filters (Whatman Ltd., Maidstone, England), which had been soaked for at least 15 minutes in 0.3% polyethylenimine and allowed to air dry. The filters were rinsed with 3 mL of ice cold assay buffer within 6 seconds. Air was allowed to pass through the filters for an additional 10 seconds to remove residual moisture. The filter mat was supported on a cold (-20°C) TEFLON (E. I. Du Pont de Nemours and Company, Wilmington, Delaware) coated support, and filters from individual wells were separated and placed in Mini Poly-Q vials (Beckman Instruments Inc, Fullerton, CA) and filled with 4 mL of scintillation cocktail (Beckman Ready Protein+).
Radioactivity retained on the filter was determined by liquid scintillation spectrophotometry. Nonspecific binding was defined as the binding in the presence of 1 mM ifenprodil. Ninety percent of the total binding of ifenprodil was specific binding at the NR1A/NR2B
NMDA receptor subtype active site (as opposed to binding at a remote site).
(iv) Data analysis:
Binding curves were statistically analyzed for a best 1- or 2-site competition fit using GRAPHPAD PRISM software (GraphPad Software Inc, San Diego, CA), a computer program used to analyze and graph scientific data. The normalized data was fitted by nonweighted nonlinear regression to either y = Bottom + (Top - Bottom) or 1 + 10 x - Log EC50 Fraction-1 1- Fraction-1 y = Bottom + (Top - Bottom) 1 + 10 x - Lo ECso-1 + x - Lo ECSO-2 g 1+10 g Control data was entered as 100%, and no parameters were constrained. Inhibition curves were compared by Anova with post-test comparisons of the log ICSp with Dunnett's multiple comparisons post-test or Student's nonpaired, 2-tailed t-test using GraphPad INSTAT (Harvey Motulsky, San Diego, CA) software.
The results of the IFPNR binding assay are reported as ICSOs in micromolar (pM) concentrations in Table 1 to Table 5 in the columns labeled "IFPNR".
II. Animal Models:
a. The Formalin Footpad Test (FT):
The FT model was used to test invention compounds for pain alleviating properties. The model produces a biphasic response in a test animal that results from a change in pain intensity over time. The FT model utilizes an injection of dilute formalin into the hindpaw of a rodent, which produces high intensity acute pain behaviors which are measured for the first minutes post formalin injection (early phase responding). High intensity acute pain behaviors include rapid licking or biting of the injected 10 hindpaw. The second phase is a prolonged period of lower intensity pain behaviors (late phase responding) which are measured from 11 to 45 minutes post-formalin injection.
(i) Test animals:
Male Wistar albino rats (Harlan Sprague-Dawley Labs), weighing approximately 100 g at the time of testing, were used. Animals were group-housed and acclimated to the housing facility for 1 week prior to testing. Animals were maintained on a 12-hour/12-hour light/dark cycle and fed block rodent chow. From 4 to 8 animals were randomly assigned to either a vehicle-only dose group or a vehicle-plus invention compound treatment group on the day of testing.
(ii) Test apparatus:
The testing apparatus was a 16" x 8" box divided into two 8" x 8"
testing chambers. Each testing chamber comprised a floor and 3 walls made of clear plastic mirrors, and a fourth wall which was clear plastic that allowed observation of animal behavior. The top of each chamber was covered with a metal screen during testing to prevent animals from climbing out of the chamber. Two animals were tested simultaneously in the adjoining boxes, but animals were unable to observe one another.
(iii) Procedure:
Animals were weighed and placed into holding cages (2 animals per cage) in the testing room prior to dosing. Following approximately 30 minutes of acclimation to the testing room, each pair of animals was administered orally (PO) by gavage a mixture of invention compound plus vehicle or vehicle alone. The treated animals were then placed in individual test chambers and allowed to acclimate to the chambers for at least 20 minutes. Then 50 ~.L of a 2.5% solution of formalin in vehicle was injected subcutaneously (SC) in the plantar surface of the left hindpaw from 30 to 120 minutes after administration of the invention compound. A session timer was started following the formalin injection, and the amount of time the animal spent licking or biting the injected paw was clocked with a hand-held stopwatch. The cumulative time spent engaging in a pain response was manually recorded at 5-minute intervals for 45 minutes post formalin injection. Early phase responding included Minutes 0 to 10, and late phase responding included Minutes 11 to 45. At the end of the testing period, animals were sacrificed using carbon dioxide.
(iv) Data Analysis:
As recited above, responding was divided into early phase (total time spent licking during Minutes 0 to 10 following the formalin injection) behaviors and late-phase (total time spent licking during Minutes 11 to 45 post formalin injection) behaviors. Time values were obtained for the vehicle only dose group (the control group) and each treatment group. For the purpose of measuring the activity of the invention compounds, the late-phase time values of a given treatment group were compared statistically to the late-phase time values obtained for the control group using either Student's t-test or One-way Analysis of Variants (ANOVA).
The results are reported in Table 1 and Table 2 under the heading "FT" as the dose tested in milligrams f invention compound per kilogram of test animal (mg/kg). A compound was characterized as active if it produced a statistically-significant decrease in the time animals administered invention compound plus vehicle spent engaging in pain-related behaviors compared to the time spent by animals receiving vehicle alone. Invention compounds were typically administered at 10 and/or 30 mg/kg, and the activities are reported in the tables as either being greater than (>) or less than (<) these doses.
b. The 6-OHDA Lesioned Rat Assay (6-OHDA):
The 6-OHDA model is used to test compounds of the invention for anti-Parkinsonism activity.
(i) 6-OHDA lesioned rat assay protocol:
6-Hydroxydopamine-lesioned rats were used (see Ungerstedt U, Arbuthnott GW: "Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostraiatal dopamine system", Brain Res., 1971;24(3):485-493). Adult male Sprague-Dawley rats were anesthetized with chloral hydrate, and unilateral lesions of the nigrostriatal dopamine system were accomplished by infusion of 8 ~,g of 6-hydroxydopamine HBr (6-OHDA) into the right medial forebrain bundle. Rats were pretreated 30 minutes before surgery with desipramine HC 1 25 mg/kg intraperitoneally (IP) to protect noradrenergic neurons, and pargyline 25 mg/kg IP to potentiate the effects of 6-OHDA. A minimum of 3 weeks after surgery, the rotational behavior induced by apomorphine HCL
50 ~g/kg administered subcutaneously (SC) was assessed. Only rats demonstrating more than 100 contraversive turns/hour to apomorphine were used for the present experiments.
(ii) Measurement of animal behavior:
Rotational behavior was measured using an automatic rotometer system (Rotorat Rotational Activity System, MED Associates, Georgia, VT). Antiparkinsonian activity was assessed as the ability of the invention compounds to potentiate the contraversive rotation induced by L-DOPA methyl ester, dosed at 10 mg/kg SC, over a 6-hour period. Experiments were conducted using a crossover paradigm where each rat received either vehicle plus L-DOPA, or an invention compound plus L-DOPA, in randomized order. Rats were tested at 7-day intervals. In experiments in which the invention compounds were tested orally (PO), rats were food deprived for 16 hours.
(iii) Data analysis:
Statistical analysis between treatment groups was performed using a paired t-test. The results are reported in Table 1 and Table 2 under the heading "6-OHDA" as the minimum effective dose (MED) in milligrams of invention compound per kilogram of test animal (mg/kg) required to produce a statistically-significant increase in total contraversive rotations in rats administered invention compound compared to rats receiving L-DOPA alone. Invention compounds were typically administered atl0 mg/kg and/or 30 mg/kg, and the MED's are reported in the tables as either being greater than (>) or less than (<) these doses.
o-N
Q ~ N ~ I ~
N
H
ExampleQ * IFPNR NR1A/ 6-OHDA FT
No. (IC50 NR2B (mg/kg) (mg/kg) ~,M) (IC50 wM) 1 H R,S 0.033 0.080 >10 (po) >10 3 F R, 0.030 NTa > 10 (po);> 10;
S
<30 (po) <30 4a F (+) 0.016 NT >10 (po);<10 <30 (po) 4b F (-) 0.280 NT >30 (po) >30 a NT means not tested.
I~
NAB
Q ~ X
~Y(O,S) N
H
ExampleB Q X1 * IFPNR FT Y
No. IC50 (mg/kg) ~m S ~ F O R,S 0.047 >30 O
6 ~~ F O NC 0.54 NT O
s 7 ~~ F S NC 0.45 NT S
s 8 ~~ H NH NC 0.066 NT O
s 9 ~~ F S NC >1 NT O
~~ H O NC >1 NT O
11 ~~ H CH2 NC >1 NT O
12 ~~ F O R,S 0.394 NT O
s 13 ~~ H O R, 0.1 O NT O
s S l ~ F O NC 0.499 NT O
21 H3c~ F O R,S 0.011 NT O
22 Ho2c~ F O R,S 0.788 NT O
23 Me02C' o-N F O R,S -- NT J
a NC means no chiral center;
b NT means not tested.
R
(CH2)h~ _ I ~ N.~ B
Q I ~ oho N
H
Example V B h Q R2 * IFPNR
No. IC50 (~,M) 2 CH2 o-N 1 H H NCa >1 \ \ CH3 14 CH2 s~ 1 H H R,S 0.688 N
17 CH2 ~ 1 H OH R,S 0.006 18 C=O ~ 1 F H R, S > 1 19 CH2CH2 ~ 1 F H R, S 0.400 20 CH2 ~ 1 F OH R,S 0.008 24 CH2 ~ 1 F C02Et R,S --25 CH2 ~ 1 F C02H R,S --34 CH2 ~ 0 F H R,S 0.280 35 CH2 ~ 0 H OH R,S >1 36 CH2CH2 ~ 0 F H R,S >1 a NC means no chiral center Z
~N~
Q B
~O
N
H
ExampleB Z Q * IFPNR
No. IC50 (~,M) 27 ~ O F R,S 0.059 28 ~ S F R,S 0.018 29 ~ S=O F R, 0.600 S
30 ~ C=O F R,S 0.759 31 ~ CH(OH) F R, > 1 S
32 ~ CMe(OH) F R,S >1 .,,.
.,,..~N. _ F v R3 V B I ~ X~O
X ~ N
Example V B R3 X 1 X2 X3 * IFPNR
No. ICSO
(~M) 16 CH2 ~ H S H H R,S 0.002 26 CH2 ~ OH O H H R, 0.023 S
33 CH2 ~ H O Me Cl R,S 0.014 As shown in the above tables, compounds of the invention are potent antagonists at the NMDA receptor and orally active in vivo in models of Parkinson's disease and pain.
In addition to the oral dosing forms described above, the compounds of the invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. The following dosage forms may comprise as the active component a compound of Formula I or a pharmaceutically acceptable salt thereof.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other Garners, is surrounded by a Garner, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or, synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 to 100 mg preferably 0.5 to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.
In therapeutic use as antagonists or as agents for the treatment of diseases, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily.
A
daily dose range of about 0.01-mg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, the compound being employed.
Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
Examples of pharmaceutical preparations of the compounds of the invention is described below. Such preparations can be administered to a human from one to six times a day for treatment of disease caused by over excitation of NMDA receptor channel complexes.
Tablet Formulation:
Ingredient Amount (mg) Compound of Example 25 Lactose 50 Cornstarch (for mix) 10 Cornstarch (paste) 10 Magnesium stearate 5 ( 1 %) Total 100 The compound of Example 1, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirnng to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1 % magnesium stearate and pressed into a tablet.
' EXAMPLE 3 8 Coated Tablets:
The tablets of Example 17 are coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth, and colorant.
Infection vials:
The pH of a solution of 500 g of the compound of Example l and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 L of double-distilled water using 2 M hydrochloric acid. The solution is sterile filtered, and the filtrate is filled into injection vials, lyophilized under sterile conditions, and aseptically sealed. Each injection vial contains 25 mg of the compound of Example 1.
Suppositories:
A mixture of 25 g of the compound of Example 1, 100 g of Soya lecithin, and 1400 g of cocoa butter is fused, poured into molds, and allowed to cool.
Each suppository contains 25 mg of the compound of Example 1.
Solution:
A solution is prepared from 1 g of the compound of Example 1, 9.38 g of NaH2P04~2H20, 28.48 g ofNa2HP04~12H20, and 0.1 g benzalkonium chloride in 940 mL of double-distilled water. The pH of the solution is adjusted to pH
6.8 using 2 M hydrochloric acid. The solution is diluted to 1.0 L with double-distilled water, and sterilized by irradiation. A 25 mL volume of the solution contains mg of the compound of Example 1.
Ointment:
500 mg of the compound of Example 1 is mixed with 99.5 g of petroleum jelly under aseptic conditions. A 5 g portion of the ointment contains 25 mg of the compound of Example 1.
Capsules:
2 kg of the compound of Example 1 are filled into hard gelatin capsules in a customary manner such that each capsule contains 25 mg of the invention compound.
Ampoules:
A solution of 2.5 kg of the compound of Example 1 is dissolved in 60 L of double-distilled water. The solution is sterile filtered, and the filtrate is filled into ampoules. The ampoules are lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 25 mg of the compound of Example 1.
While the forms of the invention exemplified herein such as, for example, the named species of Formula IV or the recitation of treatment of pain or Parkinson's disease constitute preferred embodiments of the invention, many other preferred embodiments are possible. It is not intended that the preferred embodiments of compounds of Formula IV, or preferred methods of use of said compounds, recited above should, in any manner, limit or restrict the invention from the full scope claimed herein.
R O O O R
N N
N-R
> >
N
R
S
O R O
X-s( ~N
and N-R
wherein R and X are as defined above.
It is to be appreciated that the above rings do not represent all possible isomers or rings that are described above by the term "heterocyclene".
It is also to be appreciated that the compounds of Formula I may have 10 chiral centers, in which case all stereoisomers thereof, both separately and as racemic and/or diastereoisomeric mixtures, are included.
Some of the compounds of Formula I are capable of further forming nontoxic pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the present invention.
15 For example, pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy 20 alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfate, nitrate, phosphate, monohydrogenphosphate, dihyrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977;66:1-19.
The acid addition salts of basic invention compounds are prepared by contacting the free base form of the invention compounds with a sufficient amount of the desired acid to produce the salt in the conventional manner.
Pharmaceutically acceptable base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as canons are sodium, potassium, magnesium, calcium, and the like.
Examples of suitable amines are N,N dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge, supra., 1977).
Base salts of acidic invention compounds are prepared by contacting the free acid form of the invention compounds with a sufficient amount of the desired base to produce a salt in the conventional manner.
Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
The compounds of the invention may be prepared by a number of methods well known to a person of average skill in the arts of organic and medicinal chemistries.
It should be appreciated that the organic and medicinal chemistry arts provide the skilled artisan with electronically searchable literature, reaction, and reagent databases and a wide variety of commercially available starting materials.
For example, see the databases of the Chemical Abstracts service (Columbus, Ohio); Katritzky, Alan R., Handbook of Heterocyclic Chemistry, Pergamon Press, Ltd., 1985, Volumes 4 and 5; and The Aldrich Catalog (Sigma-Aldrich Corporation, St. Louis, Missouri).
For examples of the preparation of optically pure 02-isoxazolines (i.e., chiral ~2-isoxazolines that consist of only one enantiomer, or substantially one enantiomer), see Yang, K-S, et al., Tetrahedron Letters, 2000;41:1453-1456 or Shimizu, M. et al., Chemistry Letters, 1996:455-456.
As described above, some of the invention compounds possess chiral centers. It should be appreciated that a person skilled in the medicinal and organic chemistry arts is able to prepare chiral invention compounds by classical resolution techniques and/or asymmetric synthesis.
It should also be appreciated for purposes of synthesizing the compounds of the invention that reactive functional groups present in starting materials, reaction intermediates, or reaction products may be protected during chemical reactions using protecting groups which render the reactive functional groups substantially inert to the reaction conditions (see for example, Protective Groups in Organic Synthesis, 2nd ed., Green TW and Wuts PG, John Wiley & Sons, New York, NY 1991 ). Thus, for example, protecting groups such as the following may be utilized to protect suitable amino, hydroxyl, and other groups of related reactivity: carboxylic acyl groups, such as formyl, acetyl, trifluoroacetyl;
alkoxycarbonyl groups, such as ethoxycarbonyl, t-butoxycarbonyl (BOC), (3,(3,(3-trichloroethoxycarbonyl (TCEC), ~i-iodoethoxycarbonyl;
aryloxycarbonyl groups, such as benzyloxycarbonyl (CBZ), p-methoxybenzyloxycarbonyl, phenoxycarbonyl; trialkyl silyl groups, such as trimethylsilyl and t-butyldimethylsilyl (TBDMS); and groups such as trityl, tetrahydropyranyl, vinyloxycarbonyl, o-nitrophenylsulfenyl, diphenylphosphinyl, p-toluenesulfonyl, and benzyl may all be utilized. The protecting group may be removed, after completion of the synthetic reaction of interest, by procedures known to those skilled in the art. For example, a BOC group may be removed by acidolysis, a trityl group by hydrogenolysis, TBDMS by treatment with fluoride ions, and TCEC by treatment with zinc. Use of protecting groups in organic synthesis is well within the skill of the average artisan.
It should be appreciated that reagents, solvents, and starting materials necessary for the preparation of the compounds of the invention may be purchased from a number of commercial sources or may be readily prepared by a number of methods well known to one of average skill in the art of organic chemistry.
Further, reactions used to prepare the invention compounds can be carried out under a wide variety of conditions comprising solvents, reagents, catalysts, temperatures, time, atmosphere, and pressure.
Many different methods may be used to prepare the invention compounds.
However for purposes of practicing the invention, which comprises compounds, pharmaceutical compositions, and methods of treating certain disorders and diseases, it does not matter how the compounds are made. Nevertheless, novel methods of preparing the invention compounds are valuable as they may afford improvements in ease of synthesis or purification, cost of preparation, or process time. As discussed above, the invention provides novel methods of making the invention compounds.
For example, one method of preparing the compounds of the invention is described below in Scheme 1.
Scheme 1 - ~Z IVH + L-V- Y~
(R~)g R _ _ Z N-V- Y
~1)g R3 wherein Rl, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above and L
is a leaving group such that when V is (CH2)n or (CH2)m-C=O, wherein m is not 0, L
is, for example, halogen, CH3C02-, CF3C02-, CF3S03-, p-toluyl-S03-, and the like; and when V is C=O, L is, for example, halogen, hydroxy, which can form intermediates activated for displacement by a compound of formula A by reaction with coupling agents such as, for example, carbonyldiimidazole (CDI), N,N'-dicyclohexylcarbodiimide (DCC), and the like, benzotriazol-1-yl, imidazol-1-yl, CH3C02-, and the like.
In Scheme 1, a compound of formula A, wherein R1, g, and R2 are as defined above, is allowed to react with a compound of formula B, wherein L is a leaving group which is displaced by a compound of formula A, to provide a compound of Formula I. In a preferred procedure, a compound of formula A is dissolved or suspended in an aprotic, polar solvent such as, for example, N,N-dimethylformamide (DMF), ethyl acetate, dimethylsulfoxide (DMSO), acetonitrile, nitromethane, acetone, and the like, and optionally a 1 to 2 molar equivalents of a non-nucleophilic base such as, for example, triethylamine, diisopropylethylamine, sodium hydride, and the like is added, followed by addition of a compound of formula B as a neat material (i.e., only the material itself in solid or liquid form) or in a solution of an aprotic, polar solvent such as, for example, the aprotic, polar solvents recited above, at an addition rate that maintains a desired reaction temperature, and the mixture is stirred in air or under an inert atmosphere such as, for example, nitrogen or argon, to give a compound of Formula I. In another preferred procedure, a compound of formula A is dissolved or suspended in an aprotic, nonpolar solvent such as, for example, 5 tetrahydrofuran (THF), diethylether, hexanes, and the like, and about one molar equivalent of a strong base such as, for example, n-butyl lithium, sec-butyl lithium, tert-butyl lithium, potassium hexamethyldisilazide (KI~VIDS), and the like is added, followed by addition of a compound of formula B as a neat material or in a solution of a nonpolar, aprotic solvent such as, for example, the nonpolar, 10 aprotic solvents recited above, at an addition rate that maintains a desired reaction temperature, and the mixture is stirred to give a compound of Formula I. In still another preferred procedure, a compound of formula B, wherein L-V- is HO-C(O)-, is dissolved or suspended in an aprotic solvent such as, for example, THF, DMF, ethyl acetate, and the like, and about 1 molar equivalent of a coupling 15 agent such as, for example, CDI, DCC, bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl), and the like, followed by addition of a compound of formula A
as a neat material or in a solution of an aprotic solvent such as, for example, the aprotic solvents recited above, at an addition rate that maintains a desired reaction temperature, and the mixture is stirred to give a compound of Formula I. In 20 Scheme 1, the preferred molar ratio of a compound of formula A to a compound of formula B is about 1:1.
Another method of preparing the compounds of the invention is described below in Scheme 2.
Scheme 2 PGI
r--Z N-V-B ~ ~ PGZ
~l~g R3 ~xl~d C
- ~Z N-V-B
~l~g R3 wherein R1, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above, and and PG2 are protecting groups which may be deprotected to provide the groups E
and Y, respectively, of compounds of Formula I. Illustrative examples of PG1 are hydrogen (when E is H), -O-benzyl, -S-benzyl, -NH-benzyl, -NH-(4-methoxybenzyl), -NH-BOC, -NH-CBZ, -O-TBDMS, -CH2-halo, C(O)-CH2-halo, -C02Me, C(O-CH2)2, CH2CH2C02Me, and the like. Illustrative examples of PG2 are -NH-benzyl, -NH-(4-methoxybenzyl), -NH-BOC, -NH-CBZ, C02Me, -O-benzyl, -O-TBDMS, and the like.
In Scheme 2, a compound of formula C is deprotected to give a compound of Formula I. In a preferred procedure, a compound of formula C, wherein PG1 and/or PG2 is -O-benzyl, -S-benzyl, -NH-benzyl, -NH-CBZ, and the like, is dissolved or suspended in a suitable solvent such as, for example, acetic acid, ethanol, THF, dichloromethane, and the like, and allowed to react with a deprotecting reagent such as, for example, a mixture of hydrogen gas and a suitable hydrogenation catalyst such as, for example, palladium on carbon, palladium on barium sulfate, platinum on carbon, sponge nickel, and the like, under pressure, phosphorous tribromide, hydrochloric acid, titanium tetrachloride, and the like, at an addition rate that maintains a desired reaction temperature, to give a compound of Formula I. Examples 1, 3, 4a, 4b, 5, and 9 are representative of the chemistry described in Scheme 2.
Another method of preparing the compounds of the invention is described below in Scheme 3.
Scheme 3 E
- ~Z N-V-U ~ /r-Y
(It)g R D (It)a - ~Z N-V-B
(Rt)g R
wherein R1, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above, and U
is -C(H)=C(H)- or -C=C-.
In Scheme 3, a compound of formula D is allowed to react with a 3- or 4-membered cyclization reagent to give a compound of Formula I, wherein B is a S- or 6-membered heterocyclene, respectively. In a preferred procedure, a compound of formula D is dissolved or suspended in an aprotic solvent such as, for example, THF, dichloromethane, acetone, DMF, and the like, and allowed to react with a 3-membered cyclizing reagent such as, for example, an alkylazide, alkyldiazomethane, acetonitrile oxide, prepared by reaction of an aldoxime such as, for example, acetaldoxime [i.e., CH3C(H)=N-OH] with a radical generating agent such as, N-bromosuccinimide (NBS), N-chlorosuccinimde (NCS), and the like, or a 4-membered cyclizing reagent such as, for example, H2C=C(H)-C(H)=N-EDG, wherein EDG is an electron donating group such as, for example, -N(CH3)2, -OMe, and the like, to give a compound of Formula I. Example 2 is representative of the chemistry described in Scheme 3.
Another method of preparing the compounds of the invention is described below in Scheme 4.
Scheme 4 Rz - ~Z N-(~~)g R E
~i)g wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above, B is oxazole, dihydrooxazole, thiazole, or dihydrothiazole, and T is C=O or C(H)OH.
In Scheme 4, a compound of formula E is allowed to react with a reagent and/or catalyst under cyclizing conditions to provide a compound of Formula I.
In a preferred procedure, a compound of formula D is dissolved in an aprotic solvent such as, for example, THF, ethyl acetate, DMF, DMSO, and the like, and a dehyrdating reagent such as, for example, anhydrous magnesium sulfate, anhydrous calcium chloride, activated 3 angstrom molecular sieves, trimethoxymethane, oxalyl chloride, PCIS, phosphorous pentoxide and the like, is added and optionally an acid catalyst such as, for example, trifluoroacetic acid, para-toluenesulfonic acid, and the like, is added, and the mixture is stirred to provide a compound of Formula I, wherein B is oxazole or dihydrooxazole. In another preferred procedure, a compound of formula D is dissolved in an aprotic solvent such as, for example, THF, ethyl acetate, DMF, DMSO, and the like, and a sulfurating reagent (i.e., a reagent that introduces a sulfur atom) such as, for example, P2S5, [2,4-bis(4-methoxyphenyl)-1,3-dithian-2,4-diphosphetane-2,4-disulfide] (i.e., Lawesson's reagent), and the like, is added, and the mixture is stirred to provide a compound of Formula I, wherein B is thiazole or dihydrothiazole. Examples 6(a)-6(f) and 8 are representative of the chemistry described in Scheme 4.
Another method of preparing the compounds of the invention is described below in Scheme 5.
Scheme S
E
Z R N-V-T-CH2~NHC Y
_~r v ~R1)g R3 ~X1)d F
E
-~~Z N-V-B ~ ~ Y
(R~)g R3 (X~)d wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above, B is oxazole, dihydrooxazole, thiazole, or dihydrothiazole, and T is C=O or C(H)OH.
5 In Scheme 5, a compound of Formula F is allowed to react with a reagent and/or catalyst under cyclizing conditions to provide a compound of Formula I.
Preferred procedures are as described above in Scheme 4. Examples 7(a) and 7(b) are representative of the chemistry described in Scheme 5.
Another method of preparing the compounds of the invention is described 10 below in Scheme 6.
Scheme 6 E
-~~Z N-V-B ~ ~ Y I
(R~)g R~ (X~)d Rz Z N-V- Y
(R ~ )g R
wherein R1, g, Z, h, R2, R3, V, B, X1, d, E, and Y are as defined above.
In Scheme 6, a compound of Formula I is allowed to react with a reagent to provide a different compound of Formula I. In a preferred procedure, a compound of Formula I wherein V is (CH2)mC=O is dissolved or suspended in a suitable aprotic, nonpolar solvent such as, for example, THF, methyl-tert-butylether (MTBE), hexanes, and the like, and a reducing agent such as, for example, lithium aluminum hydride, sodium borohydride, sodium triacetoxyborohydride, diisobutylaluminum hydride (DIBAL), and the like, is added at an addition rate that maintains a desired reaction temperature, and the mixture is stirred to give a compound of Formula I wherein V is (CH2)n.
Another method of preparing the compounds of the invention is described below in Scheme 7.
Scheme 7 E
Rz - ~Z N- \ + K ~ ~ Y---~
I
(Rt)g R3 (Xt)d G
H
E
- ~Z N-V-B ~ ~ Y
~1)g R3 ~Xl)d wherein R1, g, Z, h, R2, R3, V, X1, d, E, and Y are as defined above, B is isoxazole, dihydroisoxazole (i.e., isoxazoline), dihydrothiazoline, or oxazole; J is C(H)=CH2 or C=C-H, and K is C(Cl)=N-OH.
In Scheme 7, a compound of formula G is allowed to react with a compound of formula H under [3+2] cyclization conditions to provide a compound of formula I. In a preferred procedure, a compound of formula G and a compound of formula H are dissolved or suspended in a solvent such as, for example, methanol, ethanol, THF, ethyl acetate, toluene, dichloromethane, and the like, and optionally a non-nucleophilic base such as, for example, triethylamine, diisopropylethylamine, sodium hydride, and the like is added, and the mixture is stirred to provide a compound of Formula I. Examples 10 to 16 are representative of the chemistry described in Scheme 7.
Examples of the preparation of the invention compounds are described below.
6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H benzoxazol-2-one N,OH
HO / CHO Bn0 / CHO Bn0 BnBr, K CO _ z 3 ~ NHzOH / 1) NCS/DMF
OzN \ MeCN OzN \ Na O
2 3 OZN 2) ~COZMe N~O COZMe N.O OH
Bn0 / ~ DIBAL Bn0 / ~ pph CBr O N \ I THF O N \ ~ MeCN
z z OBn N.O \ \ O~N -Bn0 / ~ Br I / 6 NH ~ / N ~ ~ NOz O N \ I KZC03,MeCN
z OBn Hz, \ O.N -/ N ~ ~ NOz p~0 .N
CDI i ( \ O ~ \ / NH
/ N
Step 1: A mixture of 3-hydroxy-4-nitrobenzaldehyde (10.0 g, 0.0598 mol), benzyl bromide (7.20 mL, 0.0598 mol) and anhydrous potassium carbonate (18.20 g, 0.1316 mol) in 250 mL MeCN was heated at 60°C for 5 hours with vigorous stirring. The reaction mixture was filtered, and the filtrate was concentrated. The residue was taken up in chloroform, and an orange precipitate was removed. The filtrate was reconcentrated to an oil which crystallized on standing to give 1 (15.38 g, 100%): TLC Rf= 0.58 (1:1 hexanesBtOAc).
Step 2: To a suspension of compound of formula 1 (3.0 g, 0.0117 mol) in 30 mL
isopropanol was added hydroxylamine hydrochloride (812 mg,' 0.0117 mol), followed by sodium carbonate (2.47 g, 0.0234 mol). After addition was complete the reaction mixture was vigorously stirred at 40°C for 30 minutes (all starting material went into solution) and concentrated. The residue was taken up in water, and the aqueous mixture was washed 2X with EtOAc. The organic washings were combined and washed with saturated NaCI(a~, dried over magnesium sulfate and concentrated to a yellow solid which was used without further purification to give 2 (2.63 g, 82%); TLC Rf= 0.55 (1:1 hexanes/EtOAc); CI -MS (m/z): 273 [M + H]+.
Step 3: Compound of formula 2 (2.63 g, 9.66 mmol) was dissolved in 30 mL
N,N-dimethylformamide (DMF), and N-chlorosuccinimide (NCS, 1.29 g, 9.66 mmol) was added. The reaction mixture was stirred at room temperature under nitrogen for 4 hours and concentrated. The residue was partitioned between water and EtOAc and after thorough mixing the aqueous layer was discarded, and the organic layer was washed with saturated NaCI(a~, dried over magnesium sulfate, filtered and concentrated to an oil. The crude chlorooxime was taken up in 30 mL 1:1 (v/v) water/tetrahydrofuran (THF) and methyl acrylate (1.18 mL, 12.6 mmol) was added, followed by adding sodium bicarbonate (2.46 g, 29.0 mmol). The reaction mixture was stirred at room temperature for 1.5 hours and extracted with EtOAc. The organic extract was dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel 60, 230-400 mesh, 3:2 Hexanes/Ethyl acetate) to give 3 (3.19 g, 93%) as a yellow oil: TLC Rf= 0.40 (1:1 hexanes/EtOAc); APCI-MS
(m/z): 357 [M + H]+.
Step 4: To a solution of compound of formula 3 (3.10 g, 8.70 mmol) in 30 mL
anhydrous THF, cooled to 0°C under nitrogen, is added slowly 26.10 mL
(26.10 mmol) 1.0 molar (1.0 M) diisobutylaluminum hydride (DIBAL or DiBAIH) solution in cyclohexane (note: effervescence). After addition was complete, the reaction mixture was stirred at 0°C for 1 hour and quenched by slow addition of MeOH. The reaction mixture was partitioned between saturated aqueous potassium sodium tartrate and EtOAc and stirred for 30 minutes. The organic layer was removed, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over magnesium sulfate, filtered and concentrated to a yellow-orange oil which was used without further purification to give 4 (2.76 g, 97%): TLC Rf= 0.13 (1:1 hexanes/EtOAc); APCI-MS (m/z): 329 [M + H]+.
Step 5: To a solution of triphenylphosphine (3.42 g, 12.98 mmol) in 30 mL
MeCN is added under nitrogen carbon tetrabromide (4.29 g, 12.98 mmol), followed by compound of formula 4 (2.13 g, 6.49 mmol). After stirring at room temperature for 1.5 hours an additional 2.57 g (9.74 mmol) triphenylphosphine and 3.22 g (9.74 mmol) carbon tetrabromide was added, and stirring was continued for 15 minutes. The reaction mixture was concentrated and the crude 5 product was purified by flash chromatography (4:1 Hexanes/Ethyl acetate to 3:2 Hexanes/Ethyl acetate) to give 5 (1.57 g, 62%) as a yellow, crystalline solid:
TLC
Rf= 0.54 (1:1 hexanes/EtOAc); APCI-MS (m/z): 391 and 393 [M + H]+.
Step 6: A mixture of 4-benzylpiperidine (6) (0.56 mL, 3.26 mmol), compound of formula 5 (1.16 g, 2.96 mmol) and anhydrous potassium carbonate (1.35 g, 10 9.78 mmol) in 30 mL MeCN was heated at reflux for 24 hours. The reaction mixture was concentrated, and the residue was partitioned between water and EtOAc. The organic layer was washed with water, dried over magnesium sulfate, filtered and concentrated. The crude product was flash chromatographed (EtOAc) to give 7 (1.36 g, 95%) as a yellow oil which crystallized on standing: TLC
15 Rf= 0.36 (EtOAc); APCI-MS (m/z): 486 [M + H]+; Anal. Calcd for C29H31N304~ C~ 71.73; H, 6.43; N, 8.65. Found: C, 71.70; H, 6.59; N, 8.41.
Step 7: A mixture of compound of formula 7 (410 mg, 0.84 mmol) and 50 mg 20% Pd on C catalyst in SO mL 1:1 (v/v) MeOH/THF was hydrogenated for 11 hours under a hydrogen pressure of 47.8 psi. The catalyst was filtered off 20 (CELITE), and the filtrate was concentrated to give 8 as a brown, glassy solid;
(307 mg (100%): TLC Rf= 0.10 (EtOAc); APCI-MS (m/z): 366 [M + H]+.
Step 8: A mixture of compound of formula 8 (330 mg, 0.90 mmol) and N,N'-carbonyldiimidazole (218 mg, 1.35 mmol) in 10 mL anhydrous THF was refluxed under nitrogen for 1 hour. The reaction mixture was concentrated, and the residue 25 was taken up in EtOAc. The organic layer was washed with water, saturated aqueous NaCI, dried over magnesium sulfate, filtered and concentrated. The crude product was flash chromatographed (3% MeOH in CHCl3 to S% MeOH in CHC13) to give 6-[5-(4-benzylpiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H benzoxazol-2-one (176 mg, 50%) as an oil which crystallized on standing:
30 (176 mg, 50%): TLC Rf = 0.23 (9:1 CHC13/MeOH); APCI-MS (m/z): 392 [M +
H]+; Anal. Calcd for C23H25N303~ C~ 70.57; H, 6.44; N, 10.73. Found C, 70.04;
H, 6.52; N, 10.63.
6-[5-(4-Benzylpiperidin-1-ylmethyl)-3-methylisoxazol-4-yl]-3H benzoxazol-2-one / O Br / O
O NBS O
HOAc \
N
H H
THF H
\ I NH \ ~ N
H
6 Bra 10 Pd(PPh3)2C12/Et3N /
uI DMF \ I N
C , / ~ O.N CH3 Acetaldoxime NBS, Et3N, DMF ~ N \ O
/ ~O
N
H
Step 1: To a solution of benzoxazolinone (20 g, 0.148 mol) in 220 mL glacial acetic acid was added N-bromosuccinimide (NBS, 26.36 g, 0.148 mol), and the reaction mixture was stirred at room temperature for 63 hours before pouring into 1500 mL water. The precipitated product was washed thoroughly with water upon collection and recrystallized from EtOH to give 6-bromo-3H benzoxazol-2-one (9) (25.09 g, 79%): Theory: C, 39.28; H, 1.88; N, 6.54; Br, 37.33. Found: C, 39.36; H, 2.02; N, 6.36; Br, 37.43. MP 192-194°C.
Step 2: A mixture of 4-benzylpiperidine (6) (25 mL, 0.14 mol) and propargyl bromide (10.40 g, 0.07 mol, 80% wt. solution in toluene) in 250 mL anhydrous THF was heated at reflux under nitrogen for 19 hours. The reaction mixture was concentrated, and the residue was taken up in chloroform. The organic layer was washed with 1.0N aqueous NaOH, dried over magnesium sulfate, filtered and concentrated. The crude product was flash chromatographed (1:1 Hexanes/Ethyl acetate to 3:2 Hexanes/Ethyl acetate) to give 10 (11.90 g, 80%), as an orange oil, MS(APCI) M + 1 = 214, TLC (0.34, 1:1 Hexanes/Ethyl acetate; iodine stain).
Step 3: A mixture of compound of formula 10 (7.44 g, 0.0349 mol) and compound of formula 8 (8.19 g, 0.0383 mol) with copper (I) iodide (245 mg, 1.29 mmol), dry triethylamine (14.5 mL, 0.1048 mol), and dichlorobis(triphenylphosphine)palladium(II) (476 mg, 0.68 mmol) in 70 mL
anhydrous DMF was heated at 80°C under nitrogen with vigorous stirnng for 18 hours. The reaction mixture was concentrated, and the residue was taken up in acetone and refrigerated for a few hours. The precipitated product was washed with acetone upon collection to give 11 (4.67 g, 39%) as a tan solid, MS(APCI) M + 1 = 347, M - 1 = 345. Melting point (MP) 235-236°C (dec.), TLC
(0.44, EtOAc).
Step 4: To a solution of N-bromosuccinimide (910 mg, 5.11 mmol) in 7.0 mL
anhydrous DMF containing 2 drops pyridine was slowly added under nitrogen acetaldoxime (0.32 mL, 5.11 mmol). After addition was complete (5 minutes), the reaction mixture was stirred for 30 minutes at room temperature after which time compound of formula 11 (700 mg, 2.03 mmol) was added in one portion. The reaction mixture was heated to 90°C and triethylamine (0.70 mL, 5.11 mmol) was added in one portion. Heating was continued for 24 hours, and the reaction mixture was concentrated. The residue was allowed to stand in a small amount of acetone and over a period of time 212 mg of unreacted compound of formula 11 precipitated and was filtered off. The filtrate was concentrated, and the residue was taken up in chloroform. The organic layer was washed with water, dried over magnesium sulfate, filtered and concentrated. The crude product was flash chromatographed (EtOAc) to give 6-[5-(4-benzyl-piperidin-1-ylmethyl)-3-methyl-isoxazol-4-yl]-3H benzoxazol-2-one as an orange oil which solidified on standing, 100 mg (12%), MS(APCI) M + 1 = 404, M - 1 = 402. Theory: C, 71.44; H, 6.25;
N, 10.41. Found: C, 68.81; H, 6.20; N, 10.07. HPLC (C-18, 1:1 Water/Acetonitrile, isocratic) retention time (RT) = 15.34 min (93.8%).
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one hydrochloride -HCI F
N-O Br Bn0 1 12 \ KZCO3, KI, LiBr, CH3CN
OZN
i. 50 psi H2, 10% Pd/C, THF, 4h ii. carbonic acid di-2-pyridyl ester Et3N, THF, reflex 5 Step 1: To a solution of bromide of formula 5 (2.84 g, 7.26 mmol) and amine of formula 12 (1.67 g, 7.26 mmol) in THF (25 mL) was added K2C03 (2.25 g, 16.3 mmol), KI (120 mg, 0.726 mmol), and Liar (150 mg, 1.72 mmol). The mixture was warmed to SO°C overnight (ca. 12 hours). After cooling to ambient temperature, the reaction solvent was removed under reduced pressure. The residue was partitioned between water and ethyl acetate. Warming was necessary to form a homogenous organic layer. The organic extract was washed with brine, dried (Na2S04), filtered, and concentrated to give amine of formula 13 as a yellow residue. Purification by chromatography (silica, 1:99 to 5:95 MeOH/CH2Cl2) gave amine of formula 13 (2.36 g, 65%) as a pale yellow solid.
Step 2: To a solution of amine of formula 13 (1.25 g, 2.48 mmol) in THF (80 mL) was added 10% Pd/C (200 mg). The mixture was shaken under 50 pounds per square inch (psi) of H2 for 4 hours then rapidly filtered through CELITE under reduced pressure into a round bottom flask. The flask was capped with a septum and purged with nitrogen. To the clear solution was added carbonic acid di-2-pyridyl ester (590 mg, 2.78 mmol) and Et3N (800 ~,L, 5.45 mmol). The solution was refluxed overnight (ca. 12 hours). Although no change in RF (TLC:
1:9 MeOH/CH2C12, Rf= 0.22) was observed, a color change from green to red was observed using ninhydrin that distinguished the starting material from the product. The solvent was removed under reduced pressure to afford a yellow residue. Purification by chromatography (silica gel, 1:99 to 5:95 MeOH/CH2C12) gave a yellow product. The colored product was taken up in MeOH and the solution acidified with 1 M HCl/Et20. This solution was dripped into 200 mL of Et20. The resulting suspension was briefly sonicated, and then the solid was collected by filtration to give (~)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one hydrochloride (728 mg, 66%) as a white solid.
EXAMPLES 4(a) AND 4(b) 4(a): (+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one i HNw o S
OBn Oi ~ ~ ~ N02 H
OBn OBn N O ~ ~ ~ N~
O ~ ~ NOZ
s _ v N
~s ~ 19 Br Step 1: Washed (heptane) NaH (1.45 g, 36.3 mmol, 60% in mineral oil) in toluene (150 mL) was treated with the (1R)-sultam 14 (5.20 g, 24.2 mmol) at room temperature under N2. After stirring at room temperature for 1.5 hours, CuICI
5 (239 mg, 2.42 mmol) was added followed by acryloyl chloride (4.38 g, 4.84 mmol, 3.93 mL). After stirring for 3 hours at room temperature, the reaction was quenched with H20 (1 mL) and the solvents removed. The mixture was taken up in EtOAc and passed through a 'plug' (~20 g) of silica gel, and the EtOAc removed. The product was purified by chromatography (CH2Cl2) to yield 10 compound 15 as a white solid (3.92 g, 60%).
See J. Org. Chem., 1990;55:4585 for spectral data R f (EtOAc/C7) - 0.62 R f (2% MeOH/CH2C12) - 0.50.
Step 2: The oxime 15 (3.86 g, 14.20 mmol) and NCS (1.90 g, 14.2 mmol) were 15 stirred in DMF (75 mL) for 3 hours at room temperature. The DMF was removed and the product taken up in EtOAc, washed with brine and dried (MgS04). After removal of the solvent the material was taken up in THF/H20 (100:100 mL) and the sultam (IIa, 3.82 g, 14.20 mmol) and NaHC03 (3.78, 45 mmol) were added.
After 1 hour the mixture was diluted with EtOAc, washed with H20, brine and dried (MgS04). The crude material obtained was purified by recrystallization (EtOAc) to afford compound 16 as a very pale yellow 'fluffy' crystals (5.17 g, 68% from 3 crops of crystals).
Product from (1R)-sultam -[a]D23 = +224° (c=0.30, MeCN) m/z 540.0 (MH+), vm~ 2761, 1698, 1519, 1338, 1273, 849, 737 cm-1, 8H 1.00 (3H, s, CH3), 1.22 (3H, s, CH3), 1.40 (2H, m, CH2), 1.92 (3H, m, alkyl), 2.10 (1H, dd, CH, J8.0, 13.6 Hz), 2.20 (1H, dd, CH, J3.6, 13.6 Hz), 3.48 (1H, d, CHHS02, J 14.0 Hz), 3.59 (1H, dd, CHH, J 11.2, 17.2 Hz), 3.59 (1H, d, CHHS02, J 13.6 Hz), 3.71 (1H, dd, CHN, J6.8, 17.2 Hz), 5.26 (2H, s, OCH2), 5.76 (1H, dd, CHN, J6.8, 11.2 Hz), 7.18 (1H, dd, aromatic Carom.) J 1.6, 8.4 Hz), 7.32-7.48 (5H, m, Ph), 7.58 (1H, d, arom., J 1.2 Hz), 7.88 (1H, d. arom., J7.6 Hz).
Step 3: DiBAIH reduction of compound 16 as in Example 1, Step 4; and purification by chromatography (0-70% EtOAc/C7) gave 17 (2.19 g , 71 %).
Step 4: Bromination of compound 17 as in Example 1, Step 5 gave 18.
Step 5: Coupling of compound 18 as in Example 1, Step 6 gave 19: [a]D24 -+57° (c=0.42, CH2Cl2).
Step 6: Reduction of compound 19 as in Example 1, 7 gave 20.
Step 7: Benzoxazol-2-one ring formation of compound 20 as in Example 1, Step 8 gave (+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl }-3~benzoxazol-2-one: [a]D24 ° + 102° (c=0.31, MeOH).
Example 4(b): (-)-6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one N
O ~O
O
OBn OBn ~N
Oi \ ~ \ N~ O ~ NOZ
/N i 24 O ~O o 23 off OBn OBn o~ \ ~ ~ N~
O N
s ~ ~ ~N
B~ 25 F
S Step 1: Compound 22 was prepared in a manner similar to Example 4a, Step 1, except ( 1 S~-sultam (21) was used in place of the ( 1 R)-sultam.
Step 2: Compound 23 was prepared in a manner similar to Example 4a, Step 2:
[oc]D23 = -224° (c=0.27, MeCN).
Step 3: DiBAIH reduction of compound 23 as in Example l, Step 4 gave 24.
Step 4: Bromination of compound 24 as in Example 1, Step 5 gave 25.
Step 5: Coupling of compound 25 as in Example 1, Step 6 gave 26: [a]D24 =
_69°
(c=0.46, CH2C12).
Step 6: Reduction of compound 26 as in Example 1, Step 7 gave 27.
Step 7: Benzoxazol-2-one ring formation of compound 27 as in Example 1, Step 8 gave (-)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one: [a]D23 = -105° (c=0.44, MeOH).
6- { 3-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4, 5-dihydroisoxazol-5-yl } -3 H
benzoxazol-2-one NOZ NOZ ~ NOZ
-~ y O~ / OBn ~ / OBn EtO2C \ / OBn / OBn -~ 'OBn HO ~N~p 30 Br N-O
NOz 12 ~ F / N \ / OBn N-O
F / N ' / OH
N-O
H
~ N
~O
F / \ / O
N-O
Step 1: Butyllithium (16.0 mL, 40 mmol, 2.5 M in hexanes) was added to a suspension of methyltriphenylphosphonium bromide (12.50 g, 35.0 mmol) in THF
(300 mL at 0°C. After stirring for 1 hour, a solution of 2 (7.72 g, 30.04 mmol) was added, and the mixture stirred at room temperature for 3 hours. The solvent was removed, and the crude material was taken up in EtOAc and triturated with heptane, the solids were filtered off (x 5). The filtrate was then purified by chromatography (0-10% EtOAc in heptane) to give 28 as a yellow oil (3.04 g, 40%).
m/z 254.09 (M-H-) vm~ 1601, 1585, 1514, 1345 cm-1 SH 5.26 (2H, s, CH20), 5.45 (1H, d, CH=, J 10.4 Hz), 5/82 (1H, d, CH=, J 17.6 Hz), 6.68 ( 1 H, dd, dd, CH=, J 10.8, 17.6 Hz), 7.07 ( 1 H, dd, arom., J 1.6, 8.4 Hz), 7.11 (1H, s, arom.), 7.34 (1H, m, arom.), 7.39 (2H, m, arom.), 7.48 (2H, m, arom.), 7.88 (1H, d, arom., J8.4 Hz).
Step 2: Compound 28 (1.50 g, 5.88 mmol), ethyl 2-chloro-2-(hydroxyimino)acetate (888 mg, 5.88 mmol), NaHC03 (988 mg, 11.76 mmol) were stirred at room temperature in THF/H20 ( 10/5 mL). After 1 hour a further aliquot (888 mg, 5.88 mmol) of ethyl 2-chloro-2-(hydroxyimino)acetate was added, and stirring continued for a further 1 hour. The mixture was then diluted with EtOAc, washed with brine and dried (MgS04). Purification by chromatography (0-40% EtOAc in heptane) gave 29 as a yellow oil which solidified on standing (1.91 g, 88%).
m/z 371.15 (MH+) vm~ 1722, 1609, 1593, 1519, 1251 cm-1 8H 1.39 (3 H, t, CH3, J 7.2 Hz), 3.12 ( 1 H, dd, CHH, J 8.0, 18.0 Hz), 3.70 ( 1 H, dd, CHH, J 12.0, 17.6 Hz), 4.37 (2H, q, CH2, J 7.2 Hz), 5.25 (2H, s, CH20), 5.80 ( 1 H, dd, CH, J 8.0, 11.6 Hz), 6.94 ( 1 H, dd, arom., J 1.2, 8.0 Hz), 7.12 ( 1 H, s, arom.), 7.32-7.47 (5H, m, Ph), 7.88 (1H, d, arom., J 8.0 Hz).
Step 3: DiBAIH (12.90 mL, 12.90 mmol, 1 M in THF) was added to a solution of 29 (1.91 g, 5.16 mmol) in THF (SO mL) at 0°C. After 1 hour a further aliquot of DiBAIH (6.50 mL, 6.50 mmol, 1 M in THF) was added and the mixture stirred for another 1 hour. MeOH (1 mL) was added followed by saturated NaHC03 (20 mL) and the mixture stirred for 20 minutes. The solids were filtered off and the filtrate taken up in EtOAc, washed with brine and dried (MgS04). The material was 5 purified by chromatography (0-SO% EtOAc in heptane) to give 30 as a straw colored oil (66 mg, 39%).
m/z 329.21 (MH+) vm~ 3390, 1609, 1519, 1352 cm-1 8H 1.84 ( 1 H, t, OH, 6.0 Hz), 2.93 ( 1 H, dd, CHI, J 7.2, 17.2 Hz), 3 .54 ( 1 H, dd, 10 CHH, J 11.2, 17.2 Hz), 4.43 (2H, d, CH20H, J 6.0 Hz), 5.26 (2H, d, CH20, J
3.6 Hz), 5.65 ( 1 H, dd, CH, J 7.2, 11.2 Hz), 6.93 ( 1 H, dd, arom., J 1.2, 8.0 Hz), 7.1 S
(1H, d, arom., J 1.2 Hz), 7.32-7.48 (5H, m, Ph), 7.86 (1H, d, arom., J 8.0 Hz).
Step 4: Triphenylphosphine (799 mg, 3.05 mmol) and carbontetrabromide (1.01 g, 3.05 mmol) were added to a solution of 30 (667 mg, 2.03 mmol) in MeCN (20 15 mL) and the resulting mixture stirred at room temperature for 2 hours. The solvent was removed and the crude material purified by chromatography (0-50% EtOAc in heptane) to 31 as a yellow oil (719 mg, 90%).
m/z 393.11/391.11 (MH+) vm~ 1608, 1519, 1350 cm-1 20 8H 3.00 ( 1 H, dd, CHH, J 7.2, 17.2 Hz), 3.60 ( 1 H, dd, CHH, J 11.2, 17.2 Hz), 4.18 (2H, s, CH2Br), 5.25 (2H, s, CH20), 5.68 ( 1 H, dd, CH, J 7.6, 11.2 Hz), 6.94 ( 1 H, d, arom., J8.4 Hz), 7.13 (1H, s, arom.), 7.32-7.47 (5H, m, Ph), 7.87 (1H, d, arom., J 8.0 Hz).
Step 5: Compound 31 (7.15 mg, 1.83 mmol), 4-(4-fluorobenzyl)piperidine 25 hydrochloride (12) (504 mg, 2.19 mmol) and anhydrous K2C03 (507 mg, 3.66 mmol) in MeCN (10 mL) were stirred and heated to reflux for 16 hours. The solution was then diluted with EtOAc, washed with brine and dried (MgS04). The product was purified by chromatography (0-70% EtOAc in heptane) to yield 32 as a yellow oil (662 mg, 72%). ' m/z 504.26 (MH+) vm~ 2902, 1608, 1509, 850 cm-1 8H 1.89 (2H, m, alkyl), 1.45 ( 1 H, m, alkyl), 1.60 (2H, m, alkyl), 1.97 (2H, m, alkyl), 2.47 (2H, d, ArCH2, J 7.2 Hz), 2.67 ( 1 H, d, CH, J 11.2 Hz), 2.80 ( 1 H, d, CH, Jl 0.8 Hz), 2.90 ( 1 H, dd, CHH, J 7.2, 17.2 Hz), 3.21 (2H, dd, CH2N, J
14.0, 22.0 Hz), 3.49 ( 1 H, dd, CHH, J 11.2, 17.2 Hz), 5.22 (2H, dd, CH20, J 12.0, 16.0 Hz), 5.59 (1H, dd, CH, J7.2, 11.2 Hz), 6.95 (3H, m, arom.), 7.06 (2H, m, arom.), 7.15 ( 1 H, s, arom.), 7.31-7.47 (5H, m, Ph), 7.86 ( 1 H, d, arom., J 8.0 Hz).
Step 6: Compound 32 (595 mg, 1.38 mmol) and Pd-C (10%, 150 mg) in MeOH
(100 mL) were (in two batches) subjected to hydrogenation at 50 psi and 30°C for 1 hour. The catalyst was removed by filtration through a 'filter aid' and yielded 33 as an orange colored glass upon removal of the solvent (490 mg, 90%).
m/z 383.18 (MH+) vm~ 3370, 2923, 1509, 1219 cm-1 8H 1.25 (2H, bm, alkyl), 1.60 (4H, m, alkyl, NH2), 1.98 ( 1 H, m, alkyl), 2.48 (2H, d, ArCH2, J 6.8 Hz), 2.83 (2H, m, alkyl), 2.94 ( 1 H, dd, CHH, J 8.8, 17.6 Hz), 3.23 (2H, s, CH2N), 3 .32 ( 1 H, dd, CHH, J 10.8, 17.2 Hz), 3 .67 ( 1 H, bs, OH), 5.42 ( 1 H, dd, CH, J 8.8, 10.8 Hz), 6.70 (2H, s, arom.), 6.73 (1H, s, arom.), 6.96 (1H, s, arom.), 7.06 (2H, m, arom.).
Step 7: Compound 33 (490 mg, 1.28 mmol) and carbonyldiimidazole (CDI) (311 mg, 1.92 mmol) in THF (20 mL) were heated to reflux for 1 hour. The mixture was diluted with EtOAc, washed with brine and dried (MgS04). The compound was purified by chromatography (0-4% MeOH in CH2Cl2) and repeated (0-100%
EtOAc in heptane) to yield 6-{3-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-S-yl}-3~lbenzoxazol-2-one as a yellow foam (220 mg, 42%).
m/z 410.20 (MH+) vm~ 1776, 1509, 1219 cm-1 $H 1.26 (2H, bm, alkyl) 1.43-1.65 (3H, m, alkyl), 1.98 (1H, m, alkyl), 2.48 (2H, d, ArCH2, J 7.2 Hz), 2.75 ( 1 H, d, CHH, J 11.6 Hz), 2.84 ( 1 H, dd, CHH, J
10.8 Hz), 2.96 ( 1 H, dd, CHH, J 8.0, 17.6 Hz), 3.23 (2H, s, CH2N), 3.24 (2H, s, CH2N), 3.44 ( 1 H, dd, CHH, J 10.8, 17.2 Hz), 5.5 8 ( 1 H, dd, CH, J 8.0,.10.8 Hz), 6.93-7.16 (6H, m, arom.), 7.20 (1H, s, arom.), 7.99 (1H, bs, NH).
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H benzoxazol-2-one F / ~ ~ ~ ~COZBn COZH
F
O
\ O
~O ~ \
H ~~N
H
O O
N3 \ ~ HzN \ O
N~O ~ ~HCI I O
N
O
35 I \ O \ O
F ~ ~ I
~N
H
H
N
~0 O
~1 ~s F
Step 1: To a stirring solution of 4-(4-fluorobenzyl)piperidine (12) (10.0 g, 51.744 mmol) in dichloromethane (10 mL) at 0°C was added triethylamine (7.21 mL, 51.744 mmol), followed by benzyl-2-bromoacetate (8.20 mL, S 1.744 mmol). The resulting solution was allowed to warm to room temperature stirnng for 20 hours, then heated to 30°C for a further 6.5 hours. The reaction mixture was evaporated to dryness in vacuo to give a yellow gum. This was adsorbed onto silica gel, and subjected to column chromatography [EtOAc/Heptane (1:10)] to give 34 (5.07 g, 29%) as a colorless oil:
m/z (APCI+) 342 (MH+, 100%), S H 1.36 (2H, t, J 6.8), 1.25 (2H, t, J 3.6 Hz), 1.36 (2H, dt, J 3 .6 Hz), 1.50 ( 1 H, m), 1.60 (2H, d, J 12.4 Hz), 2.10 (2H, dt, J 2.4, 12 Hz), 2.49 (2H, d, J 6.8 Hz), 2.89 (2H, d, J 11.2 Hz), 3.20 (2H, s, N-CH2-CO), 5.14 (2H, s, OCH2Ph), 6.94 (2H, t, J 8.4 Hz), 7.05 (2H, dt, J 2 and 5.2 Hz), 7.32-7.35 (5H, m).
HPLC Rt = 1.73 min; 69.5%; (5-100% MeCN in H20 (both +0.1% trifluoroacetic acid) over 2.5 minutes at 3 mL/min, held at 100% MeCN for 0.5 minute; Prodigy ODSIIIS~,,SOx4.6mm).
Step 2: To a solution of 34 (5.07 g, 14.85 mmol) in methanol (60 mL) was added 5% palladium on activated carbon (2.50 g, 50% by wgt.) and hydrogenated at 48 psi/25°C for 15 hours. The reaction mixture was then filtered through CELITE, the catalyst washed with methanol (3 x 25 mL) and the filtrate condensed to dryness in vacuo to give a pale yellow solid. The solid was subject to column chromatography [MeOH/DCM (1:9)] to give 35 (1.70, 46.6%) as a colorless solid:
m/z (APCI+) 252 (MH+, 100%) and 266 ([M+MeOH]+, 50%), m/z (APCI-) 250 ([M-H]-, 100%).
vm~ (KBr) 1608 (C=O), 1502s, 1379s cm-1 8H 1.71 (1H, m), 1.78 (2H, m), 2.58 (2H, d, J6.4 Hz), 2.72 (2H, m), 3.48 (2H, d, J 4.8 Hz), 3.68 (2H, d, J 12.0 Hz), 4.1 ( 1 H, s, OH), 6.95 (2H , t, J 8.6 Hz), 7.07 (2H, dt, J 2.0, 5.6 Hz), HPLC Rt = 1.36 min; 100%; (5-100% MeCN in H20 (both +0.1% trifluoroacetic acid) over 2.5 minutes at 3 mL/minute, held at 100% MeCN for 0.5 minute;
Prodigy ODS III 5 ~,, 50 x 4.6 mm).
Step 3: To a stirred slurry of aluminum trichloride (49.34 g, 370.05 mmol) in 1,2-dichloroethane (150 mL) at 0°C under nitrogen was added chloroacetyl chloride (33.43 g, 23.58 mL, 296.04 mmol) dropwise over 30 minutes. After 1 hour, a suspension of 2-benzoxalinone (36) (20.0 g, 148.02 mmol) in 1,2-dichloroethane (50 mL) was added over 30 minutes. The resulting suspension was stirred at 0°C
for 2.5 hours, then heated to 50°C for 20 hours. The mixture was then poured onto crushed ice, stirred for 30 minutes, and the resulting mixture filtered. The residue was dried in vacuo at 60°C for 3 days to give 37 as a pale brown solid (13.70 g, 43%).
8H (d6-Me2S0) 5.16 (2H, s, CH2C1), 7.23 (1H, d, arom., J8.0 Hz) 7.84 (1H, dd, arom., J 1.5, 8.0 Hz) 7.88 (1H, s, arom.) HPLC retention time (R~ = 1.53 min; 79.71%; (5-100% MeCN in H20 (both +0.1 % trifluoroacetic acid) over 2.5 minutes at 3 mL/min, held at 100% MeCN
for 0.5 minute; Prodigy ODS III 5 ~,, 50 x 4.6 mm.
Step 4: To a stirred solution of 37 (6.00 g, 28.4 mmol) in DMF (60 mL) was added sodium azide (1.85 g, 28.5 mmol). After 3 hours, the DMF was removed under reduced pressure to give a solid which was washed well with water, filtered and dried to yield 38 as a brown solid (4.5 g, 73%).
m/z 217.09 ( M-H-) vm~ 3405, 2921, 2135, 1770, 1660, 1606, 1442, 1268, 1240, 1190, 920 cm-1 8H (DMSO) 4.86 (2H, s, CH2), 7.22 (1H, d, arom., J 8.1 Hz), 7.79-7.82 (1H, m, arom.), 7.83 (1H, s, arom.) NH not seen.
Step 5: A solution of 38 (100 mg, 0.46 mmol) and Pd-C (5%, 15 mg) in methanol (20 mL) and concentrated HCl (6 drops) was subjected to hydrogenation at 10 psi and 25°C for 25 minutes. The catalyst was removed by filtration through a 'filter aid' and the solvent removed to give 39 (85 mg, 81 %) as a pale brown solid.
m/z 192.97 (MH+) vm~ 3374, 2967, 1767, 1695, 1623, 1495, 1419, 1268, 1149 cm 1 8H (DMSO) 4.56 (2H, s, CH2), 7.27 (1H, d, arom., J8.3Hz), 7.89 (1H, d, arom., J8.lHz), 7.93 (1H, s, arom.), 8.34 (3H, s, NH3+), 12.34 (1H, s, NH).
Step 6: To a stirnng solution of 35 (2.43 g, 9.68 mmol) in dimethylformamide (50 mL) was added N,N diisopropylethylamine (DIPEA) (3.37 g, 19.36 mmol) 5 followed by O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) (3.67 g, 9.68 mmol). After 45 minutes, 39 (1.86 g, 9.68 mmol) was added, and the resulting solution stirred at room temperature for 3 hours. The reaction mixture was condensed to dryness in vacuo, redissolved in EtOAc, and washed with saturated aqueous sodium bicarbonate solution. A
10 precipitate formed in the partition, this was filtered and dried. The organic phase was then was then dried with magnesium sulfate and condensed to dryness in vacuo. The resulting brown oil and the filtered solid were combined, adsorbed onto silica gel, and subject to column chromatography [MeOH/DCM (0-5%
MeOH over 60 minutes)] to give 40 (0.493 g, 12%) as a tan solid:
15 vm~ (KBr) 3401w, 3079w, 1777s, 1675w, 1621s, 1510m, 1451m, 1270s, 947m, 844s.
NMR SH (DMSO-d6) 1.45 (2H, dd, J 11.2 Hz), 1.70 (3H, m), 2.53 (2H, d, J 5.5 Hz) 2.94 (2H, m), 3.37 (4H, m), 3.93 (2H, s), 4.41 (4H, s), 4.73 (2H, d, J 5.6 Hz), 7.12-7.17 (2H, t, arom., J 8.8 Hz), 7.21 (3H, m, arom.), 7.87-7.97 (2H, m, arom.), 20 8.85 (1H, brs, amide NH), m/z (APCI+) 426 (MH+, 100%), 251 (Acid+, 25%) m/z (APCI-) 424 ([M-H]-, 100%).
Step 7: Purified by preparative HPLC ( 10-100% ACN (0.1 % TFA) over 30 minutes, held at 100% for 5 minutes at 20 mLlmin, YMC-PACK ODS-A, 25 5 micron, 100 x 30 mm, 254 nm) to give 6-{2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H benzoxazol-2-one (0.031 g, 6%) as a yellow solid:
vm~ (KBr) 3420br, 3124br, 2921ms, 1613w, 151 1w, 1466s (C(S)NH), 1333ms (NC(S)N), 1190s, 807ws, m/z (APCI+) 421 (MH+, 100%), 248 ( 10%) 30 m/z (APCI-) 419 ([M-H]-, 100%), 246 (10%), NMR 8H (DMSO-d6) 1.23 (2H, m), 1.51 ( 1 H, m), 1.54 (2H, d, J 12.2 Hz), 2.04 (2H, t, J 11.0 Hz), 2.88 (2H, d, J 11.2 Hz), 3.26 (2H, d, J 10.0 Hz), 3.75 (2H, s) 7.15 (4H, d, atom., J 8.0 Hz), 7.25 (3H, t, atom., J 8.3 Hz), 7.40 (1H, d, atom., J 8.3 Hz), 8.0 (1H, s, atom.) HPLC Rt = 5.94 minutes, 97.48% (20% to 100% ACN (0.1 % TFA) in 20 minutes, held at 100% ACN for 1 minute at 1.5 mL/min, 40°C liquid chromatography-mass spectrometry (LC-MS) Prodigy ODS(3), 3 micron, 150 x 4.6 mm 250 nm.
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H benzothiazol-2-one H
N
O
S
v I ~ ~1 ~s F
Step 1: Treatment of 2-hydroxybenxothiazole with chloroacetyl chloride and aluminum trichloride, following the procedure described in Example 6, Step 3, gave 6-(2-chloroethanoyl)-3H benzothiazol-2-one: 8H (d6-Me2S0) 5.14 (2H, s, CH2C1), 7.23 ( 1 H, d, atom., J 8.5 Hz), 7.92 ( 1 H, dd, atom., J 9.0, 2.0 Hz), 8.27 ( 1 H, d, atom., J 1.5 Hz) and 12.34 ( 1 H, s, NH):
mlz (APCI-) 228 and 226 (each [M-H]-, 25 and 55%).
Step 2: Treatment of 6-(2-chloroethanoyl)-3H benzothiazol-2-one with sodium azide, following the procedure described in Example 6, Step 4, gave 6-(2-azidoethanoyl)-3H benzothiazol-2-one (6.95 g, 96%):
m/z 233.08 (M-H-) vm~ 3441, 2117, 1676, 1595, 1399, 1343, 1269, 1214, 1067cm-1 8H (DMSO) 4.84 (2H, s, CH2), 7.23 (1H, d, atom., J 8.3Hz), 7.85-7.88 (1H, m, atom.), 8.20 (1H, s, atom.), NH not seen; and Step 3: 6-(2-Azidoethanoyl)-3H benzothiazol-2-one (0.5 g, 2.14 rnmol) and Pd-C
(5%, 0.17 g) in methanol (40 mL) and concentrated HCl (0.5 mL) were subjected to hydrogenation at 20 psi and 25°C for 1 hour. The catalyst was removed by filtration through a 'filter aid' and the solvent removed to give 6-(2-aminoethanoyl)-3H benzothiazol-2-one hydrochloride as a light brown solid (0.5 g, 96%).
m/z 209.04 (MH+) vm~ 3405, 2958, 1681, 1642, 1591, 1222, 1179, 814 cm-1 8H (DMSO) 4.53 (2H, s, CH2), 7.31 ( 1 H, d, arom., J 8.5 Hz), 7.94-7.97 ( 1 H, m, arom.), 8.33 (1H, s, arom.), 8.43 (3H, s, NH3+), 12.61 (1H, s, NH).
Step 4: Coupling of 6-(2-aminoethanoyl)-3~f benzothiazol-2-one hydrochloride with 35 following the procedure described in Example 6, Step 6, gave 2-[4-(4-fluorobenzyl)piperidin-1-yl]-~ [2-oxo-2-(2-oxo-2,3-dihydrobenzothiazol-6-yl)ethyl]acetamide:
vm~ (KBr) 3404m, 3346m, 4047, 1708s (ketone C=O), 1681s and 1653s (2 x amide C=O), 1596m, 1508m, 1218m and 841s cm-1 NMR 8H (DMSO-d6) 1.40-1.60 (2H, m), 1.71-1.80 (3H, m), 2.97-2.99 (2H, m), 3.45 (2H, d, J 11 Hz, CH2C6H4F), 3.98 [2H, s, C(O)CH2N], 4.73 [2H, d, J 5 Hz, C(O)CH2NH], 7.10 (2H, t, J8.5 Hz), 7.21-7.24 (3H, m), 7.93 (1H, dd, J8 and 1 Hz), 8.31 ( 1 H, d, J 1 Hz), 8.90 ( 1 H, brs), 9.5 7 ( 1 H, brs) and 12.43 ( 1 H, brs), m/z (APCI+) 442 (MH+, 100%), mlz (APCI-) 440 ([M-H]-, 50%) and 413 (100), HPLC Rt = 8.98 min; 97.24%; (20-100% MeCN in H20 (both +0.1%
trifluoroacetic acid) over 15 minutes at 1 mL/min, held at 100% MeCN for S minutes; Prodigy ODS III 5 ~., 250 x 4.6 mm, 40°C).
Step 5: To a stirred solution of 2-[4-(4-fluorobenzyl)piperidin-1-yl]-N [2-oxo-(2-oxo-2,3-dihydrobenzothiazol-6-yl)ethyl]acetamide (0.50 g, 1.13 mmol) in 1,4-dioxan (30 mL) was added [2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide] (Lawesson's reagent) (0.69 g, 1.70 mmol). The resulting suspension was heated at reflux for 24 hours. The reaction mixture was condensed to dryness in vacuo, redissolved in EtOAc, and washed with saturated aqueous sodium hydrogen carbonate, and saturated brine. The organic phase was dried (MgS04) and condensed to dryness in vacuo. The material was then subject to column chromatography [silica gel, EtOAc/Heptanes (0-50% EtOAc over 60 min)] gave 6-{2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H
benzothiazol-2-one (0.087 g, 18%) as an off white solid:
vm~ (KBr) 2918ms, 2852m, 1681 s (ketone C=O), 1599m, 1507s, 1454ms, 1214m, 1214ms, 804ms, m/z (APCI+) 440 (MH+, 100%), 249 (10%) m/z (APCI-) 438 ([M-H]-, 100%), 247 (10%), NMR SH (DMSO-d6) 1.18-1.26 (2H, dd, J8.8, 11.7 Hz), 1.48 (1H, m), 1.56 (2H, d, J 12.9 Hz), 2.09 (2H, t, J 11.2 Hz), 2.90 (2H, d, J 11.2 Hz), 3.28 (2H, d, J 9.5 Hz), 3.75 (2H, s), 7.06-7.18 (4H, m), 7.20 (2H, t, J 8.5 Hz), 7.52 ( 1 H, dd, J 2.0, 8.3 Hz), 7.91 ( 1 H, s), 7.92 ( 1 H, s), 12.0 ( 1 H, br, NH) HPLC Rt = 5.49 Min; 98.023%, (20% to 100% in 12 minutes, held at 100% ACN
for 1 minute at 1.5 mL/min, 40 degrees. Prodigy ODS (3), 3 micron, 150 x 4.6 mm, 250 nm).
5-(2-(4-Benzylpiperidin-1-ylmethyl)thiazol-5-yl]-1,3-dihydrobenzimidazole-2-thione H
N
S
~ N
N \~ v _H
N V S
Step 1: To a stirnng solution of 4-benzylpiperidine (6) (2.00 g, 11.41 mmol) in dichloromethane (20 mL) at 0°C was added triethylamine (1.59 mL, 11.41 mmol), followed by benzyl-2-bromoacetate ( 1.81 mL, 11.41 mmol). After 10 minutes a white precipitate was observed. The reaction mixture was allowed to warm to room temperature. After 45 minutes the reaction mixture was condensed to dryness in vacuo, redissolved in EtOAc (50 mL), the organic phase washed with saturated aqueous sodium hydrogen carbonate (50 mL), and saturated brine (50 mL). The organic phase was dried (MgS04) and condensed to dryness to give (4-benzylpiperidin-1-yl)acetic acid benzyl ester (3.69 g, 100%). as a pale yellow oil:
m/z (APCI+) 324 (MH+, 100%), 8H 1.36 (2H, dt, J3.2, 8.8 Hz), 1.42 (1H, M) 1.60 (2H, d, J 13.2), 2.10 (2H, dt, J 2, 9.6 Hz), 2.52 (2H, d, J 6.8 Hz), 2.88 (2H, d, J 11.6 Hz), 3.21 (2H, s, N-CO), 5.14 (2H, s, OCH2Ph), 7.17 (2H, d, J 7.2 Hz), 7.24 (2H, d, J 6.0 Hz).
HPLC Rt = 1.64 min; 68.1 %; (S-100% MeCN in H20 (both +0.1 % trifluoroacetic acid) over 2.5 minutes at 3 mL/min, held at 100% MeCN for 0.5 minute; Prodigy ODS III 5 ~,, SO x 4.6 mm).
Step 2: Hydrogenolysis of (4-benzylpiperidin-1-yl)acetic acid benzyl ester, following the procedure described on Example 6, Step 2, gave (4-benzylpiperidin-1-yl)acetic acid (2.66 g, 100%) as a white solid:
vm~ (KBr) 1626 (C=O), 1403s cm-1 m/z (APCI+) 234 (MH+, 100%), SH 1.75-1.85 (5H, m), 2.60 (2H, d, J 5.6 Hz), 2.73 (2H, m), 3.57 (2H, d, J 5.6 Hz), 3.67 (2H, d, J 11.6 Hz), 4.0 ( 1 H, s, OH), 7.12 (2H, d, J 7.2 Hz), 7.20 ( 1 H, d, J 7.2 Hz), 7.26 (2H, t, J 7.2 Hz).
(high performance liquid chromatography) HPLC Rt = 1.25 min; 100%; (S-100%
MeCN in H20 (both +0.1 % trifluoroacetic acid) over 2.5 minutes at 3 mL/min, held at 100% MeCN for 0.5 minute; Prodigy ODS III 5 ~., 50 x 4.6 mm).
Step 3: To a stirred solution of 1,2-phenylenediamine (10.00 g, 0.092 mol) in dimethylformamide (150 cm3) was added 1,1'-carbonyldiimidiazole (CDI, 14.99 g, 0.092 mol). After 22 hours, the reaction mixture was evaporated and then slurried in ethyl acetate. The resulting mixture was filtered, washed with ethyl acetate, and the residue dried in vacuo to give 1,3-dihydrobenzoimidazol-2-one (12.10 g, 98%) as a white solid:
vm~ (KBr) 1755 (C=O) cm-1 $H (DMSO-d6) 6.91 (4H, s, arom.), 10.55 (2H, brs, 2 x NH).
Step 4: To a stirred slurry of aluminum trichloride (22.76 g, 170.73 mmol) in 1,2-dichloroethane (20 mL) at 0°C was added chloroacetyl chloride (15.42 g, 136.57 mmol). After 30 minutes, the substrate (9.16 g, 68.29 mmol) was added in three portions, along with further 1,2-dichloroethane (20 mL). A red-brown color 5 was observed. The reaction mixture was heated at 50°C for 2 hours.
The mixture was then poured onto ice, and the resulting mixture filtered. The residue was washed with ethanol, which gave a white solid (17.00 g). The material was recrystallized by dissolving the crude product in DMF (70 mL), heating to 80°C, adding ethanol (70 mL), cooling to ambient temperature, and then cooling further 10 to 0°C. The resulting precipitate was collected by filtration, washed with ethanol, and dried in vacuo to give 5-(2-chloroethanoyl)-1,3-dihydrobenzimidazol-2-one (8.09 g, 56%) as a light brown solid:
vm~ (KBr) 1747 (C=O), 1687s, 1636s, 1473s, 1398s, 1321s, 1267s, 1202s, 1157s and 101 is cm-1 15 8H (DMSO-d6) 5.12 (2H, s, CH2C1), 7.04 (1H, d, arom., J 8 Hz), 7.49 (1H, s, arom.), 7.68 ( 1 H, dd, arom., J 8.5, 1.5 Hz), 10.96 ( 1 H, s, arom.) and 11.11 ( 1 H, s, arom.).
Step 5: Treatment of give 5-(2-chloroethanoyl)-1,3-dihydrobenzimidazol-2-one with sodium azide, following the procedure described in Example 6. Step 4, gave 20 6-(2-azidoethanoyl)-1,3-dihydrobenzimidazol-2-one (5.75 g, 93%):
vm~ 3415, 2106, 1723, 1681, 1476, 1268 cm-1 8H (DMSO) 4.84 (2H, s, CH2), 7.04 (1H, d, arom., J8.3Hz), 7.45 (1H, d, arom., J 1.2 Hz), 7.63 (1H, dd, arom., J 1.5, 8.1 Hz), 10.90-11.15 (2H, m, NHx2).
Step 6: 6-(2-Azidoethanoyl)-1,3-dihydrobenzimidazol-2-one (1.0 g, 4.6 mmol) 25 and Pd-C (S%, 0.3g) in methanol (150mL) and concentrated HCl (2mL), were subjected to hydrogenation at 25 psi and 27°C for lhour. The catalyst was removed by filtration through a 'filter aid' and the solvent removed to give 6-(2-aminoethanoyl)-1,3-dihydrobenzimidazol-2-one hydrochloride (1.01 g, 96%) as a brown solid:
30 m/z 192.10 (MH+) vm~ 3183, 1681, 1625, 1475, 1276, 1178 cm-1 8H (DMSO) 4.54 (2H, d, CH2, J5.4 Hz), 7.08 (1H, d, arom., J8.1 Hz), 7.52 (1H, s, arom.), 7.71 (1H, dd, arom., J 1.5, 8.1 Hz), 8.34 (3H, s, NH3+), 11.08 (1H, s, NH), 11.24 ( 1 H, s, NH).
Step 7: Condensation of 6-(2-aminoethanoyl)-1,3-dihydrobenzimidazol-2-one hydrochloride with (4-benzylpiperidin-1-yl)acetic acid, following the procedure described in Example 6, Step 6, gave S-[2-(4-benzylpiperidin-1-ylmethyl)thiazol-5-yl]-1,3-dihydrobenzimidazole-2-one:
vm~ (KBr) 3431br, 1730s (ketone C=O), 1691s, 1681s, 1645s, 1528s, 1365s, 1288s, 1232s, 815s and 750s cm-1 NMR 8H (DMSO-d6) 1.28-1.34 (2H, m), 1.49-1.57 (3H, m), 2.00 (2H, m), 2.87-2.94 (4H, m), 4.61 (2H, d, J S.5 Hz), 7.04 (1 H, d, J 8.5 Hz), 7.16-7.20 (3H, m), 7.27-7.30 (2H, m), 7.48 ( 1 H, s), 7.69 ( 1 H, dd, J 8.5 and 1.5 Hz), 7.98 (brs, 1 H, amide NH), 10.94 and 11.11 (each 1 H, s, 2 x NH):
mlz (APCI+) 407 (MH+, 60%) and 169 (100), HPLC Rt = 3 .74 min; 96.11 %; (20-100% MeCN in H20 (both +0.1 trifluoroacetic acid) over 12 minutes at 1.5 mL/minute, held at 100% MeCN for 1 minute; Prodigy ODS III 3 ~, 150 x 4.6 mm, 40°C).
Step 8: Treatment of 5-[2-(4-benzylpiperidin-1-ylmethyl)thiazol-S-yl]-1,3-dihydrobenzimidazole-2-thione with Lawesson's reagent, following the procedure described in Example 6, Step 7, gave5-[2-(4-benzylpiperidin-1-ylmethyl)thiazol-yl]-1,3-dihydrobenzimidazole-2-thione.
Purified by preparative HPLC (10-100% ACN (0.1% TFA) over 30 minutes, held at 100% for 5 minutes at 20 mL/minute, YMC-PACK ODS-A, 5 micron, 100 x 30 mm, 254 nm). Yellow solid (0.031 g, 6%).
vm~ (KBr) 3420br, 3124br, 2921ms, 1613w, 1511w, 1466s (C(S)NH), 1333ms (NC(S)N), 1190s, 807ws, m/z (APCI+) 421 (MH+, 100%), 248 ( 10%) m/z (APCI-) 419 ([M-H]-, 100%), 246 (10%), NMR 8H (DMSO-d6) 1.23 (2H, m), 1.51 (1H, m), 1.54 (2H, d, J 12.2 Hz), 2.04 (2H, t, J 11.0 Hz), 2.88 (2H, d, J 11.2 Hz), 3.26 (2H, d, J 10.0 Hz), 3.75 (2H, s) 7.15 (4H, d, arom., J 8.0 Hz), 7.25 (3H, t, arom., J 8.3 Hz), 7.40 (1H, d, arom., J8.3 Hz), 8.0 (1H, s, arom.) S HPLC Rt = 5.94 minutes, 97.48%, (20-100% ACN (0.1% TFA) in 20 minutes, held at 100% ACN for 1 minute at 1.5 mL/minute, 40°C. liquid chromatography-mass spectrometry (LC-MS) Prodigy ODS(3), 3 micron, 150 x 4.6 mm 250 nm.
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]oxazol-5-yl}-3H benzothiazol-2-one H
N
\ ~/ ~S
I ~1 \~o vm~ (KBr) 3436br, 1682 (amide C=O), 1508s, 1468s, 1346s, 1270s, 1175s, 1136s, 1087s, 989s, 947s, 822s, and 783s cm-1 NMR 8H (DMSO-d6) 1.40-1.50 (2H, m), 1.75-1.79 (3H, m), 3.05-3.10 (2H, m), 3.55-3.58 (2H, m), 4.59 (2H, brs), 7.12 (2H, t, J 9 Hz), 7.21 (2H, t, J 8 Hz), 7.67 ( 1 H, dd, J 9 and 1.5 Hz), 7.75 ( 1 H, s), 7.86 ( 1 H, s), 8.00 ( 1 H, d, J 8 Hz) and 9.95 ( 1 H, brs), m/z (APCI-) 422 ([M-H]' 100%), HPLC Rt = 4.55 min; 96.86%; (20-100% MeCN in H20 (both +0.1%
trifluoroacetic acid) over 7 minutes at 1.5 mL/minute, held at 100% MeCN for 1 minute; Prodigy ODS III 5 ~,, 250 x 4.6 mm, 40°C).
6-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-3H benzoxazol-2-one H
N
~O
N \ ~ O
I ~ ~ I ~o Step 1: Coupling of (4-benzylpiperidin-1-yl)acetic acid with 39, following the procedure described in Example 6, Step 6, gave 2-(4-benzylpiperidin-1-yl)-N [2-oxo-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]acetamide:
vm~ (KBr) 3380w, 3091w, 3023m, 291 1w, 1773s, 1676w, 1648s, 1616m, 1528m, 1450m, 1424m, 1353w, 1266s, 923m, 912m, and 748m cm-1 NMR SH (DMSO-d6) 1.17-1.33 (2H, m), 1.50-1.57 (3H, m), 1.99-2.04 (2H, m), 2.87-2.89 (2H, m), 2.94 (2H, s), 3.29 (2H, s), 4.61 (2H, d, J S.5 Hz), 7.16-7.21 (4H, m), 7.28 (2H, t, J 8 Hz), 7.84-7.87 (2H, m), and 8.01 ( 1 H, brs, amide NH):
m/z (APCI+) 408 (MH+, 100%), m/z (APCI-) 406 ([M-H]-, 100%), HPLC Rt = 5.30 min; 96.05%; (20-100% MeCN in H20 (both +0.1 trifluoroacetic acid) over 20 minutes at 1.5 mL/minute, held at 100% MeCN for 3 minutes; Prodigy ODS III 3 ~,, 150 x 4.6 mm, 40°C).
Step 2: 6-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-3H benzoxazol-2-one was prepared from 2-(4-benzylpiperidin-1-yl)-N [2-oxo-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]acetamide following the procedure described in Example 9, Step 1:
vm~ (KBr) 3435br, 1783s, 1766s, 1495m, 1485m, 1311m, 1286m, 128m, 1053m, 968w, and 753w cm-1 NMR SH (DMSO-d6) 1.20-1.40 (2H, m), 1.25-1.70 (3H, m), 2.10-2.40 (2H, m), 2.90-3.10 (2H, m), 3.70-3.85 (2H, m), 7.16-7.26 (4H, m), 7.48-7.63 (3H, m) and 11.82 ( 1 H, brs) m/z (APCI+) 390 (MH+, 18%) and 169 (100) HPLC Rt = 6.26 min; 95.61 %; (20-100% MeCN in H20 (both +0.1 trifluoroacetic acid) over 20 minutes at 1.5 mL/minute, held at 100% MeCN for 3 minutes; Prodigy ODS III 3 ~,, 150 x 4.6 mm, 40°C).
5-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-1,3-dihydroindol-2-one H
N
O
I ~1 Step 1: 5-(2-Chloroethanoyl)-1,3-dihydroindol-2-one was prepared following the procedure decribed in Example 6, Step 3:
8H (d6-Me2S0) 3.57 (2H, s, ArCH2C(O)NH), 5.08 (2H, s, CH2Cl), 6.93 (1H, d, arom., J 8.0 Hz), 7.83 ( 1 H, s, arom.), 7.88 ( 1 H, d, arom., J 8.0 Hz) and 10.82 ( 1 H, brs, NH), m/z (APCI-) 210 and 208 (each [M-H]-, 35 and 100%).
Step 2: Treatment of 5-(2-chloroethanoyl)-1,3-dihydroindol-2-one with sodium azide, following the procedure described in Example 6, Step 4, gave 6-(2-azidoethanoyl)-1,3-dihydroindol-2-one (6.58 g, 91%):
m/z 215.08 (M-H-) vm~ 3229, 2122, 1715, 1679, 1615, 1236, 1123, 824 cm-1 8H (DMSO) 3.57 (2H, s, CH2C0), 4.79 (2H, s, CH2N3), 6.93 (1H, d, arom., J 8.1 Hz), 7.79 ( 1 H, s, arom.), 7.83 ( 1 H, s, arom., J 8.3 Hz), 10.78 ( 1 H, bs, NH).
Step 3: Reduction of 6-(2-azidoethanoyl)-1,3-dihydro-indol-2-one, following the procedure described in Example 6, Step 5, gave 6-(2-aminoethanoyl)-1,3-dihydroindol-2-one hydrochloride (2.96 g, 63%):
m/z 191.05 (MH+) vm~ 3401, 3205, 1687, 1619, 1493, 1423, 1312, 1247 cm-1 8H (DMSO) 3.58 (2H, s, CH2C0), 4.49 (2H, d, CH2~ J5.4 Hz), 6.98 (1H, d, arom., J 8.3 Hz), 7.87 (1H, s, arom.), 7.92 (1H, d, arom., J 8.3Hz), 8.35 (3H, s, NH3+), 10.95 (1H, s, NH).
Step 4: Condensation of 6-(2-aminoethanoyl)-1,3-dihydroindol-2-one 5 hydrochloride with (4-benzylpiperidin-1-yl)acetic acid, following the procedure described in Example 6, Step 6, gave 2-(4-benzyl-piperidin-1-yl)-N [2-oxo-2-(2-oxo-2,3-dihydro-1H indol-5-yl)ethyl]acetamide:
vm~ (KBr) 3352br, 3173br, 2918m, 1717s (ketone C=O), 1679s, 1649s, 1621s, 1523s, 1361s, 1252s, 1101s 10 m/z (APCI+) 406 (MH+, 100%), 169 (25%) m/z (APCI-) 404 ([M-H]-, 100%).
NMR 8H (DMSO-d6) 1.31 (2H, dt, J3.0, 12.4 Hz), 1.51 (1H, m), 1.54-1.57 (2H, d, J 12.4 Hz), 2.86 (2H, d, J 11.6 Hz), 2.92 (2H, s), 3.29 (2H, d, J 9.2 Hz), 3.56 (2H, s), 4.56 (2H, d, J 6 Hz), 6.90 (1 H, d, J 8 Hz), 7.18 (3H, m), 7.26 (2H, t, 15 arom., J 7.2 Hz) 7.90 ( 1 H, d, arom., J 8.4 Hz) 7.95 ( 1 H, t, arom., J
5.6) HPLC Rt = 4.00 Min; 97.49%, (20-100% ACN (0.1% TFA) in 12 minutes, held at 100% acetonitrile (ACN) for 1 minute at 1.5 mL/minute, 40 degrees. Prodigy ODS
(3), 3 micron, 150 x 4.6 mm, 250 nm.
Step 5:5-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-1,3-dihydroindol-2-was 20 prepared from 2-(4-benzyl-piperidin-1-yl)-N [2-oxo-2-(2-oxo-2,3-dihydro-1H
indol-5-yl)ethyl]acetamide following the procedure described in Example 9, Step 1:
vm~ (KBr) 3439br, 1697s, 1624m, 1485m, 1239m, 1112m, IOSOm and 815m ' cm-1 25 NMR 8H (DMSO-d6) 1.15-1.18 (2H, m), 1.20-1.46 (3H, m), 2.02 (2H, t, J 11 Hz), 2.83 (2H, d, J 12 Hz), 3.54 (2H, s), 3.63 (2H, s), 6.89 (1 H, d, J 8Hz), 7.13-7.18 (3 H, m), 7.24-7.2 8 (2H, m), 7.42 ( 1 H, s), 7.49 ( 1 H, d, J 8 Hz), 7. S 3 ( 1 H, s) and 10.53 (1H, s, amide NH) m/z (APCI+) 388 (MH+, 100%) 30 m/z (APCI-) 386 ([M-H]-, 100%) HPLC Rt = 4.40 minutes; 99.40%; (20-100% MeCN in H20 (both +0.1 trifluoroacetic acid) over 12 minutes at 1.5 mL/minute, held at 100% MeCN for 1 minute; Prodigy ODS III 3 ~,, 1 SO x 4.6 mm, 40°C).
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydrothiazol-2-yl}-3H
benzoxazol-2-one OH
I ~ H ~' I ~ C~
o I ~ 1 °IH
F / N~N
v42 F / F /
43 NHz 2HC1 44 NH-CBZ
HO HO
OTBDMS
/ N ~NH-CBZ
v vF
OTBDMS
F / N ~~z H H
NH2 ~ N ~ N
I~ -' I o -. I~
MeOZC OH MeO2C ~O H02C O
H
N
46 ~ ~ OTBDMS
I H I
F ~ N / O
O
H
N
OTBDMS
_ I H I
F / N N / O
51 s H
N
OH \
-~ H I ~O
F ~ N / O
52 s H
N
~O
O
F ~~'~N
Step 1: 4-(4-Fluorobenzyl)piperidine hydrochloride (12) (20.0 g, 87.1 mmol), epichlorohydrin (8.06 g, 87.0 mmol) and triethylamine (8.80 g, 87.1 mmol) in EtOH (200 mL) were stirred at ambient temperature for 96 hours. The solvent was 5 removed and the material taken up in EtOAc, washed with saturated NaHC03, brine and dried (MgS04) to give 41 (16.69 g, 67%) as an orange solid:
1H-NMR (CDC13) 8H inter alia 1.22-1.35 (2H, m), 1.47-1.53 (1H, m), 1.62 (2H, dd, J 13 and 2.5 Hz), 1.95 and 2.24 (each 1 H, dt, J 11.5, 2.5 and 2.5 Hz), 2.42-2.44 (2H, m, CH2Ph), 2.50 (2H, d, J 7 Hz), 2.80 and 2.94 (each 1 H, d, J
10 11.5 Hz), 3.55 (2H; d, JS Hz, CH2C1), 3.87-3.93 (1H, m, CHOH), 6.93-6.99 and 7.06-7.10 (each 2H, m) m/z (APCI+) 286 (MH+, 100%) and 250 ([M-Cl]+, 60).
Step 2: Compound 41 (16.69 g, 58.46 mmol) and potassium phthalimide (10.81 g, 58.46 mmol) in DMF (100 mL) were heated to 100°C for 2 hours. The solvent was removed and the material taken up in EtOAc, washed with brine dried (MgS04) and evaporated. The residue was partially purified by silica gel column chromatography (CH2C12) to yield a 1:1 mixture of 42 and phthalimide (13.91 g, 44%) as a white solid:
1H-NMR (CDC13) SH 1.16-1.30 (2H, m), 1.43-1.51 (3H, m), 1.88 and 2.20 (each 1 H, dt, J 11.5 and 2.5 Hz), 2.33-2.43 (2H, m), 2.47 (2H, d, J 7 Hz), 2.78 and 2.89 (each 1 H, d, J 4.5 Hz), 3.63-3.82 (2H, m), 3.94-4.02 ( 1 H, m), 6.97 (2H, t, J 11 Hz), 7.05-7.08 (2H, m), 7.69-7.79 (2H, m) and 7.84-7.89 (2H, m) m/z (APCI+) 267 (MH+, 100%).
Step 3: Compound 42 (13.91 g, 25.6 mmol - impure mixture) and hydrazine hydrate (3.84 g, 76.89 mmol) in ethanol (100 mL) and water (100 mL) were heated under reflux conditions for 3 hours, and then left to stir at ambient temperature for 16 hours. The solvent was removed, and the crude material was acidified with 10% aqueous hydrochloric acid. The precipitate was filtered and the pad washed with water; the filtrate was concentrated to yield 43 (13.5 g, >100%, wet) as a yellow solid which was partially dried in vacuo:
NMR SH (MeOH-d4) inter alia 1.55-1.69 (2H, m), 1.85-1.92 (3H, m), 2.60 (2H, d, J6.5 Hz), 2.86-3.24 (6H, m), 3.60-3.68 (2H, m), 4.30-4.36 (1H, m), 7.01 (2H, t, J 8.5 Hz) and 7.18-7.24 (2H, m) m/z (APCI+) 267 (MH+, 100%).
Step 4: Benzyl chloroformate (4.26 g, 25.0 mmol) was added to a mixture of 43 (5.92 g, 17.57 mmol) and sodium carbonate decahydrate (21.45 g, 75.0 mmol) in dioxane-water (100-10 mL), and the resulting mixture stirred at ambient temperature for 4 hours. The solvent was removed, the material diluted with EtOAc, washed with water followed by brine, and then dried (MgS04) and evaporated. The product was purified by column chromatography (silica gel, 0%
to 5% MeOH in CH2Cl2) 44 (2.10 g, 30%) as a clear oil which solidified on standing:
m/z 401.21 (MH+) vm~ 3339, 2924, 1716, 1509, 1220 cm-1 1H-NMR (CDC13) 8H 1.25 (3H, m, alkyl), 1.60 (2H, m, alkyl), 1.82 (1H, m, alkyl), 2.22 (1H, m, alkyl), 2.28 (2H, d, CH2, J7.2 Hz), 2.49 (2H, d, CH2, S J 7.2 Hz), 2.72 ( 1 H, d, CHH, J 12.0 Hz), 2.93 ( 1 H, d, CHH, J 12.0 Hz), 3 .10 ( 1 H, m, CHIC, 3.41 ( 1 H, m, CHH), 3.70 ( 1 H, m, CHO), 5.10 (2H, s, CH20), 5.20 ( 1 H, bs, NH), 6.98 (2H, m, arom.), 7.07 (2H, m, arom.), 7.32 (5H, m, Ph).
Step 5: tert-Butyldimethylsilyl trifluorosulfonate (1.94 g, 7.35 mmol) was added to a cooled (0°C) solution of 44 (2.10 g, 5.25 mmol) and 2,6-lutidine (1.12 g, 10.50 mmol) in dichloromethane (20 mL). After 15 minutes, the mixture was diluted with dichloromethane, washed with saturated NaHC03 followed by brine, and then dried (MgS04) and evaporated to give 45 (2.80 g, quantitative) as a clear oil:
m/z 515.29 (MH+) vm~ 3350, 1721, 1510, 1255, 1222 cm-1.
Step 6: Compound 45 (2.70 g, 5.25 mmol) was hydrogenated at 50 psi and 30°C
in the presence of Pd(OH)2-C (100 mg) in MeOH (20 mL) for 8 hours. The mixture was filtered through a 'filter-aid' and the solvent removed to yield (1.83 g, 92%) as a clear gum:
mlz 3 81.31 (MH+) vm~ 3382, 2928, 1510, 1030, 837 cm 1 1H-NMR (CDC13) bH 0.08 (6H, s, Si(CH3)2), 0.88 (9H, s, tBu), 1.25 (2H, m, CH2), 1.45 (1H, m, CH), 1.60 (2H, m, CH2), 2.02 (2H, m, CH2), 2.25 (2H, bs, NH2), 2.47 (4H, m, 2x CH2), 2.88 (2H, d, CH2, J4.4 Hz), 2.89 (2H, bt, CH2, J 12.0 Hz), 3.81 ( 1 H, m, CHO).
Step 7: Methyl 4-amino-3-hydroxybenzoate (47) (11.01 g, 65.9 mmol) and CDI
(11.21 g, 69.2 mmol) were stirred in DMF (75 mL) at room temperature for 1 hour. The DMF was then removed and the mixture diluted with EtOAc, washed with 0.5 M NaOH, 10% HC1, brine and dried (MgS04) to give 48 (7.52 g, 59%) as a brown solid:
m/z 191.98 (M-H)-vm~ 3402, 1746, 1708, 1290 cm-1 5 1H-NMR (CDC13) 8H (DMSO-d6) 3.85 (3H, s, OCH3), 7.19 (1H, d, arom., J 8.4 Hz), 7.76 ( 1 H, d, arom., J 1.6 Hz), 7.82 ( 1 H, dd, arom., J 1.6, 8.4 Hz), 12.07 (1H, bs, NH).
Step 8: Compound 48 (8.0 g, 41.5 mmol) and LiOH~H20 (3.49 g, 83.0 mmol) in MeOH-H20 (100-10 mL) were heated under reflux conditions for 4 hours. An 10 aliquot of LiOH.H20 (1.75 g, 42.0 mmol) was added and the heating continued for a further 3 hours. The solvent was removed, and the solids were slurried in 10% HCl then filtered and washed with H20 and dried in vacuo to give 49 (7.40 g, quantitative) as a brown solid:
m/z 177 (M-H)-15 vm~ 3431, 3120, 1769, 1685, 1619, 1427, 1296 cm-1 NMR SH (DMSO-d6) 7.17 ( 1 H, d, arom., J 8.4 Hz), 7.40 ( 1 H, d, arom., J 1.2 Hz), 7.80 ( 1 H, dd, arom., J 1.2, 8.4 Hz), 12.02 ( 1 H, bs, NH), 13.89 ( 1 H, bs, OH).
Step 9: Compound 49 (980 mg, 69%) as a brown foam:
20 mlz 542.27 (MH+) 1H-NMR (CDC13) SH 0.12 (3H, s, SiCH3), 0.13 (3H, s, SiCH3), 0.89 (9H, s, SitBu), 1.66 (1H, bs, alkyl), 1.80 (2H, bs, alkyl), 2.40 (2H, bs, alkyl), 2.57 (2H, m alkyl), 2.79 (1H, bs, alkyl), 2.96 (1H, bs, alkyl), 3.31 (1H, bs, alkyl), 3.53 (2H, bs, alkyl), 3.66 (2H, m, alkyl), 4.20 (1H, bs, CHO), 6.96-7.12 (5H, m, arom.), 7.58 25 ( 1 H, s, arom.), 7.66 ( 1 H, d, arom., J 8.0 Hz), 7.99 ( 1 H, bs, NH).
Step 10: Compound 50 (980 mg, 1.81 mmol) and Lawesson's reagent (366 mg, 906 ~,mol) in dioxane (5 mL) were heated under reflex conditions for 1 hour. A
further aliquot of Lawesson's reagent (732 mg, 1.81 mmol) was added, and heating continued for 1.5 hours. The solvent was removed and the product was diluted with EtOAc, washed extensively with saturated NaHC03, brine, and dried.
The product was purified by chromatography (silica gel, 0-50% EtOAc in heptane) to give 6-[5-(4-(4-fluorobenzyl)piperidin-1-ylmethyl)-4,5-dihydro-thiazol-2-yl]-3H benzoxazol-2-one (194 mg, 25%) as a white solid:
m/z 426.18 (MH+) vm~ 1773, 1509 cm-1 1H-NMR (CDC13) 8H 1.25 (2H, m, alkyl), 1.56 (3H, m, alkyl), 1.97 (2H, t, CH2, J 11.2 Hz), 2.56 (4H, m, alkyl), 2.89 (2H, bm, alkyl), 4.11 ( 1 H, 1, CHS, J
6.4 Hz), 4.35 (2H, m, CH2N), 6.96 (2H, m, arom.), 7.06 (3H, m, arom.), 7.63 (1H, dd, arom., J 1.0, 8.0 Hz), 7.73 ( 1 H, d, arom.,. J 1.2 Hz) HPLC Rt = 3.81 minutes, 99.10% (20-100% MeCN in H20 (both +0.1 % formic acid) over 7 minutes at 1.5 mL/min; Prodigy ODS III 3 ~., 150 x 4.6 mm, 40°C) 6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-2-yl]-3H benzoxazol-2-one H
N
O
S
O
I
~~"~~N
Step 1: Treatment of amine 6 with epichlorohydrin, following the procedure described in Example 12, Step l, gave crude 1-chloro-3-(4-benzylpiperidin-1-yl)propan-2-of (29.03 g, >100%) as a clear, colorless oil:
vm~ (neat) 3300 (brs, OH), 2921s, 1603m, 1494m, 1453s, 1091s, 1058s, 747s 1H-NMR (CDC13) 8H 1.24-1.30 (2H, m), 1.50-1.60 (1H, m), 1.61-1.65 (2H, m), 1.93, 2.24 (each 1 H, dt, J 11.5 and 2 Hz), 2.36-2.46 (2H, m), 2.53 (2H, d, J
7 Hz, CH2N), 2.78, 2.92 (each 1H, d, J 12 Hz, CH2Ph), 3.53-3.55 (2H, m, CH2C1), 3.86-3.92 (1H, m, CHOH), 7.09-7.29 (5H, m, Ph) mlz (APCI+) 270 and 268 (each MH+, 40 and 100%) and 232 ([M-Cl]+, 40).
Step 2: Treatment of 1-chloro-3-(4-benzylpiperidin-1-yl)propan-2-of with potassium phthalimide, following the procedure described in Example 12, Step 2, gave 2-[3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]isoindole-1,3-dione (32.44 g, 86%) as a white solid:
1H-NMR (CDC13) 8H 1.13-1.35 (2H, m), 1.45-1.49 (1H, m), 1.50-1.58 (2H, m), 1.87 and 2.19 (each 1H, dt, J 11.5, 11.5 and 2 Hz), 2.31-2.45 (2H, m), 2.50 (2H, d, J 7 Hz, NCH2CH(OH), 2.76 and 2.86 (each 1 H, d, J 12 Hz), 3.68 and 3.79 (each 1H, dd, J 13.5 and 4.5 Hz, CH2N), 3.96-4.03 (1H, m, CHOH), 7.10-7.28 (5H, m, Ph), 7.68-7.75, and 7.82-7.86 (each 2H, m, phthalimide) m/z (APCI+) 379 (MH+, 100%).
Step 3: Treatment of 2-[3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]-isoindole-1,3-dione with hydrazine hydrate, following the procedure described in Example 12, Step 3, gave 1-amino-3-[4-benzylpiperidin-1-yl]propan-2-of bis-hydrochloride salt (24.32 g) as a yellow hygroscopic solid:
vm~ (KBr) 3418br, 2934br, 1712m, 1603m, 1494m, 1454m, 1066m, 945m and 748m NMR 8H (CD30D) 1.59-1.62 (2H, m), 1.86-1.93 (3H, m), 2.61 (2H, d, J6.5 Hz), 2.90-3.31 (6H, m), 3.60-3.64 (2H, m), 4.30-4.40 (1H, m, CHOH), 7.17-7.20 (2H, m) and 7.22-7.26 (2H, m).
mlz (APCI+) 249 (MH+, 100%).
Step 4: To a stirring solution of 1-amino-3-(4-benzylpiperidin-1-yl)propan-2-of (2.00 g, 6.23 mmol) in 1,4-dioxan/H20 (4:1, 25 mL) was added solid sodium hydroxide (0.28 g, 6.85 mmol). On full dissolution of the sodium hydroxide, dibenzyl dicarbonate ( 1.96 g, 6.85 mmol) was added. The resulting solution was stirred for 22 hours. The reaction mixture was condensed to dryness in vacuo to give a yellow gum. This was redissolved in EtOAc, washed with saturated aqueous sodium bicarbonate solution, and saturated brine. The organic phase was dried (MgS04) and condensed to dryness in vacuo to give a yellow oil. The oil was subject to column chromatography [silica gel, MeOH-DCM (0-20% MeOH over 30 minutes)] to give [3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]carbamic acid benzyl ester (1.64 g, 69%) as an orange solid:
mlz (APCI+) 383 (MH+, 100%) 1H-NMR (CDC13) SH 1.2-1.3 (2H, m), 1.5 (1H, m), 1.60 (2H, d, ~ 13.1 Hz), 1.85 (1H, t, 711.2 Hz), 2.20 (1H, t, 711.2 Hz), 2.27 (2H, d, 76.8 Hz), 2.51 (2H, d, 77.0 Hz), 2.70 ( 1 H, d, ~ 11.2 Hz), 2.90 ( 1 H, d, 711.2 Hz), 3.10 ( 1 H, m), 3.40 ( 1 H, d, ~ 3.6 Hz), 3.70 ( 1 H, d, 7 3.4 Hz), 5.10 (2H, s, CH20), 5.25 ( 1 H, s, NH), 7.11 (2H, d, atom., 97.2 Hz), 7.18 (1H, t, atom., 77.6 Hz), 7.25-7.35 (7H, m, atom.) HPLC Rt = 1.62 min; 71.1 %; (5-100% MeCN in H20 (both +0.1 % trifluoroacetic acid) over 2.5 minutes at 3 mL/minute, held at 100% MeCN for 0.5 minute;
Prodigy ODS III 5 ~., 50 x 4.6 mm).
Step 5: Treatment of [3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]carbamic acid benzyl ester with tert-Butyldimethylsilyl trifluorosulfonate, following the procedure described in Example 12, Step S, gave {2-(tert-butyldimethylsilanyloxy)-3-[4-benzylpiperidin-1-yl]propyl}carbamic acid benzyl ester as a yellow oil:
m/z 497.42 (MH+) vm~ 3353, 2927, 1726, 1253, 1100, 836 cm-1 1H-NMR (CDC13) 8H 0.05 (6H, s, Si(CH3)2), 0.86 (9H, s, SitBu), 1.25 (2H, m, alkyl), 1.45 (1H, m, CH), 1.60 (2H, m, alkyl), 1.90 (2H, m, alkyl), 2.33 (2H, d, 2 x CH, J 6.0 Hz), 2.48 (2H, d, CH2, J 7.2 Hz), 2.83 (2H, bd, CH2, J 10.4 Hz), 3.27 (2H, m, CH2), 3.82 (1H, m, CHO), 5.10 (2H, s, CH20), 5.85 (1H, bm, NH), 7.11 (2H, m, atom.), 7.18 (1H, m, atom.), 7.28-7.37 (5H, m, atom.).
Step 6: Hydrogenation of {2-(tert-butyldimethylsilanyloxy)-3-[4-benzylpiperidin-1-yl]propyl}carbamic acid benzyl ester, following the procedure described in Example 12, Step 6, gave {2-(tert-butyldimethylsilanyloxy)-3-[4-benzylpiperidin-1-yl]-propylamine as a white semi-solid:
m/z 363.19 (MH+) vm~ 2927, 1252, 1075, 836, 770 cm 1 1H-NMR (CDC13) 8H 0.075 (3H, s, SiCH3), 0.08 (3H, s, SiCH3), 0.89 (9H, s, SitBu), 1.28 (1H, m, alkyl), 1.63 (5H, m, alkyl, NH2), 1.92 (2H, m, alkyl), 2.30 (2H, d, 2 x CH), 2.51 (2H, d, CH2, J 6.8 Hz), 2.69 ( 1 H, dd, CH, J 5.2, 12.8 Hz), 2.78 (0.5H, d, 0.5 x CH, J4.4 Hz), 2.82 (2.5H, m, alkyl), 3.73 (1H, m, CHO), 7.14 (2H, m, arom.), 7.20 (1H, m, arom.), 7.26 (2H, m, arom.).
Step 7: Compound 49 (271 mg, 1.51 mmol), HBTU (574 mg, 1.51 mmol) and DIPEA (391 mg, 3.03 mmol) were stirred in DMF (5 mL) for 10 minutes, then {2-(tert-butyldimethylsilanyloxy)-3-[4-(benzyl)piperidin-1-yl]propylamine (548 mg, 1.51 mmol), was added and stirring continued for 1 hour. The solvent was removed, and the mixture diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04). The crude material was purified by chromatography (silica gel, CH2C12) to give 2-oxo-2,3-dihydrobenzoxazole-6-carboxylic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethyl-silanyloxy)propyl]amide (786 mg, 99%) as a brown foam:
m/z 542.22 (MH+) vm~ 3376, 2929, 1781, 1640, 1494, 840 cm-1.
Step 8: 2-Oxo-2,3-dihydrobenzoxazole-6-carboxylic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethylsilanyloxy)propyl]amide (686 mg, 1.31 mmol) and Lawesson's reagent (530 mg, 1.31 mmol) in dioxane (5 mL) were heated under reflux conditions for 2 hours. The solvent was removed, and.the product was purified by chromatography (silica gel, 0-50% EtOAc in heptane) to give 2-oxo-2,3-dihydrobenzoxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethylsilanyloxy)propyl]amide (559 mg, 79%): as a green gum:
m/z 540.33 (MH+) vm~ 3218, 1771, 1595, 1495, 1255, 1108 cm-1 1 H-NMR (CDC13) 8H aliphatics of little use due to rotamers, 7.07 ( 1 H, d, arom., J 7.2 Hz), 7.20 ( 1 H, d, arom., 7.2 Hz), 7.21-7.29 (5H, m, Ph), 7.74 ( 1 H, s, arom.).
Step 9: Tetrabutylammonium fluoride (TBAF) ( 1.24 ~mol, 1.24 mL, 1 M in THF) was added to a mixture of 2-oxo-2,3-dihydrobenzoxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-(tert-butyldimethylsilanyloxy)propyl]amide (336 mg, 623 ~.mol) and 4th molecular sieves ( 1 g) in THF (2 mL). After stirring at room temperature for 1.5 hours, the mixture was diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04) to yield 2-oxo-2,3-5 dihydrobenzoxazole-6-carbothioic acid [3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]amide (280 mg, quantitative) as a solid yellow foam:
m/z 426.29 (MH+) vm~ 3306, 2924, 1770, 1660, 1264, 1059 cm-1 1H-NMR (CDC13) 8H some TBAF still present, hence aliphatics unclear; 2.52 10 (2H, d, CH2, J 7.2 Hz), 2.80 ( 1 H, d, CHH, J 11.2 Hz), 2.99 ( 1 H, d, CHH, J 11.2 Hz), 3.25 (2H, m, CH2), 3.83 ( 1 H, m, OH), 4.07 ( 1 H, m, CHO), 7.05 ( 1 H, d, arom., J 8.4 Hz), 7.12 (2H, d, arom., J 8.4 Hz), 7.20 ( 1 H, d, arom., J
7.2 Hz), 7.28 (2H, m, arom.), 7.59 (1H, d, arom., J8.0 Hz), 7.12 (1H, d, arom., J 1.6 Hz), 8.42 (1H, bs, NH).Step 10: 2-Oxo-2,3-dihydrobenzoxazole-6-carbothioic acid [3-15 (4-benzylpiperidin-1-yl)-2-hydroxypropyl]amide (240 mg, 565 ~.mol) and Burgess reagent (134 mg, 565 ~mol) in THF (5 mL) were heated under reflux conditions for 1 hour. The mixture was diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04). Purification by chromatography (silica gel, CH2C12) gave the product as a yellow foam (91 mg), this was then repurified by 20 chromatography (silica gel, 0-50% EtOAc in heptane) to give 6-[5-(4-benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-2-yl]-3H benzoxazol-2-one (52 mg, 23%) as an off white solid:
m/z 408.21 (MH+) vm~ 3261, 1777, 1494, 1447, 1273 cm-1 25 1H-NMR (CDC13) SH 1.31 (4H, m, alkyl), 1.60 (3H, m, alkyl), 1.97 (2H, t, CH2, J 7.2 Hz), 2.53 (4H, 2 x d, alkyl, J 6.4, 7.2 Hz), 2.90 (2H, bs, alkyl), 4.12 ( 1 H, m, CHS), 4.35 (2H, m, CH2N), 7.03 (1H, d, arom., J 8.0 Hz), 7.13-7.30 (5H, m, Ph), 7.62 (1H, dd, arom., J 1.6, 8.0 Hz), 7.73 (1H, d, arom., J 1.6 Hz).
6-[2-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-5-yl]-3H benzoxazol-2-one OH
N3 ~ O N3 O
I~ ~o ~ Iw N ~ N
OTBDMS OTBDMS
N3 \ O HZN ~ O
I ~ ~o ~ I ~o o NV \
O
~O
56 ~ N
H
O
N OTBDMS
F
O
N
H
S
N 'I OTBDMS
F
N
H
S
OH
N
F
~N
H
F ~~S ~ O
O
N
H
Step 1: Sodium borohydride (603 mg, 15.46 mmol) was added to a solution of 38 (3.37 g, 15.46 mmol) in EtOH-MeOH (50-SO mL) at 0°C and stirred and allowed to warm to room temperature over 1 hour. The solvent was removed and the mixture diluted with EtOAc, washed with brine and dried (MgS04) to give 53 (2.09 g, 61 %) as an orange/brown solid:
mlz 219.07 (M-H)-vm~ 3258, 2105, 1758 cm-1 NMR SH (DMSO-d6) 3.34 (2H, ddd, CH2, J4.0, 7.6, 12.8 Hz), 4.80 (1H, ddd, CHO, J 3.6, 4.4, 7.2 Hz), 5.48 ( 1 H, d, OH, J 4.8 Hz), 7.04 ( 1 H, d, arom., J 8.0 Hz), 7.17 ( 1 H, dd, arom., J 0.8, 7.6 Hz), 7.3 0 ( 1 H, s, arom.), 11.60 ( 1 H, bs, NH).
Step 2: 2,6-Lutidine (1.02 g, 9.5 mmol) was added to a solution of 53 (2.09 g, 9.5 mmol) in THF (50 mL) at 0°C, followed by TBDMSOTf (2.51 g, 9.50 mmol) and the solution allowed to warm to room temperature. After 2 hours, a further aliquot of TBDMSOTf (1.25 g, 4.75 mmol) was added and the solution stirred for a further 1 hour. The mixture was diluted with EtOAc, washed with saturated NaHC03, 10% HCI, brine and dried (MgS04). The material was partially purified by chromatography (silica gel, 0-30% EtOAc in heptane) to yield 54 (3.20 g, quantitative)as a yellow oil:
mlz 449.24 (M+TBDMS+H+) vm~ 3227, 2102, 1771, 1260, 838 cm-1 NMR 8H (DMSO-d6) 0.10 (3H, SICH3), 0.10 (3H, s, SiCH3), 0.87 (9H, s, SitBu), 3.32 (2H, m, CH2), 4.97 (1H, dd, CHO, J3.6, 6.8 Hz), 7.06 (1H, d, arom., J 7.6 Hz), 7.18 ( 1 H, dd, arom., J 1.2 8.0 Hz), 7.29 ( 1 H, s, arom.), 11.62 ( 1 H, bs, NH).
Step 3: Compound 54 (3.20 g, 9.5 mmol assumed) and 10% Pd-C (400 mg) in MeOH (50 mL) were hydrogenated at 50 psi and 30°C for 2 hours. The mixture was filtered through Kieselguhr, the filter cake was then washed with DMF
0300 mL), and these washings were concentrated to yield 55 (1.81 g, 62%) as an off white solid:
mlz 309.18 (MH+) vm~ 3418, 1677, 1582, 1263 cm-1 NMR SH (DMSO-d6) 0.12 (3H, SICH3), 0.05 (3H, s, SiCH3), 0.85 (9H, s, SitBu), 2.62 ( 1 H, dd, CH2, J 5.2, 6.4 Hz), 4.62 ( 1 H, dd, CHO, J 5.2, 6.4 Hz), 7.01 ( 1 H, d, arom., J 8.0 Hz), 7.06 ( 1 H, dd, arom., J 1.6 8.0 Hz), 7.17 ( 1 H, s, arom.).
Step 4: Compound 35 (1.69 g, 5.88 mmol), HBTU (2.29 g, 5.88 mmol) and DIPEA (3.03 g, 23.51 mmol) in DMF (25 mL) were stirred at room temperature for 10 minutes, then 55 (1.81 g, 5.88 mmol) was added, and the mixture stirred at room temperature for 4 hours. The solvent was removed and the mixture taken up in EtOAc, washed with saturated NaHC03, brine and dried (MgS04). The product was purified by chromatography (silica gel, 0-5% MeOH in CH2C12) to yield 56 (1.32 g, 42%) as a fawn colored foam:
m/z 542.30 (MH+) vm~ 3351, 1778, 1657, 1509 cm-1 1H-NMR (CDC13) 8H 0.09 (3H, SICH3), 0.08 (3H, s, SiCH3), 0.94 (9H, s, SitBu), 1.27 (2H, m, alkyl), 1.58 (3H, m, alkyl), 2.04 (1H, t, CH, J 11.2 Hz), 2.18 (1 H, t, CH, J 10.8 Hz), 2.51 (2H, d, CH2, J 6.8 Hz), 2.75 (2H, m, alkyl), 2.92 (2H, m, alkyl), 3.28 ( 1 H, m, alkyl), 3.56 ( 1 H, m, alkyl), 4.82 ( 1 H, dd, CHO, J 4.4, 6.0 Hz), 6.91-7.00 (3H, m, arom.), 7.09 (3H, m, arom.), 7.22 (1H, s, arom.), 7.56 (1H, bm, CONH), 8.36 (1H, bs, NH).
Step 5: Compound 56 (1.32 g, 2.44 mmol) and Lawesson's reagent (493 mg, 1.22 mmol) in dioxane (10 mL) were stirred and heated to reflux for 1.5 hours.
A
further aliquot of Lawesson's reagent (493 mg, 1.22 mmol) was added and heating continued for 1 hour. The mixture was diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04). The crude material was purified by chromatography (silica gel, 0-50% EtOAc/heptane) to give 57 (806 mg, 59%) as a cream colored oil which solidified on standing:
m/z 557.31 (MH+) vm~ 3250, 1776, 1509, 1259, 836 cm-1 1H-NMR (CDC13) 8H 0.07 (3H, SICH3), 0.07 (3H, s, SiCH3), 0.90 (9H, s, SitBu), 1.18 (2H, m, alkyl), 1.47-1.65 (3H, m, alkyl), 2.04 (1H, dt, CH, J2.2, 11.6 Hz), 2.22 ( 1 H, dt, CH, J 2.2, 11.6 Hz), 2.51 (2H, d, CH2, J 6.8 Hz), 2.57 ( 1 H, d, CHH, J 12.0 Hz), 2.72 ( 1 H, d, CHH, J 12.0 Hz), 3.40 (2H, dd, CH2, J 17.6, 25.2 Hz), 3.80 ( 1 H, m, alkyl), 4.03 ( 1 H, m, alkyl), 5.09 ( 1 H, dd, CHO, J
4.0, 6.0 Hz), 6.98 (3H, m, arom.), 7.09 (2H, m, arom.), 7.16 (1 H, d, arom., J 8.0 Hz), 7.29 ( 1 H, s, arom.), 7.90 ( 1 H, s, CONH), 9.56 ( 1 H, bs, NH).
Step 6: Compound 57 (806 mg, 1.45 mmol) in THF (10 mL) was treated with TBAF (1 M in THF, 2.90 mL, 2.90 mmol) and stirred at room temperature for 4 hours. The mixture was diluted with EtOAc, washed with 10% citric acid, saturated NaHC03, brine and dried (MgS04). The product was purified by chromatography (silica gel, 0-2% MeOH/CH2C12) to give 58 as a fawn colored foam (348 mg, 64%):
mla 444.19 (MH+) 5 vm~ 3210, 1766, 1509 cm-1 1H-NMR (CDCl3) bH 1.15 (2H, m, alkyl), 1.49-1.61 (3H, m, alkyl), 2.15 (2H, t, alkyl, J 12.0 Hz), 2.49 (2H, d, CH2, J 7.2 Hz), 2.68 (2H, t, CH2, J 12.4 Hz), 2.76 ( 1 H, bs, OH), 3.44 ~(2H, dd, CH2, J 18.0, 19.2 Hz), 3.76 ( 1 H, dd, CHH, J
8.0, 14.0 Hz), 4.25 ( 1 H, dd, CHH, J 2.8, 14.0 Hz), 5.13 ( 1 H, dd, CHO, J 3.2, 7.2 Hz), 10 6.95-7.00 (2H, m, arom.), 7.03-7.09 (3H, m, arom.), 7.22 (1H, d, arom., J
8.4 Hz), 7.33 (1H, s, arom.), 9.69 (1H, bs, NH).
Step 7: Compound 58 (348 mg, 786 ~mol) and Burgess reagent (187 mg, 786 p,mol) in THF (10 mL) were stirred and heated to reflux for 4 hours. An aliquot of Burgess Reagent (37 g, 157 p.mol) was added and heating continued for 15 a further 2 hours. Diluted with EtOAc, washed with saturated NaHC03, brine and dried (MgS04). The product was purified by chromatography (silica gel, 0-2%
MeOH/CH2C12) and then again using (silica gel, 0-75% EtOAc/heptane) to yield 6- { 2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4, 5-dihydrothiazol-5-yl } -3H
benzoxazol-2-one (98 mg, 29%) as a white solid:
20 mlz 426.26 (MH+) vm~ 3111, 1771, 1622, 1509, 1219 cm-1 1H-NMR (CDC13) 8H 1.34 (2H, m, alkyl), 1.49 (1H, m, alkyl), 1.59 (2H, m alkyl), 2.06 (2H, dd, alkyl, J 9.6, 19.2 Hz), 2.50 (2H, d, CH2, J 7.2 Hz), 2.93 (2H, dd, CH2, J 10.8, 10.8 Hz), 3.39 (2H, dd, CH2, J 16.2, 16.2 Hz), 4.37 (1H, dd, 25 CHH, J 4.8, 15.6 Hz), 4.5 8 ( 1 H, dd, CHH, J 9.2, 16.0 Hz), 4. 87 ( 1 H, dd, CHO, J5.2, 9.2 Hz), 6.94 (3H, m, arom.), 7.06 (3H, m, arom.), 7.15 (1H, d, arom., J 1.2 Hz), 8.41 ( 1 H, bs, NH).
General Methods for Examples 15-36:
HCl salts were prepared by treatment of a MeOH solution of the amine with excess HCl in Et20 (1 M). The salts were isolated either by filtration if they precipitated directly from the etherial solution, or by first removal of the solvent S under reduced pressure, and then crystallization (Et20/MeOH).
Purity was determined by reversed phase HPLC by the following methods:
Method A: column: YMC J' Sphere C 18, ODS-M80, 150 x 4.6 mm, 4 ~.; solvent A: 0.1% H3P04 in 95:5 H20/CH3CN; solvent B: 0.1% H3P04 in 95:5 CH3CN/H20; gradient: 10-100% B over 15 minutes; flow: 1 mL min-1;
detection: 210 nm.
Method B: column: YMC J'Sphere C18, ODS-M80, 150 x 4.6 mm, 4 ~,; solvent A: 0.1% H3P04 in 95:5 H20/MeOH; solvent B: 0.1% H3P04 in 95:5 MeOH/H20; gradient: 10-100% B over 15 minutes; flow: 1 mL min-1; detection:
21 S nm.
Method C: column: SYNERGI MAX-RP C 12, 80~, 150 x 4.6 mm, 4 ~,; solvent A: 95:5 H20/ CH3CN; solvent B: 95:5 CH3CN/H20; gradient: 10-100% B over 15 minutes; flow: 1 mL min-l; detection: 215 nm.
Method D: column: SYNERGI MAX-RP C 12, 80 ~, 1 SO x 4.6 mm, 4 p,; solvent A: 95:5 H20/MeOH; solvent B: 95:5 MeOH/H20; gradient: 10-100% B over 15 minutes; flow: 1 mL min' 1; detection: 215 nm.
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethylJisoxazol-3-yl}-3H benzoxazol-2-one N-OH N _O
Bn0 ~ 1. NCS, DMF Bn0 I / COzMe Dh \ ,H _ ~ \ v / 2. methyl propriolate 02N 1:1 THF/H20 02N
2 NaHC03 59 N_p OH N~O Br Bn0 I / NBS, PPh3 Bn0 \ I / ~ 1 ~F
\ v O N I ~ 61 KZCOs, ~. CH3CN
_O N-O
I
Bn0 N / i. Hy Pd/C O \ /
N ii. carbonic acid di-2-pyridyl ester O~ I / N
F ~ / F
S Step 1: A solution of oxime of formula 2 (8.41 g, 30.9 mmol) and freshly crystallized (benzene) N chlorosuccinimide (4.12 g, 30.9 mmol) in DMF (30 mL) was stirred at room temperature for 1 hour. The reaction was partitioned between EtOAc and H20. The organic layer was washed with saturated NaCI, dried (Na2S04), and concentrated under reduced pressure. The residue was dissolved in 1:1 THF/H20 (30 mL). Sodium bicarbonate (7.80 g, 92.7 mmol) and methyl propiolate (2.4 mL, 40.2 mmol) were added, and the reaction mixture was stirred overnight. The reaction was diluted with EtOAc and the organic layer was dried (Na2S04), and concentrated under reduced pressure. Ester of formula 59 (7.21 g, 66%) was isolated as a yellow solid following trituration with EtOAc/hexanes:
1 H NMR (500 MHz, CDC13): 8 7.96 (d, J 9 Hz, 1 H), 7.70 (d, J 2 Hz, 1 H), 7.48 (dd, J8, 1 Hz, 2H), 7.42-7.39 (m, 3H), 7.36-7.33 (m, 1H), 7.25 (s, 1H), 5.32 (s, 2H), 4.01 (s, 3H).
Step 2: To an ice-cold solution of the ester of formula 59 (7.21 g, 20.3 mmol) in THF (100 mL) was added diisobutylaluminum hydride (51.0 mL of a 1.0 M
solution in cyclohexane, 51.0 mmol). After 1 hour, the reaction was diluted with MeOH (2 mL) and a saturated solution of Rochelle's salt (50 mL) was added.
After stirring briefly, the solution became gel like. The gel dissolved upon addition of EtOAc (150 mL) and the solution was stirred for several hours. The organic layer was washed with H20 and saturated NaCI, dried (Na2S04) and concentrated under reduced pressure to give the alcohol of formula 60 (6.57 g, 99%) as a yellow solid:
1 H NMR (300 MHz, CDCl3): 8 7.96 (d, J 9 Hz, 1 H), 7.70 (d, J 2 Hz, 1 H), 7.49 (dd, J 8, 1 Hz, 2H), 7.42-7.30 (m, 4H), 6.60 (s, 1 H), 5.32 (s, 2H), 4.85 (s, 2H), 2.15 (s, 1 H).
Step 3: Triphenylphosphine (6.56 g, 25.0 mmol) and N bromosuccinimide (4.45 g, 25.0 mmol) were added to an ice-cold solution of alcohol of formula (6.53 g, 20.0 mmol) in THF (SO mL) and the solution was stirred for 1 hour.
The mixture was partitioned between EtOAc and saturated NaHC03. The organic layer was washed with saturated NaCI, dried (Na2S04), and concentrated under reduced pressure. Purification by chromatography (silica gel, 1:4 hexanes/EtOAc) gave bromide of formula 61 (6.88 g, 88%):
1 H NMR (500 MHz, CDC13): S 7.94 (d, J 8 Hz, 1 H), 7.67 (d, J 2 Hz, 1 H), 7.49 (dd, J8, 1 Hz, 2H), 7.42-7.34 (m, 4H), 6.62 (s, 1H), 5.30 (s, 2H), 4.51 (s, 2H).
Step 4: A solution of bromide of formula 61 (3.42 g, 8.79 mmol), amine of formula 12 (2.01 g, 8.79 mmol), K2C03 (2.41 g, 17.5 mmol), KI (146 mg, 0.879 mmol), and Liar (200 mg, 2.30 mmol) in CH3CN (30 mL) was stirred at 50°C overnight. The reaction solvent was removed under reduced pressure. The residue was partitioned between EtOAc and water. The organic layer was washed with saturated NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by chromatography (silica gel, 99:1 to 95:5 CH2C12/MeOH) gave compound of formula 62 (3.26 g, 74%) as a pale yellow oil:
1 H NMR (300 MHz, CDCl3): 8 7.94 (d, J 8 Hz, 1 H), 7.67 (d, J 2 Hz, 1 H), 7.49 (dd, J 8, 1 Hz, 2H), 7.42-7.30 (m, 4H), 7.08 (dd, J 8, 7 Hz, 2H), 6.95 (dd, J
8, 7 Hz, 2H), 6.50 (s, 1H), 5.32 (s, 2H), 3.73 (s, 2H), 2.92 (d, J 12 Hz, 2H), 2.51 (d, J7 Hz, 2H), 2.08 (ddd, J 12, 12, 2 Hz, 2H), 1.67-1.25 (m, SH).
Step 5: Palladium on charcoal (10% Pd, 200 mg) was added to a solution of compound of formula 62 (2.42 g, 4.80 mmol) in THF (100 mL), and the mixture was shaken under an atmosphere of H2 (g) at 50 psi for 4 hours. The reaction mixture was rapidly filtered through CELITE under reduced pressure into a reaction flask. The flask was capped with a septum and purged with nitrogen.
To the clear solution was added carbonic acid di-2-pyridyl ester (1.15 g, 5.28 mmol) and Et3N (1.50 mL, 10.56 mmol), and the solution was refluxed for 6 hours. The solvent was removed under reduced pressure. Purification by chromatography (silica gel, 99:1 to 95:5 CH2C12/MeOH) and subsequent crystallization from hot EtOH gave 6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]isoxazol-3-yl}-3H
benzoxazol-2-one (665 mg, 34%) as an off white solid:
mp 237-244°C
IR (KBr): 2934, 2825, 1775 cm-1;
1 H NMR (300 MHz, DMSO-d6): 8 11.87 (s, 1 H), 7.78 (d, J 1 Hz, 1 H), 7.70 (dd, J 8, 1 Hz, 1 H), 7.20-7.15 (m, 3H), 7.07 (dd, J 8, 7 Hz, 2H), 6.93 (s, 1 H), 3.66 (s, 2H), 2.84 (d, J 11 Hz, 2H), 2.47 (d, J6 Hz, 2H), 1.99 (dd, J 11, 10 Hz, 2H), 1.54-1.45 (m, 3H), 1.25-1.18 (m, 2H); ESI -MS
(m/z): 408 [M + H]+; HPLC: method A, 5.91 minutes(>99%); method B, 11.23 minutes(>99%); Anal. Calcd for C23H22~303~ C~ 67.80; H, 5.44; N, 10.31.
Found: C, 67.67; H, 5.52; N, 10.11.
6- { 5-[4-(4-Fluorobenzyl)piperidin-1-yl) methyl } -4, 5-dihydroi soxazol-3-yl } -3H
benzothiazol-2-one HN \ ~ F NaHC03, CH3CN ~N \ I F
allyl bromide HO, N
S \ Br i. MeMgBr g \ CHO NHZOHHCI S
O O '~\~H
O I ~ I 2-PrOH
N
~ \
ii. t- , a H iii. DMF H H
HO.N N~O
HCI/DMF O~S / I O~S / I N
I CI EtOH, NaHC03, O
~ N \ N \
OXONE H \ H _ 67 I ~ / F
~N
/
Step 1: 4-(4-Fluorobenzyl)piperidine hydrochloride 12 (2.55 g, 11.1 mmol) and NaHC03 (2.3 g, 27.7 mmol) were added to a solution of allyl bromide in CH3CN.
The mixture was warmed to 40°C for 3 hours. The solvent was removed under 5 reduced pressure and the residue was partitioned between EtOAc and water.
The organic layer was washed with saturated NaCI, dried (Na2S04), filtered, and the solvent removed under reduced pressure. Purification by flash chromatography (silica gel, 95:5 to 9:1 CH2C12/MeOH) gave alkene of formula 63 (1.13 g, 44%) as an oil:
10 1H NMR (500 MHz, DMSO-d6): 8 7.18-7.14 (m, 2H), 7.08-7.03 (m, 2H), 5.81-5.73 (m, 1 H), 5.11 (dd, J 17, 2 Hz, 1 H), 5.06 (dd, J 11, 2 Hz, 1 H), 2.87 (d, J 6 Hz, 2H), 2.77 (d, J 12 Hz, 2H), 2.47 (d, J7 Hz, 2H), 1.79 (dt, J 12, 2 Hz, 2H), 1.50-1.39 (m, 3H), 1.15 (tt, J 13, 3 Hz, 2H).
Step 2: To a -78°C solution of bromide of formula 64 (5.02 g, 21.8 mmol) in THF
15 (50 mL) was added MeMgBr (8.0 mL of a 3.0 M solution in diethyl ether, 24.0 mmol). After 30 minutes, anhydrous THF (170 mL) was added at a rate that maintained the internal reaction temperature below a threshold of -SO°C. After the solution returned to -78°C, tent-butyl lithium (50 mL of a 1.7 M
solution in pentane, 85 mmol) was added. After 10 minutes, DMF (10 mL, 130 mmol) was 20 added to the yellow mixture, and the cold bath was removed. After 1 hour, the reaction was quenched with water, and the THF was removed under reduced pressure. The residue was partitioned between EtOAc and 1N HCI. The aqueous layer was extracted with three portions of EtOAc. The organic extracts were combined and washed with saturated NaCI, dried (Na2S04), filtered, and concentrated under reduced pressure to give aldehyde of formula 65 (3.74 g, 96%) as a white solid:
1H NMR (500 MHz, DMSO-d6): b 12.39 (s, 1H), 9.90 (s, 1H), 8.17 (d, J 1 Hz, 1 H), 7.85 (dd, J 8, 1 Hz, 1 H), 7.3 0 (d, J 8 Hz, 1 H).
Step 3: A mixture of aldehyde of formula 65 (3.74 g, 20.8 mmol), hydroxylamine hydrochloride (1.60 g, 22.9 mmol), and sodium bicarbonate (2.18 g, 26.0 mmol) in 2-PrOH (75 mL) was heated to 75°C for 3 hours. After stirring overnight at room temperature, the mixture was diluted with 2-PrOH (200 mL). The solution was filtered and concentrated under reduced pressure to give oxime of formula 66 (4.00 g, 99%), as a white solid:
1H NMR (300 MHz, DMSO-d6): b 11.96 (s, 1H), 11.15 (s, 1H), 8.10 (s, 1H), 7.79 (d, J 1 Hz, 1 H), 7.52 (dd, J 8, 1 Hz, 1 H), 7.14 (d, J 8 Hz, 1 H).
Step 4: A mixture of oxime of formula 66 (4.00 g, 20.6 mmol) and OXONE~
(13.9 g, 22.6 mmol) was stirred in a solution of HCl in DMF (43 mL of a 0.53 M, 22.6 mmol) for 3.5 hours. The reaction mixture was partitioned between EtOAc and 1N HCI. The organic layer was washed with saturated NaCI, dried (Na2S04), filtered, and concentrated under reduced pressure. The yellow solid was triturated with 1:1 EtOAc/hexanes and filtered to give compound of formula 67 (3.53 g, 75%):
1 H NMR (300 MHz, DMSO-d6): 812.33 (s, 1 H), 12.15 (s, 1 H), 8.03 (d, J 2 Hz, 1 H), 7.73 (dd, J 8, 2 Hz, 1 H), 7.20 (d, J 8 Hz, 1 H).
Step 5: Coupling of compound of formula 67 and alkene of formula 63 following the procedure described in Example 17, Step 5, followed by conversion to the HCl salt, gave 6-{5-[4-(4-fluorobenzyl)piperidin-1-yl]methyl}-4,5-dihydroisoxazo1-yl}-3H benzothiazol-2-one (484 mg, 41%):
mp 271-276 °C
IR (KBr): 3422, 2932, 1686, 1670, 1603 cm-1 1H NMR (500 MHz, DMSO-d6): 812.19 (s, 1H), 10.58 (s, 1H), 7.88 (s, 1H), 7.60 (d, J8 Hz, 1H), 7.23-7.20 (m, 3H), 7.11 (dd, J9, 8 Hz, 2H), 5.30-5.24 (m, 1H), 3.66 (dd, J 17, 11 Hz, 1 H), 3.58 (d, J 12 Hz, 1 H), 3.48 (d, J 11 Hz, 1 H), 3.34-3.17 (m, 3H), 2.95 (m, 2H), 2.53 (d, J 5 Hz, 2H), 1.75-1.74 (m, 3H), 1.64-1.54 (m, 2H);
ESI -MS (m/z): 426 [M + H]+; HPLC: method A, 6.05 minutes (>99%); method B, 11.48 minutes (>99%); Anal. Calcd for C23H24~3C2S~HC1~0.25H20: C, 59.22; H, 5.51; N, 9.01. Found: C, 59.37; H, 5.38; N, 8.82.
6-[5-(4-Benzyl-4-hydroxypiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H
benzoxazol-2-one O / I Br i. MeMgBr O~O / I CHO ~20H~HCl ii. t-BuLi N' v NaHCO
H iii. DMF H 3 N,OH N,OH
O O / I I OXONE~ O O / I I Cl \ HCI, DMF ~ \
H H
OH OH
\ ~ Br \ EtOH, NaHC03, O
/ N O ~N I / HO..
N
/ ~Cl to O~ \ I 70 H
Step 1: To a -78°C solution of 9 (20.0 g, 93.4 mmol) in THF (180 mL) was added MeMgBr (34.5 mL of a 3.0 M solution in diethyl ether, 103 mmol). After 45 minutes, anhydrous THF (750 mL) was added at a rate that maintained the internal reaction temperature below a threshold of -SO°C. After the solution returned to -78°C, tert-butyl lithium (200 mL of a 1.7 M solution in pentane, 118 mmol) was added via a dropping funnel. After 15 minutes, DMF (44 mL, 561 mmol) was added to the yellow mixture, and the cold bath was removed.
After 2 hours, the reaction was quenched with water and the THF removed under reduced pressure. The residue was partitioned between EtOAc and 1N HCI. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. The crude solid was dissolved in hot EtOAc and hexane was added to the solution until a precipitate formed. The precipitate was collected by filtration to give 68 (12.44 g, 81%) as an off white solid:
1 H NMR (500 MHz, DMSO-d6): 812.13 (s, 1 H), 9.92 (s, 1 H), 7.78 (d, J 8 Hz, 1 H), 7.75 (s, 1 H), 7.29 (d, J 8 Hz, 1 H).
Step 2: A mixture of aldehyde 68 (10.0 g, 61.3 mmol), hydroxylamine hydrochloride (4.26 g, 61.3 mmol), and sodium bicarbonate (5.15 g, 61.3 mmol) in 2-PrOH (75 mL) was heated to 40°C for 3 hours. After cooling to ambient temperature, the mixture was diluted with 2-PrOH and filtered. Concentration under reduced pressure gave oxime 69 (11.6 g, 100%), as a white solid:
1H NMR (300 MHz, DMSO-d6): b 11.82 (s, 1H), 11.15 (s, 1H), 8.14 (s, 1H), 7.49 (s, 1H), 7.39 (d, J 8 Hz, 1H), 7.12 (d, J 8 Hz, 1H).
Step 3: A mixture of oxime 69 (11.6 g, 61.3 mmol) and OXONE~ (41.4 g, 67.4 mmol) was stirred in HCl (62 mL of a 1.09 M solution in DMF, 67.4 mmol) for 2.5 hours. The reaction mixture was partitioned between EtOAc and water.
The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. Trituration of the yellow solid with EtOAc gave 70 (7.03 g, 54%).
The washings were concentrated under reduced pressure and the residue triturated with 3:1 EtOAc/hexanes to give a second crop of 70 (2.34 g, 18%):
1H NMR (300 MHz, DMSO-d6): 812.33 (s, 1H), 11.93 (s, 1H), 7.63 (s, 1H), 7.60 (d, J 8 Hz, 1 H), 7.18 (d, J 8 Hz, 1 H).
Step 4: Alkene of formula 72 was prepared following the procedure described below for alkene of formula 63 in Example 16, Step 1, to give 420 mg, (14%):
NMR (500 MHz, CDCl3): 8 7.30 (dd, J 8, 7 Hz, 2H), 7.24-7.23 (m, 1H), 7.19 (d, J
7 Hz, 2H), 5.91-5.83 (m, 1 H), 5.17 (dd, J 17, 2 Hz, 1 H), 5.12 (dd, J 10, 2 Hz, 1 H), 3.01 (d, J 6 Hz, 2H), 2.75 (s, 2H), 2.67-2.63 (m, 2H), 2.28 (dt, J 10, 2 Hz, 2H), 1.74 (dt, J 13, 4 Hz, 2H), 1.53 (dd, J 14, 2 Hz, 2H), 1.17 (s, 1H).
Step 5: A solution of alkene of formula 72 (420 mg, 1.81 mmol) in EtOH (10 mL) was added to a mixture of NaHC03 and compound of formula 70 (425 mg, 2.0 mmol). The mixture was heated to reflux for 2 hours. Methanol and CH2C12 were added to dissolve an organic precipitate that had formed during the course of the reaction. Silica gel was added and the solvent was removed under reduced pressure. Purification by flash chromatography (silica gel, 89:10:1 CH2C12/MeOH/NH40H), trituration of the isolated solid with MeOH, and conversion to the HCl salt gave ICJPAC: 6-[5-(4-benzyl-4-hydroxypiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H benzoxazol-2-one (425 mg, 52%) as a white solid:
mp 166-170°C
IR (KBr): 3387, 2958, 1773 cm-1 1 H NMR (500 MHz, DMSO-d6): 812.01 (s, 1 H), 10.20 (s, 1 H), 7.57 (s, 1 H), 7.47 (d, J 8 Hz, 1 H), 7.30 (dd, J 8, 7 Hz, 2H), 7.24 (d, J 7 Hz, 2H), 7.14 (d, J 8 Hz, 2H), 5.23 (m, 1 H), 4.82 (s, 1 H), 3.66 (dd, J 17, 11 Hz, 1 H), 3.37-3.33 (m, 4H), 3.19-3.16 (m, 2H), 2.74 (s, 2H), 1.93-1.85 (m, 2H), 1.61 (d, J 15 Hz, 2H); ESI-MS
(mlz): 408 [M + H]+
HPLC: method A, 4.14 minutes (98.2%); method B, 9.92 minutes (>99%); Anal.
Calcd for C23H25N304' 1.125 H20: C, 59.22; H, 6.08; N, 9.01. Found: C, 59.34;
H, 5.94; N, 8.96.
6-{5-[4-(4-Fluorobenzyl)piperidine-1-carbonyl]-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one F acryloyl chloride N / F EtOH, NaHC03, OXONE~ -OH
CH
CN
Na 3, ~ N
I
12 7 O~O / I
N
H
Step 1: A mixture of 4-(4-fluorobenzyl)piperidine hydrochloride 12 (2.09 g, 9.09 mmol), NaHC03 (765 mg, 9.09 mmol) and acryloyl chloride (815 p,L, 10.0 mmol) in CH3 CN ( 15 mL) was stirred at ambient temperature for 6 hours.
The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and water. The organic layer was washed with sat. NaHC03 and sat. NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by flash chromatography (silica, 99:1 to 95:5 CH2Cl2/MeOH) gave 73 (730 mg, 33%) as an oil:
1 H NMR (500 MHz, CDCl3): 8 7.09 (dd, J 9, 8 Hz, 2H), 6.96 (dd, J 9, 8 Hz, 2H), 6.56 (dd, J 17, 11 Hz, 1 H), 6.25 (dd, J 17, 1 Hz, 1 H), 5.65 (dd, J 11, 1 Hz, 1 H), 4.65-4.58 (m, 1 H), 3.95 (d, J 13 Hz, 1 H), 2.98-2.94 (m, 1 H), 2.64-2.45 (m, 3H), 1.78-1.70 (m, 3H), 1.29-1.16 (m, 2H).
Step 2: A mixture of oxime 69 (525 mg, 2.95 mmol) and OXONE~ (1.90 g, 3.10 mmol) was stirred in HCl (2.85 mL of a 1.09 M solution in DMF, 3.10 mmol) for 1.5 hours. The reaction mixture was partitioned between EtOAc and 1N HCI. The organic layer was washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. The residue was combined with NaHC03 (750 mg, 8.85 mmol) and a solution of amide 73 (730 mg, 2.95 mmol) in 1:1 THF/H20 ( 10 mL) was added. The reaction mixture was stirred for 24 hours at ambient temperature. The solvent was removed under reduced pressure and the residue was partitioned between EtOAc and 1N HCI. The organic layer was washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by flash chromatography (silica, 5:2 hexanes/EtOAc to 9:1 CH2C12/MeOH) followed by trituration with 3:1 hexanes/EtOAc gave 6-{5-[4-(4-fluorobenzyl)piperidine-1-carbonyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (507 mg, 40%):
mp 210-213°C
IR (KBr): 3193, 2931, 1779, 1632 cm-1 1 H NMR (500 MHz, DMSO-d6): 811.84 (s, 1 H), 7.59 (s, 1 H), 7.50 (d, J 8 Hz, 1 H), 7.23-7.20 (m, 2H), 7.16 (d, J 8 Hz, 1 H), 7.10 (dd, J 9, 8 Hz, 2H), 5.58-5.51 (m, 1 H), 4.35-4.30 (m, 1 H), 4.03 (d, J 14 Hz, 1 H), 3.90-3.77 (m, 1 H), 3.54-3.47 (m, 1 H), 3:09-3 .00 (m, 1 H), 2.64-2.5 8 (m, 1 H), 2.54 (d, J 7 Hz, 2H), 1.79 (m, 1 H), 1.68-1.58 (m, 2H), 1.24-1.16 (m, 1H), 1.08-0.97 (m, 1H) ESI-MS (m/z): 424 [M + H]+
HPLC: method A, 10.06 min (98.6%); Anal. Calcd for C23H22~304~ C~ 65.24;
H, 5.24; N, 9.92. Found: C, 65.03; H, 5.20; N, 9.87.
6-(5- { 2-[4-(4-Fluorobenzyl)piperidin-1-yl] ethyl } -4, 5-dihydroisoxazol-3-yl)-3H
benzoxazol-2-one ~Br I ~ EtOH, NaHC03, O
HN / ~ wN / F
F NaHC03 70 F
N~O
I
~N
H
Step 1: Coupling of amine 12 (4.00 g, 17.4 mmol) with 4-bromo-1-butene (3.53 mL, 34.8 mmol) following the procedure described in Example 16, Step 1, followed by conversion to the HCl salt gave alkene 75 (3.57 g, 72%):
1H NMR (500 MHz, DMSO-d6): 8 10.52 (s, 1H), 7.23-7.20 (m, 2H), 7.13-7.07 (m, 2H), 5.83-5.72 (m, 1 H), 5.16 (dd, J 17, 2 Hz, 1 H), 5.09 (dd, J 10, 2 Hz, 1 H), 3.43-3.38 (m, 2H), 3.18-3.14 (m, 1H), 3.04-3.00 (m, 2H), 2.85-2.78 (m, 2H), 2.52-2.47 (m, 3H), 1.80-1.68 (m, 3H), 1.59-1.51(m, 2H).
Step 2: Coupling of 70 (156 mg, 0.734 mmol) and alkene 75 (207 mg, 0.734 mmol) following the procedure described in Example 17, Step 5, followed by conversion to the HCl salt, gave 6-(5-{2-[4-(4-fluorobenzyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one (200 mg, 58%):
mp 254-258°C
IR (KBr): 3448, 2934, 2713, 1774 cm-1 1H NMR (500 MHz, DMSO-d6): 8 11.90 (s, 1H), 10.09 (s, 1H), 7.55 (s, 1H), 7.46 (d, J 8 Hz, 1 H), 7.21 (dd, J 9, 8 Hz, 2H), 7.16 (d, J 8 Hz, 1 H), 7.11 (dd, J
9, 8 Hz, 2H), 4.79-4.73 (m, 1 H), 3.54 (dd, J 17, 11 Hz, 1 H), 3.45 (d, J 11 Hz, 2H), 3.18-3.09 (m, 4H), 2.83 (m, 2H), 2.53-2.49 (m, 2H), 2.06 (dd, J 15, 8 Hz, 2H), 1.73-1.70 (m, 2H), 1.52-1.48 (m, 2H) ESI-MS (m/z): 424 [M + H]+
HPLC: method A, 5.69 min (98.0%); method B, 10.96 min (98.4%); Anal. Calcd for C24H26~303'HC1~0.5H20: C, 61.47; H, 6.02; N, 8.96. Found: C, 61.59; H, 6.02; N, 9.87.
6- { 5-[4-(4-Fluorobenzyl)-4-hydroxypiperidin-1-ylmethyl]-4, 5-dihydroisoxazol-yl}-3H benzoxazol-2-one F ally! acetate, Pd(PPh3)a F EtOH, NaHC03, D
OH ~ ~ ~N OH ~ ~ 70 N-O
I
O~ \ I N
H OH
F
Step 1: To a suspension of the formate salt of amine 76 (14.3 g, 43.4 mmol) in toluene (225 mL) was added ally! acetate (5.2 mL, 47.7 mmol) and Et3N
(12.1 mL, 86.8 mmol). Solubility of the amine was problematic. Addition of pyridine (20 mL) and then MeOH (40 mL) resulted in a homogenous solution. The solution was deoxygenated with an argon sparge for 1 S minutes, then palladium tetrakis(triphenylphosphine)palladium(0) (500 mg, 0.434 mmol) was added. The reaction mixture was heated to 100°C in an oil bath for 1 hour and then cooled to ambient temperature. The mixture was filtered and the solution concentrated under reduced pressure. Purification by chromatography (silica, 95:5 to 9:1 CH2C12/MeOH) gave 77 (7.15 g, 70%) as a clear oil:
1 H NMR (500 MHz, CDCl3): S 7.17 (dd, J 9, 8 Hz, 2H), 7.02 (dd, J 9, 8 Hz, 2H), 6.23-6.09 (m, 1H), 5.53-5.43 (m, 2H), 3.54 (d, J7 Hz, 2H), 3.31-3.27 (m, 2H), 3.01 (br. t, J 11 Hz, 2H), 2.83 (s, 2H), 2.37 (dt, J 13, 4 Hz, 2H), 2.06 (s, 1H), 1.71 (br. d, J 13 Hz, 2H).
Step 2: Coupling of 70 (978 mg, 4.16 mmol) and alkene 77 (975 mg, 4.57 mmol) following the procedure described in Example 17, Step S, followed by conversion to the HCl salt, gave 6-{5-[4-(4-fluorobenzyl)-4-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (840 mg, 43%):
mp 195-204°C
IR (KBr): 3380, 2958, 1770, cm-1 1 H NMR (500 MHz, CD30D): 8 7.58 (s, 1 H), 7.52 (d, J 8 Hz, 1 H), 7.29-7.24 (m, 2H), 7.15 (dd, J 8, 2 Hz, 1 H), 7.06-7.00 (m, 2H), 5.28-5.23 (m, 1 H), 3.71 (dd, J 17, 11 Hz, 1H), 3.52-3.20 (m, 6H), 2.83 (s, 2H), 2.03-1.90 (m 2H), 1.79-1.70 (m, 2H), 1.18 (dt, J 7, 2 Hz, 1 H) APCI-MS (m/z): 426 [M + H]+
HPLC: method A, 5.37 min (96.4%); method B, 10.38 min (98.3%); Anal. Calcd for C23H24~304'HC1~O.SH20: C, 58.66; H, 5.56; N, 8.92. Found: C, 58.61; H, 5.60; N, 8.40.
6-{ 5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-5-methyl-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one N-O
I
I \ EtOH, NaHC03, ~ O ~ N
~N I / F ~O O~ \
% v 7g H
F
Step 1: A mixture of 4-(4-fluorobenzyl)piperidine hydrochloride (12) (3.05 g, 13.2 mmol) and NaHC03 (2.76 g, 32.8 mmol) in CH3CN (50 mL) was heated to reflux for 30 minutes. After cooling to ambient temperature, methallyl bromide (1.7 mL, 17 mmol) was added, and the mixture was heated to reflux for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure.
Purification liy flash chromatography (silica, 98:2 to 9:1 CH2C12/MeOH) gave (2.67 g, 81 %) as an oil:
1H NMR (300 MHz, DMSO-d6): b 7.21-7.16 (m, 2H), 7.11-7.05 (m, 2H), 4.81 (m, 2H), 2.75-2.70 (m, 4H), 2.49 (m, 2H), 1.72 (m, 2H), 1.65 (s, 3H), 1.51-1.48 (m, 3H), 1.17-1.13 (m, 2H).
Step 2: Coupling of 70 (610 mg, 2.87 mmol) and alkene 78 (644 mg, 2.60 mmol) following the procedure described in Example 17, Step 5, gave 6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-5-methyl-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one (299 mg, 26%) as a white solid: mp 82-86°C
IR (KBr): 2925, 1774 cm-1 1 H NMR (500 MHz, DMSO-d6): 811.79 ,(s, 1 H), 7.54 (d, J 1 Hz, 1 H), 7.43 (dd, J 8, 1 Hz, 1 H), 7.17-712 (m, 3 H), 7.05 (dd, J 9, 9 Hz, 2H), 3 .3 8 (d, J 17 Hz, 1 H), 3.17 (s, 2H), 3.07 (d, J 17 Hz, 1 H), 2.90-2.88 (m, 2H), 2.44 (d, J 7 Hz, 2H), 2.07 1.97 (m, 2H), 1.49-1.36 (m, 3H), 1.29 (s, 3H), 1.20-1.06 (m, 2H) APCI-MS (m/z): 424 [M + H]+
HPLC: method A, 6.57 min (97.8%); method B, 11.89 min (96.5%); Anal. Calcd for C24H26~303'0.75H20: C, 65.96; H, 6.34; N, 9.62. Found: C, 66.03; H, 6.62; N, 9.25.
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid COZEt \ i. EtOH, NaHC03, D
%vN I ~ 70 ii. LiOH, MeOH
S Step 1: To a suspension of the hydrochloride salt of amine 12 (2.06 g, 8.96 mmol) in toluene (50 mL) was added 2-acetoxymethylacrylic acid ethyl ester (1.70 g, 9.86 mmol) and Et3N (1.37 mL, 9.86 mmol). The solution was deoxygenated with an argon sparge for 10 minutes, then palladium tetrakis(triphenylphosphine)-palladium(0) (260 mg, 0.224) was added. The reaction mixture was heated to 100°C in an oil ,bath for 1 hour, and then cooled to ambient temperature. The mixture was filtered and then concentrated under reduced pressure.
Purification by chromatography (silica, 95:5 to 9:1 CH2C12/MeOH) gave a yellow oil. The oil was dissolved in 3:1 EtOAc/hexanes and then acidified with 1N HCl/Et20 to give alkene 79 (7.1 S g, 70%) as a white solid:
1H NMR (500 MHz, DMSO-d6): 812.44 (s, 1H), 7.07 (dd, J 8, 8 Hz, 2H), 6.96 (dd, J 8, 8 Hz, 2H), 6.89 (s, 1 H), 6.84 (s, 1 H), 4.25 (q, J 7 Hz, 2H), 3.87 (d, J 5 Hz, 2H), 3.47 (br. d, J 12 Hz, 2H), 2.66-2.62 (m, 2H), 2.60 (d, J 7 Hz, 2H), 2.11-2.03 (m, 2H), 1.79 (br. d, J 14 Hz, 2H), 1.69-1.63 (m, 1H), 1.31 (t, J7 Hz, 3H).
Step 2: Coupling of 70 (600 mg, 2.82 mmol) and alkene 79 (875 mg, 2.56 mmol) following the procedure described in Example 17, Step 5, gave the ester as an impure solid. The crude ester was saponified with excess LiOH in 1:1 MeOH/THF
(15 mL). After stirnng overnight, the reaction solvent was removed under reduced pressure. Purification by chromatography (silica, 89:10:1 to 79:20:1 CH2C12/MeOH/AcOH) followed by trituration with MeOH gave 5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid (275 mg, 85%) as a white solid:
mp 188-194°C
IR (KBr): 2959, 2921, 1774, 1630, 1509 cm-1 1 H NMR (300 MHz, DMSO-d6): 8 11.92 (s, 1 H), 7.58 (s, 1 H), 7.48 (d, J 8 Hz, 1H), 7.24-7.07 (m, 8H), 3.89 (d, J 17 Hz, 1H), 3.45-3.16 (m, SH), 2.60-2.50 (m, 2H), 1.64 (m, 3H), 1.31 (m, 2H) ESI-MS (m/z): 454 [M + H]+
HPLC: method C, 6.56 min (97.0%); method D, 12.33 min (99.5%); Anal. Calcd for C24H24~305'O.SH20: C, 62.33; H, 5.45; N, 9.09. Found: C, 62.57; H, 5.47;
N, 9.00.
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid methyl ester N-O COzMe I
O~O / I N
N
H
/ F
To a solution of 5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-S-carboxylic acid (687 mg, 0.909 mmol) in MeOH (20 mL) and TFA (1.5 mL) was addedp-toluenesulfonic acid monohydrate (190 mg, 0.999 mmol). The reaction mixture was heated to reflux overnight, then concentrated and purified by flash chromatography (silica gel, 5% MeOH in CH2C12) to give S-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid methyl ester (133 mg, 31%), as an off white solid:
mp 146-155°C
IR (KBr): 2930, 1767, 1508, 1448 cm-1 1H NMR (S00 MHz, CD30D): b 7.58 (d, J 1 Hz, 1H), 7.51 (dd, J 8, 1 Hz, 1H), 7.20 (dd, J 8, 5 Hz, 2 H), 7.16 (d, J 8 Hz, 1 H), 7.03 (d, J 9 Hz, 1 H), 7.00 (d, J 9 Hz, 1 H), 3.96 (d, J 18 Hz, 1 H), 3.92-3.90 (m, 4H), 3.68 (d, J 18 Hz, 1 H), 3.68-3.55 (m, 3H), 3.21-3.05 (m, 2H), 2.62 (d, J7 Hz, 2H), 1.97-1.83 (m, 3H), 1.71-1.55 (m, 2H) APCI (m/z): 468 [M + H]+
HPLC: method A, 6.32 min, 98.7%; Anal. Calcd for C24H26~305'HCI: C, 59.58; H, 5.40; N, 8.34. Found: C, 59.19; H, 5.56; N, 8.01.
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester COZEt Pd(Ph3)4, toluene /~ LDA, TI-IF
~N~COZEt N allyl acetat ~/e H ~ ~ F
Br N-O
COzEt I
N 0 O ~ N
NaHC03, EtOH, D ~ /
N
/ -70 H EtO2C ~ ~ F
Step 1: Treatment of amine 80 (2.0 g, 13 mmol) with allyl acetate (1.6 mL, 14 mmol), and Pd(Ph3)4 (440 mg, 3.8 mmol), following the procedure described in Example 20, Step 1, gave 81 (2.3 g, 88%):
1H NMR (300 MHz, CDC13): b 5.97-5.79 (m, 1H), 5.26-5.10 (m, 2H), 4.21-4.09 (m, 2H), 2.99-2.87 (m, 4H), 2.35-2.20 (m, 1H), 2.04-1.65 (m, 6H), 1.27-1.22 (m, 3H).
Step 2: To an ice-cold solution of diisopropylamine (0.78 mL, 5.6 mmol) in THF
(22 mL) was added n-BuLi (2.2 mL of a 2.5 M solution in hexanes, 5.6 mmol).
After 15 minutes, the reaction mixture was cooled in a -78°C dry ice/2-PrOH bath and then a solution of 81 (1.0 g, 5.1 mmol) in THF (10 mL) was added dropwise over 15 minutes. After 1.5 hours, a solution of 4-fluorobenzyl bromide (0.66 mL, 5.3 mmol) in THF ( 10 mL) was added dropwise to the reaction mixture over 1.5 hours. The reaction mixture was stirred for an additional 35 minutes and then warmed to ambient temperature. The reaction mixture was poured into H20 and extracted with EtOAc (3x). The combined organics were dried (Na2S04) and concentrated under reduced pressure. Purification by flash chromatography (silica, 95:4.5:0.5 CH2Cl2/MeOH/NH40H) gave 82 ( 1.3 g, 81 %):
1H NMR (300 MHz, CDC13) 8 7.03-6.90 (m, 4H), 5.90-5.79 (m, 1H), 5.18-5.11 (m, 2H), 4.09 (q, J 7 Hz, 2H), 2.94 (d, J 7 Hz, 2H), 2.78 (s, 4H), 2.13 (d, J
13 Hz, 2H), 1.96 (dd, J 12, 12 Hz, 2H), 1.61-1.51 (m, 2H), 1.19 (t, J 7 Hz, 3H).
Step 3: Coupling of 70 (1.0 g, 4.7 mmol) and alkene 82 (1.3 g, 4.2 mmol) following the procedure described in Example 17, Step 5, gave 4-(4-fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester (630 mg, 31 %), as a white solid:
mp 212-214°C
IR (KBr): 2836, 1767, 1705, 1511, 1451 cm-1 1H NMR (300 MHz, DMSO-d6): ~ 11.80 (br s, 1H), 7.55 (d, J 1 Hz, 1H), 7.45 (dd, J 8, 1 Hz, 1 H), 7.14 (d, J 8 Hz, 1 H), 7.08 (d, J 8 Hz, 4H), 4.83-4.77 (m, 1 H), 4.04 (dd, J 14, 7 Hz, 2H), 3.44 (dd, J 17, 7 Hz, 1 H), 3.12 (dd, J 17, 7 Hz, 1 H), 2.84-2.76 (m, 4H), 2.52- 2.43 (m, 2H), 2.08-2.00 (m, 2H), 1.94-1.91 (m, 2H), 1.53-1.47 (m, 2H), 1.14 (dd, J 7, 7 Hz, 3H) APCI (m/z): 482 [M + H]+
HPLC: method B, 11.50 min (97.5%); Anal. Calcd for C26H28~305~ C~ 64.85;
H, 5.86; N, 8.73. Found: C, 64.56; H, 5.74; N, 8.62.
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid N_O N_O
I NaOH, EtOH I
O~N I / N O"1N I / N
H EtOZC ~ ~ F HOZC ~ ~ F
Step 1: A mixture of 4-(4-fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester (390 mg, 0.81 mmol) and 20% aq. NaOH (4.5 mL) in EtOH (4.5 mL) was heated to reflux for 16 hours. After stirring at ambient temperature overnight, the reaction solvent was removed under reduced pressure. The reaction mixture was diluted with water, brought to pH 3 with 1N HCI, and extracted with EtOAc (2x). The combined extracts were dried (Na2S04) and concentrated under reduced pressure.
Purification by chromatography (silica, 79:20:1 CH2C12/MeOH/AcOH) followed by recrystallization from MeOH/Et20 gave 4-(4-fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid (28 mg, 8%) as a yellow solid:
IR (KBr): 2922, 1767, 1600, 1508, 1448 cm'1 1 H NMR (500 MHz, DMSO-d6): 8 7.55 (d, J 1 Hz, 1 H), 7.45 (dd, J 8, 2 Hz, 1 H), 7.14-7.11 (m, 3H), 7.07 (d, J 8, 8 Hz, 2H), 3.46-3.10 (m, 4H), 2.79-2.73 (m, 4H), 2.52-2.43 (m, 2H), 2.13-2.06 (m, 2H), 1.89-1.87 (m, 2H), 1.47-1.42 (m, 2H) ESI-MS (m/z): 454 [M + H]+
HPLC: method A, 5.30 min (>99%).
6-{5-[4-(4-Fluorobenzyl)-3-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one / F
O O F ~ ~ Bt O \ I O
~o~ of \
N NaH,~MF N HCI, E ~tOH N I
O F
/ I 83 \ I 84 \ I 85 OH
~.' \ HC02NHy, Pd(OH)z/C ~H
K-Selectride N~~, I / F MeOH, A
F
OH N-O
~ ~I ~
~ %Y \ " N
Pd(Phy)4. toluene N~'~'' I ~ NeHC03, EtOH, D O~N I // ~" OH
allyl acetate r F 70 H
/ 88 ~ ~ F
Step 1: To an ice-cold suspension of NaH (2.6 g, 110 mmol) in DMF (130 mL) was added 83 (15.0 g, 50 mmol) portionwise so that the internal reaction temperature was maintained between 5°C to 10°C. After stirring at ambient temperature for 1 hour, the reaction mixture was cooled in an ice/H20 bath and a solution of 4-fluorobenzyl bromide (9.4 g, 50 mmol) in DMF (26 mL) was added.
After stirnng at ambient temperature for 15 hours, the reaction mixture was cooled in an ice/H20 bath, and quenched by the addition of sat. NaHC03. The mixture was diluted with H20 (200 mL) and extracted with EtOAc (3 x 200 mL). The combined extracts were washed with H20 (100 mL) and sat. NaCI (100 mL), dried (MgS04), and concentrated under reduced pressure. Purification by flash chromatography (silica, 8:1 hexanes/EtOAc followed by 4:1 hexanes/EtOAc) gave 84 (9.0 g, 49%):
1H NMR (300 MHz, CDC13): 8 7.35-7.19 (m, 5H), 7.11 (dd, J 8, 3 Hz, 2H), 6.92 (dd, J 8, 8 Hz, 2H), 4.16-3.99 (m, 2H), 3.51 (q, J 13 Hz, 2H), 3.28-2.84 (m, 4H), 2.78-2.61 (m, 1H), 2.61-2.48 (m, 2H), 1.68-1.58 (m, 1H), 1.09 (t, J7 Hz, 3H).
Step 2: To a solution of 84 (8.9 g, 24 mmol) in EtOH (13 mL) was added conc.
HCl (30 mL), and the solution was heated to reflux. After 21 hours, the reaction mixture was cooled in an ice/H20 bath, brought to pH 8 with 1N NaOH and then extracted with EtOAc (3 x 200 mL). The combined extracts were washed with H20 (100 mL) and sat. NaCI (100 mL), dried (Na2S04), and concentrated under reduced pressure to give 85 (6.5 g, 89%), which was used without further purification:
1H NMR (500 MHz, CDC13) 8 7.34-7.23 (m, 5H), 7.11 (dd, J 8, 3 Hz, 2H), 6.95 (dd, J 8, 8 Hz, 2H), 3.57 (s, 2H), 3.26 (d, J 12 Hz, 2H), 2.94-2.79 (m, 2H), 2.47-2.34 (m, 3H), 1.93-1.87 (m, 1H), 1.71-1.52 (m, 1H).
Step 3: To a cold (-78°C dry ice/2-PrOH bath) solution of 85 (8.8 g, 29 mmol) in THF (200 mL) was added K-selectrideTM (44 mL of a 1 M solution in THF, 44 mmol) at a rate that maintained the internal reaction temperature below -65°C.
After the addition was complete, the reaction mixture was stirred for 1 hour (internal temperature -65°C) and then warmed to ambient temperature.
The reaction was quenched by the addition of sat. NaHC03 (100 mL) and then extracted with EtOAc (2 x 200 mL). The combined extracts were washed with H20 (100 mL) and sat. NaCI (100 mL), dried (Na2S04), and concentrated under reduced pressure. Purification by flash chromatography (silica, 2:1 hexanes/EtOAc followed by 1:2 hexaneslEtOAc) gave 86 (4.0 g, 46%):
1H NMR (300 MHz, CDC13): 8 7.33-7.25 (m, SH), 7.15 (dd, J6, 3 Hz, 2H), 6.95 (dd, J8, 8 Hz, 2H), 3.57-3.52 (m, 1H), 3.50 (s, 2H), 2.96-2.71 (m, 3H), 2.58-2.49 (m, 1H), 2.07 (d, J 12 Hz, 1H), 2.09-1.92 (m, 1H), 1.62-1.30 (m, 4H).
Step 4: A mixture of compound 86 (4.0 g, 13 mmol), ammonium formate (1.7, 27 mmol), and 20% Pd(OH)2/C (500 mg) in MeOH (50 mL) was heated at reflux for 1.5 hours. The reaction mixture was cooled to ambient temperature, filtered through Celite, and the filtrate was concentrated under reduced pressure to give amine 87 (2.8 g, 100%), which was used without further purification:
1 H NMR (300 MHz, CDC13): S 7.1 S (dd, J 6, 3 Hz, 2H), 6.96 (dd, J 8, 8 Hz, 2H), 3.55 (br. s, 1H), 3.48 (s, 2H), 3.03 (dd, J 12, 12 Hz, 2H), 2.75-2.48 (m, 4H), 1.68-1.31 (m, 3H).
Step 5: Treatment of amine 87 (1.4 g, 6.6 mmol) with allyl acetate (0.79 mL, 7.3 mmol), and Pd(Ph3)4 (380 mg, 0.30 mmol), following the procedure described in Example 20, Step l, gave 88 (1.1 g, 66%):
1H NMR (300 MHz, CDCI3): S 7.14 (dd, J 8, 3 Hz, 2H), 6.96 (dd, J 8, 8 Hz, 2H), 5.90-5.76 (m, 1H), 5.18-5.11 (m, 2H), 3.58-3.56 (m, 1H), 3.00-2.48 (m, 6H), 2.05 1.81 (m, 2H), 1.61-1.31 (m, 4H).
Step 6: Coupling of 70 (500 mg, 2.4 mmol) and alkene 88 (530 mg, 2.1 mmol) following the procedure described in Example 17, Step 5, followed by conversion to the HCl salt, gave 6-{S-[4-(4-fluorobenzyl)-3-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (288 mg, 29%), as a white solid:
mp 224-233°C
IR (KBr): 2957, 1771, 1509, 1453 cm-I
1H NMR (300 MHz, CD30D): 8 7.58-7.57 (m, 1H), 7.53-7.49 (m, 1H), 7.27-7.23 (m, 2H), 7.16-7.12 (m, I H), 7.05-6.99 (m, 2H), 5.28-5.07 (m, 1 H), 3.89 (br s, 1 H), 3.76-3.62 (m, 1H), 3.48-3.01 (m, 6H), 2.82-2.59 (m, 2H), 2.11-1.85 (m, 2H), 1.75-1.62 (m, 2H) APCI (m/z): 426 [M + H]+
HRMS-API (m/z): [M + H]+ Calcd for C23H24~304~ 426.1829; Found, 426.1834 HPLC: method A, 6.15 min (96.1 %); method B, 11.07 min (>99%); Anal. Calcd for C23H24~304'HC1~0.25H20: C, 59.23; H, 5.51; N, 9.01. Found: C, 59.16; H, 5.41; N, 8.87.
6-{ 5-[4-(4-Fluorophenoxy)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl }-3H
benzoxazol-2-one N~O I ~ EtOH, NaHC03, O
1~ ~IJ F 70 Step 1: A mixture of 4-(4-fluorophenoxy)piperidine hydrochloride (1.48 g, 6.40 mmol) and NaHC03 (1.34 g, 16.0 mmol) in DMF (30 mL) was heated to 50°C for 30 minutes. Allyl bromide (0.550 mL, 6.40 mmol) was added and the reaction mixture was stirred at 50°C for 2 hours. The reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (lx). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. Purification by flash chromatography (silica, 95:5 to 9:1 CH2Cl2/MeOH) gave 89 (621 mg, 41%) as an oil:
1H NMR (300 MHz, CDC13): 8 6.96 (dd, J9, 9 Hz, 2H), 6.88-6.83 (m, 2H), 5.95-5.82 (m, 1 H), 5.22-5.13 (m, 2H), 4.26-4.19 (m, 1 H), 3.03 (d, J 7 Hz, 2H), 2.74-2.72 (m, 2H), 2.32-2.25 (m, 2H), 2.02-1.95 (m, 2H), 1.86-1.75 (m, 2H).
Step 2: To a mixture of alkene 89 (620 mg, 2.63 mmol) and NaHC03 (400 mg, 4.76 mmol) in 2:1 DMF/H20 (3 mL) was added a solution of 70 (500 mg, 2.35 mmol) in DMF (2 mL). The mixture was heated to 50°C for 2 hours.
The reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by flash chromatography (silica, 89:10:1 CH2C12/MeOH/NH40H) and (silica, 1:1 hexanes/EtOAc to EtOAc to 89:10:1 CH2C12/MeOH/NH40H) followed by crystallization from MeOH gave 6-{5-[4-(4-fluorophenoxy)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (225 mg, 19%):
mp 192-194°C
IR (KBr): 2951, 1779 cm-1 1H NMR (500 MHz, DMSO-d6): 8 11.78 (s, 1H), 7.55 (d, J 1 Hz, 1H), 7,45 (dd, J 8, 1 Hz, 1 H), 7.13 (d, J 8 Hz, 1 H), 7.07 (dd, J 9, 9 Hz, 2H), 6.94 (dd, J
9, 4 Hz, 2H), 4.86-4.80 (m, 1 H), 4.31-4.26 (m, 1 H), 3.46 (dd, J 17, 11 Hz, 1 H), 3.16 (dd, J 17, 8 Hz, 1H), 2.81-2.75 (m, 2H), 2.60-2.51 (m, 2H), 2.38-2.30 (m, 2H), 1.91-1.88 (m, 2H), 1.63-1.56 (m, 2H) APCI-MS (m/z): 412 [M + H]+
HPLC: method A; 6.23 min (>99%) Anal. Calcd for C22H22~304~ C~ 64.22; H, 5.39; N, 10.21. Found: C, 64.00; H, 5.46; N, 10.08.
6-{5-[4-(4-Fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one N-O
S
~N~ I ~ EtOH, NaHC03, D O ,O / I N
/ F 70 ~(N
S ~ / F
Step 1: Coupling of 4-(4-fluorophenylsulfanyl)piperidine hydrochloride (647 mg, 2.61 mmol) with allyl bromide (250 ~,L, 2.87 mmol) following the procedure described in Example 16, Step 1, gave alkene 90 (271 mg, 40%):
1 H NMR (500 MHz, CD30D): S 7.46 (dd, J 9, 5 Hz, 2H), 7.05 (dd, J 9, 9 Hz, 2H), 5.89-5.80 (m, 1 H), 5.21-5.15 (m, 2H), 3.08-3.02 (m, 1 H), 3.00 (d, J 7 Hz, 2H), 2.90-2.87 (m, 2H), 2.13-2.08 (m, 2H), 1.95-1.91 (m, 2H), 1.63-1.56 (m, 2H).
Step 2: Coupling of 70 (252 mg, 1.18 mmol) and alkene 90 (271 mg, 1.08 mmol) following the procedure described in Example 17, Step 5, gave 6-{5-[4-(4-fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl }-3H
benzoxazol-2-one (370 mg, 80%):
mp 190-192°C
IR (KBr): 2945, 1774 cm-1 1 H NMR (500 MHz, DMSO-d6): S 11.80 (s, 1 H), 7.54 (d, J 1 Hz, 1 H), 7.47-7.43 (m, 3 H), 7.18 (dd, J 9, 9 Hz, 1 H), 7.13 (d, J 8 Hz, 1 H), 4.84-4.78 (m, 1 H), 3 .44 (dd, J 17, 11 Hz, 1H), 3.18-3.09 (m, 2H), 2.90-2.83 (m, 2H), 2.56-2.48 (m, 2H), 2.21-2.14 (m, 2H), 1.85-1.83 (m, 2H), 1.51-1.42 (m, 2H) ESI-MS (m/z): 428 [M + H]+
HPLC: method A, 6.40 min (98.9%); method B, 11.50 min (99.0%) Anal. Calcd for C22H22~3035~ C, 61.81; H, 5.19; N, 9.83. Found: C, 62.13; H, 5.05; N, 9.86.
6-{5-[4-(4-Fluorobenzenesulfinyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one O
NaI04 r S
/\~N
/ F MeOH, H20 /~N~~
/ F
EtOH, NaHC03, O
Step 1: To a solution of 90 (0.80 g, 3.18 mmol) in MeOH (10 mL) and H20 (1.5 mL) was added NaI04 (680 mg, 3.18 mmol) at ambient temperature. The reaction mixture was stirred for 12 hours, and then additional NaI04 (100 mg, 0.47 mmol) was added. After 12 hours, the reaction mixture was filtered through Celite and concentrated under reduced pressure. Purification by flash chromatography (silica, 9:1 to 8:2 CH2CI2/MeOH) gave 91 (240 mg, 28%) as a yellow wax:
1H NMR (300 MHz, CDCI3): 8 7.69-7.57 (m, 2H), 7.33-7.16 (m, 2H), 5.82 (dddd, J 17, 13, 10, 7 Hz, 1H), 5.22-5.12 (m, 2H), 3.10-2.93 (m, 4H), 2.65-2.52 (m, 1H), 2.03-1.88 (m, 2H), 1.81-1.52 (m, 4H).
Step 2: Coupling of 70 (209 mg, 0.98 mmol) and alkene 91 (230 mg, 0.86 mmol) following the procedure described in Example 17, Step 5, followed by conversion to the HCl salt, gave 6-{5-[4-(4-fluorobenzenesulfinyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (290 mg, 76%):
mp 170-178°C
IR (KBr): 2954, 1764 cm-1 1H NMR (500 MHz, DMSO-d6): 8 11.92 (s, 1H), 10.23 (br s, 1H), 7.73 (d, J 6 Hz, 1 H), 7.71 (d, J 5 Hz, 1 H), 7.56 (s, 1 H), 7.52-7.44 (m, 3H), 7.15 (d, J 8 Hz, 1H), 5.22 (br s, 1H), 3.72 (m, 3H), 3.40-3.25 (m, 3H), 3.12 (m, 3H), 2.12 (br s, 1H), 2.01-1.75 (m, 2H), 1.67 (br s, 1H); APCI-MS (m/z): 444 [M + H]+
HPLC: method A, 4.61 min (95.0%); method B, 8.76 min (93.8%) Anal. Calcd for C22H22~304S~HC1~O.SH20: C, 54.04; H, 4.95; N, 8.59. Found:
C, 54.06; H, 4.73; N, 8.38.
6-{5-(4-(4-Fluorobenzoyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one O N~O
I
\ EtOH, NaHC03, O O ,O / I N
~N / F 70 ~(N \
O ~ / F
Step 1: Coupling of (4-fluorophenyl)piperidin-4-yl-methanone (1.50 g, 6.62 mmol) with allyl bromide (630 ~L, 7.28 mmol) following the procedure described in Example 16, Step 1 gave alkene 92 (830 mg, 51%):
1H NMR (300 MHz, CDC13): 8 7.97 (dd, J 8, 6 Hz, 2H), 7.14 (dd, J 9, 8 Hz, 2H), 5.94-5.85 (m, 1 H), 5.23-5.14 (m, 2H), 3.22-3.17 (m, 1 H), 3.04-3.00 (m, 4H), 2.13-2.05 (m, 2H), 1.92-1.80 (m, 4H) Step 2: Coupling of 708 (787 mg, 3.70 mmol) and alkene 92 (830 mg, 3.36 mmol) following the procedure described in Example 17, Step 5 gave 6-{5-[4-(4-fluorobenzoyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (465 mg, 33%):
mp 188-190°C; IR (KBr): 2950, 1776 cm-1 1H NMR (500 MHz, DMSO-d6): S 11.76 (s, 1H), 8.05 (dd, J9, 5 Hz, 2H), 7.56 (s, 1 H), 7.47 (dd, J 9, 2 Hz, 1 H), 7.34 (t, J 9 Hz, 2H), 7.14 (d, J 9 Hz, 1 H), 4.92-4.80 (m, 1 H), 3 .48-3.09 (dd, J 17, 10 Hz, 1 H), 3.3 9 (m, 1 H), 3.18 (dd, J 17, 8 Hz, 1H), 2.99 (m, 2H), 2.70-2.50 (m, 2H), 2.37-2.18 (m, 2H), 1.80-1.70 (m, 2H), 1.65-1.54 (m, 2H) ESI-MS (m/z): 424 [M + HJ+
HPLC: method A, 5.81 min (95.1 %); method B, 10.92 min (97.1 %) Anal. Calcd for C23H22~304'0.25H20: C, 64.55; H, 5.30; N, 9.82. Found: C, 64.64; H, 5.04; N, 9.75.
6-(5-{4-[(4-Fluorophenyl)hydroxymethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one OH N-O
I
\ EtOH, NaHC03, D O
N
~N 93 ~ g 70 N \
H
HO
Step 1: To an ice-cold solution of alkene 92 (507 mg, 2.05 mmol) in 1:1 MeOH/CH2C12 (10 mL) was added NaBH4 (67.3 mg, 2.41 mmol) portionwise.
The reaction was quenched with sat. NH4C1 (1 mL) and the solvent was removed under reduced pressure. The residue was partitioned between EtOAc and water.
The organic layer was washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. Purification by flash chromatography (silica, 89:10:1 CH2C12/MeOH/NH40H) gave alkene 93 (252 mg, 49%) as an off white solid:
1H NMR (300 MHz, CDC13): 8 7.29-7.25 (m, 3H), 7.05-7.00 (m, 2H), 5.92-5.78 (m, 1H), 5.18-5.10 (m, 2H), 4.37 (d, J7 Hz, 1H), 3.01-2.85 (m, 4H), 2.00-1.21 (m, 7H).
Step 2: Coupling of 70 (738 mg, 3.48 mmol) and alkene 93 (722 mg, 2.90 mmol) following the procedure described in Example 17, Step S, followed by conversion to the HCl salt gave 6-(S- f 4-[(4-fluorophenyl)hydroxymethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one (951 mg, 81%):
mp 186-191°C
IR (KBr): 3393, 2958, 1771 cm-1 1H NMR (300 MHz, CD30D): 8 7.58 (s, 1H), 7.51 (d, J 8 Hz, 1H), 7.37 (dd, J 8, 5 Hz, 2H), 7.15-7.39 (m, 3H), 5.26-5.13 (m, 1 H), 4.46 (d, J 7 Hz, 1 H), 4.04-3.62 (m, 3H), 3.42-3.19 (m, 4H), 3.12-2.97 (m, 2H), 2.19-2.10 (m, 1H), 1.98-1.82 (m, 1H), 1.80-1.55 (m, 3H) APCI-MS (m/z): 426 [M + H]+
HPLC: method A, 5.51 min (>99%); method B, 10.40 min (97.9%) Anal. Calcd for C23H24~304'HC1~0.25H20: C, 59.23; H, 5.51; N, 9.01. Found:
C, 59.11; H, 5.29; N, 8.75.
6-(5- { 4-[ 1-(4-Fluorophenyl)-1-hydroxyethyl]piperidin-1-ylmethyl } -4, 5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one OH
\ EtOH, NaHC03, 0 ~N~~F 70 Step 1: To an ice-cold solution of MeMgBr ( 1.1 S mL of a 3.0 M solution in Et20, 3.46 mmol) was added dropwise a solution of ketone 92 (712 mg, 2.88 mmol) in dry Et20. After 1 hour, the reaction was quenched with MeOH (1 mL) and sat.
NH4C1 ( 1 mL). The mixture was partitioned between water and Et20. The aqueous layer was extracted with Et20. The combined organic layers were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure.
Purification by flash chromatography (silica, 90:10 CH2C12/MeOH) gave alkene 94 as a yellow oil (755 mg, 92%):
1H NMR (300 MHz, CDC13): ~ 7.39-7.34 (m, 2H), 7.03-6.97 (m, 2H), 5.93-5.79 (m, 1H), 5.18-5.12 (m, 2H), 2.96 (d, J6 Hz, 4H), 1.89-1.81 (m, 3H), 1.63-1.48 (m, SH), 1.44-1.26 (m, 3H).
Step 2: Coupling of 70 (755 mg, 3.56 mmol) and alkene 94 (693 mg, 3.23 mmol) following the procedure described in Example 17, Step S gave 6-(5-{4-(1-(4-fluorophenyl)-1-hydroxyethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-2-one (1.00 g, 64%):
mp 125-134°C
IR (KBr): 3427, 2944, 1774 cm-1 1H NMR (300 MHz, DMSO-d6): 8 11.79 (s, 1H), 7.55 (s, 1H), 7.46-7.38 (m, 3H), 7.14-7.07 (m, 3H), 4.85-4.79 (m, 2H), 3.48-3.38 (m, 1H), 3.14-3.06 (m, 1H), 2.99 2.89 (m, 2H), 2.51-2.46 (m, 2H), 2.00-1.80 (m, 2H), 1.65-1.51 (m, 1H), 1.50-1.45 (m, 4H), 1.35-1.10 (m, 3H) APCI-MS (m/z): 440 [M + H]+
HPLC: method A, 5.60 min (97.0%); method B, 10.70 min (98.2%) Anal. Calcd for C24H26~304'0.25H20: C, 64.93; H, 6.02; N, 9.46. Found: C, 64.65; H, 5.85; N, 9.26.
4-Chloro-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-5-methyl-3H benzoxazol-2-one HO, N
O / Br i. MeMgBr O~CHO NHZOH~HCI O
H
O \ I ii. t-BuLi O~ \ I 2-PrOH, NaHC03 O
H 95 iii. DMF H 96 H I 97 HO.N ~N \ F N~O
HC~ O~O ~ I CI I ~ O ~ I N
\ \
OXONE~ H 63 CI CI
EtOH, NaHC03, D ~ ~ F
Step 1: To a -78°C solution of bromide 95 (10.3 g, 45.2 mmol) in THF
(40 mL) was added MeMgBr (16.6 mL of a 3.0 M solution in diethyl ether, 49.7 mmol).
After 40 minutes, anhydrous THF (410 mL) was added at a rate that maintained the internal reaction temperature below a threshold of -50°C. After the solution returned to -78°C, tert-butyl lithium (85 mL of a 1.7 M solution in pentane, 144 mmol) was added via a dropping funnel. After 10 minutes, DMF (21.0 mL, 271 mmol) was added to the yellow mixture, and then the cold bath was removed.
After 2 hours, the reaction was quenched with water and the THF removed under reduced pressure. The residue was partitioned between EtOAc and 1N HCI. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. Purification by crystallization from hot EtOH gave aldehyde 96 (2.86 g, 35%):
1H NMR (300 MHz, CDC13): 8 11.60 (s, 1H), 10.23 (s, 1H), 7.58 (s, 1H), 6.91 (s, 1H), 2.68 (s, 3H).
Step 2: A mixture of aldehyde 96 (2.80 g, 15.8 mmol), hydroxylamine hydrochloride (1.21 g, 17.4 mmol), and sodium bicarbonate (1.99 g, 23.7 mmol) in 2-PrOH (80 mL) was heated to 50°C for 4 hours. The warm mixture was diluted with MeOH, and filtered. Concentration under reduced pressure gave oxime 97 (3.69 g, 100%):
1H NMR (300 MHz, DMSO-d6): 8 11.17 (s, 1H), 8.30 (s, 1H), 7.41 (s, 1H), 6.91 (s, 1H), 2.36 (s, 3H).
Step 3: A mixture of oxime 97 (3.69 g, 15.8 mmol) and OXONE~ (10.7 g, 17.4 mmol) was stirred in HCl (32.8 mL of a 0.53 M solution in DMF, 17.4 mmol) for 3 hours. The reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were washed with water, sat. NaCI, dried (Na2S04), and concentrated under reduced pressure. The yellow solid was dissolved in hot EtOAc. Addition of hexane to the solution gave 98 (3.04 g, 73%) as an off white solid:
1H NMR (300 MHz, DMSO-d6): 812.45 (s, 1H), 7.96 (s, 1H), 7.42 (s, 1H), 2.33 (s, 3H); ESI-MS (negative mode) (m/z): 224 [(M-H)-HCl]-.
Step 4: Coupling of 98 (1.82 g, 6.99 mmol) and alkene 63 (1.63 g, 6.99 mmol) following the procedure described in Example 11, Step 2, gave 4-chloro-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-5-methyl-3H
benzoxazol-2-one (1.0 g, 31%):
mp 131-132°C
IR (KBr): 2922, 1780 cm-1 1H NMR (500 MHz, DMSO-d6): S 12.20 (s, 1H), 7.35 (s, 1H), 7.17 (dd, J 8, 6 Hz, 2H), 7.07 (dd, J 9, 8 Hz, 2H), 4.82-4.76 (m, 1 H), 3.48 (dd, J 17, 11 Hz, 1H), 3.18 (dd, J 17, 8 Hz 1H), 2.91 (m, 2H), 2.58-2.46 (m, 4H), 2.45 (s, 3H), 2.08-1.99 (m, 2H), 1.52-1.42 (m, 3H), 1.22-1.13 (m, 2H) ESI-MS (mlz): 458 [M + H]+
HPLC: method A, 6.95 min (96.0%); method B, 12.21 min (95.9%) Anal. Calcd for C24H25C1~303 ~ C, 62.34; H, 5.56; N, 9.09. Found: C, 62.52;
H, 5.44; N, 8. 8 8.
-{S-[4-(4-Fluorophenyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H
benzoxazol-2-one Br HN ~ ~ F ~ ~N ~ ~ F
NaHC03 N-O
EtOH, NaHC03, D I
O~O / I N
HO,, N N
O ~ H
O~ \ I ~Cl H
Step 1: Alkene of formula 100 was prepared following the procedure described below for alkene of formula 63 in Example 16, Step 1, to give 1.34 g, (50%):
1 H NMR (300 MHz, CDC13): 0 7.20-7.15 (m, 2H), 7.00-6.94 (m, 2H), 5.98-5.85 (m, 1 H), 5.23 (d, J 16 Hz, 1 H), 5.14 (d, J 10, 1 H), 3.07-3.02 (m, 4H), 2.48 (dt, J
11, 5 Hz, 1H), 2.07-1.98 (m, 2H), 1.81-1.65 (m, 4H).
Step 2: Coupling of compound of formula 70 and alkene of formula 100 following the procedure described above in Example 17, Step 5, gave 6-{5-[4-(4-fluorophenyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H benzoxazol-2-one (719 mg, 70%):
mp 214-217°C
IR (KBr): 2926, 1774 cm-1 1H NMR (S00 MHz, DMSO-d6): 8 11.80 (s, 1H), 7.57 (d, J 1 Hz, 1H), 7.48 (dd, J 8, 1 Hz, 1 H), 7.27 (dd, J 8, 6 Hz, 2H), 7.15 (d, J 8 Hz, 1 H), 7.08 (dd, J
8, 6 Hz, 2H), 4.90-4.84 (m, 1 H), 3.49 (dd, J 17, 11 Hz, 1 H), 3.18 (dd, J 17, 8 Hz, 1 H), 3.05 (d, J 11 Hz, 1 H), 3.02 (d, J 11 Hz, 1 H), 2.63-2.52 (m, 2H), 2.51-2.47 (m, 1 H), 2.20-2.13 (m, 2H), 1.74-1.71 (m, 2H), 1.67-1.58 (m, 2H) ESI-MS (m/z): 396 [M + H]+
HPLC: method A, 4.83 minutes(98.3%); method B, 10.60 minutes(>99%) Anal. Calcd for C22H22~303'0.25H20: C, 66.07; H, 5.67; N, 10.51. Found: C, 66.13; H, 5.60; N, 10.52.
6-[5-(4-Phenyl-4-hydroxy)piperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H
benzoxazol-2-one OH - ~ Br OH -N
NaHC03 EtOH, NaHC03, O N'O
O~O / I N
HO,, N
N \
N \ 70 H
Step 1: Alkene of formula 102 was prepared following the procedure described below for alkene of formula 63 in Example 16, Step 1, to give 1.24 g, (50%):
1 H NMR (300 MHz, CDC13): 8 7.53 (d, J 7 Hz, 2H), 7.36 (dd, J 7, 7 Hz, 1 H), 7.28 (d, J7 Hz, 2H), 6.00-5.86 (m, 1H), 5.25 (d, J 17 Hz, 1H), 5.16 (d, J 10 Hz, 1 H), 3.10 (d, J 7 Hz, 2H), 2.86 (d, J 12 Hz, 2H), 2.45 (ddd, J 12, 12, 2 Hz, 2H), 1.31 (ddd, J 13, 13, 4 Hz, 2H), 1.79 (d, J 12 Hz, 2H), 1.63-1.55 (m, 1H).
Step 2: Coupling of compound of formula 70 and alkene of formula 102 following the procedure described'above in Example 17, Step 5, gave 6-[5-(4-phenyl-4-hydroxy)piperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H
benzoxazol-2-one (423 mg, 38%):
mp 115-118°C
IR (KBr): 2951, 1771 cm-1 1H NMR (500 MHz, DMSO-d6): 0 11.80 (s, 1H), 7.57 (s, 1H), 7.48-7.45 (m, 3H), 7.30 (dd, J 8, 8 Hz, 2H), 7.19 (dd, J 7, 6 Hz, 1 H), 7.14 (d, J 8 Hz, 1 H), 4.90-4.84 (m, 1 H), 4.74 (s, 1 H), 3.48 (dd, J 17, 11 Hz, 1 H), 3.19 (dd, J 17, 8 Hz, 1 H), 2.76-2.69 (m, 2H), 2.64-2.50 (m, 4H), 1.92 (dt, J 13, 4 Hz, 2H), 1.60-1.55 (m, 2H) ESI-MS (m/z): 394 [M + H]+
HPLC: method A, 5.48 min (>99%); method B, 9.63 min (>99%) Anal. Calcd for C22H23N304'0~75H20: C, 64.93; H, 6.07; N, 10.33. Found: C, 65.16; H, 6.03; N, 10.27.
6-(5- { 2-[4-(4-Fluorophenyl)piperidin-1-yl] ethyl } -4, 5-dihydroisoxazol-3-yl)-3H
benzoxazol-2-one HN~~ ~ F ~ N ~ ~ F
NaHC03 EtOH, NaHC03, 0 N-O
I
HO~ O ~
N F
N o~ \ I ~
O ~ Cl H
\ I 70 H
Step 1: Alkene of formula 103 was prepared following the procedure described below for alkene of formula 63 in Example 16, Step 1, to give 2.29 g, (85%):
1H NMR (300 MHz, CDC13): S 7.22 (dd, J9, 8 Hz, 2H), 6.99 (dd, J9, 8 Hz, 2H), 5.85-5.72 (m, 1 H), 5.14 (dd, J 18, 1 Hz, 1 H), 5.12 (d, J 10 Hz, 1 H), 3.48 (d, J 12 Hz, 2H), 2.88-2.83 (m, 2H), 2.71-2.59 (m, SH), 2.36-2.31 (m, 2H), 1.97 (d, J 13 Hz, 2H).
Step 2: Coupling of compound of formula 70 and alkene of formula 103 following the procedure described above in Example 17, Step S, gave 6-(S-{2-[4-(4-fluorophenyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H benzoxazol-one (759 mg, 71%):
mp 188-194°C
IR (KBr): 3448, 2934, 1773, 1654 cm-1 1H NMR (500 MHz, DMSO-d6): S 7.55 (d, J 1 Hz, 1H), 7.46 (dd, J8, 1 Hz, 1H), 7.23 (dd, J 9, 8 Hz, 2H), 7.14 (d, J 8 Hz, 1 H), 7.08 (dd, J 9, 8 Hz, 2H), 4.76-4.70 (m, 1 H), 3.45 (dd, J 17, 11 Hz, 1 H), 3.12 (dd, J 11, 8 Hz, 1 H), 3.00 (d, J
12 Hz, 1H), 2.95 (d, J 12 Hz, 1H), 2.49-2.36 (m, 4H), 2.04-1.98 (m, 2H), 1.86-1.48 (m, 6H) ESI-MS (m/z): 410 [M + H]+
HPLC: method A, 5.58 min (98.8%); method B, 10.45 min (>99%) Anal. Calcd for C23H24~303'0.25H20: C, 66.73; H, 5.97; N, 10.15. Found: C, 66.81; H, 5.99; N, 9.91.
As noted above, the invention compounds are subtype selective NMDA
receptor antagonists. The compounds have been evaluated in standard assays commonly used to measure activity. Typical assays were carried out as follows.
BIOLOGICAL METHODS
I. Electrophysiological assays at NMDA receptor subunits (in vitro):
a. The NR1A/NR2B assay:
(i) Preparation of subunit RNA's:
cDNA clones encoding the NR1A, NR2A, NR2B, and NR2C rat NMDA receptor subtypes were used. (See, Moriyoshi et al., Nature (Lond.), 1991;354:31-37; Kutsuwada et al., Nature (Loud.), 1992;358:36-41; Monyer et al., Science (Washington, D.C.) 1992;256:1217-1221; Ikeda et al., FEBSLett. 1992;313: 34-38; Ishii et al., J. Biol. Chem., 1993;268:2836-2843 for details of these clones or their mouse homologs). The clones were transformed into appropriate host bacteria and plasmid preparations were made with conventional DNA purification techniques. A sample of each clone was linearized by restriction enzyme digestion of cRNA was synthesized with T3 RNA polymerase. The cRNA was diluted to 400 ng/~1 and stored in 1 ~1 aliquots at -80°C until injection.
(ii) The Xenopus oocyte expression system:
Mature female Xenopus laevis were anaesthetized (20 to 40 minutes) using 0.15% 3-aminobenzoic acid ethyl ester (MS-222) and 2 to 4 ovarian lobes were surgically removed. Oocytes at developmental stages IV-VI (Dumont, J.N., J. Morphol., 1972;136:153-180) were dissected from the ovary still surrounded by enveloping ovarian tissues. Follicle-enclosed oocytes were micro-injected with 1:1 mixtures of NR1A:NR2A, 2B or 2C; injecting 1 to 10 ng of RNA
encoding each receptor subunit. NR1A encoding RNA was injected alone at ~20 ng. Oocytes were stored in Barth's medium containing (in mM) :NaCI, 88; KC1, 1; CaCl2, 0.41; Ca (N03)2, 0.33; MgS04, 0.82 NaHC03, 2.4; HEPES 5, pH 7.4, with 0.11 mg/mL gentamicin sulphate. While oocytes were still surrounded by enveloping ovarian tissues the Barth's medium was supplemented with 0.1 % bovine serum. Oocytes were defolliculated 1 to 2 days following injections by treatment with collagenase (0.5 mg/mL Sigma Type I for 0.5 to 1 hour) (Miledi and Woodward, J. Phsyiol. (Loud.), 1989;416:601-621) and subsequently stored in serum-free medium.
(iii) Electrical recordings:
Electrical recordings were made using a conventional two-electrode voltage clamp (Dagan TEV-200) over periods ranging between 3 to 21 days following injection. (Woodward et al., Mol. Pharmacol., 1992;41:89-103). Oocytes were placed in a 0.1 mL recording chamber continuously perfused (5-15 mL min-1) with frog Ringer's solution containing (in mM) :NaCI, 115; KCL, 2; BaCl2, 1.8; HEPES, S; pH
7.4. Drugs were applied by bath perfusion. Using oocytes expressing different subunit combinations of NMDA receptor, NMDA currents were activated by co-application of glutamate (100 ~,M) and glycine (1-100 ~,M) as agonists. Inhibitory potency of the novel antagonists of this invention was assessed on responses elicited by fixed concentrations of glutamate and glycine agonists, by measuring reductions in current induced by progressively increasing concentrations of invention compounds.
(iv) Concentration-inhibition curves:
Concentration-inhibition curves were fitted with equation 1 control - 1/(1 + ((antagonist]/10-pIC50)n) Eq. 1 in which Icontrol is the current evoked by the agonists alone, pIC50 = -log ICSp, IC50 is the concentration of invention compound that produced half maximal inhibition of the electrical current, and n is the slope factor (see De Lean et al., Am. J. Physiol., 1978;235:
E97-102). For incomplete curves, analysis by fitting was unreliable, and IC50 values were calculated by simple regression over linear portions of the curves using an ORIGIN software (Microcal Software, Boston, MA), a computer program for collection, analysis, and presentation of scientific data. The results of this assay for representative invention compounds is given in Table 1, in the column labeled "NR1A/NR2B", and the activity is reported as the IC50 in micromolar (pM) concentration.
b. [3H]Ifenprodil Binding Assay (IFPNR) Protocol:
(i) Materials:
Ifenprodil, [phenyl-3H]- (specific activity, 66.2 Ci/mmol) was purchased from Dupont NEN Research Products (Boston, MA).
Ifenprodil tartrate was purchased from Research Biochemicals International (Natick, MA). HEPES, glutamate and glycine were purchased from Sigma Chemical Co. (St. Louis, MO).
(ii) Preparations:
All buffers and reagents used in assay incubations or to dissolve drugs were prepared using water purified through a Milli-Q reverse osmosis system (Millipore Corp., Bedford, MA) and treated with UV
emissions. Prior to use in the assays buffers were further filtered through a sterile Corning filtration unit (Corning Glass Works, Corning, N~ containing a 0.2 micron filter. Buffer used to rinse the membranes on the assay filters was prepared with purified water, but was not refiltered and was stored no longer than 5 days. Stock solutions of the drugs (usually 10 mM) were dissolved in 20 mM
HEPES-KOH buffer pH 7.4 (assay buffer) with the addition of 1 to 5 pL of glacial AcOH, if needed to keep them in solution. Eliprodil was used as the reference NMDA antagonist. A stock solution of eliprodil was prepared, and was buffered with the addition of 10%
DMSO. All subsequent dilutions from the stock solution were made in buffer.
An extensively washed huffy coat membrane fraction was prepared from frozen adult rat forebrains (Zivic-Miller Laboratories, Inc., Zelienople, PA) as described by Coughenour L.L.; Cordon, J.J., J. Pharmacol. Exp. Ther., 1997;280:584-592, and stored at -80°C.
On the day of the assay, pellets of the frozen membrane fractions were resuspended in 35 mL of assay buffer at pH 7.4 using a POLYTRON (Kinematica A.G. Company, Littau, Switzerland) mixer at setting 6. After incubation at 37°C for 30 minutes in a shaking water bath, the homogenate was centrifuged 40,000 x g for 10 minutes at 4°C. The pellets were resuspended in fresh buffer and 1 S centrifuged 3 more times before final suspension for use in the assay.
(iii) [3H]Ifenprodil Binding protocol:
Triplicate incubations were carried out in a volume of 0.5 mL in 1.3 mL polypropylene tubes (Marsh Biomedical Products Inc, Rochester, NY) for 2 hours at room temperature. Incubations contained invention compounds, membranes (100-200 pg protein) and 4 nM [3H]-ifenprodil in 20 mM HEPES-KOH buffer, pH 7.4 (assay buffer). Assays were started by addition of the membranes.
Bound radioligand was separated by filtration under reduced pressure using a TOMTEC Mach II, 96-well cell harvester (Tomtec Inc, Orange, Connecticut). Filtration was through Whatman GF/B glass fiber filters (Whatman Ltd., Maidstone, England), which had been soaked for at least 15 minutes in 0.3% polyethylenimine and allowed to air dry. The filters were rinsed with 3 mL of ice cold assay buffer within 6 seconds. Air was allowed to pass through the filters for an additional 10 seconds to remove residual moisture. The filter mat was supported on a cold (-20°C) TEFLON (E. I. Du Pont de Nemours and Company, Wilmington, Delaware) coated support, and filters from individual wells were separated and placed in Mini Poly-Q vials (Beckman Instruments Inc, Fullerton, CA) and filled with 4 mL of scintillation cocktail (Beckman Ready Protein+).
Radioactivity retained on the filter was determined by liquid scintillation spectrophotometry. Nonspecific binding was defined as the binding in the presence of 1 mM ifenprodil. Ninety percent of the total binding of ifenprodil was specific binding at the NR1A/NR2B
NMDA receptor subtype active site (as opposed to binding at a remote site).
(iv) Data analysis:
Binding curves were statistically analyzed for a best 1- or 2-site competition fit using GRAPHPAD PRISM software (GraphPad Software Inc, San Diego, CA), a computer program used to analyze and graph scientific data. The normalized data was fitted by nonweighted nonlinear regression to either y = Bottom + (Top - Bottom) or 1 + 10 x - Log EC50 Fraction-1 1- Fraction-1 y = Bottom + (Top - Bottom) 1 + 10 x - Lo ECso-1 + x - Lo ECSO-2 g 1+10 g Control data was entered as 100%, and no parameters were constrained. Inhibition curves were compared by Anova with post-test comparisons of the log ICSp with Dunnett's multiple comparisons post-test or Student's nonpaired, 2-tailed t-test using GraphPad INSTAT (Harvey Motulsky, San Diego, CA) software.
The results of the IFPNR binding assay are reported as ICSOs in micromolar (pM) concentrations in Table 1 to Table 5 in the columns labeled "IFPNR".
II. Animal Models:
a. The Formalin Footpad Test (FT):
The FT model was used to test invention compounds for pain alleviating properties. The model produces a biphasic response in a test animal that results from a change in pain intensity over time. The FT model utilizes an injection of dilute formalin into the hindpaw of a rodent, which produces high intensity acute pain behaviors which are measured for the first minutes post formalin injection (early phase responding). High intensity acute pain behaviors include rapid licking or biting of the injected 10 hindpaw. The second phase is a prolonged period of lower intensity pain behaviors (late phase responding) which are measured from 11 to 45 minutes post-formalin injection.
(i) Test animals:
Male Wistar albino rats (Harlan Sprague-Dawley Labs), weighing approximately 100 g at the time of testing, were used. Animals were group-housed and acclimated to the housing facility for 1 week prior to testing. Animals were maintained on a 12-hour/12-hour light/dark cycle and fed block rodent chow. From 4 to 8 animals were randomly assigned to either a vehicle-only dose group or a vehicle-plus invention compound treatment group on the day of testing.
(ii) Test apparatus:
The testing apparatus was a 16" x 8" box divided into two 8" x 8"
testing chambers. Each testing chamber comprised a floor and 3 walls made of clear plastic mirrors, and a fourth wall which was clear plastic that allowed observation of animal behavior. The top of each chamber was covered with a metal screen during testing to prevent animals from climbing out of the chamber. Two animals were tested simultaneously in the adjoining boxes, but animals were unable to observe one another.
(iii) Procedure:
Animals were weighed and placed into holding cages (2 animals per cage) in the testing room prior to dosing. Following approximately 30 minutes of acclimation to the testing room, each pair of animals was administered orally (PO) by gavage a mixture of invention compound plus vehicle or vehicle alone. The treated animals were then placed in individual test chambers and allowed to acclimate to the chambers for at least 20 minutes. Then 50 ~.L of a 2.5% solution of formalin in vehicle was injected subcutaneously (SC) in the plantar surface of the left hindpaw from 30 to 120 minutes after administration of the invention compound. A session timer was started following the formalin injection, and the amount of time the animal spent licking or biting the injected paw was clocked with a hand-held stopwatch. The cumulative time spent engaging in a pain response was manually recorded at 5-minute intervals for 45 minutes post formalin injection. Early phase responding included Minutes 0 to 10, and late phase responding included Minutes 11 to 45. At the end of the testing period, animals were sacrificed using carbon dioxide.
(iv) Data Analysis:
As recited above, responding was divided into early phase (total time spent licking during Minutes 0 to 10 following the formalin injection) behaviors and late-phase (total time spent licking during Minutes 11 to 45 post formalin injection) behaviors. Time values were obtained for the vehicle only dose group (the control group) and each treatment group. For the purpose of measuring the activity of the invention compounds, the late-phase time values of a given treatment group were compared statistically to the late-phase time values obtained for the control group using either Student's t-test or One-way Analysis of Variants (ANOVA).
The results are reported in Table 1 and Table 2 under the heading "FT" as the dose tested in milligrams f invention compound per kilogram of test animal (mg/kg). A compound was characterized as active if it produced a statistically-significant decrease in the time animals administered invention compound plus vehicle spent engaging in pain-related behaviors compared to the time spent by animals receiving vehicle alone. Invention compounds were typically administered at 10 and/or 30 mg/kg, and the activities are reported in the tables as either being greater than (>) or less than (<) these doses.
b. The 6-OHDA Lesioned Rat Assay (6-OHDA):
The 6-OHDA model is used to test compounds of the invention for anti-Parkinsonism activity.
(i) 6-OHDA lesioned rat assay protocol:
6-Hydroxydopamine-lesioned rats were used (see Ungerstedt U, Arbuthnott GW: "Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostraiatal dopamine system", Brain Res., 1971;24(3):485-493). Adult male Sprague-Dawley rats were anesthetized with chloral hydrate, and unilateral lesions of the nigrostriatal dopamine system were accomplished by infusion of 8 ~,g of 6-hydroxydopamine HBr (6-OHDA) into the right medial forebrain bundle. Rats were pretreated 30 minutes before surgery with desipramine HC 1 25 mg/kg intraperitoneally (IP) to protect noradrenergic neurons, and pargyline 25 mg/kg IP to potentiate the effects of 6-OHDA. A minimum of 3 weeks after surgery, the rotational behavior induced by apomorphine HCL
50 ~g/kg administered subcutaneously (SC) was assessed. Only rats demonstrating more than 100 contraversive turns/hour to apomorphine were used for the present experiments.
(ii) Measurement of animal behavior:
Rotational behavior was measured using an automatic rotometer system (Rotorat Rotational Activity System, MED Associates, Georgia, VT). Antiparkinsonian activity was assessed as the ability of the invention compounds to potentiate the contraversive rotation induced by L-DOPA methyl ester, dosed at 10 mg/kg SC, over a 6-hour period. Experiments were conducted using a crossover paradigm where each rat received either vehicle plus L-DOPA, or an invention compound plus L-DOPA, in randomized order. Rats were tested at 7-day intervals. In experiments in which the invention compounds were tested orally (PO), rats were food deprived for 16 hours.
(iii) Data analysis:
Statistical analysis between treatment groups was performed using a paired t-test. The results are reported in Table 1 and Table 2 under the heading "6-OHDA" as the minimum effective dose (MED) in milligrams of invention compound per kilogram of test animal (mg/kg) required to produce a statistically-significant increase in total contraversive rotations in rats administered invention compound compared to rats receiving L-DOPA alone. Invention compounds were typically administered atl0 mg/kg and/or 30 mg/kg, and the MED's are reported in the tables as either being greater than (>) or less than (<) these doses.
o-N
Q ~ N ~ I ~
N
H
ExampleQ * IFPNR NR1A/ 6-OHDA FT
No. (IC50 NR2B (mg/kg) (mg/kg) ~,M) (IC50 wM) 1 H R,S 0.033 0.080 >10 (po) >10 3 F R, 0.030 NTa > 10 (po);> 10;
S
<30 (po) <30 4a F (+) 0.016 NT >10 (po);<10 <30 (po) 4b F (-) 0.280 NT >30 (po) >30 a NT means not tested.
I~
NAB
Q ~ X
~Y(O,S) N
H
ExampleB Q X1 * IFPNR FT Y
No. IC50 (mg/kg) ~m S ~ F O R,S 0.047 >30 O
6 ~~ F O NC 0.54 NT O
s 7 ~~ F S NC 0.45 NT S
s 8 ~~ H NH NC 0.066 NT O
s 9 ~~ F S NC >1 NT O
~~ H O NC >1 NT O
11 ~~ H CH2 NC >1 NT O
12 ~~ F O R,S 0.394 NT O
s 13 ~~ H O R, 0.1 O NT O
s S l ~ F O NC 0.499 NT O
21 H3c~ F O R,S 0.011 NT O
22 Ho2c~ F O R,S 0.788 NT O
23 Me02C' o-N F O R,S -- NT J
a NC means no chiral center;
b NT means not tested.
R
(CH2)h~ _ I ~ N.~ B
Q I ~ oho N
H
Example V B h Q R2 * IFPNR
No. IC50 (~,M) 2 CH2 o-N 1 H H NCa >1 \ \ CH3 14 CH2 s~ 1 H H R,S 0.688 N
17 CH2 ~ 1 H OH R,S 0.006 18 C=O ~ 1 F H R, S > 1 19 CH2CH2 ~ 1 F H R, S 0.400 20 CH2 ~ 1 F OH R,S 0.008 24 CH2 ~ 1 F C02Et R,S --25 CH2 ~ 1 F C02H R,S --34 CH2 ~ 0 F H R,S 0.280 35 CH2 ~ 0 H OH R,S >1 36 CH2CH2 ~ 0 F H R,S >1 a NC means no chiral center Z
~N~
Q B
~O
N
H
ExampleB Z Q * IFPNR
No. IC50 (~,M) 27 ~ O F R,S 0.059 28 ~ S F R,S 0.018 29 ~ S=O F R, 0.600 S
30 ~ C=O F R,S 0.759 31 ~ CH(OH) F R, > 1 S
32 ~ CMe(OH) F R,S >1 .,,.
.,,..~N. _ F v R3 V B I ~ X~O
X ~ N
Example V B R3 X 1 X2 X3 * IFPNR
No. ICSO
(~M) 16 CH2 ~ H S H H R,S 0.002 26 CH2 ~ OH O H H R, 0.023 S
33 CH2 ~ H O Me Cl R,S 0.014 As shown in the above tables, compounds of the invention are potent antagonists at the NMDA receptor and orally active in vivo in models of Parkinson's disease and pain.
In addition to the oral dosing forms described above, the compounds of the invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. The following dosage forms may comprise as the active component a compound of Formula I or a pharmaceutically acceptable salt thereof.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other Garners, is surrounded by a Garner, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or, synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 to 100 mg preferably 0.5 to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.
In therapeutic use as antagonists or as agents for the treatment of diseases, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily.
A
daily dose range of about 0.01-mg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, the compound being employed.
Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
Examples of pharmaceutical preparations of the compounds of the invention is described below. Such preparations can be administered to a human from one to six times a day for treatment of disease caused by over excitation of NMDA receptor channel complexes.
Tablet Formulation:
Ingredient Amount (mg) Compound of Example 25 Lactose 50 Cornstarch (for mix) 10 Cornstarch (paste) 10 Magnesium stearate 5 ( 1 %) Total 100 The compound of Example 1, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirnng to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1 % magnesium stearate and pressed into a tablet.
' EXAMPLE 3 8 Coated Tablets:
The tablets of Example 17 are coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth, and colorant.
Infection vials:
The pH of a solution of 500 g of the compound of Example l and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 L of double-distilled water using 2 M hydrochloric acid. The solution is sterile filtered, and the filtrate is filled into injection vials, lyophilized under sterile conditions, and aseptically sealed. Each injection vial contains 25 mg of the compound of Example 1.
Suppositories:
A mixture of 25 g of the compound of Example 1, 100 g of Soya lecithin, and 1400 g of cocoa butter is fused, poured into molds, and allowed to cool.
Each suppository contains 25 mg of the compound of Example 1.
Solution:
A solution is prepared from 1 g of the compound of Example 1, 9.38 g of NaH2P04~2H20, 28.48 g ofNa2HP04~12H20, and 0.1 g benzalkonium chloride in 940 mL of double-distilled water. The pH of the solution is adjusted to pH
6.8 using 2 M hydrochloric acid. The solution is diluted to 1.0 L with double-distilled water, and sterilized by irradiation. A 25 mL volume of the solution contains mg of the compound of Example 1.
Ointment:
500 mg of the compound of Example 1 is mixed with 99.5 g of petroleum jelly under aseptic conditions. A 5 g portion of the ointment contains 25 mg of the compound of Example 1.
Capsules:
2 kg of the compound of Example 1 are filled into hard gelatin capsules in a customary manner such that each capsule contains 25 mg of the invention compound.
Ampoules:
A solution of 2.5 kg of the compound of Example 1 is dissolved in 60 L of double-distilled water. The solution is sterile filtered, and the filtrate is filled into ampoules. The ampoules are lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 25 mg of the compound of Example 1.
While the forms of the invention exemplified herein such as, for example, the named species of Formula IV or the recitation of treatment of pain or Parkinson's disease constitute preferred embodiments of the invention, many other preferred embodiments are possible. It is not intended that the preferred embodiments of compounds of Formula IV, or preferred methods of use of said compounds, recited above should, in any manner, limit or restrict the invention from the full scope claimed herein.
Claims (15)
1. A compound of Formula I
and pharmaceutically acceptable salts thereof wherein:
R1 is independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, alkylaminoalkyl, hydroxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, carboxyalkyl, haloalkyl, and halogen;
g is an integer of from 0 to 3;
h is an integer of from 0 or 1;
R2 is hydrogen, OH, alkoxy, or substituted alkoxy;
R3 is hydrogen, OH, alkoxy, or substituted alkoxy;
V is (CH2)n or (CH2)m-C=O, wherein n is an integer of from 1 to 4, and m is an integer of from 0 to 4;
B is a 4-, 5-, or 6-membered, carbon-linked, substituted or unsubstituted, heterocyclene, containing from 1 to 3 heteroatoms, which are N, O, or S, selected from the group consisting of:
(i) 1-aza-2-cyclobutanon-3,4-diyl of formula (ii) a 5-membered aromatic, nonaromatic dihydro, or nonaromatic tetrahydro diradical heterocyclic ring having carbon atoms and from 1 to 3 heteroatoms selected from N, O, and S;
(iii) a 5-membered oxo-substituted, nonaromatic tetrahydro, diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S;
(iv) a 6-membered aromatic, nonaromatic tetrahydro, or nonaromatic hexahydro diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms, which heteroatoms are nitrogen, and (v) a 6-membered nonaromatic oxo-substituted hexahydro diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms which are nitrogen and 0 or 1 heteroatom which is oxygen wherein the atoms of the heterocyclene ring that are bonded to the group V
and the phenyl bearing the group (X1)d are carbon atoms, and further wherein when B is a nonaromatic heterocycle containing sulfur, said sulfur may further comprise X1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, aralkyl, substituted aralkyl, halogen, haloalkyl, cyano, nitro, amino, aminoalkyl, alkylaminoalkyl, hydroxyalkyl, carboxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, or C(O)-alkyl;
d is an integer of from 0 to 2;
E is hydrogen; and Y is OH; or E and Y may be taken together with the phenylene to which they are attached to form a fused 9- or 10-membered bicyclic ring, containing from 0 to 3 heteroatoms in E-Y selected from N, O, and S, wherein E is a linker group containing 2 or 3 atoms of the bicyclic ring, and Y is a hydrogen bond donor group containing 1 atom of the bicyclic ring.
and pharmaceutically acceptable salts thereof wherein:
R1 is independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, alkylaminoalkyl, hydroxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, carboxyalkyl, haloalkyl, and halogen;
g is an integer of from 0 to 3;
h is an integer of from 0 or 1;
R2 is hydrogen, OH, alkoxy, or substituted alkoxy;
R3 is hydrogen, OH, alkoxy, or substituted alkoxy;
V is (CH2)n or (CH2)m-C=O, wherein n is an integer of from 1 to 4, and m is an integer of from 0 to 4;
B is a 4-, 5-, or 6-membered, carbon-linked, substituted or unsubstituted, heterocyclene, containing from 1 to 3 heteroatoms, which are N, O, or S, selected from the group consisting of:
(i) 1-aza-2-cyclobutanon-3,4-diyl of formula (ii) a 5-membered aromatic, nonaromatic dihydro, or nonaromatic tetrahydro diradical heterocyclic ring having carbon atoms and from 1 to 3 heteroatoms selected from N, O, and S;
(iii) a 5-membered oxo-substituted, nonaromatic tetrahydro, diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S;
(iv) a 6-membered aromatic, nonaromatic tetrahydro, or nonaromatic hexahydro diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms, which heteroatoms are nitrogen, and (v) a 6-membered nonaromatic oxo-substituted hexahydro diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms which are nitrogen and 0 or 1 heteroatom which is oxygen wherein the atoms of the heterocyclene ring that are bonded to the group V
and the phenyl bearing the group (X1)d are carbon atoms, and further wherein when B is a nonaromatic heterocycle containing sulfur, said sulfur may further comprise X1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, aralkyl, substituted aralkyl, halogen, haloalkyl, cyano, nitro, amino, aminoalkyl, alkylaminoalkyl, hydroxyalkyl, carboxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, or C(O)-alkyl;
d is an integer of from 0 to 2;
E is hydrogen; and Y is OH; or E and Y may be taken together with the phenylene to which they are attached to form a fused 9- or 10-membered bicyclic ring, containing from 0 to 3 heteroatoms in E-Y selected from N, O, and S, wherein E is a linker group containing 2 or 3 atoms of the bicyclic ring, and Y is a hydrogen bond donor group containing 1 atom of the bicyclic ring.
2. A compound according to Claim 1 wherein:
B is a heterocyclene selected from the group consisting of:
wherein X is selected from O, S, and N-R, wherein R is hydrogen or alkyl;
X1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, aralkyl, halogen, haloalkyl, cyano, nitro, amino, aminoalkyl, alkylaminoalkyl, hydroxyalkyl, carboxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, or C(O)CH3, and one X1 is ortho to V and para to E; and R2 is hydrogen or OH;
V is CH2 or C=O; and h is 1.
B is a heterocyclene selected from the group consisting of:
wherein X is selected from O, S, and N-R, wherein R is hydrogen or alkyl;
X1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, aralkyl, halogen, haloalkyl, cyano, nitro, amino, aminoalkyl, alkylaminoalkyl, hydroxyalkyl, carboxyalkyl, (aminocarbonyl)-alkyl, (alkylthio)-alkyl, or C(O)CH3, and one X1 is ortho to V and para to E; and R2 is hydrogen or OH;
V is CH2 or C=O; and h is 1.
3. A compound according to Claim 1 of Formula II
and pharmaceutically acceptable salts thereof wherein when B is a 5-membered oxo-substituted, nonaromatic tetrahydro, diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S which is an oxazolidinone, the oxazolidinone is selected from
and pharmaceutically acceptable salts thereof wherein when B is a 5-membered oxo-substituted, nonaromatic tetrahydro, diradical heterocyclic ring having carbon atoms and 1 or 2 heteroatoms selected from N, O, and S which is an oxazolidinone, the oxazolidinone is selected from
4. A compound according to Claim 1 of Formula III
and pharmaceutically acceptable salts thereof wherein E and Y together with the phenylene to which they are attached form a 9- or 10-membered bicyclic ring, containing from 0 to 3 heteroatoms selected from N, O, and S wherein E is a linker group containing 2 or 3 atoms of the bicyclic ring; and Y is a hydrogen bond donor group containing 1 atom of the bicyclic ring.
and pharmaceutically acceptable salts thereof wherein E and Y together with the phenylene to which they are attached form a 9- or 10-membered bicyclic ring, containing from 0 to 3 heteroatoms selected from N, O, and S wherein E is a linker group containing 2 or 3 atoms of the bicyclic ring; and Y is a hydrogen bond donor group containing 1 atom of the bicyclic ring.
5. A compound according to Claim 4 wherein:
Y is selected from -N(H)-, -CH(OH)-, and -N(OH)-, and E is selected from -CH=CH-, -CH2-CH2-, -CH=N-, -C(O)-CH2-, -CH2-C(O)-, -CH2-S(O)-, -CH2-S(O)2-, -N=C(H)-, -N(H)-C(O)-, -O-C(O)-, -S-C(O)-, -N=N-, -CH=CH-C(H)-, -CH2-CH2-CH2-, -CH2-CH2-C(O)-, -CH2-CH2-S(O)-, -CH2-CH2-S(O)2-, -CH=CH-C(O)-, -N=CH-C(O)-, -O-CH2-C(O)-, -S-CH2-C(O)-, and -N(H)-C(O)-C(O)-; or Y is selected from =C(OH)-; and E is selected from -CH=CH-C(H)=, -C(O)-C(H)=, -C(O)-N=, -O-N=, -S-N=, -C(O)-N(H)-N=, -CH=N-N=, -CH=N(O)-N=, and -N(H)-C(O)-N=.
Y is selected from -N(H)-, -CH(OH)-, and -N(OH)-, and E is selected from -CH=CH-, -CH2-CH2-, -CH=N-, -C(O)-CH2-, -CH2-C(O)-, -CH2-S(O)-, -CH2-S(O)2-, -N=C(H)-, -N(H)-C(O)-, -O-C(O)-, -S-C(O)-, -N=N-, -CH=CH-C(H)-, -CH2-CH2-CH2-, -CH2-CH2-C(O)-, -CH2-CH2-S(O)-, -CH2-CH2-S(O)2-, -CH=CH-C(O)-, -N=CH-C(O)-, -O-CH2-C(O)-, -S-CH2-C(O)-, and -N(H)-C(O)-C(O)-; or Y is selected from =C(OH)-; and E is selected from -CH=CH-C(H)=, -C(O)-C(H)=, -C(O)-N=, -O-N=, -S-N=, -C(O)-N(H)-N=, -CH=N-N=, -CH=N(O)-N=, and -N(H)-C(O)-N=.
6. A compound according to Claim 5 wherein:
-E-Y- is selected from the group consisting of -CH=CH-N(H)-, -(CH2)2-N(H)-, -CH=N-N(H)-, C(O)-CH2-N(H)-, -CH2-C(O)-N(H)-, -CH2-S(O)-N(H)-, -CH2-S(O)2-N(H)-, -CH=CH-CH(OH)-, -(CH2)2-CH(OH)-, -C(O)-C(H)=C(OH)-, -C(O)-N=C(OH)-, -N=CH-N(H)-, -N(H)-C(O)-N(H)-, -O-C(O)-NH-, -S-C(O)-NH-, -O-N=CH(OH)-, -S-N=CH(OH)-, -N=N-N(H)-, -N=N-N(OH)-, -CH=CH-CH=C(OH)-, -(CH2)3-CH(OH)-, -(CH2)2-C(O)-N(H)-, -(CH2)2-S(O)-N)H)-, -(CH2)2-S(O)2-N(H)-, -CH=CH-C(O)-N(H)-, -C(O)-NH-N=C(OH)-, -CH=N-N=C(OH)-, -CH=N(O)-N=C(OH)-, -N(H)-C(O)-N=C(OH)-, -N=CH-C(O)-NH-, -O-CH2-C(O)-NH-, -S-CH2-C(O)-NH-, and -N(H)-C(O)-C(O)-N(H)-.
-E-Y- is selected from the group consisting of -CH=CH-N(H)-, -(CH2)2-N(H)-, -CH=N-N(H)-, C(O)-CH2-N(H)-, -CH2-C(O)-N(H)-, -CH2-S(O)-N(H)-, -CH2-S(O)2-N(H)-, -CH=CH-CH(OH)-, -(CH2)2-CH(OH)-, -C(O)-C(H)=C(OH)-, -C(O)-N=C(OH)-, -N=CH-N(H)-, -N(H)-C(O)-N(H)-, -O-C(O)-NH-, -S-C(O)-NH-, -O-N=CH(OH)-, -S-N=CH(OH)-, -N=N-N(H)-, -N=N-N(OH)-, -CH=CH-CH=C(OH)-, -(CH2)3-CH(OH)-, -(CH2)2-C(O)-N(H)-, -(CH2)2-S(O)-N)H)-, -(CH2)2-S(O)2-N(H)-, -CH=CH-C(O)-N(H)-, -C(O)-NH-N=C(OH)-, -CH=N-N=C(OH)-, -CH=N(O)-N=C(OH)-, -N(H)-C(O)-N=C(OH)-, -N=CH-C(O)-NH-, -O-CH2-C(O)-NH-, -S-CH2-C(O)-NH-, and -N(H)-C(O)-C(O)-N(H)-.
7. A compound according to Claim 6 of Formula IV
and pharmaceutically acceptable salts thereof wherein X2 is selected from O, S, NH, and CH2; and B is selected from the group consisting of:
wherein X is selected from O, S, and N-R, wherein R is hydrogen or alkyl, and wherein Z is from O or S.
and pharmaceutically acceptable salts thereof wherein X2 is selected from O, S, NH, and CH2; and B is selected from the group consisting of:
wherein X is selected from O, S, and N-R, wherein R is hydrogen or alkyl, and wherein Z is from O or S.
8. A compound according to Claim 4 selected from the group consisting of 6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H-benzoxazol-2-one;
6-[5-(4-Benzylpiperidin-1-ylmethyl)-3-methylisoxazol-4-yl]-3H-benzoxazol-2-one;
6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one hydrochloride;
(+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
(-)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{3-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-5-yl}-3H-benzoxazol-2-one;
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H-benzoxazol-2-one;
6-{2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H-benzothiazol-2-one;
5-[2-(4-Benzylpiperidin-1-ylmethyl)thiazol-5-yl]-1,3-dihydrobenzimidazole-2-thione;
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]oxazol-5-yl}-3H-benzothiazol-2-one;
6-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-3H-benzoxazol-2-one;
5-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-1,3-dihydroindol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydrothiazol-2-yl}-3H-benzoxazol-2-one;
6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-2-yl]-3H-benzoxazol-2-one;
6-[2-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-5-yl]-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]isoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-yl]methyl}-4,5-dihydroisoxazol-3-yl}-3H-benzothiazol-2-one;
6-[5-(4-Benzyl-4-hydroxypiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidine-1-carbonyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-(5-{2-[4-(4-Fluorobenzyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)-4-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-5-methyl-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid;
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid methyl ester;
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester;
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid;
6-{5-[4-(4-Fluorobenzyl)-3-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorophenoxy)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzenesulfinyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzoyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-(5-{4-[(4-Fluorophenyl)hydroxymethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H-benzoxazol-2-one;
4-Chloro-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-5-methyl-3H-benzoxazol-2-one;
-{5-[4-(4-Fluorophenyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-[5-(4-Phenyl-4-hydroxy)piperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H-benzoxazol-2-one; and 6-(5-{2-[4-(4-Fluorophenyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H-benzoxazol-2-one.
6-[5-(4-Benzylpiperidin-1-ylmethyl)-3-methylisoxazol-4-yl]-3H-benzoxazol-2-one;
6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one hydrochloride;
(+)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
(-)-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{3-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-5-yl}-3H-benzoxazol-2-one;
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H-benzoxazol-2-one;
6-{2-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]thiazol-5-yl}-3H-benzothiazol-2-one;
5-[2-(4-Benzylpiperidin-1-ylmethyl)thiazol-5-yl]-1,3-dihydrobenzimidazole-2-thione;
6-{2-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]oxazol-5-yl}-3H-benzothiazol-2-one;
6-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-3H-benzoxazol-2-one;
5-[2-(4-Benzylpiperidin-1-ylmethyl)oxazol-5-yl]-1,3-dihydroindol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydrothiazol-2-yl}-3H-benzoxazol-2-one;
6-[5-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-2-yl]-3H-benzoxazol-2-one;
6-[2-(4-Benzylpiperidin-1-ylmethyl)-4,5-dihydrothiazol-5-yl]-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]isoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-yl]methyl}-4,5-dihydroisoxazol-3-yl}-3H-benzothiazol-2-one;
6-[5-(4-Benzyl-4-hydroxypiperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidine-1-carbonyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-(5-{2-[4-(4-Fluorobenzyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)-4-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-5-methyl-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid;
5-[4-(4-Fluorobenzyl)piperidin-1-ylmethyl]-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazole-5-carboxylic acid methyl ester;
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid ethyl ester;
4-(4-Fluorobenzyl)-1-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydroisoxazol-5-ylmethyl]piperidine-4-carboxylic acid;
6-{5-[4-(4-Fluorobenzyl)-3-hydroxypiperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorophenoxy)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorophenylsulfanyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzenesulfinyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-{5-[4-(4-Fluorobenzoyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-(5-{4-[(4-Fluorophenyl)hydroxymethyl]piperidin-1-ylmethyl}-4,5-dihydroisoxazol-3-yl)-3H-benzoxazol-2-one;
4-Chloro-6-{5-[4-(4-fluorobenzyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-5-methyl-3H-benzoxazol-2-one;
-{5-[4-(4-Fluorophenyl)piperidin-1-ylmethyl]-4,5-dihydroisoxazol-3-yl}-3H-benzoxazol-2-one;
6-[5-(4-Phenyl-4-hydroxy)piperidin-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-3H-benzoxazol-2-one; and 6-(5-{2-[4-(4-Fluorophenyl)piperidin-1-yl]ethyl}-4,5-dihydroisoxazol-3-yl)-3H-benzoxazol-2-one.
9. A compound according to Claim 4 named (+)-6-{5-[4-(4-Fluoro-benzyl)-piperidin-1-ylmethyl]-4,5-dihydro-isoxazol-3-yl}-3H-benzoxazol-3-one.
10. A compound according to Claim 4 named (-)-6-{5-[4-(4-Fluoro-benzyl)-piperidin-1-ylmethyl]-4,5-dihydro-isoxazol-3-yl}-3H-benzoxazol-3-one.
11. A compound according to Claim 1 of Formulae V, and pharmaceutically acceptable salts thereof wherein X is O, S, or N-R, wherein R is hydrogen, alkyl, or substituted alkyl; and * means a chiral center designated R, S, or mixtures thereof.
12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I-XV, or a pharmaceutically acceptable salt thereof, together with a diluent, carrier, or excipient.
13. A pharmaceutical composition according to Claim 12 comprising a therapeutically effective amount of a compound selected from the group consisting of:
(+)-6-{ S-[4-(4-Fluoro-benzyl)-piperidin-1-ylmethyl]-4,5-dihydro-isoxazol-3-yl}-3H-benzoxazol-3-one; and (-)-6-{5-[4-(4-Fluoro-benzyl)-piperidin-1-ylmethyl)-4,5-dihydro-isoxazol-3-yl}-3 H-benzoxazol-3-one.
(+)-6-{ S-[4-(4-Fluoro-benzyl)-piperidin-1-ylmethyl]-4,5-dihydro-isoxazol-3-yl}-3H-benzoxazol-3-one; and (-)-6-{5-[4-(4-Fluoro-benzyl)-piperidin-1-ylmethyl)-4,5-dihydro-isoxazol-3-yl}-3 H-benzoxazol-3-one.
14. A method of treating disorders responsive to the selective blockade of the N-methyl-D-aspartate receptor subtypes in a mammal, including a human, suffering therefrom, comprising administering a compound of Formula I-XV, or a pharmaceutically acceptable salt thereof.
15. A method according to Claim 14 wherein the disorders are selected from stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, including Parakinson's disease, anxiety, migraine headache, convulsions, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, pain, including chronic pain, neuropathic pain, or surgical pain, and urinary incontinence.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25783200P | 2000-12-21 | 2000-12-21 | |
US60/257,832 | 2000-12-21 | ||
PCT/IB2001/002277 WO2002050070A2 (en) | 2000-12-21 | 2001-11-30 | Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2436699A1 true CA2436699A1 (en) | 2002-06-27 |
Family
ID=22977943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002436699A Abandoned CA2436699A1 (en) | 2000-12-21 | 2001-11-30 | Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
Country Status (13)
Country | Link |
---|---|
US (1) | US6642256B2 (en) |
EP (1) | EP1345935A2 (en) |
JP (1) | JP2004516295A (en) |
AU (1) | AU2002223968A1 (en) |
BR (1) | BR0116311A (en) |
CA (1) | CA2436699A1 (en) |
HN (1) | HN2001000280A (en) |
MX (1) | MXPA03004652A (en) |
PA (1) | PA8535901A1 (en) |
PE (1) | PE20020882A1 (en) |
TN (1) | TNSN01175A1 (en) |
UY (1) | UY27081A1 (en) |
WO (1) | WO2002050070A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19952147A1 (en) * | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation |
TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
AU2004268847A1 (en) | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
SE0400208D0 (en) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
GT200600042A (en) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | BIS ARILO AND HETEROARILO COMPOUNDS REPLACED AS SELECTIVE ANTAGONISTS OF 5HT2A |
WO2006137465A1 (en) * | 2005-06-24 | 2006-12-28 | Shionogi & Co., Ltd. | Nitrogenated heterocyclic derivative |
WO2007029077A1 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Substituted indazoles as inhibitors of phosphodiesterase type-iv |
US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
MX2009009793A (en) | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors. |
JP5573307B2 (en) * | 2010-03-31 | 2014-08-20 | Jsr株式会社 | Radiation sensitive resin composition, polymer and compound |
ES2666404T3 (en) | 2010-06-11 | 2018-05-04 | Rhodes Technologies | Transition metal catalyzed processes for the preparation and use of N-allyl compounds |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
CA3055215A1 (en) * | 2017-03-12 | 2018-09-20 | Xiaodong Wang | Polycyclic amines as opioid receptor modulators |
KR101798840B1 (en) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2941950B2 (en) * | 1994-11-23 | 1999-08-30 | ニューロゲン コーポレイション | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; a novel class of dopamine receptor subtype specific ligands |
DE19531321A1 (en) | 1995-08-25 | 1997-02-27 | Merck Patent Gmbh | Piperidinylmethyloxazolidinone |
ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610736B (en) | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
DE19739332C1 (en) * | 1997-09-09 | 1998-11-26 | Merck Patent Gmbh | New 5-Ý4-(4-fluorobenzyl)-piperidin-1-yl¨-3(4-hydroxyphenyl)-oxazolidine-2-one |
US6015824A (en) | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
DE19812331A1 (en) | 1998-03-20 | 1999-09-23 | Merck Patent Gmbh | New benzo-heterocyclic substituted piperidine derivatives useful as excitatory aminoacid receptor antagonists, used e.g. for treating neurodegenerative diseases |
AU2960599A (en) | 1998-03-30 | 1999-10-18 | Akira Karasawa | Quinazoline derivatives |
WO2000018763A2 (en) * | 1998-09-29 | 2000-04-06 | Neurogen Corporation | 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands |
-
2001
- 2001-11-30 CA CA002436699A patent/CA2436699A1/en not_active Abandoned
- 2001-11-30 EP EP01271104A patent/EP1345935A2/en not_active Withdrawn
- 2001-11-30 US US09/998,479 patent/US6642256B2/en not_active Expired - Fee Related
- 2001-11-30 AU AU2002223968A patent/AU2002223968A1/en not_active Abandoned
- 2001-11-30 BR BR0116311-6A patent/BR0116311A/en not_active IP Right Cessation
- 2001-11-30 WO PCT/IB2001/002277 patent/WO2002050070A2/en not_active Application Discontinuation
- 2001-11-30 MX MXPA03004652A patent/MXPA03004652A/en not_active Application Discontinuation
- 2001-11-30 JP JP2002551566A patent/JP2004516295A/en not_active Abandoned
- 2001-12-18 UY UY27081A patent/UY27081A1/en not_active Application Discontinuation
- 2001-12-18 PE PE2001001265A patent/PE20020882A1/en not_active Application Discontinuation
- 2001-12-19 HN HN2001000280A patent/HN2001000280A/en unknown
- 2001-12-20 TN TNTNSN01175A patent/TNSN01175A1/en unknown
- 2001-12-21 PA PA20018535901A patent/PA8535901A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002050070A3 (en) | 2002-09-19 |
TNSN01175A1 (en) | 2005-11-10 |
MXPA03004652A (en) | 2003-09-05 |
WO2002050070A2 (en) | 2002-06-27 |
PA8535901A1 (en) | 2002-08-29 |
JP2004516295A (en) | 2004-06-03 |
AU2002223968A1 (en) | 2002-07-01 |
EP1345935A2 (en) | 2003-09-24 |
HN2001000280A (en) | 2002-01-30 |
PE20020882A1 (en) | 2002-09-28 |
UY27081A1 (en) | 2002-07-31 |
US20030018021A1 (en) | 2003-01-23 |
BR0116311A (en) | 2003-09-23 |
US6642256B2 (en) | 2003-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017263361B2 (en) | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | |
US5750549A (en) | Cycloalkyl tachykinin receptor antagonists | |
US6642256B2 (en) | Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | |
AU722883B2 (en) | Cyclopentyl tachykinin receptor antagonists | |
AU2003284984B2 (en) | Gamma-aminoamide modulators of chemokine receptor activity | |
JP2024054111A (en) | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and methods for preparing fused tricyclic compounds containing substituted phenyl or pyridinyl moieties and methods of using them | |
TW201734001A (en) | Modulators of ROR-gamma | |
JP6837431B2 (en) | A novel bicyclic derivative with beta2 adrenergic agonist activity and M3 muscarinic antagonist activity | |
ES2245985T3 (en) | BICYCLE CYCLHEXILAMINS AND ITS USE AS NMDA RECEIVER AGONISTS. | |
TW200934487A (en) | TRPV1 antagonists | |
CA2897259A1 (en) | Benzoheterocyclic compounds and use thereof | |
CA3028347A1 (en) | Anti-infective heterocyclic compounds and uses thereof | |
US6828341B2 (en) | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | |
TW201625600A (en) | Aminoester derivatives | |
CA2234913A1 (en) | Cyclopentyl tachykinin receptor antagonists | |
JPH11217377A (en) | New alkylamino derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |